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ABSTRACT  
Many studies have shown a negative effect of depot-medroxyprogesterone acetate 
(DMPA) hormonal contraception on bone mineral density (BMD) in women. There is 
limited information on the effect of norethisterone enanthate (NET-EN) on BMD  and  
the effect of combined oral contraceptives (COCs) on  BMD is inconclusive, however 
emerging evidence is showing that low-dose COCs maybe detrimental to BMD in young 
women.  The aim of this research was to evaluate, in a 5-year follow-up study, the 
possible effect of DMPA, NET-EN and COCs on BMD among young (15-19 years) and 
older (40-49 years) South African women.  
 
Method: This prospective study was conducted at the Commercial City Family Planning 
clinic in Durban, South Africa between  2000  and 2007.   In the adolescent group women 
with no history of hormonal contraception who were initiating use of DMPA (n=115), 
NET-EN (n=115) or COCs (n=116) and 144 nonuser controls were recruited. In the older 
group, one hundred and twenty seven users of DMPA, 102 NET-EN users and 106 COC 
users  of at least one year were compared to 161 nonuser controls. BMD was measured at 
the distal radius and  midshaft of the ulna using dual x-ray absorptiometry.  In the cross-
sectional component of the study  conducted at the end of the longitudinal phase, BMD 
was measured at the hip, spine and femoral neck in a sub-group of 96 of the younger 
women.  
 
Results: In the longitudinal study of adolescents, BMD increased in all four groups 
during follow-up (p<.001). There was evidence for lower BMD increases per annum in 
ix 
NET-EN (p=.050) and COC (p=.010) users compared to nonusers but no difference 
between DMPA and nonusers (p=.76). In 14 NET-EN discontinuers, an overall reduction 
of 0.61% per year BMD was followed, upon cessation, by an increase of 0.69% per year 
(p=.066).  The cross-sectional sub-study found that young women in the injectables-only 
user group had lower BMDs compared to the non-user group  after adjusting for BMI  at 
the spine (p=0.042), hip (p=0.025), and femoral neck (p=0.023). The mixed 
COC/injectable user group BMD values were lower than controls; however, they were 
not significant at any of the three sites.   
 
In the older women, there was no significant difference in radius BMD between the  
contraceptive user groups  and the non-user controls (p=.26) with and without adjustment 
for age at baseline, or after two and a half years of follow-up (p=0.52).  
 
Conclusion: This study suggests that BMD increases in adolescents may be less in NET-
EN and COC users; however, recovery of BMD in NET-EN users was found in the small 
sample of adolescents followed post-discontinuation. The cross-sectional sub-study 
showed similar findings in long-term injectable users, but not when women had mixed 
injectable and COC use.  There was no evidence that long-term use of DMPA, NET-EN 
and COCs affected BMD in the older women.  
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CHAPTER 1  INTRODUCTION  
1.1 Background and statement of the problem 
1.1.1 Factors affecting bone formation  
Bone mass increases rapidly from birth, and during adolescence women will gain 40-50% 
of their skeletal mass (Sabatier et al, 1996). Up to 90% of total adult bone content will be 
accumulated by the age of 20 years (Cromer and Harel, 2000). More recent data from a 
longitudinal study found  bone mineral density plateaued by age 18. Bone strength, 
known as bone mineral density (BMD), can be assessed by a bone mineral density test 
which measures how many grams of calcium and other bone minerals are packed into a 
segment of bone (Hayes et al, 1991).  The World Health Organization (WHO) has 
developed a classification system which uses the population mean as a reference against 
which a BMD measurement can be compared (WHO, 1994). A BMD measurement can 
be reported as a T-score and is expressed in standard deviations (SDs) from the normal 
population mean. The definition of normal BMD is no more than 1 SD below the young 
adult normal value. Low bone mass (osteopenia) is defined as 1 SD to 2.5 SDs below the 
population mean and below this level osteoporosis is diagnosed (WHO, 1994). 
  
BMD remains fairly stable in adult premenopausal women (Dempster,1995), and 
although some studies report that a small percentage (<1%) of  bone is lost on an annual 
basis in premenopausal women (Genant et al, 1988), others show there is no loss or loss 
is limited to some bone sites only (Sowers, and Galuska, 1993). Women lose bone mass 
over and above age-related bone loss in association with menopause (Duursma et al, 
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1991; Lindsay 1987; Hui et al, 1982). It is  important to know what factors affect bone 
formation and resorption generally. In particular, factors affecting peak bone mass in 
young women and bone loss in older woman are important, as these are the chief 
determinants of a woman’s susceptibility to osteoporosis, a major health problem in 
older/menopausal women, causing fractures, disability, pain and deformity (Riggs and 
Melton, 1986).  
 
There are several areas of influence on bone mass including:- lifestyle factors such as 
diet, alcohol consumption, smoking, low body weight especially anorexia nervosa, and 
physical exercise (Baxter-Jones et al, 2008;, 1992; Mazess and Barden, 1991;Slemenda et 
al, 1991; Stevenson, et al, 1989;   Dalsky, 1987; Krolner et al, 1983); race, and  genetic 
factors  (Morrison et al, 1994; Sowers and Galuska 1993); the rapid growth phase during 
adolescence has been shown to be particularly sensitive to diet and exercise (Baxter-
Jones et al, 2008; Slemenda et al, 1991); chronic diseases affecting bone metabolism and 
calcium metabolism are known to aggravate bone loss. Finally hormonal status, including 
reproductive hormones are known to affect peak bone mass, and bone maintenance 
(Sowers and Galuska, 1993). 
 
1.1.2 Reproductive hormones and bone mass 
Of the range of hormones that can affect bone, estrogen is a reproductive hormone that 
plays the most important role in BMD maintenance in women (De Cherney, 1993). 
Estrogen deprivation can lead to bone loss and this situation can arise in a number of 
ways. Estrogen production begins to decline in association with the menopause and this 
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decline is thought to begin as early as 40 years (Duursma, 1991; Hui et al, 1982; Lindsay, 
1980). Hysterectomy has been linked to reduced blood supply to the ovaries, which in 
turn diminishes oestrogen production (Siddle et al, 1987). Increase in the rate of bone loss 
is also associated with oopherectomy (Richelson et al, 1984; Cann et al, 1980; Lindsay et 
al, 1980). The relationship between bone loss and lactation remains unresolved as the 
biological process involved in the suppression of ovarian function and lactation is not 
clear. Some studies report that bone mass is lost as a result of lactation (Hayslip, 1989; 
Chan et al, 1987), while others have shown no effect (Silverstein, 1992; Alderman, 
1986). Hormone replacement therapy (HRT) also provides strong evidence for the effect 
of estrogen on bone loss (Munk-Jensen, et al, 1988; Ettinger et al, 1987; Lindsay et al 
1984; Hammond and Maxson, 1982; Aitken, 1973). Estrogen has an anabolic effect on 
bone, as demonstrated by the increase in BMD measurements in post-menopausal women 
on HRT, suggesting there may be new bone formation as well as preservation (Munk-
Jensen et al, 1988).  
 
 1.1.3 Hormonal contraceptive use and bone mass 
The relationship between estrogen deficiency and bone loss suggests that hormonal 
contraceptive use may affect BMD. The non-contraceptive benefits of estrogen and 
progestin combined oral contraceptives (COCs) have included treatment of  
hypoestrogenic conditions in women where BMD is affected (Castelo-Branco et al, 2001; 
Haenggi et al, 1994; Seeman et al, 1992). Conversely, concerns have been raised 
regarding progestogen-only contraceptives, as the absence of estrogens from these 
methods and the resulting hypo-estrogenic effect could lead to suppression of  bone mass 
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acquisition. In particular, concern is greatest in the age groups where BMD is in 
transition; younger women who have yet to reach peak bone mass and older women 
entering perimenopause and menopause where age-related bone loss has commenced.    
 
Depot-medroxyprogesterone acetate (DMPA), marketed as Depo-Provera®, and 
norethisterone enanthate (NET-EN) marketed as Nur-isterate® are both long-acting, 
synthetic, progestogen-only injectable contraceptives. In 1991, the first study showing a 
negative impact of DMPA on BMD in adult women users was published (Cundy et al, 
1991). Although many studies about DMPA and bone health followed, due to its limited 
availability  globally, no studies were conducted on NET-EN. 
 
Various regulatory bodies acted swiftly in response to emerging data reporting bone loss 
in DMPA users. In 2004, the United States Food and Drug Administration (US FDA) 
required the addition of a black box to the product labeling with a warning stating that 
DMPA may impair BMD (United States Food and Drug Administration, 2004).  New 
patient labeling was  introduced for DMPA which states “losing calcium from your 
bones” is  a risk of the method and indicates that long term use (for more than 2 years) 
increases the risk of “weakening” the bones and suggests that after two years of use the 
healthcare provider may suggest another method or advise a “test of the bones.” Similar 
recommendations were made by the UK Medicines and Healthcare Products Regulatory 
Agency (MHRA) (Faculty of Family Planning and Reproductive Health Care, 2004), 
however, neither of these regulatory bodies specified which method of contraception 
users should switch to after two years of DMPA use. 
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The third edition of the World Health Organization (WHO) Medical Eligibility Criteria 
for contraceptive Use (WHO, 2004) changed the classification of use of DMPA and 
NET-EN for women below 18 years and above 45 years from category 1 which states 
that there is no restriction to the use of the contraceptive method, to category 2 where the 
advantages of using the method generally outweigh the theoretical or proven risks. 
Although there was an absence of evidence for NET-EN similar recommendations were 
applied.  
 
In 2005, shortly after the changes in regulatory recommendations, the WHO convened an 
expert consultation to assess current evidence on the relationship between the use of all 
available steroid hormonal contraceptives and bone health. A statement on hormonal 
contraception and bone health (WHO, 2006) followed the meeting concluding that 
adolescent COC users may gain less BMD compared to non-users of the same age but not 
of clinical significance, whilst perimenopausal COC users may benefit from some gain in 
BMD compared to non-users, however findings were inconsistent.  Data on the other 
combined hormonal contraceptives (i.e. containing estrogen and progestogens), such as 
the combined injectables, vaginal rings and skin patches was too limited to review. Data 
on progestogen-only methods showed that levonorgestrel implants did not appear to have 
any effect on BMD.  
 
With regard to the progestogen injectables, both DMPA and NET-EN were considered at 
the meeting. The data reviewed indicated that DMPA reduced BMD in women who had 
 6
attained peak bone mass and impaired the acquisition of BMD in those who have not yet 
attained peak bone mass (adolescents and young women).  For DMPA, the magnitude of 
effect seen in cross-sectional studies of long-term users showed an approximate reduction 
of BMD of 0.5 SD at the hip and spine compared to non-users. In longitudinal studies of 
adults and adolescents around 5-7% of bone was reported to be lost (approximately 0.5 
SD at hip and spine after two years of use) however, the rate of loss appeared to decrease 
over time.  On discontinuation of DMPA, BMD increased regardless of age, and within a 
two-to three year period BMD recovered to the level of a comparable non-DMPA user 
population. However, BMD did not recover in DMPA users who had reached 
menopause. The consultation agreed that there was not enough data to indicate whether 
women who had yet to reach peak bone mass would be affected i.e. whether the recovery 
seen in adult women could in fact apply to adolescents and young women. In addition, 
woman using these methods during the menopausal transition who would be losing bone 
for age related reasons could also be at risk, in that they would not have had a period of 
recovery before they enter menopause. The consultation stated that there was not enough 
evidence to assess whether DMPA use modified fracture risk of users in the long term. 
However, since the effect of DMPA on BMD was reversible, any lifetime increase in 
fracture risk was likely to be small. Again, in the continued absence of any evidence for 
NET-EN the consultation applied similar recommendations made for DMPA to use of 
NET-EN (WHO 2006).  
 
In South Africa, the manufacturers of both the locally used hormonal injectable 
contraceptives (DMPA and NET-EN) were requested, in October 2005, to provide all 
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available evidence to the National Department of Health on how their methods affect 
BMD (DoH, personal communication, 2005). However, no changes have been made to 
prescribing injectable contraceptives to adults or adolescents, in regard to BMD in South 
Africa. 
 
There was some concern that these new recommendations could cause negative publicity 
and that women of certain age groups may be cautioned against using DMPA and other 
progestogen-only methods. A position paper published in 2006 by the Society of 
Adolescent Medicine (Society of Adolescent Medicine, 2006) which supported the WHO 
position on DMPA, stated clearly that with existing evidence, the advantages of using 
DMPA in women below 18 years outweigh the disadvantages. The lack of evidence on 
the consequences of long-term use of DMPA was acknowledged and until data became 
available it was recommended that prescribing DMPA to adolescents should be 
considered on a case by case basis and that practitioners should continue to presecribe 
DMPA to adolescents who have none of the listed risk factors.. The debate on DMPA 
and its effect on BMD, and restrictions and concerns around use especially in 
adolescents, have been published in many reviews and opinion pieces (Guilbert et al, 
2009; Cromer, 2003; Westhoff, 2003; Bachrach et al, 2000; Kass-Wolff, 2000; Davis, 
1996).  The focus has been on the need to balance  effective pregnancy prevention against 
concerns for future bone health. 
 
The question of change in contraceptive method after two years of DMPA use has raised 
fresh concerns. Recent studies have reported that COCs with very low doses of estrogen 
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(ethinyl estradiol) may no longer provide the once assumed benefit of BMD maintenance, 
but in addition some studies have reported that BMD is lower in adolescent and young 
women users of  low-dose COCs (Martins et al, 2006).  Some researchers have  cautioned 
against the 2-year recommendation which may lead to DMPA users switching to a low-
dose COC product (Berenson et al, 2008; Albertazzi et al 2006) as their data have shown 
that women using low-dose COCs after DMPA may be particularly at risk to loss of 
BMD.  
 
1.2 Justification for the research 
 In South Africa hormonal  contraceptive use is high as reported in  the South African 
Demographic and Health survey (SADHS) of  2003 with approximately 58.5% of Black 
African women practicing contraception, using either DMPA or NET-EN and 9.9% using 
COCs (Department of Health, South Africa, 2006). Of the two available injections, older 
women (>40 years) almost exclusively use DMPA (81%) compared to NET-EN (19%). 
These highly effective methods of contraception may be the method of choice for many  
women over 40 who have finished childbearing and are concerned about avoiding 
pregnancy.  Hormonal injectables are not generally recommended in perimenopausal 
women where use of these methods is viewed as “contraceptive overkill” (Guillebaud, 
2001).  However in South Africa alternative methods suitable for older women such as 
sterilization and the IUD are not readily accessible in the public health sector. Women 
will often continue to use hormonal injectables into their late forties and beyond 
menopause as menopausal symptoms such as amenorrhea may be masked by use of 
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progestogen-only hormonal contraceptives which also cause amenorrhea (Guillebaud, 
2001).  
 
As menopause is known to be associated with bone loss (Duursma, 1991; Lindsay 1987; 
Hui et al, 1982), it is important to understand more about whether using certain hormonal 
methods of contraception could further contribute to bone loss in this group of older 
South African women.  
 
In the case of younger women, NET-EN is the more commonly used hormonal injectable 
(Department of Health, South Africa, 2006), with over half of young sexually active 
women African women aged 15-19 years  using this method, fewer use DMPA (12%) 
and less  COCs (7%).  At the start of the study reported in this thesis there was limited 
data to indicate whether women who have yet to reach peak bone mass would recover 
BMD on discontinuation from DMPA, and there was no information on NET-EN use and 
its effect on BMD. Almost all studies on the effect of hormonal contraception and BMD 
have been conducted in the US and Europe, thus, in South Africa specifically and 
internationally there is a need for more information.  
 
1.3 Aim and research questions 
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The aim of the research was to evaluate, in a prospective study, the possible effect of 
commonly used progestogen-only injectable contraceptives (DMPA and NET-EN) and 
COCs on BMD among young (15-19 years) and older (40-49 years) women.1  
 
The main research question was to determine if long term use of hormonal contraceptives 
(COCs, DMPA and NET-EN) compared to non-use is associated with an increase, 
decrease or no change in bone mass in women aged 15-19 or 40-49 years. A secondary 
objective was to investigate the relationship between hormonal injectable use and follicle 
stimulating hormone (FSH) levels to see if FSH could be used as an indicator of 
menopausal status in older injectable users. This was due to the high prevalence of 
amenorrhea among injectable users, which made it impossible to use the menstrual cycle 
as an indicator of menopausal status. 
 
1.4 Format of the thesis 
This thesis is divided into 4 Chapters as follows: 1.Introduction including the literature 
review; 2. Methodology;  3. Results in the form of published papers and papers in print 
and preparation and 4. Conclusion which briefly summarises key findings in the context 
of the published literature, looks at implications of the results and makes 
recommendations for future work. The published papers contain their own methodology 
however, chapter 2 provides  detailed aspects of methodology and study procedures.  
                                                          
1 Footnote: Other hormonal methods were not included as they are not widely used and 
not available in the South African public health sector 
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1.5 Contribution to the field 
Although there is a growing body of evidence on the effect of hormonal contraceptives 
on BMD, this was the first study to date to investigate the effect of NET-EN on BMD, as 
this contraceptive method has not been widely used outside South Africa. NET-EN is 
increasing in popularity in this country (Department of Health South Africa, 2006) and in 
other countries.  Therefore this work will inform national and international organizations’ 
and regulatory bodies’ guidelines and recommendations.  In addition there is limited 
information regarding BMD and DMPA and COC use in African women. Finally, a 
unique aspect of this study was to investigate BMD in young women who have a history 
of mixed hormonal contraceptive use.   
 
Published findings from this thesis on the baseline data from the older users (Beksinska et 
al, 2005) have been cited 11 times in other peer-reviewed journals. As the first study  
examining NET-EN and BMD it was included in two comprehensive international 
reviews examining progestogen-only contraception and bone mineral density (Curtis et 
al, 2006), and COCs and bone health (Martins et al, 2006). The cross-sectional baseline 
component of this study (longitudinal data was not available at the time from the study) 
was rated and graded  as II-3, Fair, in these reviews using the system developed by the 
United States Preventive Services Task Force (USPSTF) (Harris et al, 2001) and was one 
of only 21  from 167 available studies considered for inclusion in the review. This article 
is also cited in a Cochrane review (Lopez et al, 2006). Preliminary analysis of this study 
was made available to the WHO review of bone health in 2005 (described earlier; p.5).  
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Two published papers  have reported on the longitudinal findings from the younger age 
group, the first,  an interim analysis conducted after 2 and a half years (Beksinska et al, 
2007) has been cited 5 times. On completion of the follow-up  a second paper including 
information on discontinuation has been published recently (Beksinska et al, 2009).  A 
further  paper due for publication in August 09, is a cross-sectional  investigation of 
BMD in the spine, hip and neck in the younger age group at the end of the five-year 
follow-up period and  is the first study to investigate the effect of long term mixed 
hormonal contraceptive use on BMD (Beksinska et al, 2009 in press). 
 
The sub-study which examines BMD and FSH levels in DMPA and NET-EN users 
(Beksinska et al, 2003) has been cited 6 times and has been used by the Faculty of Family 
Planning and Reproductive Health Care (FFPRHC) UK to provide international guidance 
for contraception in women aged over 40 (Journal of Family Planning and Reproductive 
Health Care, 2005). This finding has important implications for guiding family planning 
providers in the management of older women using hormonal injectable contraception.    
The information published from this study has been submitted to and discussed with the 
South African National Department of Health. The national contraceptive guidelines are 
currently under revision and the information arising from this work will be included as a 
recommendation in the revised guidelines.  The information from this study has also 
contributed to the Global family planning handbook. Family Planning: A Global 
Handbook for Providers (WHO, 2007).  
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Further publications will include a review of the status of BMD and hormonal 
contraception in adolescents, based on the literature review. Data analysis continues and 
papers are in preparation on other areas of data collected during the course of the study 
including weight change in long-term contraceptive users and the relationship between 
FSH and BMD. 
 
1.6 Literature review 
1.6.1  Organisation of the literature review 
This literature review will focus on the relationship between hormonal contraceptive 
methods used in this study (DMPA, NET-EN and COCs) and BMD. Other hormonal 
contraceptive methods and their reported relationship with BMD are documented in less 
detail in section 1.6.5  
 
There are over 170 articles published that have contributed research results on 
progestogen-only hormonal contraception and bone mineral density (Curtis and Martins, 
2006), and almost 1000 on combined hormonal contraception and bone health (Martins et 
al, 2006).  Available data on the effect of steroid hormone contraceptive use on BMD is 
from studies on combined oral contraceptives, progesterone-only oral contraceptives, 
progestogen-only injectable contraceptives, progesterone vaginal rings, combined 
monthly injectables, levonorgestrel implants and intrauterine systems. In  the 
progesterone-only injectable group there is a large body of information on the 3-monthly 
depot medroxyprogesterone acetate (DMPA), but limited information on the 2-monthly 
norethisterone enanthate (NET-EN) until information was published from this thesis 
(Beksinska et al, 2005) and another South African study (Rosenburg et al, 2007).    
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For each hormonal contraceptive method,  the literature on the effect of the hormonal 
method on fracture risk is first reviewed, followed by the relationship of the hormonal 
method with BMD outcome. This thesis did not investigate if there was any relationship 
between fracture risk and hormonal contraception and there is generally very limited data 
available in this area. However, as fracture is an important outcome, available 
information is included. For BMD outcome the review has been divided into three broad 
age categories 1. Adult premenopausal women 2. Adolescents and young women 3. 
Older women (peri and post menopausal).  Within these age categories both longitudinal  
(prospective) and cross-sectional studies are reviewed. The review will begin with 
combined oral contraception and its relationship with bone health as historically the link 
between use of hormonal contraception and BMD developed from work in this area. A 
review of DMPA will follow and then the third method investigated in this thesis NET-
EN will be reviewed.  The hormonal methods not included in this study will be discussed 
in the final part of the literature review.  
 
This literature review has attempted to limit discussion in each section to one hormonal 
method. Where studies reviewed include other methods, the results of the other methods 
are mentioned only briefly. More information is given in the section dealing with that 
particular method. Although this means that some studies may be reported in two 
sections, repetition has been kept to a minimum. The alternative would have been to 
discuss studies together which would have made the literature review difficult to follow.   
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1.6.2 Combined oral contraception  
1.6. 2.1 Background and historical perspective 
Combined oral contraceptives are made up of two hormones- a progestogen and an 
estrogen. Their action to prevent pregnancy is primarily by preventing the release of eggs 
from the ovaries. Prior to the first report suggesting a relationship between BMD and  
hormonal contraception in humans, a number of studies reported lowered serum and 
urinary concentrations of magnesium, calcium and phosphorous after relatively short-
term use of a number of contraceptive steroids (Simpson, 1972; Goldsmith, 1966). These 
values remained low even after prolonged use of the method (Simpson, 1972). Further, 
BMD in female rats was found to increase when they were treated with Envoid, an oral 
contraceptive (Goldsmith, 1967). It was then postulated that COCs would have a similar 
effect in women. The early body of work on the effect of steroid contraceptive use and 
BMD was initially limited to the COCs with one of the first studies published in 1975 
(Goldsmith and Johnston, 1975) indicating that COCs containing oestrogen (100mcg 
mestranol) showed an increase in BMD at the distal radius compared to non-user 
controls. 
 
Numerous studies to date have investigated the association between COC use and BMD. 
Most of these studies have used BMD as an outcome, with fracture risk outcome reported 
far less frequently. Early studies conducted were mainly cross-sectional and in most cases 
the COC formulation was not reported. Since the introduction of COCs in the early 60’s 
there has been a gradual reduction in the dosage of steroids. The relationship between 
high estrogen doses and thrombotic risk led to recommendations by the USFDA that the 
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dose of the estrogenic component of oral contraceptives be as low as possible. The 
phasing in of lower dose oral contraceptives that are equal to or less then 30mcg/day 
ethinyl estradiol (EE) has addressed this health issue,  however the once assumed benefits 
of BMD maintenance now requires review and may be lost at these low estrogen levels.  
 
Unlike some  progestogen-only methods of contraception such as DMPA and NET-EN 
which have not changed in formulation, the changes in dose of EE in COCs over time has 
made it more difficult to compare results from earlier published studies where EE content 
of COCs may have been much higher. The literature review for the relationship between 
COCs and BMD will therefore focus on more recent studies, and also more importantly, 
where the COC formulation is reported. Cohort studies published since the late 90s  have 
been more likely to specify the formulations whilst many cross-sectional studies have 
collected data from women who may not have known the formulation of the COCs they 
have used. This is obviously a particular problem when collecting data from women who 
have had a long history of COC use. In addition, long term users may have changed COC 
brand and started with a higher dose COC in their early contraceptive history but over the 
years this may have changed. It is still important to examine some of the early work 
because the general consensus of effect of COCs on BMD from these early studies was 
considerably more positive. There is a need to re-evaluate the implications for BMD as 
EE doses have come down. 
 
1.6.2.2 COCs and Fracture risk 
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The first study investigating COC use and fracture risk (Cooper et al, 1993) was a large 
prospective cohort of women aged between 25 and 65 years which contributed 484,083 
women years of follow-up. The group of ever-users of COCs (n=284,882) were more 
likely to have a fracture than never users (Relative Risk=1.2, 95% CI 1.08-1.34). There 
was however no effect of duration of use on fracture risk and COC dose was not 
specified. Two further large prospective cohorts (Barad et al, 2005; Vessey et al, 1998) 
also found an increase in fracture at all sites in COC users. Vessey et al, 1998  found an 
increase in fracture risk with duration of use of COCs in 187,000 COC  users aged 
between 25 and 39 years compared to 123,00 non-users. More recently (Barad et al, 
2005) found that postmenopausal women using COCs for over five years had no 
increased risk of fracture whilst those who used COCs for a shorter duration (5 years or 
less) had an increased risk of fracture. Neither of these studies specified COC 
formulation. 
 
Three large cross-sectional studies (Johansson and Mellstrom, 1996; O’Neill et al, 1996; 
Tuppurainen et al, 1994)  have reported on fracture outcomes. Tuppurainen et al, (1994) 
found no difference in fracture rates between perimenopausal ever users and never users 
of COCs regardless of duration of COC use. O’Neill (1996) found a protective effect of 
COC use in prevalence of vertebral deformity in women aged 50-79 years. Johansson et 
al (1996) also found a lowered risk of repeat fracture in 1489 COC users compared to 
1723 never users. These women were part of a European birth cohort with a mean age of 
51.2 years, however there was no detail on the relationship between COC use and initial 
fracture. Some studies have used a case control design to see if ever use of COCs is 
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different in women experiencing fracture at the hip (Michaelsson et al, 2001; La Vecchia 
et al, 1999; Michaelsson et al 1999,) and fracture at the forearm (Mallmin, 1994).  
Michaelsson et al, (2001) and Michaelsson et al, (1999) found that ever-users of COCs  
were 25%  less likely to have hip fracture compared to never users with the higher dose 
COCs providing even further protection against hip fracture. This was the only study of 
fracture outcome that specified COC formulation, however there were no exclusive low-
dose COC users. La Vecchia et al, (1999) found no difference in prevalence of hip 
fracture between ever users and never users, however the prevalence of COC use in the 
sample was low. Mallmin (1994) found no difference in distal forearm fracture rates in 
301 cases and 301 controls. A recent Cochrane review (Lopez et al, 2006) found no COC 
randomised controlled trials (RCTs) conducted to date that have had fracture as an 
outcome. 
 
In summary the fracture evidence is inconclusive. The estrogen formulation of the COCs 
was not available except for one study and some studies had not adjusted for variables 
linked to facture risk. The limitations of the fracture evidence are discussed in more detail 
in a systematic review of combined hormonal contraception and bone health (Curtis et al, 
2006) in which studies were graded  using the system developed by the United States 
Preventive Services Task Force (USPSTF) (Harris et al, 2001). Studies with fracture as 
an outcome were considered to be fair with some poor, no studies were graded as good.  
 
1.6.2.3 COCs and BMD outcome 
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The first major review of COC use and BMD outcome was published in 1993 (Mehta, 
1993).  This review concluded that COC use and its relationship with bone density was 
not conclusive. While seven of these early studies reported a strong protective effect 
(Fortney et al, 1994; Kleerkoper et al, 1991;Stevenson et al, 1989; Enzelsberger et al, 
1988; Lindsay et al, 1986; Kanders et al, 1984; Goldsmith and Baumberger, 1967), six 
found no association between oral contraceptive use and bone mineral  density (Mazess 
et al, 1991; Rodin et al, 1991; Lloyd et al, 1989; Stevenson et al, 1989; Hreshchshyn et al, 
1988; Lindsay et al, 1986). No study was found to show a decrease in BMD. All but one 
(Mazess et al, 1991) of the studies included were cross-sectional. The review also 
identified that although COCs and BMD were being investigated there was a lack of 
information on other hormonal contraceptives, with the review only citing one  published 
study on DMPA (Cundy et al, 1991) which will be discussed later. 
 
The lack of consensus on the effect of COCs  at this time can be attributed to a number of 
study design issues including small numbers of women and many studies not adequately 
controlling for factors affecting the process of bone loss. The age groups of women also 
varied widely with some including women across wide age ranges of 15-91 years 
(Kleerekoper et al, 1991), women only in their reproductive age (15-49 years), and 
narrow age ranges (10 years) (Lindsay et al, 1980). Composition of the brands of COCs 
were either not mentioned or varied   in terms of the dosage of EE. Studies on COC’s and 
BMD are described in more detail below according to age group studied. 
 
Use of COCs and BMD outcome in adult  premenopausal women 
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Cross-sectional studies 
Numerous  cross-sectional studies including premenopausal women have generally found 
no difference between COC users and controls (Afghani  et al, 2004; Hawker et al, 2002; 
Ott et al, 2001;  Perrotti et al, 2001; Prior et al 2001;  Pascoe et al, 2000; Pettitti et al 
2000; MacDougall et al, 1999;  Hartard et al, 1997; Garnero et al, 1995; Fortney et al, 
1994; Hansen, 1994; Melton et al, 1993; Murphy et al, 1993; Kleerekoper et al, 1991; 
Laitinen et al, 1991; Nelson et al, 1991; Rodin et al, 1991; Hall et al, 1990; Lloyd et al, 
1989; Collins et al, 1988; Hreshchyshyn et al, 1988; Picard et al, 1988; Lindsey et al, 
1986; Sowers et al, 1985;  Kanders et al, 1984; Goldsmith et al, 1975). In a recent 
systematic review of COC use and bone health (Martins et al, 2006) BMD Z scores in 
cross-sectional studies were graphed by age group, site of measurement and duration of 
COC use. The Z scores fell within the 1SD of the reference mean for almost all studies, 
and suggested no differences in BMD between COC users and non-users. 
 
Prospective studies 
Prospective studies have included randomized controlled trials (RCTs) and cohorts of 
current COC users. Nappi et al (2003) conducted a randomized trial where women were 
allocated to either low-dose, ultra low dose or non user groups. After one year of follow-
up there was no difference between user groups and controls in spine BMD. The samples 
in each group (n=20) were small, however retention was high. A further RCT conducted 
by the same group (Nappi et al, 2005) randomized women to two types of 30 mcg EE 
COCs. Spinal BMD increased slightly compared to non-user controls but this was not 
significant.  Another cohort with partial randomization (Berenson et al 2001; Berenson et 
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al, 2004) followed up women who were randomized to two types of COC (30ug EE/0.15 
mg desogestrel or 35mcg EE/1.0mg norethindrone). These two groups were compared to 
DMPA users and non-hormonal user controls. After 12 months the BMD in both COC 
groups increased compared to DMPA and controls. After 24 months, desogestrel COC 
users  experienced a loss of 2.6%  and DMPA users had an average BMD loss of 5.7%, 
however this was not significant from the controls and no difference was found between 
either COC users groups and controls at 24 months. Another RCT that compared two 
COC formulations but had no non user controls (Endrikat et al, 2004) found no difference 
between a 20mcg EE and a 30mcg EE COC after 3 years of use. 
 
Cohorts that have followed up new and continuing users have also found few differences 
between COC users and controls (Elgan et al, 2004; Paoletti  et al, 2004; Elgan et al, 
2003; Reed et al, 2003; Cobb et al, 2002; Weaver et al, 2001; Mais et al, 1993; Recker et 
al, 1992; Mazess et al, 1991).  Most of these studies measured BMD at the spine and 
other central sites except for  three studies (Elgan et al, 2004; Paoletti  et al, 2004; Elgan 
et al, 2003) where BMD was measured at the heel. 
 
A recent study (Gargano et al, 2008) looked at both BMD and markers for bone turnover 
(urinary pyridinoline and deoxypyridinoline) in young post adolescent woman using low-
dose  (20 & 30 mcg EE) COCs for 12 months. Although bone turnover increased 
significantly in the two user groups compared to controls, there was no change in  BMD 
over the 12 months. Another recent study using investigating very low-dose (20mcg) EE 
COCs (Berenson et al, 2008) found that BMD was lost compared to non-users after 3 
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years of COC use. The loss was small and much lower than another study group of 
DMPA users. Women who discontinued DMPA and commenced COCs recovered BMD 
in the spine but not the femoral neck. The authors concluded that very low-dose COCs 
may result in minimal bone loss and in addition prevent recovery in those that move from 
DMPA to COCs. This is discussed further in the DMPA and BMD literature. 
 
In summary, COC use and BMD outcome in adult current users in both prospective and 
cross-sectional studies have generally found few differences between current users and 
non-users. Emerging evidence is pointing towards a small loss of BMD in some studies 
of very low-dose COCs 
 
 Use of COCs and BMD outcome in Adolescents and young women 
A number of studies have focused on adolescent users of COCs  (Cromer et al, 2008; 
Hartard et al, 2007; Hartard et al, 2006; Lara-Torre et al, 2004; Cromer et al, 2004; Lloyd 
et al 2004;Rome et al, 2004; Tharnprisan et al, 2002;  Lloyd et al, 2000; Cromer, 1996;  
Polatti et al 1995). The majority of studies have been longitudinal, with three cross-
sectional studies (Hartard et al, 2007; Lloyd et al 2004; Lloyd et al 2000). 
 
Cross-sectional studies  
Lloyd et al, (2000, 2004) compared COC users and never users of COCs in a cross-
sectional analyses as part of a longitudinal eight year observational study of adolescents 
followed–up between the ages of 12 and 20. In total 28 subjects had used COCs for at 
least 6 months by the age of 20 years.  No difference was found in total body and hip 
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BMD in the two groups. Although it was known the COC users had used low-dose 
monophasic COCs, the actual dose of EE or type and amount of progestin was not 
reported and only one-third (30%) of women had commenced COCs before the age of 18.  
 
A recent cross-sectional study (Hartard et al, 2007) of young women aged 18-24 years 
included 248 users of   monophasic COCs, 47 never users and 201 ever users of COCs. 
The users were further subdivided into sub-groups depending on length of use and age of 
initiation.  Measurements were taken in the lumbar spine, femoral neck and tibia. Results 
showed that women who had ever used COCs had significantly lower BMD at the 
femoral neck and tibial shaft compared to never users. Within the sub-groups increasing 
duration of use and earlier start of COCs increased risk of lower BMD in the femoral 
neck and lower bone mineral content (BMC) in the distal tibia. Women in the group with 
greater than 2 years COC use and initiation within 3 years of menarche were most 
compromised with a 10% reduction of BMD at the femoral neck and a non- significant 
5% reduction at the spine compared to controls. Although the study stated that these 
women were low-dose COC users, there was no information on EE formulation, only 
those women using COCs with EE >50mcg were excluded. 
 
Prospective studies 
The earliest prospective study  including adolescent and young women (aged 12-21) 
users of COCs, DMPA, Norplant, and non-user controls was published in 1996 (Cromer 
et al, 1996). This study found an increase of 1.5% in lumbar spine BMD at one year in 
COC users, although the increase in controls was greater (2.9%), this difference was not 
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statistically significant.  This study continued to a two-year follow-up, but none of the 
nine COC users at year one follow-up, had continued using the method.   
   
In further  work, Cromer et al (2004) conducted a two-year follow-up in  a much larger 
sample of 370 adolescents aged 12-18 who self selected for either a low dose (20mcg EE) 
COC (n=165), DMPA (n=53), or controls who received no hormonal method (n=152). At 
the 12-month follow-up, the mean BMD of the COC group increased by 2.3% compared 
to 3.8% in the control group in the lumbar spine. In the femoral neck only a small 
increase of 0.3% was observed in the COC group compared to 2.3% in the control group.  
In addition, the mean percent change in the low-dose COC group although not negative 
was significantly lower than the controls. The authors concluded that a COC containing 
20 mcg EE/100 mg levonorgestrel could have an adverse effect   on bone health in 
adolescents. The DMPA group showed decreases in BMD at both sites and is discussed 
later in this chapter. At the end of the  two- year follow-up in the same study (Cromer et 
al, 2008)  the COC group showed a mean BMD increase of 3.0 % in the neck and 4.2% in 
the spine. Controls were similar in the neck (+3.8%) but higher in the spine (+6.3%). In 
this group of adolescent girls, the bone biochemical markers serum bone specific alkaline 
phosphatase (BSAP) and urinary deoxypyridinoline (DPD) were measured and BSAP 
was found to be significantly higher in the control group compared to the COC and 
DMPA group (Rome et al, 2004). There was a non-significant trend towards higher DPD 
levels in the COC and DMPA group compared to controls.  Over a 12 month period there 
was evidence of increased bone formation and resorption in the control group when 
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compared to that in the DMPA and COC groups. There was no relationship between the 
biochemical markers and BMD at the lumbar spine or the femoral neck.   
 
Lara-Torre et al  (2004) followed up new users of COCs and DMPA aged between 11 
and 19 years and compared them to non-users. Women were followed for two years and 
although 71 women commenced participation in the COC group at baseline only 16 
women completed one year of follow-up, and fewer (n=5), two years of  follow-up. No 
statistically significant difference was found between COC users and controls at one and 
two years, however by 24 months there was a reduction of 1% in BMD in the lumbar 
spine among COC users compared to an increase in controls of almost 6%. At all follow-
up points the COC users had higher BMD values than DMPA users and this was 
significant from 12 months.   This longitudinal study was particularly compromised by 
attrition which was greatest in the COC group. The COC formulation was not specified 
and the study was classified as II-2, poor in the recent systematic review by Martins et al, 
(2006). 
 
Polatti et al, (1995) randomized young women aged 19-22 years to receive either a low-
dose COC (EE 20 mcg, desogestrel 0.150mg) or no treatment. After five years the 
treatment group showed no change in lumbar spine BMD from baseline whilst the control 
groups showed a significant increase of 7.8%. It was concluded that the COCs, although 
not decreasing BMD, was preventing the natural increase in BMD expected in this age 
group. 
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In a partly randomized cohort (Hartard et al, 2006) 52 women were randomized into 
either into a 20 mcg EE and 100mg levonorgestrel COC group or a 150 mg desogestrel 
COC group. After 12 months women in the desogestrel group lost 1.5% BMD at the 
spine while no changes in BMD were found in the spine of levonorgestrel group. In a 
recent study (Pikkarainen et al, 2008), bone mineral content (BMC) was measured in the 
spine and neck of 122 adolescent woman aged 19-22 in a four-year follow-up. Results 
showed a trend for a  lower increase in BMC in the woman who had used COCs of <  35 
mcg for more than two years compared to non-users and those with 1-2 years use. 
 
In summary, adolescents and young women should show increases in BMD over time, 
however the longitudinal studies discussed in this section have mainly found that 
although BMD does not decrease in COC users, the comparison control groups show 
marked increases in BMD. Some of these studies have, in addition to controls, included 
DMPA users, and COC users generally have higher BMDs in comparison to these users. 
Lifestyle and relationship factors in adolescents and young women result in high 
discontinuation rates and so compromise studies in being able to show significant 
changes over time with very reduced sample sizes. The current literature appears to point 
towards low-dose COC preparations compromising active bone growth, in that BMD 
values appear to remain static. There is limited data available on recovery in adolescent 
users mainly due to methodology, since those that discontinue from the method are not 
usually followed-up.  
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Use of COCs and BMD outcome in older women (perimenopausal and 
postmenopausal) 
Perimenopausal women 
The number of women using COCs in the perimenopause is limited. One cross-sectional 
study (Fortney et al, 1994) which aimed to recruit equal numbers of current COC users, 
former users and never users in women aged 40-54, only found 7 current users in a total 
sample of 352 which included predominantly former users. Whilst some cross-sectional 
studies have included older women users in their wider age range, the low numbers of  
perimenopausal users has resulted in few cross-sectional or longitudinal studies being 
able to look at this particular user group alone. Three cross-sectional studies including 
perimenopausal women currently using COCs have not found differences compared to 
non-users (Masaryk et al, 1998; Tuppurainem et al, 1994; Johnell and Nilsson, 1984). 
 
A limited number of  randomized controlled trials have been able to investigate women in 
the perimenopausal period (Gambacciani et al, 2000; Gambacciani et al, 1999; Volpe et 
al, 1997); Gambacciani et al, 1994a and Gambacciani et al, 1994b; Shargil, 1985. The 
Gambacciani study group randomized oligomenorrheaic women in all four studies to a 
COC (20mcg EE/150 mg desogestrel or 30mcg EE/75 mg gestodene) or calcium 
(500mg/day). In two of the studies normal age matched menstruating women were 
included as controls who received no treatment. After a two-year follow-up 
oligomenorrheic women in the COC group had increased BMD in the neck, wards 
triangle and trochanter, with no differences in BMD found compared to the normal 
menstruating control group (Gambacciani et al, 1994b; Gambacciani et al, 2000). The 
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studies not including normal menstruating controls also found increases in the COC 
treated groups compared to the oligomenorrheic women treated with calcium alone. Two 
further studies (Shargil, 1985; Volpe et al, 1997) also found that BMD was maintained 
(Shargil, 1985) or increased (Volpe et al, 1997) in women treated with COCs.  
 
 
 
Postmenopausal women 
Cross-sectional studies in postmenopausal women have found that there is limited 
evidence to suggest that history of COC use confers any benefit in BMD post-menopause 
(Sultana et al, 2002; Forsmo et al, 2001; Grainge et al 2001; Pasco et al, 2000; Masaryk 
et al, 1998; Ulrich et al, 1996;  Fortney et al, 1994; Berning et al 1993; Kris-Silverstein et 
al, 1993; Melton et al, 1993; Murphy et al, 1993; Hansen, 1991; Stevenson et al, 1989; 
Lindsay et al, 1986). In a recent systematic review of BMD and COC use (Martins et al, 
2006) found that in cross-sectional studies of postmenopausal ever users, most studies 
included in the review were non-significant, six found higher BMD in ever users of 
COCs  and one found lower BMD values (Hansen, 1991).  
 
 One randomized controlled trial in postmenopausal women (Taechakraichana et al, 
2000) randomized women to receive either COCs (30mcg EE/150 mg desogestrel) or 
Hormone replacement therapy (HRT). After a one-year follow-up both groups showed 
significant gains in all sites measured. A second prospective study followed up women  
for 12 years from a baseline where they had reached natural menopause within the last 3 
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years. Although BMD was higher in ever-users at baseline, by the 12 year follow-up no 
difference was found between users and never users. 
 
In summary, existing evidence suggests there are benefits in use of COCs with users 
gaining or maintaining their BMD in perimenopausal and menopausal women. 
 
Overview summary of COC use and fracture risk/BMD outcome 
The association between COC use and fracture is inconsistent. More data will become 
available as past users of COCs move into menopause. Although COCs have been 
available since the 1960s the change in formulation has meant that more evidence is 
required to establish if there is a link between low-dose COC formulations and fracture 
risk.  
 
COC use and BMD outcome appears to vary by age-group with few differences found in 
adult current users in both prospective and cross-sectional studies compared to control 
non-users. However, some very low-dose COCs may cause small decreases in BMD. In 
perimenopausal and menopausal women existing evidence suggests there are benefits in 
use of COCs with users gaining or maintaining their BMD. There is growing concern, as 
the body of evidence related to adolescent users of COCs use increases, that low-dose 
COC formulations may be detrimental to BMD in an age group who are  yet to reach 
peak bone mass. 
 
1.6.3  Depot medroxyprogesterone acetate  
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1.6.3.1 Background and historical perspective 
Depot medroxyprogesterone acetate (DMPA) is a long-acting, synthetic, progestin-only 
injectable contraceptive. Marketed as Depo-Provera®, it is available in over 90 countries 
and is a widely used method of contraception in Africa, Thailand and New Zealand and 
has been widely available in developing countries including South Africa since 1964. 
Although first reviewed by the US FDA in 1973, only 20 years later in 1992 was final 
approval granted, after concerns regarding risk of development of  cancer were addressed 
(Kaunitz, 1994). Since receiving FDA approval, DMPA use has increased in the 
developed world. The number of woman using the method in the United Kingdom (UK) 
rose from 40,000 in 1993 to 270,000 in 1996 (Bigrigg et al, 1999), however the 
percentage using the method in the UK has stayed constant at 3% of contraceptive use 
between 2000 and 2007/08 (Lader and Hopkins, 2008).  Hormonal contraceptive 
injections are  increasing in popularity among younger women in particular adolescents 
(Margulies and Miller, 2001; Chotnopparatpattara and Taneepanichskul, 2000; Davis, 
1996; American Health consultants, 1994). In South Africa injectable hormonal 
contraception continues to lead over other methods,  with 50% of women using a method 
choosing an injectable hormonal method. Of these injectable users, just over half (58%) 
are using Depo Provera® and slightly less (42%) using Nur-isterate® (Department of 
Health, South Africa, 2006). In addition, the South African Demographic and Health 
Survey (SADHS)  found that a higher proportion of younger women were using the 
injectable method whilst methods such as sterilisation and COCs are being used less 
frequently (Department of Health, South Africa, 2003, 2006).  
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DMPA is administered as an aqueous microcrystalline suspension as a dose of 150 mg as 
a deep intramuscular injection at 3-monthly intervals. Its primary mechanism of action is 
by causing anovulation via inhibition of pituitary gonadotrophin. This occurs through the 
disruption of the hypothalamic-pituitary-ovarian axis. In addition there is modification of 
the endometrial lining and cervical mucus (Mishel, 1996). At the hypothalamic level, 
gonadotropin-releasing hormone frequency increases, whereas at the pituitary level, the 
lutenising hormone (LH) surge is absent, and Follicle Stimulating hormone (FSH) is 
inhibited. Ovarian oestrogen production is  suppressed leading to the reduction in 
synthesis and secretion of ovarian estradiol  (Mishell, 1996) and long term users 
commonly have plasma estradiol levels that are at or below normal levels present in the 
early follicular phase (Ortiz et al, 1977). Other studies have found that the estradiol levels 
can be similar to those of post-menopausal women which could be lower than 
100pmol/L, particularly if the woman is amenorrhoic (Gbolade et al, 1998). Although 
menstrual side effects vary between women, many women become amenorrhoic after 
prolonged use (1 year or more) and have hypoestrogenism (Ortiz et al, 1977). 
Amenorrhea can occur as early as the first three months after the first injection and in one 
study found 8% of women becoming amenorrhoic after the first injection and 45% by one 
year of use (Belsey, 1988). As estradiol is important in bone maintenance the 
amenorrhoic woman with low estradiol levels may be at greater risk of bone loss. The 
loss of BMD in the case of DMPA has been associated with estrogen deficiency and 
concerns were raised that long-term users of DMPA could be at risk for postmenopausal 
osteoporosis and that women using DMPA should discontinue the method before 
reaching menopause (Scholes et al, 2005).  
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Many studies have investigated the role of DMPA and its effect on BMD with the 
concern that the suppression of estradiol may lead to osteopenia and ultimately cause an 
increase in risk of fractures in older women. The studies investigating the effect of 
DMPA on bone mass first appeared in the literature over a decade after the first reports 
on the possible relationship between COCs and BMD. The first documented study 
addressing DMPA and BMD was published in 1991 (Cundy et al, 1991). This  cross-
sectional study was conducted among 30 adult current users of DMPA in New Zealand 
and compared pre-menopausal users with a median use of at least five years with non-
user controls in the same age range. Results showed that users of DMPA had a 
significantly lower femoral (6.6%) and vertebral (7.5%) bone density. As the first study 
published and a British Medical Journal (BMJ) publication it received a great deal of 
attention and raised concerns regarding use of the method. The difference in bone density 
values was too small to pose a fracture risk and BMD values were still higher then post 
menopausal women. After publication, a letter raising concerns about the methodology 
used by the authors was published in the BMJ.  The study was criticized for poor 
matching of cases and controls and self selection bias (Szarewski et al, 1991). In addition 
it was commented that there was no baseline data for the women, the sample size was 
small and smoking prevalence was much higher in the DMPA group. Since 1991 
numerous further studies have added to the body of information and evidence in this area 
and these will be discussed in this section of the literature review. 
 
1.6.3.2 DMPA and fracture risk 
 33
Although there is a large body of literature now available with BMD as an outcome in 
DMPA users, there has only been one report on fracture risk in users of DMPA (Lappe et 
al, 1997)  This study measured BMD in the heel bone using quantitative ultrasound 
(speed  of sound). DMPA use at baseline was associated with an increased risk of stress 
fracture following an 8-week follow-up. However once adjustment for speed of sound 
had been made, at baseline, the association with DMPA became non significant. This 
study was given a quality rating of “II-2 poor” in a recent review (Curtis et al, 2006) due 
to the limitations of the data. 
 
1.6.3.3 DMPA and BMD outcome 
Use of DMPA and BMD outcome in adult premenopausal women   
Cross-sectional studies 
Many studies published on predominantly adult current users of DMPA have been cross-
sectional (Rosenburg et al, 2007; Albertazzi et al, 2006; Shaarawy  et al, 2006; 
Tharnprisarn and Taneepanichskul, 2002; Wanichsetakul et al, 2002; Ott et al, 2001; 
Perrotti et al, 2001; Petitti et al, 2000; Bahmondes et al, 1999; Tang et al, 1999; Scholes, 
1999; Cundy et al, 1998; Gbolade et al, 1998; Pavia et al, 1998; Taneepanichskul et al, 
1997a; Taneepanichskul et al, 1997b; Virutamasen et al, 1994;  Cundy et al, 1991).  
 
Most cross-sectional studies have shown negative effects of DMPA on BMD (Rosenberg 
et al, 2007, Albertazzi et al, 2006; Shaarawy et al 2006; Wanichsetakul et al, 2002; Pettiti 
et al, 2000; Scholes et al 1999; Tang et al,1999; Cundy et al 1998; Pavia et al 1998;  
Cundy et al, 1994). Fewer have shown no  effect of DMPA on BMD (Perrotti et al, 2001; 
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Ott et al, 2001; Bahmondes et al, 1999; Gbolade et al, 1998; Taneepanichskul et al, 1997a 
& 1997b; Virtumasen et al, 1994).  No study has reported or shown a positive effect of 
DMPA on BMD. A number of   cross sectional studies have been able to analyse the data 
further to look at the effect of DMPA on BMD by duration of use of DMPA (Albertazzi 
et al, 2006; Shaarawy et al, 2006; Tang et al, 1999; Scholes et al, 1999; Cundy et al, 
1998). 
 
Following the first publication investigating DMPA and BMD in 1991 (Cundy et al, 
1991), Cundy provided further evidence of a  negative effect of DMPA on BMD (Cundy 
et al, 1998). In this study  the BMD of  200 current users of DMPA  was measured at the 
lumbar spine and compared with 350 non-user controls. This study included the original 
30 DMPA users from the 1991 study. Bone density was significantly lower in DMPA 
users. Within the users sample women who had commenced DMPA over 20 years of age 
and had used it for less than 15 years had significantly higher BMD values compared to 
the users who had used between 16-26 years of use and started at < 20 years. This study 
reported that length of use was associated with lower bone density, however the 
relationship was weak. This study was again criticized in a letter (Szarewski and 
Mansour, 1999) for similar reasons that the 1991 study drew criticism.  However, further 
studies followed in agreement with Cundy’s findings adding to the body of evidence that 
current use of DMPA was detrimental to BMD.  
 
Scholes et al, (1999) recruited 457 women in a population based study of whom 183 
women were using injections and 274 were not. BMD was measured at femoral neck, 
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trochanter, spine and whole body.   This study observed a relationship between length of 
use and decrease in BMD with young women (aged 18-21) using DMPA for over two 
years being most affected.   However,  there were no significant differences in mean bone 
density at any site measured in women over 21 years of age.  
 
Wanichsetakul et al, 2002 measured BMD at the lumbar spine, femurs and forearms in 
women who had used DMPA for at least 2 years. DMPA users were matched by age, 
body mass index (BMI) and lifestyles with non-users of any steroid hormonal 
contraceptives for at least 6 months and found that the lumbar spine was significantly 
lower in DMPA users compared to the controls, however, there was no differences in 
BMD noted at the 3 sites measured in the femur and forearm. No information was given 
on the effect of length of use and reduction of BMD. In addition this study also included 
COC users where, as discussed earlier, there was no difference found compared to the 
control group at any of the three bone sites measured.  Tang et al  (1999) found that BMD 
was reduced in both lumbar spine and  femoral neck in 67 DMPA users with  at least five 
years of use compared with never users. Pavia et al (1998) found that the mean bone 
density in 72 users was significantly lower than the control group in all sites evaluated 
(hip, spine, trochanter and wards triangle). However, multiple regression showed DMPA 
was only associated with BMD in the lumbar spine and that BMI, age and length of 
amenorrhea were associated with lower BMD at the femoral neck.  
 
In response to  concerns raised by the many studies published and their disagreement in 
effect, the WHO funded a multi-centred cross-sectional study conducted in seven centres 
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in three regions of the developing world between 1994 and 1997 (Pettiti et al, 2000). This 
study included DMPA, COC and levonorgestrel implant users who had at least 24 months 
of lifetime use of one of these methods and they were compared to never users of 
hormonal contraception or less than 6 months of life time use. The age range of women 
recruited was narrow with only women within the five–year age range of 30-34 included. 
The study included 2474 women in total and found that forearm BMD was significantly 
lower in short–term, current users of DMPA, compared to never users. The changes 
observed were found to be less than one standard deviation (SD) from the mean of never 
users. Although short term current users were found to have a lower BMD compared to 
never users of hormonal methods, this difference was not found in the long term users of 
DMPA, and the authors commented that this could indicate that these initial decreases 
were reversible and there could potentially be a return to never user levels after long 
periods of continued use. The median length of use was 3-5 years in this study and the 
authors suggest that only a longitudinal study following users for a long duration could 
really adequately answer the question of recovery during use.   
 
More recent studies (Rosenberg et al, 2007; Albertazzi et al, 2006; Shaarawy et al, 2006) 
have also found DMPA to lower BMD, however Shaaraway (2006) found that  lumbar 
spine BMD was not significantly different in short term users of DMPA (<1year) 
compared to non-users. In this study only users of between 1 and 2 years and > 5 years 
recorded lowered BMD (9% and 11.8% respectively). Albertazzi et al, (2006) measured 
hip and spine in 218 DMPA users who had also used other methods of contraception. The 
prevalence of a T score below -2.5% was 5%. Woman who had used DMPA before 
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COCs were found to be most compromised in BMD. The authors suggested that this 
information needs to inform the debate on switching women from DMPA to COCs due to 
concerns about bone density. In one of the largest and most recent studies conducted in 
South Africa (Rosenberg et al, 2007), 3487 women had ultrasound measurements taken 
of the left calcaneus. Current users of  injectable contraception (DMPA and NET-EN) 
had the lowest ultrasound measurements.  
 
Cross-sectional studies finding no significant effect of DMPA on BMD have 
predominately measured forearm BMD (Ott et al, 2001; Perrotti et al, 2001;  Bahmondes 
et al, 1999; Taneepanichskul et al, 1997a; Virtumasen et al, 1994). Perrotti et al (2001), in 
a cross sectional study of women who had used either DMPA or COCs for at least two 
years  compared  to a control group of never users found no difference in forearm BMD. 
Taneepanichskul et al (1997a), found no difference in BMD in long term users of DMPA 
and Norplant. The authors concluded that any initial loss of BMD associated with use of 
DMPA had been recovered during long-term use. In a similar study by the same 
researchers (Taneepanichskul et al, 1997b) there was again no difference between DMPA 
users who had used the method for at least 3 years compared to IUD user controls.  
Tharnprisarn et al (2002) found no statistically significant differences in forearm BMD 
between Thai women using either DMPA or COCs for a mean of approximately 2 years. 
Bahmondes et al, (1999) measured BMD in two different sites in the forearm in 50 
DMPA users of approximately one year and 50 never users of hormonal contraception.  
A lower but non-significant decrease was found in the midshaft of the forearm of the 
DMPA users and this became a significant difference in the distal forearm. Pettitti et al 
 38
(2000) as mentioned earlier found a significant difference between DMPA users and 
controls only in the forearm of short term current users, there was no difference in long 
term users.   
 
Fewer cross-sectional studies measuring BMD at central sites (lumbar spine, femoral 
neck and hip) have found no effect of DMPA on BMD (Walsh et al, 2008a; Gbolade et 
al, 1998; Virutamasen et al, 1994). Gbolade et al (1998) measured spine and femoral 
neck in women who had used DMPA for between 1 and 16 years with a median of 5 
years. These women were compared to a database of values of over 3000 women and 
BMD in these sites was only minimally below the population mean for the lumbar spine 
and there was no significant difference in the femoral neck between the two groups. This 
study also looked at length of DMPA use and found a very weak negative correlation 
without statistical significance.  There was also no clear relationship found between 
serum estradiol level and length of DMPA use. The authors suggested that any bone loss 
would occur in approximately the first three years of use and a steady state would be 
reached thereafter. They concluded that there was no clinically adverse effect of DMPA 
on BMD.  Virutamasen et al (1994) conducted a cross-sectional study that included 75 
long term DMPA users (>3 years of use). No difference was found in BMD at the 
femoral neck between DMPA users and non-user controls even in the group that 
consisted of users of greater than 7 years. One of the few case-control studies (Walsh et 
al, 2008a) matched 100 DMPA users with control non-users and took a single 
measurement at the spine and hip and found in the 35-45 age group there was no 
difference in BMD. 
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In summary the cross-sectional studies have generally shown decreases in BMD with use 
of DMPA in central sites such as the spine but not consistently with the hip. In most 
studies where forearm BMD has been measured, there appears to be minimal or no 
change in BMD. Decrease in BMD appears to be linked to duration of use with those 
using DMPA for longer being more compromised. Studies that have suggested that there 
may be long term recovery during use have measured the forearm where generally no 
changes have been found in BMD  (Petitti et al, 2000). 
 
Prospective studies    
 There is now a strong body of evidence from longitudinal data that shows that DMPA 
compromises BMD in adult current users. Some of these studies have enrolled and 
followed up adult women as new users of DMPA (Berenson et al, 2008; Clark, 2006; 
Kaunitz et al, 2006; Berenson et al, 2004; Clark et al, 2004; Berenson et al, 2001;  
Naessen et al, 1995). Some have enrolled continuing DMPA users (Cundy et al, 2003; 
Merki-Feld et al, 2003; Tang et al, 2000; Cundy et al, 1994) and some have included a 
combination of new users and continuing users (Scholes et al, 2002).  Of these studies a 
small number have been RCTs (Berenson et al, 2004; Cundy et al, 2003; Berenson et al, 
2001; Naessen et al, 1995). In these studies, women have been followed for between 1 
and four and a half years. Almost all longitudinal studies found a negative effect of 
DMPA on BMD. In studies of new initiators of DMPA one RCT (Berenson et al 2001)  
followed-up 33 new users of DMPA  for a year and found  a mean loss of BMD of 2.74% 
over 12 months compared to non-hormonal contraceptive user controls (n=59) who lost 
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0.37% in  the lumbar spine. COC users were also included in this study (n=63) and they 
demonstrated a gain in BMD compared to controls. The same authors (Berenson et al, 
2004) conducted a further RCT and found that the loss of bone was linear over a two-year 
period with a total loss of 5.7%  in the spine after two years. Recently, Berenson et al 
(2008), conducted a 3-year follow-up study in women aged 16 to 33. DMPA users lost  
3.7% BMD in the spine and 5.2% in the femoral neck compared to gains in the non-user 
controls. The loss was greater in the younger users (16-24 years) who lost 4.2% at the 
spine, and 6.0% at the femoral neck.  In a 2- year follow-up Clark et al, (2004) reported a 
similar loss of 5.8% in the hip and 5.7% in the spine in 178 DMPA users. Non-hormonal 
contraceptive users maintained BMD in this study. These women continued their follow-
up for 48 months (Clark et al, 2006), when it was found that hip BMD declined further to 
a loss of 7.7% and spine a loss of 6.4%. The BMD of controls however also declined by 
1.6%. This study found a slowing in loss of BMD, and after 48 months of use the BMD 
loss slowed to 0.6% per year.  
 
 Kaunitz et al (2006), conducted a 7 year prospective matched-cohort study. This study 
aimed to follow-up 248 new users of DMPA for 240 weeks of treatment (approximately 
4.5 years) and 360 non-hormonal user controls.  Women discontinuing DMPA before the 
240 weeks, and those discontinuing at 240 weeks continued to be followed up to look at 
recovery. For DMPA users continuing in the study until 240 weeks, BMD had decreased 
from baseline by -5.16% in the hip and a similar loss of -5.38% in the spine. For non-
hormonal users the change in spine and hip was negligible. The rate of loss was more 
pronounced in year 1 for DMPA users.   
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Only one longitudinal study of new users  found stable values for BMD during follow-up 
(Naessen et al, 1995). This RCT randomized 22 women to use either DMPA or Norplant. 
BMD was measured at the forearm and 18 women completed the six month follow-up. 
BMD decreased in the DMPA group by 0.41% but this was not significant. Bone 
metabolism markers indicated an increased turnover in bone resorption, however this was 
only significant in serum calcium. This study was limited by its short duration of follow-
up and the small number of women involved. 
 
The second group of prospective studies have followed-up existing users of DMPA 
(Walsh et al. 2008b;  Merki-Feld et al, 2003; Cundy et al, 2003; Tang et al, 2000; Cundy 
et al, 1994). The first longitudinal study published (Cundy et al, 1994), included 22 
women who were continuers of DMPA. This group was compared with a group of 18 
non-user controls. Baseline values showed the lumbar spine was lower by approximately 
9% and femoral neck by 5.7% in the user group compared to the controls. At follow-up 
(median 12 months) there was no change in femoral neck or spine in either group.  
 
Merki-Feld et al, 2003 recruited 35 existing users of DMPA who had used the method for 
a mean of 42 months and 10 non-exposed controls. Twenty three DMPA users completed 
two years follow-up and in this group there had been an increase in trabecular bone mass 
of 0.6% but a decrease of 0.1% in cortical bone mass. This decrease however was not 
different from that seen in the control group. After one year of follow-up women with a   
trabecular bone loss of more than 1% received treatment with calcium or estrogen during 
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the second year of follow-up. Over the two-year period there was no significant change 
found in the BMD in both sites in the untreated DMPA group. There was no comparison 
with the controls at year 2 as 6 of the 10 controls had dropped out of the study.  
 
Thirty-eight long term users of DMPA with low spinal BMD were randomized to receive 
conjugated estrogen (0.625mg daily) or placebo (Cundy et al, 2003). At the end of two 
years the treatment group gained 1% spinal BMD whilst the placebo group had lost 2.6% 
and this difference was significant. One study that had originally reported on a cross-
sectional population   (Tang et al, 1999) followed up 64 of the original 67 women in the 
study for 3 years (Tang et al, 2000). These women were already long term DMPA users 
(of approximately 5 years) on recruitment into the cross-sectional study. In the 
prospective component of the study women lost substantially less BMD than had been 
anticipated from the values found in the cross-sectional study. The rate of bone loss per 
year was not related to the length of DMPA use. BMD decreased over the 3 year period 
in the spine, hip and wards triangle and was significantly lower compared with 218 never 
users of hormonal contraception. BMD in the trochanter showed a non-significant gain in 
DMPA users. The conclusion put forward by the authors was that the initial reduction of 
BMD would level off after 5 years. The rate of loss per year was found to be far lower 
than other studies for the spine (0.442%) and hip (0.403%), compared to other 
longitudinal studies that have shown BMD loses of between 2-5%.   This study therefore 
did not suggest recovery during use, but rather stabilization of loss of bone.  They 
postulated that BMD would remain lower than in a population of comparable non-users 
however would not continue to decline on continued use. 
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Scholes et al (2002)  followed- up 183 women for three years and included women who 
were existing DMPA users, but  also managed to include 43 women who were new users 
of DMPA in that they were enrolled after their first injection and prior to their second and 
so could be described as initiators.  BMD at the spine and hip decreased every six months 
in the users compared to the 258 non-users. The annualized mean rate of change in 
DMPA users was   -0.87% at the spine and -1.12% at the hip compared to +0.40% in the 
spine and -0.05% in the hip of the controls.  
 
Only one study of continuing users has found no difference between DMPA users and 
controls after 3 years follow-up (Walsh et al, 2008b). However due to method 
discontinuation only 23 of the original 50 users attended the 3 year follow-up and an 
additional 14 attended but had discontinued.  There were also no interim measurements 
between baseline and 3 years. 
  
In summary most longitudinal studies have shown that current adult users of DMPA will 
lose BMD. This loss appears to commence from about 6 months of use and appears linear 
for the first 2 years. Longer follow-up in several studies indicates that the rate of loss 
plateaus and by five years the loss may stabilise although recovery does not occur during 
use.  
 
Use of DMPA and BMD outcome in adolescents and young women 
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Some studies have investigated the effect of DMPA on BMD primarily in adolescents 
and young women (Cromer et al, 2008; Cromer et al, 2005; Scholes, 2005; Cromer et al, 
2004; Rome et al, 2004;  Scholes et al, 2004; Lara-Torre et al, 2004; Busen, 2003; 
Cromer et al 1996).  Other studies have analysed the younger woman as a sub-set of a 
sample in a wider age range (Berenson et al, 2008; Walsh et al, 2008; Tharnprisan et al, 
2002; Scholes et al, 1999; Cundy et al, 1998). Most of the studies including adolescents 
have found a negative association between DMPA and BMD (Cromer et al, 2005; 
Scholes et al, 2005; Cromer et al, 2004; Lara-Torre et al, 2004;  Busen, 2003; Scholes et 
al, 1999; Cromer et al, 1996). 
 
Cross-sectional studies 
There exist  four published cross-sectional and one case-control study of adolescent users 
of DMPA (Walsh et al, 2008a; Scholes et al, 2004; Tharnprisan et al, 2002; Scholes et al, 
1999;Cundy et al, 1998). Scholes et al (2004)  found a non significant reduction in the 
BMD of the hip and spine in 81 adolescent DMPA users (14-18 years) compared to 
controls. Women in this study had used between 1-13 injections with a median of 3. The  
Tharnprisan et al, (2002) study refers to adolescent and young Thai girls in the title of the 
publication, however,  this is slightly misleading as although all 60 women in the sample 
were 30 years or younger,  only 3 DMPA  and 3 COC users were under 20 years 
(adolescents), with almost half over 25 years. This study found no difference in the 
forearm BMD of DMPA and COC users all of whom had used the method for at least 
two years. A sub analysis of young women in Cundy et al (1998), found that the lumbar 
spine Z score was lowest in the 26 women who commenced DMPA use at 20 years or 
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younger.  Scholes et al (1999), found in age specific comparisons that the youngest group  
(18-21 years) were the most affected with a significant decrease  compared to controls  at 
all anatomic sites (neck hip, spine, whole body).  Above 21 years there was no difference 
between DMPA users and controls and the age adjusted mean BMD was significantly 
higher in the unexposed groups in the spine and trochanter only.  Spine and hip BMD 
was measured in a subset of 50 women aged 18-25 who started DMPA prior to 20 years 
in a case-control study (Walsh et al, 2008a).  DMPA use was associated with a 5%  lower 
BMD compared to controls.  
 
Prospective studies 
The earliest longitudinal study including adolescent users of DMPA, Norplant, COCs and 
non-user controls was published in 1996 (Cromer et al, 1996). In a limited 2 year follow-
up in this study, DMPA users had significantly lower BMD compared to the Norplant 
and non-user control groups.  The sample sizes in the different groups were very small 
(DMPA n=15) and by the second year of follow up only 15 women of the original 48 
recruited across all groups were still participating in the study. Further longitudinal work 
by the same author (Cromer et al, 2004) looked at a much larger sample of 370 
adolescents aged 12-18 who self selected for either a low dose (20 mcg EE) COC, DMPA  
or controls who received no hormonal method. After a one-year follow-up the DMPA 
group showed mean percent change of -1.4% in the spine compared to controls. Over a 
12 month period there was evidence of increased bone formation and resorption in the 
control group when compared to that in the DMPA and COC groups. There was no 
relationship between the biochemical markers and BMD at the lumbar spine or the 
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femoral neck.  A two-year follow-up by the same researchers (Cromer et al, 2008) 
included postmenarcheal girls aged 12-18 using DMPA (n=58), COCs (n= 187) and non-
user controls (n=188). Measurements were taken at the spine and femoral neck and after 
24 months the mean % change in the DMPA group was -1.5% in the spine and -5.2% in 
the femoral neck compared to increases in the COC and non-user group. It was reported 
that most BMD loss in DMPA users occurred in the spine in year 1 with only a change of 
-0.1% recorded in year 2.  
 
Cromer et al (2005) looked at estrogen supplementation in a group of adolescents 
commencing DMPA.  Initiators of DMPA were randomly assigned to receive monthly 
injections of estradiol cypionate or placebo. Participants were followed up at 1 and 2 
years. At two years,  those receiving estrogen supplementation increased BMD in the 
spine +2.8%  and femoral neck +4.7%, compared to a loss of 1.8% in the spine and 5.1% 
in the femoral neck of those DMPA users without supplementation. As seen in other 
studies including adolescents, less than one-third completed the two-year follow-up. 
 
Lara-Torre et al, (2004) also found a statistically different decrease in BMD of the 
lumbar spine between new users of DMPA and controls after six months (-3.02%).  After 
two years this decrease increased to -6.81% relative to controls.  Comparison with the 
COC users found that although the BMD of DMPA users was lower compared to COC 
users these differences only reached significance at 12 and 18 months. Although 148 
adolescents aged between 12 and 21 years commenced the study,  only 32 completed 
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follow-up. This study recognized the low rate of compliance with contraception making 
studies of contraceptive users in this age group difficult to complete.   
 
Scholes et al, (2005) continued to follow women who entered the cross-sectional study in 
1999 (Scholes et al, 1999) and these women continued in the study for 36 months. The 
DMPA users showed significant declines in BMD at the hip and spine but not the whole 
body, relative to non users. In this study new DMPA users lost bone more rapidly 
compared to prevalent users. Berensen et al, (2008), analysed a subset of adolescents and 
young women age 16-24 years in their 3-year follow-up of new DMPA and COC users. 
This younger group of DMPA users lost more BMD when compared to the women aged 
25-33 years. 
 Busen (2003) recruited 22 girls aged 15-19 of whom only 6 continued participation at 
one year and four at year 2. At one year all six DMPA users had shown a mean decrease 
in BMD of 3.31% in the femoral neck and 3.52% in the lumbar spine. No control groups 
were included and 2 of the four girls had shown recovery of BMD with one returning to 
baseline and the other showing a slight increase in BMD at 2 years. This study reported 
that it was compromised by small sample size and attrition of the sample.  
 
In summary there is similar evidence of decreases in BMD in young women current users 
of DMPA as in adult users. Decreases as well as lack of increase in BMD are important 
in adolescents where increases in BMD should be found as age group is still progressing 
to peak BMD. Many of these studies have been affected by poor follow-up due to young 
women discontinuing use of their contraceptive methods. 
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Use of DMPA and BMD outcome in older women (perimenopausal and post 
menopausal) 
 
The populations investigated in studies looking at the effect of DMPA have included 
women using the method in their 40s but there is limited information in this age group 
specifically. The age ranges of women in some studies have included users up to the age 
of 52, however the numbers have been small. In one cross-sectional study older users 
were disaggregated in the data (Gbolade et al 1998) and no differences were found in 
BMD in women aged between 40-49 and a slightly older group of 50-52 compared to a 
normal population mean in the lumbar spine and femoral neck. The population of women 
in the Tang et al (1999) cross-sectional study were generally older than other studies with 
a mean age of 43 years. In this study those who had used DMPA for 5 years or more had 
significantly lower BMD in the spine, femoral neck, trochanter and ward’s triangle 
compared to never users.  From the initial cross-sectional sample of 67 women, 59 were 
followed up in the 3-year prospective component of the study (Tang et al, 2000). Small 
losses were noted of less than 1% in all sites but not the trochanter. In addition there was 
no effect seen with duration of use aside from a weak negative  between BMD in the 
femoral neck and duration of use. One longitudinal study (Sanches, 2008) followed up 
women who had been long-term users of  either DMPA or the IUD until menopause. This 
study found no difference in forearm BMD between these two groups at each of the three 
one-year follow-ups post-menopause. 
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In summary there is limited data available on DMPA use in this group of older women 
due to the low prevalence of use in this age-group. Information in this age group has 
come from studies including a wider age range of women. However, loss of BMD has 
been found in these older DMPA users. 
 
Recovery of BMD Post discontinuation of DMPA  
The previous sections have addressed current users of DMPA and how their BMD has 
been affected. Several studies have tried to investigate potential long term consequences 
of DMPA use. Some studies have looked at ex-users of DMPA to see if BMD has 
returned to normal population values and therefore inferred that recovery may have taken 
place (Rosenberg et al, 2008;Pettiti et al, 2000; Orr-Walker et al, 1998). Women have  
also been followed-up from the point of discontinuation of DMPA to look at potential 
recovery and additionally, the rate of recovery in terms of the timeframe taken for a full 
recovery to baseline values (Walsh et al, 2008b; Clark et al, 2006; Kaunitz et al, 2006; 
Scholes et al, 2005; Scholes et al, 2002).  
 
Cross –sectional studies including ex-users  of DMPA 
A number of studies have looked at the history of DMPA use in past users of the method. 
These studies have generally found few differences between ex-users and never users of 
DMPA (Rosenberg et al, 2008;Pettiti et al, 2000; Orr-Walker et al, 1998). Pettiti et al, 
(2000) found no difference in forearm BMD between past users and never user controls, 
even among those who had used the method for 4 or more years. The largest cross-
sectional study (Rosenberg et al, 2007) included 3487 women of whom 3151 had ever 
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used injectable contraception (DMPA and NET-EN).There was no difference in the BMD 
of the calcaneus  in never users and  ex-users of injectable contraception of at least 2-3 
years.  
 
By investigating post menopausal women who continued use of DMPA up until natural 
menopause, we could see if DMPA use had long term effects, however, only one study 
has investigated this (Orr-walker et al, 1998). This study included 34 post menopausal 
women who had used DMPA in the past. Most of these women had commenced DMPA 
in their later reproductive years (median age 41 years) and women had used DMPA for a 
median of 3 years. The median age of discontinuation was 45 years (probably before 
menopause).  At the three sites measured that there was no significant difference in 
BMD, however, they did report a trend towards lowered BMD in these former users 
(1.6% in the lumbar spine, and 3.1% the femoral neck). There was no association 
between   duration of use of DMPA, the age at discontinuation and the point of 
discontinuation relative to the menopause.  This study concluded that the use of DMPA 
did not have a residual effect on BMD and therefore should not pose a risk to women in 
their post- menopausal years.  
 
Longitudinal Studies of women post discontinuation of DMPA 
Cundy et al, (2002) looked at 16 women aged 45-53 years who had used DMPA 
continuously for a minimum of five years and who had reached menopause. This group 
was compared to 15 controls with no history of DMPA use. These women were followed 
over 3 years to assess early postmenopausal bone loss. At baseline the women using 
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DMPA were found to have a mean BMD of 7% lower at spine and 9% lower at the hip 
compared to controls. The early menopausal bone loss was found to be rapid in the non-
hormonal contraceptive user control group, with 6% loss of BMD from both sites over 
the 3 year period. The women who had used DMPA up to menopause showed a 
negligible change in BMD over the same period of time. The percentage change was 
statistically significant at both the spine and hip between the two groups. Given the 
changes observed over the three year period, Cundy, (2002) estimated that the deficit in 
BMD in DMPA users, relative to control subjects, would have been eliminated 
completely at the lumbar spine and by more than one-half at the hip. Further into 
menopause it was assumed that these differences would be negligible. In conclusion the 
authors stated that women who would normally choose to use this method of 
contraception until menopause should not be discouraged from doing so. The women in 
this study commenced DMPA use after 25 years of age and therefore caution was 
expressed about applying this conclusion to women who commence the method during 
their teenage years, where there is less evidence for issues of recovery in the long term.  
 
Longitudinal studies in premenopausal women during use and post-discontinuation of 
DMPA  
Some studies have measured BMD in  premenopausal (including adolescent) women 
during use and post discontinuation  (Walsh et al, 2008b; Clark et al, 2006; Kaunitz et al, 
2006; Scholes et al, 2005; Scholes et al, 2002. Walsh et al (2008b) measured hip, spine 
and femoral neck in 14 discontinuers of DMPA and found no difference between this 
group and controls at the 3-year follow-up visit. Clark et al, (2006) followed up 178 
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DMPA users post discontinuation and found that BMD increased between 0.3% to 2.0% 
per year depending on the length of DMPA use and bone site. Eighteen months after 
discontinuation the women with the longest recorded DMPA use  still remained 4.7% and 
2.9% lower at hip and spine compared to baseline.  
 
Cundy et al, (1994) measured BMD in  a small group (n=14) of adult women who had 
been users and had discontinued DMPA  and found that despite weight loss which 
usually decreases BMD, the BMD increased  by 3.4% in the spine after a one-year 
follow-up after cessation of use. A sub-group of 8 discontinuers were followed for a 
further year and the increase continued at the same rate, resulting in a total increase of 
6.4% over two years. It was suggested that BMD loss was probably completely reversible 
within 2 years of discontinuation. A prospective study followed up DMPA users for 3 
years measuring BMD every 6 months (Scholes et al, 2002).  Discontinuers of the 
method continued to be followed-up and in total 110 women discontinued the method 
during the follow-up and showed a marked increase in BMD for each six-monthly 
interval of +0.0067 gm/cm2 . After 30 months the mean bone density of the DMPA 
discontinuers was similar to that of non-users.  
 
Kaunitz et al, (2006) was able to follow-up 44 adult women for 96 weeks of post-
discontinuation and at this point change from baseline was -0.20% for total hip and -
1.19% for lumbar spine. Duration of exposure to DMPA appeared to affect speed of 
recovery, in that women with longer periods of use took longer to recover, compared to 
women who used DMPA for shorter lengths of time. 
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Scholes et al, (2005) undertook the first study that has been able to produce data 
indicating recovery of BMD in young women using DMPA and were able to follow-up 
adolescents post-discontinuation. Women who continued in the study but discontinued 
DMPA exhibited significant increases in BMD relative to non-users at all anatomic sites. 
In this study over 80% of the adolescents had discontinued DMPA use during the 36 
month follow-up period and this group consisted of 62 of the original 80 baseline users. 
The authors concluded that the gains in BMD post discontinuation provided evidence that 
the loss of BMD could be reversed. 
  
In a systematic review of studies published between 1996 and 2006, Kaunitz et al (2008),  
evaluated changes in BMD after discontinuation of DMPA. They reported that BMD 
values started to recover from as early as 24 weeks post discontinuation and continued 
during the reported follow-up period which varied depending on the study. 
  
Recovery of BMD in long term users of DMPA 
Most studies have found that long term users remain compromised with respect to their 
BMD. In only one study (Pettiti et al, 2000) was there a suggestion that long term users 
could recover BMD. This may have been suggested as this study found that short-term 
users of DMPA had lower BMD compared to non-users, but this was not found in long 
term users. However, considering the measurement site used was the forearm, where few 
studies have found a difference between user and non-users of DMPA, this is not 
regarded as a plausible theory. 
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Overview and summary of DMPA use and fracture risk/BMD outcome 
Most studies have indicated a negative effect of DMPA on bone mass and those showing 
minimal or no effect have mainly measured the forearm (Curtis and Martins, 2006). Loss 
of BMD appears to be greatest in the lumbar spine and femoral neck. The differences 
have usually been within 1SD of the mean BMD in non-users. Loss of BMD appears to 
be greater in the first year of use (2-5%)  and  loss  begins to stabilize by five years, with 
losses in continuing users stabilizing at around 1% a year. There is no longitudinal 
follow-up of users beyond five years that would provide evidence about whether this loss 
plateaus in longer-term use. Cross-sectional studies that have included women who have 
used DMPA for more than five years have lower BMD, but if BMD loss was linear from 
year one the BMD in these long term users would be expected to be considerably lower. 
There is only one study (Pettiti et al, 2000) that found no difference in long term users 
compared to non users in a cross-sectional study. Studies that have followed users beyond 
discontinuation show that these negative changes are reversible and there is a return to 
pre-use levels on discontinuation of the method (Kaunitz, et al, 2008).   No studies have 
found a positive effect of DMPA on BMD. In longitudinal studies that have enrolled new 
users of DMPA, few have been able to follow-up users for more than four years and 
therefore longer term evaluations will be needed to inform the effect of DMPA on BMD 
in longer term users.  
 
Limitations of the longitudinal studies include sample size, length of follow-up, 
discontinuation rates and adjustment for confounding. Some studies have included less 
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than 20 DMPA users at baseline (Busen, 2003; Cromer et al, 1996; Naessen et al, 1995; 
Cundy et al, 1994.  Discontinuation before the end of the study follow-up period is a 
general problem in many of the longitudinal studies and in particular those that have 
looked at adolescents and young women, this further reduces the numbers available for 
long term follow-up. Discontinuation rates of up to 60% are common in adolescents in 
these studies (Busen, 2003; Scholes et al, 2002).  
 
 Studies that have measured bone metabolism markers concurrently with BMD 
measurements have found an increased turnover in bone resorption in DMPA users. The 
quality of studies have been variable and a systematic review of progestogen-only 
contraception and bone mineral density published in 2006 by Curtis et al, classified few 
studies as “good” based on the criteria for grading the internal validity of a study using   
the system for grading evidence developed by the United States Prevention Task Force 
(USPTF) (Harris et al, 2001).  
 
1.6.4 Norethisterone enanthate 
Norethisterone enanthate (NET-EN), marketed as Noristerat® is the only currently 
available 2-monthly injection and is administered every 8 weeks as a dose of 200mg. Its 
mode of action is more complex than that of DMPA. Primarily there is inhibition of 
ovulation, thickening of the cervical mucus, prevention of implantation and possibly 
alteration of tubal function (Fraser and Weisberg, 1981; El-Mahgoub and Karim,1972). 
After 60 days, ovulation may no longer be inhibited and the main action is reported to be 
on the cervix (Fraser et al, 1981). There is limited information available on the effect of 
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NET-EN on BMD.  Only one large cross-sectional study of 3487 premenopausal South 
African women found current NET-EN users had lower BMD in the calcaneus compared 
to control never users (Rosenburg et al, 2007).  Some published studies on norethisterone 
(NET) have shown a positive effect on BMD (Horowitz et al, 1993; Eldred et al, 1992; 
Riis et al,1990). It is suggested that NET may protect against calcium loss via a direct 
topic effect on bone or by the action of estrogenic metabolites (Christiansen et al, 1985). 
NET-EN can be considered to be similar in action to NET as the oenthate (EN) is added 
primarily to give it its depot characteristics. Published studies have followed up women 
on treatment with NET for a year or less and therefore there are no data demonstrating 
that the positive effect of NET would be sustained in long term use. The lack of data on 
the effect of NET-EN on BMD may be because the method is not as widely used as 
DMPA. However, in South Africa this method has increased in popularity in recent years 
and is often the method of choice for younger women (Dept of Health, 2006). This two 
monthly injectable contraceptive was introduced later then DMPA in South Africa. In 
recent years the use of NET-EN has increased considerably in a number of countries 
especially in South Africa.    
 
1.6.5 Other hormonal methods of contraception  
1.6.5.1 Contraceptive implants 
A small number of studies have looked at the effect of levonorgestrel releasing subdermal 
contraceptive implants (Monteiro-Dantas et al, 2007; Bahmondes et al, 2006a;  
Vanderjagt et al, 2005; Beerthuizen et al, 2000; Pettiti et al, 2000; Di et al, 1999; Diaz et 
al, 1999; Intaraprasert et al, 1997; Taneepanichskul et al, 1997a; Cromer et al, 1996; 
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Naessen et al, 1995). The products used in these studies included Norplant®, Jadelle® and 
Implanon®. Norplant is a six-capsule subdermal implant releasing 50-85 ug of 
levonorgestrel per day in the first 9 months of use and about 35ug per day after one year. 
Implanon® is a single-rod etonogestrel-releasing implant and   Jadelle® is a two silicone 
rod levonorgestrel-releasing implant. In this section studies will be discussed together as 
there are fewer reported studies and the age group using implants has mainly included 
adult premenopausal women. Only one study (Cromer et al, 1996) focused on adolescent 
users. 
  
Some of these studies included other hormonal methods as comparison groups (Pettitti et 
al, 2000; Di et al, 1999; Taneepanichskul et al, 1997a;Cromer et al, 1996; Naessen et al 
1995). One study conducted in China (Di et al, 1999) used Norplant with a comparison 
group using a similar levonorgestrel implant but manufactured domestically. The largest 
of the cross sectional studies (Pettitti et al, 2000), included DMPA and COCs with a non-
user control group. The analysis restricted to exclusive users of Norplant (n=308), found 
the adjusted BMD at the midshaft of the Ulna was significantly lower for Norplant users 
compared with never users  of hormonal contraceptives. This is the only cross-sectional 
study that reports a negative effect of Norplant on BMD. Taneepanichskul et al, (1997a) 
compared long-term users of DMPA with a mean duration of use of 31 months with 
Norplant users (mean duration of use 59 months). There was no non-user control group 
included. Measurement of BMD was taken at the distal and ultra distal forearm and there 
was no difference found between the two groups. Inaraprasert et al (1997), found no 
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difference in forearm BMD between 41 Norplant users aged 19-42 with a mean length of 
use of 31 months compared to 50 current IUD users. 
 
Looking at the prospective studies, Naesson et al, (1995) included 22 women aged 
between 20 and 45 years who were randomized to either DMPA or Norplant. Only 18 
women had a baseline forearm BMD measurement taken and only 19 completed the 6-
month follow-up period. Forearm bone density increased in the Norplant group by 2.94% 
in the 10 women in the Norplant group compared to a non-significant decrease of 0.41% 
in the DMPA group. Biochemical indicies showed that in DMPA users there were signs 
of increased bone turnover with increases in bone resorption with increased levels of 
alkaline phosphatase and osteocalcin. The Norplant group showed an increase in bone 
formation with increased levels of alkaline phosphotase and osteocalcin. Di, et al, (1999) 
conducted a prospective study using Norplant and the domestically manufactured 
implant. In total, 60 women aged between 25 and 40 years were included who were 
randomised into either group (Norplant n=29 and domestic implant n=31). All women 
had a BMD measurement taken at one year at the lumbar spine and proximal femur. Both 
groups showed a significant increase in BMD at one year with a 2.4% increase in the 
Norplant group and a 2.75% increase in the domestic implant group. In the third 
prospective study (Cromer et al, 1996),  Norplant, DMPA, COC users and control groups, 
were included, however, numbers were small with a total of 48 women aged 12-21 across 
all groups. New users of the methods were included and a BMD was taken at one year 
with an even smaller subsample measured at two years. No COC users were included at 2 
years as all had discontinued the method. At one year there was no significant difference 
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between the user groups in BMD however within groups there was a 1.5% decrease in 
DMPA users compared to an increase of 1.52% in COC users and a larger increase 
(2.46%) in the Norplant users.  One study compared lactating women who initiated 
Norplant, progesterone vaginal rings or the IUD (Diaz et al, 1999). There was no 
difference in spinal BMD between the three groups at 12 months postpartum.  
 
There have been three studies published that have included Implanon (Beerthuizen et al, 
2000; Bahmondes et al, 2006a; Monteiro-dantas et al, 2007). Beerthuizen  et al (2000), 
compared  Implanon and IUD users and found no difference after two years of use in 
BMD at a number of skeletal sites. Bahmondes et al, (2006a)  included both Implanon 
and Jadelle and after 18 months of use BMD was found to be significantly lower in the 
midshaft of the ulna compared with baseline in both implants. However, no difference 
was found in the distal radius. Similar results were found after 36 months of follow-up in 
the same study (Monteiro-Dantas et al, 2007). No other skeletal sites were measured.   
 
In summary although most of the studies show no effect of Norplant, these studies were 
limited by small numbers and different types of users. The largest study (Pettitti et al, 
2000) is limited to cross-sectional data, long term users and many different population 
groups. A Consensus statement and background review published in 1998 (Fraser et al, 
1998) was only able to review two published studies at that time (Cromer et al, 1996; 
Naessen et al,1995) and reported increase of BMD in users of Norplant. Studies of other 
implants are inconclusive. 
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1.6.5.2 Monthly injectables 
There are two monthly injectable products currently available (Mesigyna and Cyclofem). 
Mesigyna is a preparation consisting of 50 ug Norethisterone enanthate and 5ug estradiol 
valerate. Cyclofem consists of 25mg medroxyprogesterone acetate and 5 mg estradiol 
cypionate. Two studies have investigated the effect of a monthly hormonal injectable on 
BMD (Bahmondes et al, 2006b; Von Kesseru et al, 2000,).  In a randomized trial (Von 
Kesseru et al, 2000), 148 women aged between 38 and 50 years were randomized to 
either Mesigyna (n=49) or IUD (n=99) in a ratio of 1:2. Bone densitometry was only 
performed on half the women at the end of one and two years of follow-up. Although the 
study title stated special emphasis on serum lipids and bone density patterns, the primary 
focus was on serum lipids with minimum information in the results and discussion on the 
BMD data collected. Results reported there was no difference in BMD at the lumbar 
spine between the Mesigyna and IUD groups. Although not discussed, follow-up 
appeared to be poor with only around 50% of  either group still using the method at one 
year and no detail as to how many of those included in the initial subsample for BMD, 
were still using the method at year 1. The second and most recent study (Bahmondes et 
al, 2006c) compared women using two kinds of once-a-month injectable contraceptives 
(Cyclofem and Mesigyna) with a control group of IUD users. This cross-sectional study 
found no difference in forearm BMD between either of the two injectables and the 
control group. 
 
1.6.5.3 Progesterone only oral contraceptives  
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Progesterone only oral contraceptives (POPs) contain a microdose of one of three 
progestagens (norethisterone, levonorgestrel and ethynodial diacetate). The main mode of 
action is by alteration of the cervical mucus and in addition an effect on ovulation. In 
over half of women (60%) amenorrhoea will result due to cessation of ovulation. The 
POPs have received little attention thus far with respect to their effect on BMD. This may 
be due to their low prevalence of use (Guillebaud, 2001). The POPs account for only 8% 
of the UK oral contraceptive market and in South Africa they are rarely available in the 
public sector. Only one study has been identified (Caird et al, 1994) which included 9 
breastfeeding women using POPs and compared them to 19 women using barrier 
methods as controls. However half of the control women (n=10) were formula feeding. 
Although all women showed a significant decrease in lumbar spine BMD at 6 months 
postpartum, the decrease was significantly lower in the POP users compared to non users. 
This study did not control for frequency of breastfeeding and with a small number of 
women, it is not possible to use these data to comment on any relationship between POPs 
and BMD. 
 
1.6.5.4 Progesterone vaginal ring 
Progesterone vaginal rings are inserted into and can remain in the vagina for 90 days. 
They are ring shaped and around 5-6 cm in diameter. The silastic carrier of the ring 
releases a controlled dose of progesterone to the vaginal mucosa. Since 1980 research has 
centered on a levonorgestrel releasing ring of a daily dosage of 20 mg. Only one study 
has been identified (Diaz et al, 1999) that looks at BMD and use of the progesterone 
vaginal ring. In this study breastfeeding women (n=28) using the ring were compared to 
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51 breastfeeding IUD users. No difference was found in BMD at the lumbar spine or 
femoral neck up to one year post weaning. 
 
1.6.5.5 Intrauterine systems 
Only one study (Bahamondes et al, 2006c)  has evaluated BMD in users of the 
levonorgestrel-releasing intrauterine system (LNG-IUS) and compared this group with 
standard intrauterine device (IUD) users. This cross-sectional study paired long term 
LNG-IUS users with IUD users by age and BMI. BMD was measured at the ulna and 
distal radius. No difference was found in BMD values between the two groups. 
 
1.6.6 Review of Study limitations:- Sites measured and equipment  used 
in studies on BMD and hormonal contraception 
Although there are numerous studies addressing the issue of hormonal contraception and 
its effect on BMD, there are limitations with a large number of studies and wide 
variations between studies in a number of areas including:- sites measured, equipment 
used; study design; length of follow-up and high rates of loss to follow-up; confounding 
variables not adjusted for; wide age ranges and lack of or inappropriate control groups. 
The following section briefly discusses these limitations. 
Studies that have investigated hormonal methods of contraception and BMD have 
measured bone mass density at different skeletal sites.  Sites used have included both a 
range of central and peripheral sites. Central sites have included the lumbar spine, 
femoral neck and hip whilst peripheral sites include the forearm and ankle. The generally 
higher costs and greater space requirements needed to measure central BMD sites will no 
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doubt have been considerations in research studies. Equipment for peripheral 
measurements such as the forearm, are cheaper to purchase and maintain and are more 
portable for study requirements. Some studies have used a combination of central and 
peripheral sites whilst others have used either central or peripheral. There has been some 
debate in the literature as to whether the peripheral sites are less able to predict fracture 
risk at spine and proximal femur. Some prospective studies have not demonstrated that 
the a spinal BMD is superior to  peripheral measurement and concluded that forearm 
measurements predicted future vertebral fractures as well as spinal BMD measurements 
(Melton et al , 1993; Duppe et al, 1997). However although a large number of studies 
have confirmed that forearm BMD measurements can predict future fracture risk, many 
clinicians  will continue to prefer to base their advice to patients on spine and hip 
measurements, since these sites are widely recognized as those where fractures may have 
the most serious consequences for quality of life and cost of treatment.   
 
Within studies using both central and peripheral sites there have been some differences in 
the effect of hormonal contraception and BMD. Studies that have used the forearm only 
have been less likely to find a decrease in BMD in DMPA users   (Ott et al, 2001; Perrotti 
et al, 2001;  Bahmondes et al, 1999;Gbolade et al, 1998; Taneepanichskul et al, 1997; 
Virtumasen et al, 1994). If a decrease in BMD has been found at the forearm in DMPA 
users then it has not been statistically significant (Naessen et al, 1995). Of the studies 
using the forearm that have found a negative effect in DMPA users (Pettiti et al, 2000) 
the change was small and less than one standard deviation.  In one study looking at users 
of hormonal implants (Bahmondes et al, 2006a) although no difference was found in the 
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radius a significant difference was found at the ulna. Studies that have included both 
central and peripheral sites have found that changes in BMD have not always occurred 
equally at all sites (Wanichsetakul et al, 2002).  
 
There are various methods of measuring or estimating BMD and guidelines published in 
2007 by the International Society for Clinical Densitometry (ISCD) outline alternative 
methods to measuring osteopenia (low bone mass) and osteoporosis in pre-menopausal 
females (Lewiecki, et al, 2007). Although many different sites have been measured, most 
studies investigating hormonal contraception and BMD have used equipment using Dual-
energy x-ray absorptiometry (DXA) as a measurement. Fewer have used single-energy x-
ray absorptiometry (SXA) and there are even fewer examples of use of peripheral 
quantitative computed tomography. Only one recent study has utilized  peripheral 
quantative computed tomography of the calcaneus (Rosenburg et al, 2007) and this 
method was chosen asthe study sites that had no access to DXA technology 
 
 Studies have included both cross-sectional and longitudinal designs but few RCTs. 
Longitudinal designs have often been varied in type of user and have included both new 
and continuing users. The length of follow-up has gradually increased as research is 
showing that the length of hormonal contraceptive use may impact on the rate of BMD 
loss. The need to follow up beyond discontinuation is now considered key in studies. For 
adolescents long-term follow up is lacking to investigate any long term effects of 
hormonal contraception on BMD. Poor follow-up has impacted on sample size, in 
particular in studies involving adolescents. 
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As previously described there are many factors affecting bone formation and resorption. 
It is therefore important to adjust for some of these key factors. Although many studies 
have adjusted for key variables such as age, BMI and years of lactation, many studies 
have made no or minimal adjustments. Age ranges have been both wide and narrow and 
control groups of non-users have not always been included.  
 
The change in COC formulation over the years has required that researchers investigate 
the new low-dose formulations. These have been found to have a different and opposite 
effect to the higher-dose formulations available when this area of research became active. 
 
In conclusion this literature review has included and described the history and the current 
understanding of the effect of hormonal contraception on the BMD of women in 
adolescence through to the menopause. Although a wide body of work exists and a 
consensus has been reached on the effect of hormonal contraception such as DMPA, 
there are still outstanding questions to be answered for COCs and BMD and less 
researched methods such as NET-EN.   
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CHAPTER 2.0 MATERIALS AND METHODS 
2.1 General outline 
This longitudinal study examines the relationship between current hormonal 
contraceptive use and bone mineral density (BMD) in women aged 15-19 years and 40-
49 years. Hormonal and non-hormonal contraceptive users attending the Commercial 
City family planning clinic, Durban, were asked to take part in the study and once 
recruited were followed-up for a five year period. Non users of hormonal contraceptives 
included barrier method and IUD users.  At recruitment, clients had a medical history 
taken and measurements of anthropometry (height and weight). Forearm BMD was 
measured using dual energy x-ray absorptiometry (DEXA) technique. The admission 
questionnaire was designed to collect information on socioeconomic variables: education, 
employment and income. Information was also collected on factors known to be 
associated with BMD including; pregnancies and lactation history: current and past use of 
tobacco, alcohol and caffeine  (Sowers and Galuska,1993, Lamke at al, 1976). A detailed 
contraceptive history was also taken to include methods used and duration of use in the 
older age group. Repeat measurements of BMD and anthropometry  were taken every six 
months during the five year follow-up. A follow-up questionnaire was administered at 
each follow-up visit and collected similar information to the admission questionnaire. An 
interim analysis was made at two-and-a-half years.  
 
Additional funding from the William and Flora Hewlett Foundation awarded towards the 
end of the study enabled a sub sample of women to have a total hip,  spine and femoral 
neck measurement taken (n= 96). These women were all in the younger age group and 
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the measurement was taken on the same day or within  5-6 weeks of their last follow-up 
visit. 
 
2.2 Recruitment procedure 
All women were given an information sheet (Appendix 1) to read and asked to give 
written consent for participation in the study.Consent forms in Zulu and English can be 
found in Appendix 1.  
The following numbers of women were required for the longitudinal study.  
1. Women in the 15-19 age group; at least 100 in each of the four categories. 
a. New users of depot medroxyprogesterone acetate (DMPA). 
b. New users of norethisterone enanthate (NET-EN).     
c. New users of combined oral contraceptives (COCs).  
d. Women who had no history of hormonal contraceptive use and who were not                      
current users. 
2.  Women in the 40-49 age group; at least 100 women in four categories: 
 a. Current users of depot medroxyprogesterone acetate (at least 1 year of use). 
 b. Current users of norethisterone enanthate (at least 1 year of use). 
 c. Current users of combined oral contraceptives (at least 1 year of use). 
     d. Women who had not used hormonal contraceptives for the past five years. 
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2.3 Criteria for selection of subjects 
 Women were screened prior to recruitment to ensure they were eligible to participate. A 
screening questionnaire was completed prior to recruitment (Appendix 2) using the 
following criteria: 
Inclusion criteria: 
 
1.15-19 age group 
a. Aged between 15-19 years 
b. New acceptors of DMPA, NET-EN and COCs, and never users of 
hormonal  contraceptives (control group). 
 
2. 40-49 age group 
a. Aged between 40-49 years 
b. Women who were current users of  DMPA, NET-EN and COCs with 
one year or more use, and women who currently did not use a hormonal 
method and who had not used hormonal  contraceptives in the last 5 years. 
 
Exclusion criteria: 
 
1.  Age less than 15 or more than 19 (15-19 age group), age less than 40 or more 
than 49 (40-49 age group) 
2.  Currently lactating or lactation that ended within six months. 
3.  Recent pregnancy (pregnancy that ended during the last six months). 
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4.  Current or past medication of any drug for more than 3 months, known to 
affect calcium metabolism (anticonvulsants, corticosteroids; thyroid 
supplement; drugs to treat hyperthyroidism; vitamin D or calcium supplement; 
thiazide diuretics). 
5. Chronic disease affecting bone metabolism (liver disease and diabetes mellitus)                   
especially diseases known to affect calcium metabolism (chronic renal failure;                         
hyperparathyroidism or hypoparathyroidism; hyperthyroidism or 
hypothyroidism; cancer; rickets, pituitary disease). 
 6. Hysterectomy or oophorectomy. 
             7. Bone mass 2 Standard deviations (SDs) below normal range. 
  8. Known to be HIV positive 
  9. Known to have menopaused (no menstrual cycle for at least 1 year) 
  10.. Indicators suggesting risk of HIV infection:- 
 Significant weight loss in last 6 months (5kg or more) 
 Chronic diarrhoea 
 Lymphadenopathy 
 Tuberculosis 
 
Exclusion criteria during follow-up 15-19 & 40-49 
1.  Medication of any drug for more than 3 months, known to affect calcium 
metabolism (anticonvulsants, corticosteroids; thyroid supplement; drugs to 
treat hyperthyroidism; vitamin D or calcium supplement; thiazide diuretics). 
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2. Chronic disease affecting bone metabolism (liver disease and diabetes mellitus)                   
especially diseases known to affect calcium metabolism (chronic renal failure;                         
hyperparathyroidism or hypoparathyroidism; hyperthyroidism or 
hypothyroidism; cancer; rickets, pituitary disease). 
 3. Hysterectomy or oophorectomy. 
             4. Bone mass 2(SD) (Standard deviations) below normal range1. 
  5. Known to be HIV positive 
6. Pregnancy excluded women from the BMD measurement, however if women 
were willing to continue 6 months postpartum they could be continued in the 
study. 
 
2.4 Admission procedure 
Women who were eligible and volunteered to enter the study were taken through the 
informed consent process where written consent was sought prior to participation 
(Appendix 1). The admission interview took approximately thirty minutes to administer 
and was conducted in the client's home language by a trained research nurse employed by 
the Reproductive Health and HIV Research Unit (RHRU). (Appendix 2). Information 
collected included socioeconomic variables: education, employment and income; 
pregnancies and lactation history: current and past use of tobacco, alcohol and caffeine. A 
detailed contraceptive history was taken which included methods used and duration of 
use. If the participant was an existing client at the clinic, the client-retained family 
                                                          
1 This was possible for the 40-49 age group where there are established reference populations available. 
The reference population in this study consisted of white European women and therefore was not directly 
comparable to a population of African women. There was no normal reference group available for the 
younger study group. The baseline data was used to compile a range for the population. 
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planning card was used to verify the contraceptive history taken. The medical 
examination included BMD measurement, blood pressure, anthropometry (height, 
weight, waist and hip) to assess health status. These results were recorded in the 
examination form (Appendix 2). 
 
2.5 Bone mineral density measurements 
 Forearm BMD was measured by dual x-ray absorptiometry (DEXA). For each subject, 
two measures of forearm BMD density were made:- at the distal radius and at the 
midshaft of the forearm. At the distal end of the radius trabbecular bone predominates, 
while the midshaft is mostly cortical in nature. In view of the differences in bone 
morphology at these sites, bone density measurement at two sites is useful and has a 
larger application. 
 
Quality control for the bone measurements was achieved by ensuring that the research 
staff were thoroughly trained initially in the technique and repeated training thereafter. 
 The test/ retest reliability of the bone measurements was assessed during the pilot phase 
and on an on-going basis during the main phase of the study by repeating  measurements 
taken during the examination. The principal investigator, who conducted the repeat 
measurements, did not have access to records of previous measurements. Repeat 
measurements (n=5) were conducted randomly on a bi-monthly basis. Daily phantom 
measurements were taken every morning on start-up of the equipment. Data from the 
phantom measurement was plotted daily to monitor measurement drift. Equipment was 
serviced yearly by a trained technician. 
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2.6 Visit Schedule 
Study participants were interviewed by the research nurse at admission and scheduled for 
a follow-up visit every six- months. However if late for a scheduled follow-up or unable 
to attend, longer durations between follows ups were accepted in circumstances where as 
women were able to present family planning cards and give detailed contraceptive 
histories since last visit. At each follow-up visit all participants had repeat BMD and 
anthropometry measurements taken. Participants in the older age group had a blood test 
every year for follicle stimulating hormone (FSH) levels.  Risk behaviour assessment was 
repeated at each six-monthly visit. Participants who discontinued their method continued 
to be followed-up for the five-year study period if they agreed to continue participation in 
the study.  
 
2.7 Description of the DEXA equipment for BMD 
measurement 
A number of techniques/ procedures are available to quantify BMD. These include 
radiogrammetry, single and dual photon/x-ray absorptiometry, computed tomography and 
total body calcium measurement by neutron activation analysis. The choice of the 
technique depends on several considerations, such as the site in the body selected for 
bone mass measurement (different body sites contain different ratios of 
trabecular/cortical bone), purpose of investigation (whether to identify individuals at risk 
of fracture, for diagnosis of a suspected metabolic disease, to monitor progress of a 
disease or therapy), level of precision and accuracy acceptable, cost of the 
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equipment/procedure, time required to carry out the procedure, and safety in terms of 
radiation exposure. 
 
DEXA was chosen as the method for measuring bone mineral density in this study for 
several reasons.  DEXA accurately reflects total body calcium, measures of bone mineral 
density using the method are highly reproducible: the co-efficient of variation is 1%.  
DEXA equipment is not expensive relative to other equipment used to measure bone 
mass and the method is easy to learn. Examinations using DEXA take about five minutes 
per subject to complete and so do not require a complicated procedure for the subject.  
 
This study considered DEXA equipment that could measure central sites (spine, femoral 
neck and hip) however the cost of this equipment purchased exclusively for study use 
was prohibitive. The study further considered collaborations with academic departments 
to use their equipment however the amount of space required for the study and the 
volume of study participants seen daily would have been too disruptive for their routine 
appointment system. The cost per spine/hip scan in the private sector were also 
prohibitive for the study. The World Health Organisation (WHO) funded the study 
including the equipment. Funding for equipment covered  the cost of new equipment 
similar to that used in a previous WHO BMD multi-centre study (Pettiti et al, 2000). In 
this study forearm BMD was measured in women aged 25-35 years in 7 centres 
internationally including Africa. A number of studies have shown that measurement of 
forearm bone mass is a good indicator of the bone mass situation at other sites  (Need and 
Nordin, 1990, Duppe et al, 1997).  The equipment purchased to measure BMD in this 
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study by dual photon/ x-ray absorptiometry was the DEXA model DTX-200  (Osteometer 
MediTech A/S Co, Rodovre, Denmark). The technique involved exposure to negligible 
radiation dose.  The skin dose on the forearm was 0.2 mGy and the effective dose was 
0.1Sv per scan. The bone mineral content was expressed as mg/cm2. The DEXA 
equipment was standardized daily using a phantom as prescribed by the manufacturer’s 
instructions.  Accuracy to the standard during the recruitment period was 0.53%. and in 
vivo precision was 0.94%.   
An example of the forearm DEXA scan conducted in this study and information on the 
equipment can be found in Appendix 3.  
 
The DEXA equipment used in the sub-study to measure hip, spine and femoral neck was 
a Hologic QDR discovery, version 12,6, Model: Discovery w(s/n) 49369. An example of 
this scan can  be found in Appendix 3. 
 
2.8  Menopausal status of women in the 40-49 age group  
One of the challenges identified at the outset of the study was how to classify women by 
menopausal status.  The injectable groups in particular required special consideration due 
to menstrual cycle irregularities.  The sub-study around FSH levels (Chapter 3.8) 
confirmed that FSH levels were not masked by DMPA/NET-EN use outside of the peak 
suppression period.  FSH levels were therefore used in this study as one of the criteria to 
indicate menopausal status. 
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Standard criteria for menopause can only be applied retrospectively.  To consider a 
woman as having reached menopause, she should not have had any menstrual bleeding 
within the past 2 years.  This criteria was adequate for the non-hormonal contraceptive 
user group.  For injectable users this was not appropriate, therefore FSH levels were used 
in addition to bleeding patterns. 
 
Women were classified as (a) normal, (b) peri-menopausal and (c) menopaused. This 
system was used yearly at the end of each following full year of follow-up. 
 
At admission, menopause was an exclusion criteria.  This was because the period of the 
study aimed to include the menopausal transition and those recruited could have 
potentially reached menopause at some point during the study follow-up. Women were 
accepted into the study if their menstruation was not regular.  This was because it was 
anticipated that most women presenting for recruitment, in particular those aged 47-49, 
would have some menstrual irregularities and would be clinically defined as peri-
menopausal. 
 
Menopausal symptoms as indicators of menopause were asked at baseline and follow-up, 
however,  hormone replacement therapy (HRT) treatment is not generally available in the 
public sector to most of these women so few women seek care. Table 2.1 presents the 
menopause classification system for the study. 
 
 
76 
 
Table 2.1  Menopause classification 
Criteria Normal perimenopause Menopausal 
FSH level in last 
year (Miu/mL) 
 
*Bleeding pattern 
in last year 
<20 
 
 
Regular cycle 
between 21 -35 days 
>20 <25.8 
 
 
Irregular bleeding 
cycle 
25.8-134 
 
 
No bleeding seen in 
past 2 years 
*Only applicable to non-users of hormonal contraception 
 
A woman in the non-user group must have had amenorrhea for two consecutive years 
before she was classified as fully menopaused.    Women in the hormonal contraceptive 
groups (DMPA & NET-EN) must have had FSH levels in the menopausal range for two 
consecutive years and in addition have had no bleeding/spotting during this time.  COC 
users who had FSH measured in the pill free cycle also used the same classification 
system as the injectable users. Their bleeding cycles would be artificially affected by 
their method. 
 
Women enrolled in the 40-49 age group had a blood test taken at admission and every 
year to measure FSH levels. Women were also asked about any menopausal symptoms 
they may have experienced since the previous visit. Women with high FSH levels (above 
30IU/l) and who exhibited vasomotor symptoms were referred to the clinic staff. 
Information on bleeding patterns, other menopausal symptoms and FSH/LH levels were 
monitored after discontinuation. If the FSH was still above 30 IU/L and there had been no 
bleeding for two years the woman was considered to be menopausal.  All women 
discontinuing their method as a result of menopause were followed up for the full five 
years on the same six-monthly appointment schedule.   
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2.9 Sample Size 
The proposed study aimed to be able to detect a half standard deviation difference in 
BMD between users and non-users of injectable contraceptives. This would be of 
biological significance as this difference would translate into a large difference in the risk 
of fracture in the older woman. Information on the mean and standard deviation of cross-
sectional measurements of forearm  bone mass made in white, European, premenopausal 
women that was reported by Nordin (1987) was used to estimate sample size. Data 
available on the association of bone mass with use of hormonal contraceptive has not 
always been consistent in showing an association in one direction, the sample size 
required for each category assuming a two-tailed statistical test with a probability value 
(alpha) of 0.05 and with a power (beta) of 0.80 was 63 subjects. Loss to follow up was 
estimated at 8-10% per year. Sample size was adjusted for this loss after consideration of 
potential levels of loss-to-follow-up rates in each age-group. It was anticipated that the 
younger woman may have higher rates of loss-to-follow-up compared to the older age-
group, as this age group is more mobile and on completing their education may move 
home for education or work purposes. The sample size was increased to 110  as it was 
expected rates of loss-to-follow-up may be at least 10% per year.  In addition it was 
expected that a proportion of the 15-19 year old non-users would commence on a method 
of contraception within the study period. To compensate for this the sample size for non-
users was increased to 150.   
 
It was anticipated that the older women would have loss to follow-up rates of 
approximately 8% per year and the sample size was adjusted to 100. We raised the 
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sample number of non-users in the 40-49 years age group as clinic records during the 
study preparation phase showed that this age group was not regular clinic attendees at the 
study site. These women were usually accompanying friends and relatives or attending 
for pap smears, and it was felt that loss-to-follow-up may be greater in this group 
compared to those who attended the clinic regularly for family planning supplies. The 
sample in this group was increased to 150 
 
2.10 Statistical analysis 
Multivariate analysis was performed to assess the effect of various factors, as well as to 
control for confounders. Since the data set contains repeat measures for each subject, it 
was necessary to take into account the within-subject correlation of observations. This 
was achieved by using generalised estimating equations (GEE) models or multi-level 
models as implemented by the ‘xt’ commands for panel data in the software package 
STATA (V.10 College station, TX, USA). The analysis had to use bone mass at various 
times as end products. Furthermore, subjects changing between contraceptive methods 
had to be taken into account by aggregating person years of exposure. 
 
Multivariate adjustment was necessary in the analysis for several reasons. First, it was not 
possible to identify a comparison group of non-users of hormonal contraceptives who are 
identical to users of such methods in every way, except in their use of hormonal 
contraception, and even after exclusions, we expected some non-comparability between 
users and non-users of  hormonal contraceptives.  In the younger age group, only women 
79 
 
who were new users of either injectable or oral contraceptives were recruited, so 
eliminating the need to adjust for history of contraceptive use in this age group. 
 
Linear regression was used to assess differences in bone mass between non-users of 
hormonal contraceptives and users of COCs and progestin-only injectable contraceptives, 
adjusting for differences between the groups on characteristics other than bone mass. 
Descriptive measures were used to assess variables such as past reproductive history, 
body mass, social characteristics and personal habits.  An interim analysis was made after 
two-and-a-half years. BMD was measured in users and discontinuers. 
 
Body mass index was calculated from the weight and height as kg/m2. BMD was 
measured in grams/centimetre2 (g/cm2) at two sites in the distal forearm (radius and ulna). 
The characteristics of women in the study were quantified as means + SD, medians, or 
percentages. Differences in BMD between contraceptive groups, and the associations 
between BMD and selected characteristics of the study participants by contraceptive 
group were assessed using one way analysis of variance and multiple variable linear 
regression for BMD measured at the two anatomic sites.  
 
Menopause was classified as amenorrhoea for at least one year. For injectable hormonal 
contraceptive users this criterion could not always be used as women commonly 
experienced amenorrhea induced by the method. Therefore in addition to amenorrhea, 
Follicle stimulating hormone (FSH) levels from blood samples were measured. An FSH 
level of ≥25.8 milli International units per milliliter (mIU/mL) was considered to be in 
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the menopausal range (King Edward VIII Hospital Durban; Chemical Pathology 
Laboratory criteria using Roche Elecsys FSH expected values). FSH levels were divided 
into two categories according to laboratory cut-off levels for premenopausal (<25.8 
mIU/mL) and peri-menopausal/menopausal (≥25.8 mIU/mL). 
 
 
Follow-up of all women was cumulated up to their last visit, or up to the visit preceding a 
visit at which they reported a change in contraceptive method, whichever occurred first.  
Interim analysis of this study found that BMI was significantly associated with radius 
BMD. To assess the effect of contraceptive method on radius BMD, and to allow for 
within subject correlation of responses whilst controlling for the confounding effect of 
changes in BMI, random effects linear regression methods were used with radius BMD at 
the time of a study visit as the response variable, and contraceptive method, duration of 
follow-up  and BMI at time of the visit as explanatory variables.  Differences in rate of 
change in radius BMD per year between methods were calculated by including 
interaction terms in the model for method and follow-up time. Additionally, we 
investigated whether change in radius BMD varied between two time periods by 
including an interaction term between follow-up time up to the last visit occurring before 
2.5 years and follow-up time between 2.5 and 5 years, for each user-group separately.  
These two time periods were chosen as the literature indicates that the greatest loss of 
BMD as a result of hormonal contraceptive use occurs over the first two years of use 
(Tang et al, 2000) and then loss continues at a slower rate and appears to stabilize. 
Finally, we investigated BMD in women who discontinued hormonal contraception. Data 
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analysis commenced on completion of baseline data collection in 2002. Analysis of the 
main data-set commenced in 2007. 
 
2.11 Data management 
2.11.1 Data collection 
Data were collected via questionnaire and clinical record form (Appendix 2). On the 
clinical record forms, the results of the measurements of height and weight, 
anthropometry and bone density value were recorded. Details of completion of 
questionnaires and coding can be found in Appendix 2. 
 
3.11.2 Data entry 
Questionnaires were collected from the site  approximately every two weeks. Data were 
double entered by the trial assistants at the RHRU. The data entry programmes for all 
study instruments were written in Epi-info 6.04 (CDC, Atlanta).  The data was routinely 
cleaned and checked by running frequencies and checking outliers in the dataset. 
Baseline data was finalized in 2003 in preparation for two publications. The data was 
imported into the STATA statistical analysis package  for analysis (V.8- V10 College 
station, TX, USA). On completion of the study in May 2006, the final dataset was  
checked and cleaned and this process was completed by February 2007.  
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2.12 Duration of the study 
2.12.1 Overview 
The study was funded by the World Health organisation for six years (Jan 2000- April 
2006). This enabled the women recruited in year one of the study to complete 5 years of 
follow-up. Those recruited in year 2 potentially were able to complete between 4 and 5 
years of follow-up. The study had five phases; preparation (3 months); pilot (2 months); 
enrolment only (6 months); enrolment and follow-up (two years) and follow-up only (3 
years). The main recruitment commenced in June 2000.  
 
2.12.2  Preparation phase 
This part of the study included gaining ethics approval, site preparation and planning, 
meeting with Department of Health staff to secure accommodation, training of staff in 
use of equipment and data collection, finalisation of the questionnaires and translation, 
writing of data entry programmes and purchasing supplies. 
 
2.12.3 Pilot phase 
The pilot phase tested the questionnaire, recruitment strategies, quality control 
procedures, rate of recruitment and acceptability of the measurement to clients. 
 
2.12.4 Enrolment phase 
It was anticipated that enrolment to complete all study groups would take in the region of 
18-24 months.  Some study groups were recruited in a shorter period.  
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2.13 Main problems experienced 
NET-EN is the injectable product used by the majority of younger women and so 
recruitment of the DMPA and the COC group took longer in the younger age groups. The 
five-year follow-up required considerable effort to motivate the women to stay in the 
study for the full five years. At recruitment only women who were intending to live in the 
area for the next five years were enrolled. This was emphasised in the study information 
sheet and was discussed with the client during the screening interview. A trial assistant 
was employed to trace non-attendees.  
 
2.14 Ethical considerations 
Ethical approval was granted from the University of the Witwatersrand Human subjects 
Ethics Committee and the Scientific and Ethical Review Group  (SERG) at the WHO 
(Appendix 4). 
 
1. Women were  asked to volunteer for the study 
2. The study was explained in detail and an information sheet was available 
(Appendix 1). 
3. Women were asked to sign a consent form (Appendix 1) 
4. Participation involved an extra 30-45 minutes to the clinic consultation 
including the questionnaire administration and the physical measurements. 
5. There was no pain or discomfort involved in the procedures involved. 
6. The DEXA technique involved exposure to a negligible radiation dose. 
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7. All women received a stipend of R50.00 for each visit which was intended to 
cover any transport costs. 
 
2.15 Study procedures  
This following section provides comprehensive information on the study and its 
procedures.  All aspects of the study and documentation used are recorded in this thesis.  
Additional information arising in the course of the study was added in the relevant 
section.  Guidelines were developed to give further information on the conduct of this 
study. All staff involved in the study used these guidelines so that they were familiar with 
the aims, design and investigations of the research study.   
 
2.15.1 General Principles 
1. Each member of staff participating in the study was expected to be familiar with the 
protocol, not only with the part in which he or she was directly involved, but also 
with the other aspects of the study.  In addition, all staff members were kept regularly 
informed about the study’s progress.  
 
2. It was essential that the study be carried out exactly as described in the protocol and 
that all data was recorded from all subjects.  Incomplete observations and protocol 
violations would reduce the number of data suitable for analysis, and this could 
jeopardize achieving the study’s objectives. 
  
85 
 
3. Women who volunteered to participate in this study were clearly informed about its 
purpose and about what their participation involved. The basic underlying object was 
to make participants aware that the contribution they were making was important and 
voluntary.  Much of the information collected during the study was of a personal and 
sometimes sensitive nature.  Health workers and other personnel involved in the study 
were expected to observe the rules of confidentiality and make it clear to women 
taking part that this was being done. 
 
2.15.2  Recruitment 
The study site was situated at the Commercial City family planning Clinic.  This clinic is 
managed by the Department of Health and provides family planning, sexually transmitted 
infection (STI) management and counseling and referral for HIV testing and termination 
of pregnancy.  It is located in the centre of Durban and is used mainly by women living,  
working and studying in and around the Durban city centre. It has easy access for 
transport and is open daily. At the start of the study the clinic was open on Saturday 
mornings, however in 2001 due to staff shortages the opening hours were restricted to 
week days. The clinic sees approximately 6-7,000 clients a month for family planning. 
The clinic is attended by mainly African woman but around 10-15% of clients are Indian 
or Coloured. 
 
 One consultation room in the clinic was given to the study for a period of six years.  All 
screening, admission and follow-up procedures were conducted in this clinic. The 
research nurse and trial assistant were permanently based at the clinic at this time. 
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Flyers and posters informing clients about the study were displayed on the clinic walls 
and can be found in Appendix 5.   For non-users of hormonal methods, flyers were 
folded and inserted into condom packets placed near the entrance of the clinic. 
 
2.15.2.1  15-19 age group 
Recruitment took place directly from the youth clinic waiting area.  Clients normally 
reported directly to the reception clerk on entry to clinic and  presented a client retained 
card.   New clients had a card made for them. The reception clerk placed the cards in 
order of attendance time (no fixed appointments were made).   
 
The research nurse checked cards for potential study age group criteria (15-19).  If the 
client was in the correct age group, she would introduce herself to the client and explain 
the study.  The nurse determined if the client could be screened whilst waiting for her 
appointment or after she has been seen by the clinic nurse, depending on how busy the 
clinic was at the time. 
 
All new clients for family planning were seen by routine clinic staff for their initial 
assessment and prescription of method. Thereafter if recruited into the study at repeat 
visits, subjects could choose to be given their usual family planning method by the study 
nurse. This was an incentive for the participant as they did not need to wait in the normal 
clinic queue. The research nurse or study assistant took the client to the study consulting 
room for full screening followed by admission if eligibility was confirmed.  
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2.15.2.2  40-49 age group 
Recruitment took place from the adult clinic.  The receptionist at the adult clinic 
contacted the trial assistant if any woman in the 40-49 age group attended the clinic.  The 
trial assistant would go to the adult clinic to explain the study. If the client was interested 
in taking part she was screened at the youth clinic. Non- users of hormonal contraception 
in this age group who were, attending for cervical smears, condoms, IUD checkups or 
accompanying friends and relatives were asked if they were interested in participating.  
 
2.15.3   Screening 
Potential candidates for the study completed the informed consent form and were 
screened by the research nurse in a private consulting room.  If a woman was eligible she 
was informed in detail about te study procedures.  If found to be ineligible for any reason, 
the screening form was kept for analysis. 
 
2.15.4 Admission 
Subjects admitted to the study completed the admission questionnaire and physical 
examination. Questionnaire details can be found in Appendix 1. Full procedures for 
examination are described in the following section: 
 
2.15.4.1 Physical measurements 
A number of measurements were taken during the admission visit.  All these 
measurements were taken in privacy and other study staff members avoided entering the 
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room whilst measurements were being taken so as not to make the subject feel 
uncomfortable.   
The measurements were taken in the following order:- 
 Height 
 Weight 
 Waist/hip/arm circumference 
 Blood pressure 
 Blood test (40-49 age group) (FSH, LH) 
 Bone mineral density measurement 
 
Height 
A scale fixed to a wall in the examination room was employed to measure height.  After 
removing the shoes, the subject stood on a flat floor  with feet parallel and with heels, 
buttocks, shoulder and back of head touching the upright.  The head was held 
comfortably erect, with the lower border of the orbit (eye socket) in the same horizontal 
plane as the external auditory meatus.  The arms were hanging at the sides in a natural 
manner. The bar was lowered making contact with the top of the head. Height was 
recorded to the nearest 0.1 of a centimeter. 
 
Weight 
The subjects stood on the centre of the platform wearing ordinary light clothing without 
touching anything else.   Shoes were removed. Weight was recorded to the nearest 0.2 of 
a kilogram. 
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Circumferential measurements for assessment of adiposity 
Waist circumference and hip circumference provide a readily measurable objective 
method for assessment of the type and degree of adiposity.  When used along with the 
body mass index, these measurements provide a reliable method of documenting the 
degree of adiposity.  All circumferential measurements were made with the non stretch 
study tape.  The markings of the tape faced away from the skin of the subject and towards 
the observer. 
 
The measurements were taken with the subject  standing and waist exposed.  Waist was 
measured just above the level of the lateral iliac crest, below the lowest rib, with the 
subject’s arms hanging down passively.  Hip circumference was measured just under the 
inferior rim of the symphysis at the midline.  Circumferences were recorded to the 
nearest centimeter. 
 
Arm circumference 
To measure the arm circumference, the tape was placed gently, but firmly around the 
limb to avoid compression of the soft tissues. The midpoint of the upper arm was taken as 
halfway between the acromial process of the scapula and the olecranon process of the 
ulna.  Measurements to the nearest 0.1 of a centimeter were recorded. The less dominant 
arm (i.e. left arm in right-handed subjects and right arm in left-handed subjects) was 
measured, while hanging freely, at its midpoint. 
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Blood pressure measurement 
The subject was asked to remove their outer garments and expose the upper right arm for 
the blood pressure cuff.  The arm should rest comfortably, palm up, on the desk.  The 
investigator sat at the front of the desk close to the right-hand.  The shirt sleeve was 
rolled or slid up to allow sufficient room to place the cuff.  The shirt sleeve should not 
constrict the arm.  If it did, the subject was asked to take her arm out of her shirt.  The 
cuff was wrapped round the arm.  The brachial pulse is located just medial to the biceps 
tendon and the cuff is positioned so that the centre of the inflation bag lay over the 
brachial artery.  The lower edge should be 2 to 3 finger-breadths (about 2.5 cm) above the 
cubital fosca.  The investigator felt the subject’s radial pulse with one hand and keeping 
her hand on it, inflated the cuff slowly with her other hand until the radial pulse 
disappeared.  This is the pulse obliteration pressure.  The column of mercury was allowed 
to fall at 2mm per second.  She listened for korotkoff sounds with the stethoscope on the 
brachial pulse, recorded systolic pressure (pressure at which first sound heard clearly) 
and phase v diastolic pressure (pressure at which sound disappears).  These were 
recorded to the nearest 2mm Hg and the readings were recorded. 
 
Bone Mineral Density Measurement 
Forearm BMD measurement 
The non-dominant arm (left in most cases) was used for measurement purposes.  If the 
women indicated history of fracture in the non-dominant arm,  the dominant arm was 
used. 
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The research nurse followed the following procedures: 
 Completed the relevant details required for entry prior to the scan.  Most of this 
information was collected prior to the measurement itself (age, height, weight etc) 
 Asked the woman to roll up her sleeve past the elbow and remove her watch/bracelets 
etc.  Rings were to be left in place. 
 The arm was inserted into the scanner while the subject was seated comfortably next 
to the DEXA equipment and the hand held the central stem.  The client was asked to 
find a comfortable seated position as they were required to keep the arm still for the 
duration of the measurement (4-5 minutes). 
 On completion of the measurement  the screen was checked  to view the image of the 
forearm for the following important points: 
 
a Previous fracture unknown to the subject in the scanned area (area  appeared        
dense and white and  resulted in a raised measurement result). 
b. Movement of the subject could be detected by changes in smooth outline of 
forearm visible on the scan. 
c. Tissue area between bones on the scan was checked to see if any area was not 
represented by the red  colour. In this case the cursor was used to indicate the 
correct areas on the scan and the information was entered. 
 
Only when these major points had been considered was the scan accepted. If the 
scan was unclear or the participant moved the scan was repeated. 
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Spine/Hip/Femoral neck BMD measurement 
 The measurement was taken at Jackpersad, Rooknoodeen and partners Inc, Westridge 
Medical centre, Durban. This scan was taken by a qualified radiologist in the X-ray 
department. A study staff member was in attendance to welcome study participants and 
explained the process to them. The measurement was taken while the participant was 
lying flat on an examination couch and the measurement time was approximately 3 
minutes.  
 
Blood tests (40-49 age group) 
 
Blood tests were taken at admission and yearly thereafter for measurement of FSH and 
LH. 
The research nurse followed the following procedures: 
Completed all the documentation and ensured that the blood tube was labeled with name, 
study number and project name.  Any blood tubes collected were taken on the same day 
to Addington Hospital, chemical pathology laboratory for separation and storage.  The 
trial  assistant was responsible for daily transfer of samples between clinic and Addington 
Hospital. 
 
 3.15.4.2 Forms completed and information given at admission 
The following forms were completed at admission: 
 Admission 
 Examination 
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 Contact details 
 Lab form (40-49 age group) 
Other administrative details 
 FP card checked 
 Follow-up appointment arranged 
Verbal reminder of important points to subject  
 Subjects were seen again after six months for full examination 
 Subjects should come back for the appointment even if they change clinic / method. 
 Subjects could phone study nurse at any time (phone number supplied). 
 
After all the admission study procedures were completed, women using a hormonal 
method were given reminders of their  repeat family planning visit 2/3 months later 
(depending on the hormonal method). They were given R50.00 compensation for study 
participation.  At this and any following routine family planning visit,  if the participant 
was seen by the study nurse for her contraceptive method she would be reminded  of her 
next study visit.   
 
2.15.5  Follow-up 
2.15.5.1 General outline 
Follow-up appointments were scheduled to be at approximately six-monthly intervals.  
An appointment slip with a return date was given to the woman or she could choose  to 
have the date entered on her family planning card or she put the date in her diary. The 
window period for the six-month follow-up was 6-12  months after the follow-up 
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appointment date.  No woman was seen earlier than 6 months. Women were seen before 
or after their routine family planning appointment depending on waiting times.  
Appointments were staggered to ensure least possible waiting times for subjects.  Non-
users of contraception who did not need to attend the clinic, were given appointments at 
six months intervals. Women were given R50.00  at each follow-up visit as compensation 
for study participation. This covered transport costs to the site. In cases where women 
moved out of the Durban area and still wished to continue in the study, arrangements 
were made to see women at a time when they were visiting Durban or the study paid 
additional travel costs.  
 
2.15.5.2 Examinations 
The same examinations and procedures were undertaken as at the admission visit: 
 Height 
 Weight 
 Waist / hip / arm circumference 
 Bone mass measurement 
 Blood tests once a year for 40 – 49 age group (yearly at every other follow-up) 
 
2.15.5.3 Forms completed and information given at follow-up visits 
The following forms were completed at admission:- 
 Examination 
 Follow-up 
 New contact forms if required 
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Verbal information given 
 Motivation to continue with study 
 Blood test results from test taken at last visit 
 
2.15.6 Non-attendees 
If a subject did not attend for her appointment on her stated return month, she would be 
contacted by telephone if she had consented and had given the study nurse her details on 
the confidential address form (Appendix 1). She would be reminded of her appointment 
and rebooked. Women in the study who did not have access to a telephone were sent 
reminder letters by post. If there was no response to either telephone calls or letters the 
trial assistant  would visit the address and deliver a letter if the subject was not present.    
If the subject wished to discontinue, a discontinuation form was completed with details of 
why the subject withdrew from the study. All non-attendees’ study cards were kept in a 
separate file until they had been contacted. If there was no contact with a subject for 18 
months or the letter was returned undelivered the subject was discontinued as a loss-to-
follow-up. 
 
2.15.7  Blood test processing 
Blood tests for measurement of FSH and LH were undertaken by: 
Albert Luthuli Hospital, Dept of Chemical Pathology,Cato Manor, Durban 
Initial processing of blood tests and storage were conducted by: 
Addington Hospital, Dept of Chemical Pathology,Prince Street, Durban 
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Blood sample procedure: 
All samples were  labeled and transferred to Addington Hospital, Chemical Pathology on 
a daily basis.  Samples were checked in, centrifuged and separated by lab staff and stored 
at -20oC.  Depending on sample load, samples were taken every 2-4 weeks to Albert 
Luthuli for  analysis.  Test results were faxed to the Reproductive Health and HIV 
Research Unit within 2 days.  Original test results were faxed or collected by a member 
of the study team. 
 
2.15.8 Notification of results to subjects 
2.15.8.1 Blood test results 
If the FSH / LH fell within normal levels, this was reported to participants at their next 
visit to clinic.  If the level was raised (above 25.8 lU/Ml), another test was taken at the 
next follow-up visit.  If raised again the participant was referred to a clinician who would 
discuss appropriate changes in method. 
 
2.15.8.2   Need for referral and referral criteria 
There were instances where the subjects needed to be referred for further investigation, in 
these cases the following criteria were used: 
 Subject was found to fall 2SD below limits set at the outset of the study for bone 
mass measurements. 
 Subject requests procedure not undertaken by study, HIV test, sterilization or other 
medical treatment. 
 Study nurse diagnoses a condition that requires referral e.g. high blood pressure. 
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 FSH/LH raised as per ( 2.15.8.1) 
Standard referral letters were given to participants (Appendix 6) 
 
The following referral mechanisms were agreed to with individuals and institutions. 
 Subjects requested examination or test that is not part of the study.  For example, 
the subject complained of symptoms of STIs.  The study nurse will referred her to 
the routine clinic staff. 
 Any conditions detected by the study nurse such as high blood pressure was 
referred to clinic staff. 
 A clinician was available at the clinic on a sessional basis.  Issues around 
menopause and test results related to menopause were referred to the clinic doctor 
(Dr Popis).  The study nurse asked the  subject to return during the doctor’s sessions 
and provided the doctor with all necessary documentation that the study had 
collected in relation to the event in question. 
 If the subject chose to be referred to her own local general practitioner a referral 
letter was be given to the subject to take with her.  
 If the bone mass fell below 2SD of the normal range the client was referred for 
further investigation.  
 
2.15.9 Quality Control 
2.15.9.1    Bone mass measurement  
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Every two months a random sample of 5 women was re-measured.  Measurements were  
conducted by a different investigator who did not have access to the original 
measurement.  
 
Phantom measurement 
Daily QC measurement was conducted by using the “phantom”.  This is a perspex block 
representing the bone area measured in the forearm. This measurement should provide 
the same results on a daily basis which can be plotted to monitor measurement drift. The 
phantom block was inserted into the same position as the arm and a phantom scan was 
run on a daily basis as the first measurement of the day.  The data generated by the 
phantom were checked daily to ensure it lay within expected limits.  A monthly printout 
of phantom records were generated and filed in the QC file (Appendix 3).  If the phantom 
reading showed signs of drift or any one measurement fell outside normal limits the 
technician from Marcus Medical was  contacted immediately (Appendix 7 contact 
details). The equipment was serviced yearly throughout the study. 
 
2.15.9.2   FSH / LH measurement 
The laboratory had its own internal QC procedure.  In addition every 20th blood sample 
drawn was duplicated.   Extra blood was taken and an extra test was sent blind to the 
laboratory. 
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2.15.9.3 Physical measurements 
Every two months a random sample of five women had a repeat height, weight, waist, 
hip, BP and arm circumference taken.  Measurement was conducted by a different 
investigator who did not have access to original measurements. 
 
2.15.9.4 Data forms 
All forms were double-entered for verification, any discrepancies or queries were verified 
with the principal investigator  
 
2.15.10 Collaborators 
Details of collaborators and nature of collaboration can be found in Appendix 7. 
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CHAPTER 3.0 RESULTS  
3.1 Organisation of the results 
The results chapter is divided into seven sections and this first section briefly overviews 
the contents of each section. Section  3.2 describes the screening, recruitment and follow-
up. Section 3.3 to 3.8 are made up of six papers (4 published, 1 in print and one in 
preparation) generated from the data collected during the study. The reprints of published 
work can be found in Appendix 8.  Each paper contains its own methodology, results and 
discussion.  
 
Section 3.3  presents the results of the analysis of the effect of hormonal contraception 
and BMD in the complete adolescent cohort follow-up. It  also reports on the BMD of a 
small group of women who have discontinued NET-EN. This paper was published in 
May 2009. 
 
Section 3.4 presents the results of a cross-sectional substudy, where hip, spine and 
femoral neck were measured. On completion of the five year cohort follow-up, a 
subsample of women  (n=96) in the adolescent group participated in this component of 
the  study. This paper will be published in August 09 
 
 
Section 3.5 presents the results of the interim analysis based on the first 3 years of the 
study and  includes the adolescent women. These women had been recruited between 
June 2000 and July 2002 and so by early 2004 women had been participating for between 
18 months to 3 years. This interim analysis was published in 2007. 
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Section 3.6  presents cross-sectional baseline data from the older age group of women. 
This paper was published in 2005 on completion of  baseline data  collection. 
 
Section 3.7  presents the anlaysis of the longitudinal data  in the older age group. This 
paper is in preparation and will be submitted in 2009. 
 
Section 3.8 Presents the data from baseline analysis of the FSH and BMD  in older 
woman using DMPA and NET-EN. 
 
3.2 Screening, recruitment and follow-up 
3.2.1 Screening and recruitment 
Study recruitment commenced in June 2000. In total 1107 women were screened and 991 
women were recruited. Five women were excluded shortly after recruitment and these 
exclusions were related to undisclosed medical conditions at screening (n=2) and women 
found to be outside the study age ranges (n=3) at screening. These 3 women had 
indicated they were in the correct age range at admission however all women were asked 
to bring in at the first follow-up visit (if not seen at admission) proof of age by means of 
an official document (ID book or family planning card).   These 5 women were removed 
from the database. This resulted in a total of 986 eligible women continuing in the study. 
The breakdown of the participants by study group is shown in the flow chart (Fig 1).   
The minimum sample size for each group (100) was achieved across all groups. Groups 
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were over recruited where it was anticipated that there was potential for greater loss-to 
follow-up.  
 
Figure 3.2.1 Number of women admitted into each study group 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          5 excluded 
 
 
 
 
 
 
 
 
  
  
Table 3.2.1 shows the main reasons for exclusion at screening. In the older group many 
women were excluded due to existing medical conditions that could affect BMD. Some 
women had gynaecological histories that indicated that they may already have 
      1107 Screened
      N=991 Admitted 
     40-49yrs 
     N=496 
    15-19yrs 
       N=490 
DMPA 
N=115 
NET- 
EN 
N=115 
COC 
N=116 
Nonuser 
N=144 
Nonuser 
N=161 
DMP
A 
N=127 
NET -
EN 
N=102 
COC 
N=106 
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menopaused.  In the younger group women were mainly excluded for current or recent 
pregnancy and/or breastfeeding.  
 
 
Table 3.2.1 Reasons for exclusion at screening 
 
 
 
 
 
*Screening form lists medical conditions  (Appendix 1)  
Exclusion criteria Age group  
15-19 
%         (n=58)
Age group 
40-49 
%    (n=63) 
Currently breastfeeding 
Pregnant in last 6 months 
TB 
Out of age range 
Hysterectomy/opherectomy 
menopause 
Medical conditions* 
Previous contraceptive use 
8.6           (5) 
51.7         (30) 
17.2         (10) 
8.6            (5) 
0              (0) 
N/A 
3.7            (2) 
10.3          (6) 
14.2    (9) 
3.1       (2) 
3.1      (2) 
20.6    (13) 
9.5       (6) 
7.9       (5) 
41.2     (26) 
N/A 
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Women were recruited and admitted from June 2000 until May 2003. Fifty five 
percent of women were recruited in the first year of the study and by the end of the 
second year all younger women had been recruited.  The remaining 8% were recruited 
in year 3 and composed of older NET-EN users who were the most difficult category 
to recruit due to the low numbers of women who use this injectable product in this age 
group. The majority of women over 40 years of age and using injectable contraception 
use DMPA and the recruitment in this study group was completed within 18 months. 
In the younger group the slowest recruitment was in the DMPA group as NET-EN is 
the injectable method most popular with young women. This age group differential in 
use of the two available injectables persists across South Africa and has been well 
documented previously (Department of Health, South Africa, 2006). 
3.2.2  Follow-up 
The study continued to follow-up women until April 2006 when the study was 
completed. All women recruited in the first 10 months of the study were potentially 
able to participate in  the full 5 years of follow-up. Those recruited after this time  
were followed up for a maximum of 3-4 years depending on their date of recruitment.  
Follow-up rates are shown in table 3.2.2 for both 2 and 4 years. It can be seen that the 
older age group follow-up rates are higher than those of the younger women.  
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Table 3.2.2 Follow-up rates at two and four years in each age group 
 
 
 
 
 
*Follow-up rate at four years is only shown for those women who potentially were able to 
complete at least 4 years in the study. 
  
The study attempted to contact all women who did not attend their 6-monthly 
appointments. Women were contacted telephonically after they were one month late 
for their scheduled visit. If no telephone contact number was available a letter was sent 
as a reminder. After three letters had been sent a fieldworker attempted to visit the 
address given to locate the participant. If the participant had moved away they were 
discontinued from the study. A follow-up form was completed for non-attendees 
(Appendix 1), and those who were lost-to follow-up were discontinued and a 
discontinuation/end of study form was completed (Appendix 1). Women who were 
traced and still wished to participate were allowed to continue as long as they were 
able to document their contraceptive use and their family planning cards were 
checked. 
Reasons for discontinuation before end of study are shown in Table 3.2.3.  The main 
reasons for discontinuation was loss to follow-up and women moving out of the area.  
In cases of loss-to-follow-up the study staff were unable to contact the participant. 
Women who moved away often reported to the study that they would not be able to 
attend again.  Eighteen women had died and the study was informed by a friend or 
Age group 2 years 
% 
4 years*  
% 
15-19 
40-49 
 73 
 83 
43 
61 
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relative. Where available, cause of death was collected. Most of the deaths appeared to 
be AIDS related with several deaths due to TB.    
 
Table 3.2.3 Reasons for study discontinuation 
Reason for 
discontinuation 
%          N=986 
End of study (completed)  
Loss to follow-up* 
Pregnancy 
Medical condition 
Moved away** 
Death 
Withdrew 
52.0            (513) 
18.1            (179) 
 3.0               (30) 
 1.9              (19) 
22.1           (218 ) 
  1.8             (18) 
  0.9               (9) 
Total 100             986 
* Loss to follow-up was defined as no contact after non-attendance 
** Moved was defined as verbal or written contact with participant that she had moved 
out of the area and was no longer able to attend 
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Abstract 
Background: Depot-medroxyprogesterone acetate (DMPA), norethisterone enanthate 
(NET-EN) and combined oral contraceptives (COCs) have been shown to have a negative 
effect on bone mineral density (BMD) in adolescents. The aim of this study was to 
investigate BMD in 15-to 19-year-old new users of DMPA, NET-EN and COCs. 
Study Design: This 5-year longitudinal study followed-up new users of DMPA (n=115), 
NET-EN (n=115), and COCs (n=116), and 144 nonuser controls. BMD was measured at 
the distal radius using dual x-ray absorptiometry.  
Results:  BMD increased in all groups (annual percent increase: nonusers, 1.49%; 
DMPA, 1.39%; NET-EN, 1.03%; COCs, 0.84%) during follow-up (p<0.001). There was 
evidence for lower BMD increases per annum in NET-EN (p=.050) and COC (p=.010) 
users compared to nonusers but no difference between DMPA and nonusers (p=.76). In 
14 NET-EN discontinuers, an overall reduction of 0.61%  per year BMD was followed 
upon cessation by an increase of 0.69% per year (p=.066).  
Conclusion: This study suggests that BMD increases in adolescents may be less in NET-
EN and COC users; however,  recovery of BMD in NET-EN users was found in the small 
sample of adolescents followed post-discontinuation. 
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Introduction 
Depot-medroxyprogesterone acetate (DMPA) has been found to have a negative effect on 
bone mineral density (BMD) in adult premenopausal women (Curtis and Martins, 2006; 
Wanichsetakul et al, 2002; Petitti et al, 2000; Scholes et al, 1999;; Cundy et al, 1991) and 
in adolescents (Cromer et al, 2008; Clark et al, 2006; Scholes et al, 2005; Cromer et al, 
2004; Lara-Torre et al, 2004; Scholes et al, 2004; Busen et al, 2003; Cromer et al, 1996). 
Limited data on the effect of norethisterone enanthate (NET-EN) have found a negative 
effect on BMD in adult (Rosenburg, et al,2007) and adolescent users (Beksinska, et al 
2007). A comprehensive review concluded that combined oral contraceptive (COC) use 
in adult premenopausal women was not associated with changes in BMD (Martins, et al, 
2006).   However, emerging data show that BMD may be compromised in adolescent 
users of low-dose COCs (Hartard, et al, 2006; Cromer, et al, 2004; Polatti et al, 1995).   
 
Studies that have followed women after discontinuation of DMPA have found that BMD 
recovers in adult pre-menopausal women within approximately 2-3 years of cessation of 
the method (Kaunitz, et al, 2008; Scholes, et al, 2002). Two studies have followed-up 
adolescent users of DMPA post-discontinuation (Clark et al, 2006; Scholes et al, 2005), 
and in both these studies, a significant increase in BMD was found in adolescents who 
discontinued DMPA.  No longitudinal data are available on recovery of BMD in 
adolescent NET-EN and low-dose COC users. More evidence is needed to show if the 
recovery of BMD found in adult users of hormonal contraception is replicated in 
adolescents.  The objective of this study was to determine if long-term use of hormonal 
110 
 
contraceptives (COC, DMPA and NET-EN) compared to non-use, was associated with a 
change in bone mass in women aged 15-19 years. 
 
Subjects and methods 
This was a prospective longitudinal study of adolescents aged 15 to 19 years who had 
never used hormonal contraception prior to recruitment to the study. Initiators of DMPA, 
NET-EN, COCs, and nonusers of contraception were enrolled from a family planning 
clinic in Durban, South Africa. The study cohort was recruited between July 2000 and 
July 2002 and follow-up continued until April 2006.  All DMPA users were started on a 
regimen of 150 mg every 12 weeks and NET-EN users on 200 mg every 8 weeks. Both 
DMPA and NET-EN was administered intramuscularly. The COCs used by women 
included a range of formulations, with almost all (93%) using low-dose formulations 
containing between 30-40 mcg of estrogen. Women were eligible to participate if they 
had not lactated or delivered in the past 6 months, were not currently or had never used 
medication known to affect calcium metabolism for more than 3 months, and did not 
have a chronic disease affecting calcium metabolism. At the baseline visit, participants’ 
height, weight and blood pressure were measured using a standard protocol and a 
questionnaire was administered to elicit information on demographic characteristics, 
regularity of the menstrual cycle, smoking, diet, exercise and caffeine and alcohol intake. 
 
Forearm BMD was measured by dual energy x-ray absorptionmetry (DXA model DTX-
200,  Osteometer MediTech A/S Co, Rodovre, Denmark).  BMD was measured in grams 
per square centimetre (g/cm2) at the distal radius in the forearm. The DXA equipment was 
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standardized daily using a phantom as prescribed by the manufacturer’s instructions.   
Accuracy to the standard during the recruitment and follow-up period was 0.53%.  
 
Study participants were followed-up at approximately six-monthly intervals. Forearm 
BMD, height and weight were measured at each follow-up visit. History of contraceptive 
use since last visit was recorded. Those recruited between July 2000 and April 2001 and 
who continued to participate until the end of the study completed 5 years of follow-up. 
Those recruited after April 2001 who continued until the end of the study, completed 
between 4 and 5 years of follow-up. Follow-up could not continue beyond April 2006 
when project funding came to an end. Women continued the same follow-up schedule 
even if they stopped, changed or started another contraceptive method in order to 
investigate issues of recovery of BMD post-discontinuation of a hormonal method.  
 
The characteristics of women in the study were quantified as means + SD, medians, or 
percentages. The study was powered to detect a half standard deviation difference in bone 
mass between users and nonusers of hormonal contraceptives. This would be of 
biological significance as this difference is expected to translate into a large difference in 
the risk of fracture in older women. Information on the mean and standard deviation of 
cross-sectional measurements of forearm bone mass in white, European, premenopausal 
women reported by Nordin (Nordin, 1987) was used to estimate sample size. A sample of 
63 participants per contraceptive group was required assuming a two-tailed statistical test 
with a significance level of 5% and power of 80%. Allowing for 10-15% loss to follow-
up per year, this sample was increased to at least 110 women in each group to ensure 
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adequate numbers in long-term follow-up. The nonuser group was over recruited 
compared to other groups as, in addition to loss to follow-up, it was anticipated that some 
of these women would commence a method of contraception or become pregnant.  
 
Differences in BMD between contraceptive groups, and the associations between BMD 
and selected characteristics of the study participants by contraceptive group were 
assessed using one-way analysis of variance and multiple variable linear regression.  
BMD was measured in users and discontinuers. Follow-up of all women was cumulated 
up to their last visit, or up to the visit preceding a visit at which they reported a change in 
contraceptive method, whichever occurred first.  
 
Interim analysis of this study found that BMI was significantly associated with radius 
BMD (Beksinska, et al, 2007). To assess the effect of contraceptive method on radius 
BMD, and to allow for within subject correlation of responses whilst controlling for the 
confounding effect of changes in BMI, we used random effects linear regression methods 
with radius BMD at the time of a study visit as the response variable, and contraceptive 
method, duration of follow-up and BMI at time of the visit as explanatory variables 
(STATA V.10, College Station, TX, USA). Differences in rate of change in radius BMD 
per year between methods were calculated by including interaction terms in the model for 
method and follow-up time. Additionally, we investigated whether change in radius 
BMD varied between two time periods by including an interaction term between follow-
up time up to the last visit occurring before 2.5 years and follow-up time between 2.5 and 
5 years, for each user-group separately.  These two time periods were chosen as the 
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literature indicates that the greatest loss of BMD as a result of hormonal contraceptive 
use occurs over the first 2 years of use (Tang,et al, 2000) and then loss continues at a 
slower rate and appears to stabilize. Finally, we investigated BMD in women who 
discontinued hormonal contraception. 
 
Ethical approval was granted by the University of the Witwatersrand, Human Subjects 
Research Committee (protocol number M981001), and by the Scientific and Ethical 
Review Group of the World Health Organization (WHO). 
 
Results 
In total, 490 women aged 15-19 years were recruited. All women including those in the 
DMPA, NET-EN and COC groups had no past use of hormonal contraception before 
recruitment into the study.  Baseline information about these women is summarized in 
Table 3.3.1. Mean age was just under 18 years and most women were still in full-time 
education. The majority of women were African except in the COC group, which 
included 22% women of Indian origin and 21% Coloured. More than a quarter of women 
(29.3%) in the DMPA user group had ever been pregnant compared to low prevalence of 
pregnancy in the other groups. COC users were more likely to be smokers than other 
method users, although smoking generally was low across all groups. 
 
In total, 277 women continued with the same method of contraception for at least two 
follow-up visits, while the rest had changed method or stopped using contraception. Total 
same-method follow-up time was 648 person-years in these 277 participants. Women 
114 
 
who continued in the study using a different method of contraception, or stopped using 
contraception, were included up to the visit they changed method. Overall, 64% of 
woman continued in the study for between 2-3 years and 43% completed between 4-5 
years of follow-up depending on time of recruitment. Main reasons for discontinuation 
from the study included pregnancy, illness that could have affected BMD such as 
tuberculosis, loss to follow-up and moving out of the area.  
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Table 3.3.1 Socio-demographic, lifestyle and reproductive characteristics of subjects 
aged 15-19 years by contraceptive user group, at baseline.  
 
Characteristics DMPA 
(n=115) 
NET-EN 
(n=115) 
COC 
(n=116) 
Non user 
controls  
(n=144) 
 
P value 
Mean age, years (SD) 
Mean highest education grade 
(SD) 
Marital status, % 
        Married/cohabiting  
        Reg partner-not cohabiting 
        Casual partner 
         No partner 
 
Employment status % 
         Employed full/part-time 
         Unemployed        
         Student/scholar 
 
Ethnicity %   
         African 
         Coloured 
         Indian 
 
Ever pregnant % 
Ever lactated % 
Lactation (yrs) median 
Mean age at menarche, years(SD) 
 
Exercise 
          No regular exercise (%) 
          At least once a week (%) 
 
Dieted in last 6 months (%) 
 
Ever smoked cigarettes (%) 
 
Current smoker (%) 
17.8 (1.4) 
10.9 (1.5) 
 
   
  5.3 
92.1 
  2.6 
    0 
 
 
  6.2 
11.4 
82.5 
 
 
94 
  5 
  1 
 
29.3 
16.7 
<1 
13.9±1.3 
 
 
78.1 
21.9 
 
  3.5 
   
  9.6 
  
  6.0 
17.4 (1.3) 
10.5 (1.5) 
 
 
  5.2 
83.8 
  5.2 
  0.9 
 
 
  2.6 
10.5 
86.8 
 
 
89 
  7 
  4 
 
 3 
0.9 
<1 
13.8±1.2 
 
 
72.8 
27.2 
 
  2.6 
 
11.3 
   
  7.0 
17.8 (1.0) 
11.3(0.8) 
 
 
10.3 
87.1 
  2.6 
     0 
 
 
  9.5 
  8.5 
79.1 
 
 
57 
21 
22 
 
 6 
2.6 
<1 
13.6±1.48 
 
 
64.9 
35.1 
 
  5.3 
 
27.3 
 
13.9 
17.4 (1.2) 
10.3 (1.4) 
 
 
12.8 
63.5 
23.0 
  0.7 
 
 
  2.7 
  7.4 
98.8 
 
 
92 
  4 
  4 
 
  2 
1.4 
<1 
13.5±1.29 
 
 
77.7 
22.3 
 
  2.0 
  
  4.8 
   
  3.4 
0.0002 
0.0001 
 
 
0.0001 
 
 
 
 
 
<0.0001 
 
 
 
<0.0001 
 
 
 
 
<0.0001 
 
 
0.19 
 
 
0.0001 
 
 
0.54 
 
< 0.001 
 
0.006 
 
DMPA= depot medroxyprogesterone acetate; NET-EN = Norethisterone enanthate; 
COC= combined oral contraceptive    SD= standard deviation;  
 
 
 
 
Table 3.3.2 shows mean BMD and BMI at enrolment for each group. Radius BMD was 
similar in all four contraceptive user groups at baseline (p=.196). The regression model 
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showed that BMI was the only baseline characteristic associated with radius BMD (p< 
0.001). BMI increased consistently by 0.11 kg/m2  per year (95% CI 0.04 to 0.18) in all 
user groups with no evidence of differences in growth between groups (p=0.14). 
 
Table 3.3.2 Mean BMD and BMI at admission by contraceptive group  
 
 
 Variable 
DMPA 
n=115 
NET-EN 
n=115 
COC 
n=116 
Nonuser 
n=144 
p value 
Radius BMD g/cm2  
Body weight (kg) 
Height (cm) 
BMI (kg/m2) 
0.459 (0.06) 
59.1   (12.1) 
154.8  (5.2) 
24.63 (4.77) 
0.446 (0.06) 
59.5   (9.8) 
156.1 (5.7) 
24.31 (3.75) 
0.460 (0.05) 
56.7  (11.4) 
156.2  (7.5) 
23.18 (4.97) 
0.455(0.05) 
59.7 (11.6) 
155.9 (7.3) 
24.61 (5.85) 
0.196 
0.13 
0.30 
0.097 
BMD= bone mineral density; BMI=body mass index 
Data are expressed as mean + SD 
 
 
Radius BMD increased in all groups during follow-up (Table 3.3.3), even after adjusting 
for changes in BMI (p<.001) with an overall increase for all women combined of 1.39% 
per annum (95% CI 1.19 % to 1.59 %). In nonusers, BMD increased by 1.49% per 
annum; in the DMPA, NET-EN and COC users, the increases were less 1.39% (p=.76), 
1.03 % (p=.05) and 0.84% (p=.01),  respectively (Table 3.4.3). There was moderate to 
strong evidence for smaller increases per annum in NET-EN (p=.050) and COC (p=.010) 
users compared to nonusers. There was no evidence for a difference in BMD between 
DMPA and nonusers (p=.76) (Table 3.3.3).  
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Table 3.3.3 Factors associated with radius BMD at study visit, estimated from 
random effects liner regression model. 
 
Variable % change in BMD  
(95% CI) per annum 
 % change in 
BMD per 
method relative 
to non user (p) 
 
N 
Time at 
risk 
(years)  
Use of contraceptive 
method,  per year*   
Non user (reference) 
DMPA, 
NET-EN 
COC 
 
Effect of BMI, per unit 
change in BMI (% per 
kg/m2)† 
 
 
1.49 (1.25-1.72) 
1.39 (0.79-1.98) 
1.03 (0.63-1.44) 
0.84 (0.39-1.28) 
 
0.267 (0.157-0.377)  
 
 
0 
-0.10 (p=0.76) 
-0.45 (p=0.050) 
-0.65(p=0.010) 
 
 
96 
51 
71 
59 
 
277 
 
 
311 
76 
146 
116 
 
648 
 
*Adjusted for BMI 
† Adjusted for contraceptive method 
 
There was no evidence of a difference in change in radius BMD in the two time periods 
(up to 2.5 years and 2.5 years and longer) in any of the four study groups (DMPA 
p=0.105, NET-EN p=0.7, nonusers p=0.46, COC p=0.06).  
 
We investigated changes in BMD in a group of 14 NET-EN users who discontinued use 
of the method without restarting another method during the course of the study. An 
overall reduction in radius BMD of 0.61% (95% CI= -2.53% to 1.34%) per year was seen 
in the 14 NET-EN users during use of the method, followed upon cessation of method by 
an increase of 0.69% (95% CI= -0.18% to 1.56%) per year. After adjusting for BMI, 
there was some evidence of a difference in rate of BMD change pre and post use of NET-
EN (p=0.066). Most COC and DMPA discontinuers restarted other methods, thus there 
were too few to conduct a group analysis.  
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Discussion  
Our results show that radius BMD increased during follow-up in the nonuser and all three 
user groups after adjusting for BMI. There was some evidence of less increase in NET-
EN and COC groups compared to the nonuser group. Our results confirm those obtained 
from an interim analysis of this study (Beksinska, et al, 2007) in regard to NET-EN. 
However, in the preliminary analysis, COC users did not show any differences in BMD 
growth from nonusers, possibly because the interim analysis lacked power. In the only 
other study that has previously investigated the effect of NET-EN use (Rosenburg, et al, 
2007), BMD was measured in the left calcaneus in a large cross-sectional sample of adult 
premenopausal women. NET-EN users had similar values to DMPA users and these were 
both significantly lower compared to never users.   
 
We found no evidence of any change in BMD growth in the period up to 2.5 years of use 
compared to the period from 2.5 years of use.  Several studies have reported that the rate 
of loss of BMD in DMPA users is greatest in the first two years of use (Clark, et al, 2006; 
Curtis and Martins, 2006; Scholes, et al, 2005; Tang, et al, 2000). Only one of these 
studies has investigated rate of change in adolescents (Scholes, et al, 2005). 
 
Several longitudinal studies have found that adolescent users of low-dose COCs may gain 
bone mass at a slower rate compared to nonusers (Hartard et al, 2006; Cromer, et al 2004; 
Polatti, et al, 1995). The COC formulations in our study were similar to those reported in 
these studies. Our study also showed that COC users gained BMD at a slower rate than 
nonusers.  Although DMPA users had a lower yearly increase in BMD compared to 
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nonusers, this was not significant. Other studies measuring BMD at central sites such as 
the hip and spine have found that adolescent DMPA users have lower BMD values 
compared to nonusers (Cromer et al, 2008; Clark et al, 2006; Scholes et al, 2005; Cromer 
et al, 2004; Lara-Torre et al, 2004; Scholes et al, 2004; Busen et al, 2003; Cromer et al, 
1996). Studies using the forearm as a site of BMD measurement have generally not found 
significant differences between DMPA users and controls (Bahmondes, et al, 1999; 
Tharnprisarn, et al, 2002). Our study has found similar results to others measuring the 
forearm with respect to DMPA.  The forearm may be more sensitive to the effect of 
NET- EN and COC and it may be that these results would be magnified if measured at a 
central site such as the hip or spine. No studies have measured BMD at central sites in 
NET-EN users. 
 
Our study shows some evidence of a recovery in growth in BMD in a very small sample 
of NET-EN discontinuers who did not use another method of contraception after 
cessation.  The cross-sectional study that investigated women who commenced NET-EN 
during adolescence (18 years and younger) and then ceased using the method 
(Rosenburg, et al, 2007), found no difference in BMD values between those who had 
ceased use 2-3 years before and never users regardless of whether they were early starters 
(adolescents) or late starters (post-adolescence). It was not possible to make any 
statement about BMD recovery in the COC and DMPA discontinuers in our study as 
numbers were so small.  
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DMPA suppresses estradiol production, leading to estrogen deficiency (Ortiz, et al, 
1977). This leads to greater bone resorption and hence loss of BMD. There is less 
information on NET-EN and the mechanisms by which it could affect BMD. Studies on 
NET alone have not found negative effects on BMD (Horowitz, et al, 1993; Eldred, et al, 
1992; Riis, et al, 1990).  There is now limited data available on recovery of BMD in 
women who commence DMPA in adolescence (Clark, et al, 2006; Scholes, et al, 2005). 
This is the first longitudinal study which has included NET-EN users and discontinuers. 
Further evidence is needed to ensure that any losses of BMD as a result of DMPA and 
NET-EN in adolescence are fully recovered and peak bone mass is not compromised. 
Until that time, the recommendations for DMPA and NET-EN in adolescents will 
continue to caution long-term use in young women.  
 
The third edition (2004) of the World Health Organization’s Medical Eligibility Criteria 
for contraceptive Use (WHO, 2004) has changed the classification of use of DMPA and 
NET-EN for women below 18 years and above 45 years from category 1 (no restriction 
for the use of the contraceptive method), to category 2 (advantages of using the method 
generally outweigh the theoretical or proven risks). This is backed up in the document by 
a number of statements reporting on current evidence of the effect of DMPA on BMD. 
The WHO has recommended that in the absence of evidence on NET-EN, the same 
restrictions should apply to NET-EN users.  
 
Our study shows that although BMD continues to increase in adolescent users of NET-
EN and COCs, these increases are lower than in nonusers. Although the percent yearly 
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increase in DMPA users was lower than nonusers, there was no evidence of a difference 
and this may have been because this group had the lowest number of years at risk 
included in the analysis. 
 
Limitations 
Longitudinal studies of adolescent users of hormonal contraception are often limited by 
method discontinuation. This was the case in our study where few women remained on 
hormonal contraception for more than two years without a change of method or stopping 
use of contraception altogether. Concerns regarding long-term use of DMPA and NET-
EN in adolescents should take this into consideration as many young women will have 
discontinued use before the 2-year review suggested on the patient labelling. Our study 
has used the forearm as its site of measurement which may be less sensitive than the hip 
and spine to changes in BMD resulting from hormonal contraceptive use. 
 
122 
 
3.4 Bone mineral density in young women aged 19-24 after 4-5 
years of exclusive and mixed use of hormonal contraception 
 
Mags E Beksinska1 , Immo Kleinschmidt2, Jenni A Smit1 Timothy M M Farley3 
 
 
This paper is in press at Contraception 2009; vol.79, no.8  (Appendix 8) 
 
 
 
 
1Reproductive Health and HIV Research Unit, Department of Obstetrics and 
Gynaecology, University of the Witwatersrand,  Mayville, 4091, South Africa  
2 London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 
3UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and 
Research Training in Human Reproduction, CH 1211 Geneva 27, Switzerland. 
 
123 
 
 Abstract  
Background: Use of Depot-medroxyprogesterone acetate (DMPA), norethisterone 
enanthate (NET-EN) and low-dose combined oral contraceptives (COCs) has been 
associated with loss of bone mineral density (BMD) in adolescents. However, the effect 
of using a combination of these methods over time in this age-group is limited. The aim 
of this cross-sectional study was to investigate BMD in young women (aged 19-24 years) 
with a history of mixed hormonal contraceptive use.  
Study design: BMD was measured at the spine, hip and femoral neck using dual X-ray 
absorptiometry. Women were classified into 3 groups; 1) injectable users (DMPA, NET-
EN or both) (n=40), 2) Mixed COC and injectable users (n=13), and 3)  nonuser control. 
(n=41).  
Results: Women in the injectables only user group were found to have lower BMDs 
compared to the  nonuser group at all three sites and there was  evidence of a difference 
in BMD  between these two groups at the spine after adjusting for BMI (p=0.042), hip 
(p=0.025), and femoral neck (p=0.023). The mixed COC/injectable user group BMD 
values were lower than controls; however, there was no evidence of a significant 
difference between this group and the nonuser group at any of the three sites.   
Conclusion: This study suggests that BMD is lower in long-term injectable users, but not 
when women have mixed injectable and COC use.  
124 
 
 Introduction 
The long-acting progestogen injectable contraceptives depot-medroxyprogesterone 
acetate (DMPA) and norethisterone enanthate (NET-EN) have been found to have a 
negative effect on bone mineral density (BMD) in adult premenopausal women (Curtis 
and Martins, 2006; Wanichsetakul et al, 2002; Petitti et al, 2000; Scholes et al, 1999; 
Cundy et al, 1991)  and in adolescents (Beksinska, et al, 2009; Cromer et al, 2008; 
Rosenburg, et al, 2007; Clark et al, 2006; Scholes et al, 2005; Cromer et al, 2004; Lara-
Torre et al, 2004; Scholes et al, 2004; Busen et al, 2003; Cromer et al, 1996). The effect 
of  combined oral contraceptives (COCs) on BMD has been found to be variable with no 
effect reported in adult premenopausal women (Martins, et al, 2006) but growing 
evidence that low-dose COCs may be detrimental to BMD in adolescents and young 
women (Hartard, et al, 2006; Cromer, et al, 2004; Polatti, et al, 1995).   
 
Although recovery of BMD following discontinuation of DMPA is documented in adult 
pre-menopausal women (Kaunitz, et al, 2006; Scholes, et al, 2002) and in adolescent 
users (Clark, et al, 2006; Scholes, et al, 2005), concerns regarding bone loss in DMPA 
users resulted in an US Food and Drug Administration Black Box warning for DMPA 
stating its use may impair BMD (FDA, 2004). In the UK, the Medicines and Healthcare 
Products Regulatory Board (MHRA) suggest that another contraceptive method be used 
after 2 years of DMPA use (FFPRHC, 2004). Much less information is available on 
recovery in NET-EN users as it is not as widely used as DMPA and not available in the 
US or UK. Limited data have found recovery of BMD in adolescent NET-EN users 
(Beksinska, et al, 2009; Rosenburg, et al, 2007).   
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More evidence is needed on long-term use of hormonal contraception and, in particular, 
on women who switch from hormonl injectables to another hormonal method of 
contraception.  The objective of this study was to determine if long-term use of hormonal 
contraceptives, including mixed use (COCs and/or, DMPA and/or NET-EN), was 
associated with a change in bone mass in women aged 19-24 years compared to nonusers. 
 
Subjects and methods 
This cross-sectional study of young women aged 19-24 years measured BMD in the hip, 
spine and femoral neck.  All the women had been recruited 4-5 years previously into a 
longitudinal study where the BMD in the distal radius had been measured at 6-month 
intervals. Details of the longitudinal study methodology and results are described 
elsewhere (Beksinska, et al, 2009). At the end of the follow-up period, additional funds 
allowed for 100 single measurements of the central BMD sites providing an opportunity 
for measurements at other sites. A subsample of women attending their final longitudinal 
follow-up visit were  informed about this additional component of the study at their last 
cohort visit and  were invited to participate. This subsample included all women 
completing the study over a 5-month period. 
 
At the start of the 5-year longitudinal study, initiators of DMPA, NET-EN, COCs and 
nonusers of contraception were enrolled from a family planning clinic in Durban, South 
Africa. All women recruited had no history of hormonal contraceptive use prior to 
enrolment (n=490). The study cohort was recruited between July 2000 and July 2002, and 
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follow-up continued until April 2006.  All DMPA users were started on a regimen of 150 
mg every 12 weeks and NET-EN users on 200 mg every 8 weeks. Both DMPA and NET-
EN was administered intramuscularly. The COCs used by women included a range of 
formulations, with almost all (93%) using low-dose formulations containing between 30-
40 mcg of estrogen. Women were eligible to participate if they had not lactated or 
delivered in the past 6 months; were not currently using and had not  used medication 
known to affect calcium metabolism for more than 3 months; and did not have a chronic 
disease affecting calcium metabolism. At the baseline and follow-up visits, participants’ 
height, weight and blood pressure were measured using a standard protocol and a 
questionnaire was administered to elicit information on demographic characteristics, 
regularity of the menstrual cycle, smoking, diet, exercise and caffeine and alcohol intake. 
It was from this cohort that the 100 women were recruited for the cross-sectional study 
reported here. 
 
History of contraceptive use had been recorded in the longitudinal study over the total 
follow-up period at approximately 6-monthly intervals. Women in the cohort continued 
the same follow-up schedule even if they stopped, changed or started a contraceptive 
method.  The additional visit to measure the hip, spine and femoral neck BMD was 
conducted between Oct 2005 and Feb 2006. The DXA equipment used in the cross-
sectional substudy to measure hip, spine and femoral neck was a Hologic QDR 
discovery, version 12,6, Model: Discovery w(s/n) 49369, Hologic. Inc, USA. The DXA 
equipment was standardized daily using a phantom and accuracy to the standard during 
the measurement phase was 0.44%. 
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The characteristics of women in the study were quantified as means + SD, medians, or 
percentages. Differences in BMD and weight between contraceptive groups, and the 
associations between spine, hip and femoral neck BMD and contraceptive group were 
assessed using one-way analysis of variance and multiple variable linear regression. Data 
were analyzed using the statistical package STATA V.10, (College Station, TX, USA).   
 
 Ethical approval was granted by the University of the Witwatersrand, Human Subjects 
Research Committee (protocol number M981001), and by the Scientific and Ethical 
Review Group of the World Health Organization. 
 
Results 
A group of 100 women who had completed follow-up in the longitudinal phase agreed to 
participate in the cross-sectional substudy. Of these, 96 women attended their 
appointment and 4 women were unable to attend due to work commitments. The 
contraceptive history of these women varied considerably as women had not been 
discontinued from the longitudinal study if they changed or stopped a method. Thirty 
women presented with a history of mixed contraceptive use, including women who had 
used at least two of the study methods (DMPA, NET-EN, and COCs) in the preceding 4-
5 years. Of these 30, 17 women had used both DMPA and NET-EN, 10 had mixed COCs 
and either DMPA or NET-EN, and three women had used all three methods. Far fewer 
women presented as exclusive users of one method at the end of the follow-up period 
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(DMPA  n=9,  NET-EN  n=14,  COC users n=2). The remaining 41 women were 
nonusers of hormonal contraception.  
 
The small number of women who had used one method only, made data difficult to 
anlayse and we therefore classified the women into three broad groups for analysis, 
according to their contraceptive history over the previous 4-5 years in the longitudinal 
component of the study. The first group (n=40) included all users of injectable hormonal 
contraception, regardless of whether they had used only one or both of the injection 
types. The second user group comprised of women who mixed COCs with injections 
(n=13).  Finally, the non-hormonal contraceptive users (n=41) included 22 never users of 
hormonal contraception and 19 ex-users. The ex-users had not used a hormonal method 
for approximately 2 years or longer and almost all had less than 1 year of lifetime use. 
These women had started a method on recruitment into the longitudinal study and had 
subsequently discontinued use.  We excluded the two exclusive COC users as they could 
not be classified into any of the three groups. Fig. 3.5.1 shows details of the three groups.  
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100
Recruited
GROUP 3: Non users (n=41)
↓  
Never-users n=22 
Ex-users n=19
GROUP 1: Injectable users (n=40)   
↓ 
NET-EN n=14
DMPA n=9
NET-EN & DMPA n=17
GROUP 2: Mixed injectable/COC users (n=13)
↓ 
COC & NET-EN n=7
COC & DMPA n=3
COC & NET-EN & DMPA n=3
Unable to attend n=4
Fig 1. Participant Contraceptive history by study analysis group
Note: 2 COC exclusive users excluded
 
Baseline information about these women is summarized in Table 3.4.1. Mean age was 
approximately 22 years in all groups and the majority of women were African. Few 
women participated in any regular exercise and only one woman was a current smoker. 
Alcohol consumption was low across all groups. 
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Table 3.4.1 Characteristics of subjects aged 19-24 years by contraceptive user group 
Characteristics Injectable 
Users  
 
(n=40) 
Mixed COC 
and injectable 
users  
(n=13) 
Nonusers  
 
 
(n=41) 
P value 
Mean age, years (SD) 22.3 (1.4) 22.1 (1.2) 22.0(1.6) 0.7 
 
Ethnicity %   
         African 
         Coloured 
         Indian 
 
Ever pregnant % 
 
Mean age at menarche, 
years(SD) 
 
Exercise > once a week (%) 
 
Dieted in last 6 months (%) 
 
 
90.0 
  7.5 
  2.5 
 
12.5 
   
13.9 (1.5) 
 
 
5.1 
 
2.5 
 
 
100.0 
    0 
    0 
 
0 
 
13.8 (1.2) 
 
 
16.7 
 
   0 
 
 
97.6 
  2.4 
  0 
 
  4.8 
 
13.7 (1.3) 
 
 
5.4 
 
  0 
 
 
0.5 
 
 
 
0.23 
 
0.47 
 
 
0.05 
 
0.52 
       
Current smoker (%) 
Alcohol consumption, units per 
week % 
Never  
1-2 units 
3-4 units 
  0.0 
 
 
92.5 
7.5 
0 
   0 
 
 
100.0 
0 
0 
2.6 
 
 
73.2 
22.0 
4.9 
0.51 
 
 
0.17 
   SD=standard deviation 
 
There was evidence that BMD was associated with BMI for all three sites, with one unit 
of BMI corresponding to an average increase in BMD of 0.010 (0.006-0.015), 0.014 
(0.009-0.017) and 0.017 (0.012-0.021) g/cm2 for spine, hip and femoral neck, 
respectively.   
 
Table 3.4.2 shows mean BMD at the three sites measured. Women in the injectables-
only user group were found to have lower BMDs compared to the  nonuser group at all 
three sites. There was some evidence of a significant difference in BMD between the 
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injectable and nonuser groups at the spine (p=0.042), hip (p=0.025), and femoral neck 
(p=0.023) after adjusting for BMI. In the mixed COC and injectable group, the BMD 
values were lower than the nonusers at all sites; however, there was no evidence of a 
difference between this group and the nonusers (spine p=0.54, hip p=0.15, femoral neck 
p=0.43).   
 
Table 3.4.2 Mean spine, hip and femoral neck BMD by contraceptive user group, 
relative to nonusers  
 Injectable users  
 
(n=40) 
Mixed COC and 
injectable users 
(n=13) 
Nonusers  
 
(n=41) 
MeanBMDg/cm2 (SD) 
                 Spine       
                    Hip                
     femoral neck        
 
Mean BMI (kg/m2) (SD)  
 
0.944 (0.109)(p=0.042) 
0.928 (0.116)(p=0.025) 
0.844 (0.125)(p=0.023) 
 
26.4 (4.9)   (p=0.14) 
 
0.960(0.094) (P= 0.54) 
0.919 (0.099) (P=0.15) 
0.855(0.101)  (P= 0.43) 
 
25.4 (3.1) (p= 0.71) 
 
0.975 (0.115) 
0.954 (0.102) 
0.871 (0.130) 
 
24.9 (4.3) 
BMD=bone mineral density; BMI=body mass index; p-values from regression model 
adjusting for BMI 
 
 
Weight in the nonuser group remained similar to that at baseline, whilst women in the 
injectable user group had gained on average 6.7 kg and the mixed COC/injectable group 
gained 1.9 kg (data not shown) over the 4-5 year follow-up.  
 
Discussion  
Our results show evidence of significantly lower BMD values in the hip, spine and 
femoral neck, between the adolescent users of injectable hormonal methods and 
nonusers, but not those women who have used COCs in combination with injectables. 
The absence of a significant difference in BMD between this group and the nonusers, 
may be due to the small number in this group (n=13). Over the follow-up period, this 
mixed-use group used COCs before and after injectable use and some moved between 
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these methods several times. However, this group had less overall injectable exposure 
over the follow-up period compared to the injectable-only group.   
 
Although we are unable to comment on any specific method, our sample consisted of a 
representative group of women completing follow-up in the longitudinal study during a 
specific time period. At the end of our study, the mixed hormonal contraceptive  users 
were found to be far more common than the exclusive users.  Few women stayed on one 
hormonal method and many had discontinued hormonal contraception altogether.  
Although the study was designed to collect reasons for discontinuation of method, 
anecdotal reports indicated that various side effects and change in relationship status 
resulted in breaks and changes in method.  
 
The literature has shown that discontinuation rates amongst adolescent DMPA users are 
particularly high, and continuation rates as low as 27% at one year have been found in the 
US (Polaneczky and Liblanc, 1998). In the longitudinal component of our study, there 
was an incidence of 37% method change per person-year for DMPA and 26% for NET-
EN (Beksinska, et al, 2007). Although concerns remain regarding hormonal contraceptive 
use in adolescents, data indicate that few women are long-term exclusive users of one 
method of contraception. If mixed users are more prevalent, as was seen in our study, it 
would be important  to include them in studies looking at hormonal contraceptive use and 
BMD.  
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 Two studies have looked at young women who commenced low-dose COCs  after use of 
DMPA and found they were  at risk for loss of BMD (Berenson, et al, 2008; Albertazzi, 
et al, 2006). Our study could not confirm this finding as our numbers using DMPA 
followed by COCs was too small. In addition, the ethinyl estradiol (EE)  formulations 
used by the COC users in our study was 30-40 mcg whereas studies that have found a 
detrimental effect of COCs on BMD have used even lower (20 mcg) EE formulations 
(Berenson, et al, 2008;  Hartard, et al, 2006; Cromer, et al, 2004; Polatti, et al, 1995)  The 
Medicines and Healthcare Product Regulatory Agency, UK (MHRA) guidelines 
(FFPRHC, 2004) recommend changing from DMPA to another method of contraception 
after 2 years of use; however, there is no advice as to what would be the most suitable 
method post-discontinuation.  As the body of evidence increases on recovery of BMD in 
adult and adolescent women post discontinuation of DMPA (Kaunitz, 2008), this 
recommendation may need to be reviewed and balanced against the benefit of using 
DMPA as a long-term effective contraceptive. The third edition of the WHO Medical  
Eligibility Criteria for contraceptive Use (WHO, 2004)  states the advantages of using 
DMPA generally outweigh the theoretical or proven risks in relation to bone mineral 
density. A position paper published in 2006 by the Society of Adolescent Medicine 
(Society for Adolescent Medicine, 2006) supports the WHO position on DMPA for 
woman below 18 and above 45 years and states that with existing evidence, the 
advantages of using DMPA in women below 18 years outweigh the disadvantages.  
 
Limited data on recovery of BMD on cessation of hormonal contraceptive use in 
adolescents have been reported in exclusive users of  DMPA  (Clark, et al 2006; Scholes, 
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et al, 2005) and NET-EN (Rosenburg, et al, 2007; Beksinska, et al, 2009). Further 
evidence is needed to show that any loss of BMD, resulting from hormonal contraceptive 
use in adolescence, are fully recovered, and peak bone mass is not compromised. Until 
this time, the recommendations for DMPA and NET-EN use in adolescents will continue 
to caution long-term use in young women.  
 
Limitations 
This study was unable to analyze the individual effects of any of the three hormonal 
methods used as the sample size of exclusive users was too small for analysis.  
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Abstract  
Purpose: Most studies have shown a negative effect of depot-medroxyprogesterone 
acetate (DMPA) on the bone mineral density (BMD) of adolescents. There is no 
information available on the effect of norethisterone enanthate (NET-EN) on BMD in 
adolescents and  the effect of combined oral contraceptives (COCs) on adolescent BMD 
is inconclusive.  The aim of this longitudinal study was to investigate BMD in adolescent 
(aged 15-19 years) new users of hormonal contraception (DMPA, NET-EN and COCs). 
Method: New users of DMPA (n=115), NET-EN (n=115), COCs (n=116) and 144 
nonuser controls were recruited. BMD was measured at the distal radius and  midshaft of 
the ulna using dual x-ray absorptiometry.   
Results: In total, 275 women were included in this interim analysis and total follow up 
time was 553 person years. There was no significant difference in radius BMD between 
users of different contraceptive methods at baseline, p= 0.40. Overall, an increase in 
radius BMD of 0.00522 per person year was observed. This result was similar when 
adjusting for BMI in the random effects regression model (p=0.88). The regression model 
showed that BMI was significantly associated with radius BMD, with each unit increase 
in BMI corresponding to an increase of 0.0029 g/cm2 in BMD [95% CI 0.0023 to 0.0036, 
p<0.001]. Interaction between contraceptive method and follow-up time adjusted for 
BMI, was  not significant  (p=0.07). The increase in BMD for NET-EN users of 0.0013 
g/cm2 per person year [95% CI -0.0017 to 0.0043] was significantly lower than that of 
non users (p= 0.017). For DMPA and COC  users the increase in BMD was not 
significantly different  compared to the  nonusers. This study suggests that NET-EN users 
had lower increase in BMD over time compared to the other user groups. 
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 Introduction 
Studies undertaken to investigate the effect of hormonal contraception  on bone mineral 
density (BMD) have mostly found that depot-medroxyprogesterone acetate (DMPA) has 
a negative effect on bone mass (Curtis and Martins, 2006; Wanichsetakul et al, 2002; 
Petitti et al, 2000; Scholes et al, 1999; Cundy et al, 1991), although some have shown 
minimal or no effect (Bahamodes et al, 1999; Gbolade et al, 1998; Taneepanichskul et al, 
1997). There is limited  information available on the effect of norethisterone enanthate 
(NET-EN) on BMD (Beksinska et al, 2005). The evidence for the effect of combined oral 
contraceptives (COCs) in premenopausal women has shown  that in general COCs are 
not  associated with changes in BMD   (Martins et al, 2006; Paoletti et al, 2004; Nappi et 
al, 2003). 
 
A number of studies have investigated  the effect of hormonal contraceptives on BMD in  
adolescents aged less than 20 years (Scholes et al, 2005; Cromer et al, 2004; Lara-Torre 
et al, 2004; Scholes et al, 2004; Busen et al, 2003; Tharnprisan et al, 2002; Cromer et al, 
1996) and almost all of these have found that DMPA has  an adverse effect on BMD 
(Scholes et al, 2005; Cromer et al, 2004; Lara-Torre et al, 2004; Scholes et al, 2004; 
Busen et al, 2003; Cromer et al, 1996). No studies have looked at adolescent NET-EN 
users. Emerging data in young COC users are showing that BMD may be compromised 
in users  of low-dose COCs (Hartard et al, 2006; Martins et al, 2006; Cromer et al, 2004).  
Studies of adolescent users of hormonal contraception have often been limited by small 
sample sizes (Busen et al, 2003; Cromer et al, 1996) and follow-up in longitudinal studies 
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on adolescents is often poor due to method discontinuation (Lara-Torre et al, 2004; Busen 
et al, 2003), 
 
DMPA and NET-EN are effective contraceptives with low failure rates (WHO, 1983). In 
South Africa use of both hormonal injectable contraceptives is high amongst adolescents, 
with about 70% of Black African women aged 15-19 years practising contraception using 
either DMPA or NET-EN (DOH, 2006).  Adolescence is a period of rapid growth and 
women  gain 40-50% of their skeletal mass during this time (Sabatier et al, 1996).  Loss 
of bone mass as a result of hormonal contraceptive use may have more serious 
implications in these women who have yet to achieve peak bone mass.  It would be 
important to know if using hormonal methods of contraception interferes with the process 
of bone mineralisation. The objective of the study was to determine whether long-term 
use of hormonal contraceptives (COCs, DMPA and NET-EN) compared to non-use, is 
associated with a change in bone mass in women aged 15-19 years. 
 
Subjects and Methods 
A cohort of adolescent never-users of hormonal contraception aged 15 to 19 years 
starting use of DMPA, NET-EN, COCs, and nonusers of contraception were recruited 
from a large family planning clinic in Durban, South Africa. All eligible women were 
informed about the study and invited to participate if they wished. Recruitment 
commenced in July 2000 and was completed in 2002.   For inclusion into the study 
women had to have no history of hormonal contraceptive use.   All DMPA users were 
started on a regimen of 150mg every 12 weeks and NET-EN users on 200mg every 8 
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weeks. Both DMPA and NET-EN were administered intramuscularly. The COCs used by 
women included a range of formulations, with most (93%) using formulations containing 
between 30-40 mcg of oestrogen. Women were eligible to participate if they had not 
lactated or delivered in the past 6 months; were not currently or had never used 
medication known to affect calcium metabolism for more than 3 months; and did not 
have a chronic disease affecting calcium metabolism.  On recruitment, a questionnaire 
was administered by a trained research nurse to elicit information on lifetime 
contraceptive history, fertility history and regularity of the menstrual cycle.  Questions 
were also asked on smoking, diet, exercise and caffeine and alcohol intake.  The 
examination included height, weight and blood pressure  using a standard protocol.  
 
Body mass index (BMI) was calculated from the weight and height as kilograms per 
square metre (kg/m2).   Forearm BMD was measured by dual energy x-ray 
absorptionmetry (DXA model DTX-200,  Osteometer MediTech A/S Co, Rodovre, 
Denmark).  BMD was measured in grams per square centimetre (g/cm2) at two distal sites 
in the forearm (radius and ulna). The distal site contains approximately 25% trabecular 
bone and 75% cortical bone. The DXA equipment was standardized daily using a 
phantom as per manufacturers instructions.   Accuracy to the standard  during the 
recruitment and follow-up period was 0.53%. and in vivo precision was 0.94%.   
 
Study participants are being followed-up at six-monthly intervals for a total of 5 years. 
Forearm BMD, height and weight were measured at each  follow-up visit. The findings 
presented in this paper are based on an interim analysis and  data collected up to the end 
140 
 
of 2004 are included. Those recruited early in the study had completed over 3 years  
follow-up, however those recruited in 2002 have approximately 18 months  follow-up. 
Women were not excluded from the study if they stopped, changed or started a 
contraceptive method. This was done to investigate issues of recovery of BMD post 
discontinuation of a hormonal method. The method of contraception used was recorded at 
each follow-up visit. Women were assigned to the contraceptive method they were using 
until their next follow-up visit. If at any visit a change was recorded, the woman would 
be  assigned according to the new contraceptive method. Thus, each woman could 
contribute to more than one of the exposure categories. This interim analysis is conducted 
on all women who remained  on the same method for at least two visits inclusive of the 
baseline visit (minimum six months) and data are included up to the time the method was 
changed.  
 
 Ethical approval was granted by the University of the Witwatersrand, Human Subjects 
Research Committee, and by the Scientific and Ethical Review Group of the World 
Health Organization (WHO). 
 
The characteristics of women in the study were quantified as means + SD, medians, or 
percentages. The  study was powered to be able to  detect a half standard deviation 
difference in bone mass between users and nonusers of hormonal contraceptives. This 
could be of biological significance as this difference would translate into a large 
difference in the risk of fracture in the older woman. Information on the mean 
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and standard deviation of cross-sectional measurements of forearm bone mass in white, 
European, premenopausal women  reported by Nordin (Nordin, 1987) was used to 
estimate sample size. A sample of 110 participants per contraceptive group was required 
assuming a two-tailed statistical  test with a significance level  of 5%, power of 80%, and 
allowing for 10-15% loss to follow-up per year. The nonuser group was over recruited 
compared to other groups as in addition to loss to follow-up it was anticipated that some 
women would commence  a method of contraception or become pregnant.  
 
Differences in BMD between contraceptive groups, and the associations between BMD 
and selected characteristics of the study participants by contraceptive group were 
assessed using one way analysis of variance and multiple variable linear regression.  
Follow-up of all women was cumulated up to their last visit, or up to the visit preceding a 
visit at which they reported a change in contraceptive method, whichever occurred first. 
To assess the effect of contraceptive method on radius BMD, and to control for the 
confounding effect of changes in BMI, a random effects linear regression model was set 
up using STATA (V.8 College station, TX, USA) with radius BMD at the time of a study 
visit as the response variable, and contraceptive method, follow-up since last study visit 
and BMI at time of the visit as explanatory variables, and allowing for within-subject 
correlation of responses. Differences in rate of change in radius BMD per year between 
method were assessed by including interaction terms in the model for method and follow-
up time.  
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Results 
In total, 490 women aged 15-19 were recruited. All women including those in the 
DMPA, NET-EN and COC groups had no past use of hormonal contraception before 
recruitment into the study.  Baseline information about these women is summarised in 
Table 3.6.1. Mean age was between 17 and 18 years with the DMPA and COC groups 
being 4 months older than the nonuser and NET-EN groups (p=0.0002). Almost all 
women were African except in the COC group which included about a quarter (22%) of 
Indian women. This resulted in a significant difference in ethnicity between the groups.  
Smoking was low across all groups.  
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 Table 3.5.1 Socio-demographic, lifestyle and reproductive characteristics of 
subjects aged 15-19 years  by contraceptive user group, at baseline. 
Characteristics DMPA 
(n=115) 
NET-EN 
(n=115) 
COC 
(n=116) 
Non user 
controls  
(n=144) 
 
P value 
Mean age, years (SD) 17.8 (1.4) 17.4 (1.3) 17.8 (1.0) 17.4 (1.2) 0.0002 
Mean highest education grade 
(SD) 
Marital status, % 
   Married/cohabiting  
   Reg partner-not cohabiting 
   Casual partner 
   No partner 
 
Employment status % 
   Employed full/part-time 
   Unemployed        
   Student/scholar 
 
Ethnicity %   
   African 
   Coloured 
   Indian 
 
Ever pregnant % 
Ever lactated % 
Lactation (yrs) median 
Mean age at menarche, years(SD) 
 
Exercise 
          No regular exercise (%) 
          at least once a week (%) 
 
Dieted in last 6 months (%) 
10.9 (1.5) 
 
   
5.3 
92.1 
  2.6 
    0 
 
 
  6.2 
11.4 
82.5 
 
 
94 
  5 
  1 
 
29.3 
16.7 
<1 
13.9±1.3 
 
 
78.1 
21.9 
 
3.5 
 
10.5 (1.5) 
 
 
  5.2 
83.8 
  5.2 
  0.9 
 
 
  2.6 
10.5 
86.8 
 
 
89 
  7 
  4 
 
 3 
0.9 
<1 
13.8±1.2 
 
 
72.8 
27.2 
 
2.6 
 
11.3(0.8) 
 
 
10.3 
87.1 
  2.6 
     0 
 
 
  9.5 
  8.5 
79.1 
 
 
57 
21 
22 
 
 6 
2.6 
<1 
13.6±1.48 
 
 
64.9 
35.1 
 
5.3 
 
10.3 (1.4) 
 
 
12.8 
63.5 
23.0 
  0.7 
 
 
  2.7 
  7.4 
98.8 
 
 
92 
  4 
  4 
 
  2 
1.4 
<1 
13.5±1.29 
 
 
77.7 
22.3 
 
2.0 
0.0001 
 
 
0.0001 
 
 
 
 
 
<0.0001 
 
 
 
<0.0001 
 
 
 
 
<0.0001 
 
 
0.19 
 
 
0.0001 
 
 
0.54 
Ever smoked cigarettes (%) 9.6 11.3 27.3 4.8 >0.00001 
Current smoker (%)    6   7.0 13.9 3.4 0.006 
 
DMPA= depot medroxyprogesterone acetate; NET-EN = Norethisterone enanthate; 
COC= combined oral contraceptive;    SD= standard deviation.  
 
The reproductive characteristics of the woman are summarised in Table 3.5.1. Few 
women had ever been pregnant (teenage pregnancies) except in the DMPA group with a 
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quarter of women (29%) reporting that they were ever pregnant.  Age of menarche was 
similar in all groups and at recruitment all had regular menstrual cycles, between 21 and 
35 days duration (data not shown).   
 
Table 3.5.2 shows mean BMD at both sites and BMI at enrolment for each group. There 
was no significant difference in  radius (p=.196) and ulna (p=.0534) BMD between the 
four contraceptive user groups at baseline. The COC group had a slightly lower BMI at 
baseline but this was not significant.  
 
Table 3.5.2 Mean BMD and BMI at admission by contraceptive group  
 DMPA 
n=115 
NET-EN 
n=115 
COC 
n=116 
Nonuser 
n=144 
p value
Radius BMD g/cm2 (SD) 
Ulna BMD g/cm2 (SD)   
Mean BMI (kg/m2) (SD)  
0.459(0.06) 
0.443(0.06) 
24.6 (4.77) 
0.446(0.06) 
0.432(0.06) 
24.3 (3.75) 
0.460(0.05) 
0.429(0.05) 
23.2 (4.9) 
0.455(0.05) 
0.436(0.06) 
24.6 (5.8) 
0.196 
0.053 
0.097 
BMI=body mass index 
 
 
Table 3.5.3 shows the baseline BMD of women by age at enrolment. The increase in 
Radius and Ulna BMD  of  approximately 3% per year of age was significant. 
 
Table 3.5.3 Mean BMD and BMI by year of age in 15-19 age group at admission  
 15 
n=36 
16 
n=57 
17 
n=101 
18 
n=173 
19 
n=123 
P value 
Radius  g/cm2 
(SD)                  
0.412 
(0.049)  
0.443 
(0.054) 
0.457 
(0.053) 
0.455 
(0.52) 
 
0.472 
(0.056) 
 
<.00001 
Ulna g/cm2 
(SD) 
              
0.405 
(0.054) 
0.419 
(0.053) 
0.440 
(0.053) 
 
0.436 
(0.053) 
 
0.452 
(0.062) 
 
<.00001 
Mean BMI 
(kg/m2)  (SD) 
23.6  (4.3) 23.0 (3.5) 24.2 (4.8) 24.3 (5.6) 24.9 (4.9) 0.169 
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In this interim analysis period, 401 women had attended at least once for follow-up 
(82%). Of these women, 31 presented with criteria that made them ineligible to continue 
in the study. Pregnancy was the main reason for discontinuation and this was high in the 
nonuser control group. In total, 76% (n=370) women completed their second visit. Main 
reasons for discontinuation from the study included pregnancy, illness that could have 
affected BMD e.g. Tuberculosis, and moving out of the area. Of those who continued 
participation in the study 50% changed, stopped or started a method at least once during 
their  follow-up. Some women (15%) changed, stopped or started a new method at least 
twice. Incidence of method change per year is shown in Table 3.5.4. Reasons given for 
method change were mainly change in relationship status or complaints about side effects 
of the method. This was lowest in the nonuser group  where 19% started a method of 
contraception during their follow-up and highest in the DMPA group where 74% changed 
or stopped use. DMPA users often changed to NET-EN which is the more popular choice 
amongst young women. 
 
 
Table 3.5.4  Radius BMD at baseline, follow-up time and incidence of method 
change by contraceptive group  
 
Method N Follow-up time in 
person yrs 
Incidence of method 
change per person year 
 
Radius BMD g/cm² 
(unadjusted) at  baseline 
        (SD)       p value 
DMPA   
NET-EN 
Non user 
COC       
51 
68 
96 
60 
75.42 
125.68 
248.65 
103.67 
0.37 
0.26 
0.004 
0.19 
0.46 (0.06)      0.40 
0.44 (0.06) 
0.45 (0.05) 
0.46 (0.05) 
Total 275 553   
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In total, 275 women had continued the same method for at six months (two visits). Some 
women had contributed 7 study visits (approximately 3.5 years) in the study. Total follow 
up time was 553 person years in 275 participants (Table 3.5.4).  
 
Overall, an increase in radius BMD of 0.00522 per person year was observed. Mean 
BMD of the women in this analysis was 0.45 g/cm2 (SD=0.053) at baseline. There was 
no significant difference in radius BMD between prospective users of different 
contraceptive methods at baseline, p= 0.40 (Table 3.5.4). This result was similar when 
adjusting for BMI in the random effects regression model (p=0.88). The regression 
model showed that BMI was significantly associated with radius BMD, with each unit 
increase in BMI corresponding to an increase of 0.0029 g/cm2 in BMD [95% CI 0.0023 
to 0.0036, p<0.001] (Table 3.5.5). 
 
Table 3.5.5. Factors associated with radius BMD at study visit, estimated from the 
random effects liner regression model. 
 
Variable Effect on 
radius BMD 
95% Confidence 
interval 
p 
BMI, change in radius BMD per unit 
change in BMI (g/ cm2 per kg/m2) 
 
Method  relative to nonuser (g/cm2) 
 Non user (reference) 
 DMPA, 
 NET-EN 
 COC 
Change in radius BMD over time 
(g/cm2 per person year)† 
 Non user  
 DMPA, 
 NET-EN 
 COC 
0.0029 
 
 
0 
0.0058 
-0.0022 
0.0026 
 
 
 
0.0055 
0.0069 
0.0013 
0.0053 
0.0023 to 0.0036 
 
 
 
-0.011 to 0.022 
-0.017 to 0.013 
-0.013 to 0.018 
 
 
 
0.0037 to 0.0073 
0.0028 to 0.011 
-0.0017 to 0.0043 
0.0022 to 0.0085 
<0.001
 
 
 
0.69 
0.77 
0.74 
 
 
 
<0.001
0.001 
0.40 
0.001 
Interaction effect of change in radius BMD over time and contraceptive user groups was marginally 
significant, p=0.07.  
†In a model without BMI, interaction between method and follow-up time was significant with p=0.036. 
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Interaction between contraceptive method and follow-up time adjusted for BMI, was 
marginally non-significant overall (p=0.07). For DMPA users, the increase in radius 
BMD of 0.0069 g/cm2 per person year [95% CI 0.0028 to 0.011] was non-significantly 
different compared to the increase of 0.0055 g/cm2 per person year [95% CI 0.0037 to 
0.0073] for nonusers (p=.55). Similarly the increase of 0.0053g/cm2 per person year [95% 
CI 0.0022 to 0.0085] for COC users was non-significantly different from the controls.  
The increase in BMD for NET-EN users of 0.0013 g/cm2 per person year [95% CI -
0.0017 to 0.0043] was significantly lower than that of non users (p= .017), and not 
inconsistent with the null hypothesis of no increase in BMD over time for these women 
(p=0.40). 
  
Discussion  
Women in the 15-19 age group have yet to reach peak bone mass and our baseline data 
indicates that there is a small yearly increase of approximately 2-3% per year in a 
population that had no exposure to hormonal methods of contraception on recruitment 
into the study. This increase would be expected in woman in this age range (Sabatier, et 
al, 1996) and our data indicate that forearm BMD is sensitive enough  to document this  
increase. 
 
The multiple variable analysis shows that BMD is strongly related to BMI (p<0.001). 
BMD in the non user reference group, the DMPA user group and the COC users group 
increased significantly during follow-up, by similar amounts (0.0055, 0.0069 and 
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0.0053g/cm2 per year respectively) after adjusting for BMI. By contrast, the NET-EN 
group differed significantly from the nonuser group (p=0.017), achieving no significant 
growth in BMD during follow-up.  This is the first study to date that has investigated the 
effect of NET-EN on BMD. NET-EN was the only group  where  there was no significant 
increase in BMD found over time (p=.4). No significant difference was found between 
either the COC and the nonuser control group or the DMPA and the nonuser control 
group. 
 
Our study has used the forearm as its site of measurement and it may be that differences 
in the lumber spine and hip are more sensitive and any decreases are magnified at these 
sites. Other studies (Tharnprisan et al, 2002; Bahamodes et al, 1999) using the forearm as 
the site of measurement found no significant differences between DMPA and controls. 
Studies finding decreases in BMD in users of DMPA have mainly used the hip and spine 
for measurement of BMD.  
 
The loss of BMD in the case of DMPA has been associated with estrogen deficiency 
(Ortiz et al, 1977).  Some studies show that these negative changes may be reversible and 
there is a return to pre-use levels on discontinuation of DMPA (Kaunitz et al, 2006; 
Petitti et al, 2000). In addition, there seems to be recovery of BMD in long term users of 
DMPA (Petitti et al, 2000; Taneepanichskul et al, 1997).  However there is no long term 
data on women who commence DMPA in adolescence and therefore there is a need to 
investigate whether the recovery seen in older age groups applies to this younger group 
whose BMD may be compromised prior to achieving peak bone mass. It has been 
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suggested that norethisterone (NET) on its own may protect against calcium loss via a 
direct topic effect on bone or by the action of estrogenic metabolites.  
 
 The studies that have included NET (Horowitz et al, 1993; Eldred et al, 1992; Riis et al, 
1990) have shown a positive effect on BMD; however, NET-EN may be different in that 
the depot characteristics are added to this compound through the addition of the enanthate 
(EN).   The lack of data on the effect of NET-EN on BMD may be because the method is 
not as widely used internationally as DMPA. However, in South Africa this method has 
increased in popularity in recent years and is often the method of choice for younger 
women (DOH, 2006; Smit et al, 2001).  
 
In 2004, the US FDA required the addition of  a black box warning stating that DMPA 
may impair BMD (FDA, 2004) and adolescents were mentioned as a group that could be 
particularly at risk of bone loss. The following year the WHO  issued a statement on 
hormonal contraception and bone health (WHO, 2006). Recommendations with regard to 
bone metabolism are that there should be no restriction on the use of DMPA and its 
duration of use in women below 18 and above 45 years. Evidence around potential safety 
concerns for women under 18 years using DMPA was not considered adequate at the 
time and therefore the WHO stated that the advantages of using DMPA outweighed the 
concerns regarding fracture risk. Recommendations for DMPA applied to NET-EN use.  
No restriction was placed on use of other  progestogen-only or combined hormonal 
contraceptive methods. A position paper published in 2006 by the  society of adolescent 
medicine (Society of Adolescent Medicine, 2006) supports the WHO position on DMPA 
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for woman below 18 years and above 45 years and states that with existing evidence, the 
advantages of using DMPA in women below 18 years outweigh the disadvantages. The 
lack of evidence on the consequences of long-term use of DMPA was acknowledged and 
until data became available, it was recommended that prescribing DMPA to adolescents 
should be considered on a case-by-case basis. A recently published paper (Albertazzi et 
al, 2006) has cautioned against the recommendation made by the  UK Medicines and 
Healthcare Products Regulatory Agency (MHRA) (FFPRHC, 2004) that DMPA users 
should switch to another method of contraception after two years of use. Data in the 
Albertazzi et al  paper (Albertazzi et al, 2006) shows that women using COCs after 
DMPA may be particularly at risk to loss of BMD. This present study suggests that 
DMPA and COCs do not affect BMD in younger women, but raises questions about the 
effect of NET-EN on BMD in younger users. 
 
Future analysis on completion of our study  will include information from a larger sample 
with longer follow-up and may clarify the effect of NET-EN further. In addition we will 
be able to examine potential recovery in those who stop using hormonal contraceptive 
methods. A sub sample of women  in our study will have a hip and  spine BMD 
measurements, but these data are not yet available.  
 
The main limitations to our study were that long-term follow-up in our adolescent women 
has been affected by frequent method change and discontinuation.  Our study has used 
the forearm as its site of measurement which may be less sensitive than the hip and spine 
to changes in BMD resulting from  hormonal contraceptive use. 
151 
 
 
152 
 
 
3.6 Bone mineral density in women aged 40-49 years using 
depot-medroxyprogesterone acetate, norethisterone enanthate 
or combined oral contraceptives for contraception. 
 
Mags E Beksinska1, Jenni A Smit1, Immo Kleinschmidt2, Timothy MM Farley3,  
Fikile Mbatha1, 
 
 
This paper has been published in Contraception 2005; vol.71, no.3, pp.170-5.  
(Appendix 8) 
 
 
 
1The Reproductive Health and HIV  Research Unit, Department of Obstetrics and 
Gynaecology, University of the Witwatersrand, South Africa, Suite 1301, Maritime 
House, 143 Salmon Grove, Durban, South Africa. 
2 Medical Research Council, 491 Ridge Road, Durban, 4019, South Africa. 
3Special Programme for Research, Development and Research Training in Human 
Reproduction, Department of Reproductive Health and Research, World Health 
Organization, CH-1211 Geneva 27, Switzerland. 
 
153 
 
 Abstract 
Background: Most studies show that depot-medroxyprogesterone acetate (DMPA) has a 
negative effect on bone mass. There are conflicting reports with respect to recovery of 
bone mass in long-term use of DMPA.  No information is available on the effect of 
norethisterone enanthate (NET-EN) on bone mass, and combined oral contraceptives 
(COCs) have not been found to be associated with loss of bone mass.  The aim of this 
study was to investigate bone mineral density (BMD) in older women (40-49 years) in 
relation to use of DMPA, NET-EN and COCs for at least 12 months preceding 
recruitment into the study. 
Study Design: One hundred and twenty seven users of DMPA, 102 NET-EN users and 
106 COC users were compared to 161 nonuser controls. BMD was measured at the distal 
radius and midshaft of the ulna using dual X-ray absorptiometry. 
Results: There was no significant difference in BMD between the four contraceptive user 
groups (p=0.26) with and without adjustment for age. Although a small decrease in BMD 
was noted in the age range 40 to 49 years this was not statistically significant  (p=0.7). 
The BMD was found to be significantly associated with body mass index (BMI) 
(p=<0.0001) at both measurement sites, with an increase of one unit of BMI translating to 
an increase of 0.0044 g/cm2 in radius BMD. Follicle stimulating hormone (FSH) level > 
25.8 mIU/mL was associated  with a decrease of 0.017  g/cm2 in radius BMD  relative to 
women with FSH  <25.8 mIU/mL. Significant interaction between FSH and BMI in their 
effect on BMD was observed (p=.006).  This study found no evidence that long-term use 
of DMPA, NET-EN and COCs  affects BMD in this population.  
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Introduction 
Cross-sectional studies undertaken to investigate the effect of hormonal contraceptives on 
bone mineral density (BMD) have produced conflicting reports (Wanichsetakul et al, 
2002; Petitti et al, 2000; Bahamondes et al, 1999;Scholes et al, 1999; Taneepanichskul et 
al, 1997; Cundy et al, 1996; Cundy et al, 1991).  Most have indicated that depot-
medroxyprogesterone acetate (DMPA) has a negative effect on bone mass 
(Wanichsetakul et al, 2002; Petitti et al, 2000; Scholes et al, 1999; Cundy et al, 1996; 
Cundy et al, 1991), and some have shown minimal or no effect (Gbolade et al, 1998; 
Bahamondes et al, 1997;Taneepanichskul et al, 1997). The loss of BMD in the case of 
DMPA has been associated with estrogen deficiency (Ortiz et al, 1977).  Some of these 
studies show that these negative changes are reversible and there is a return to pre-use 
levels on discontinuation of the method (Petitti, et al, 2000; Orr-Walker et al, 1998). In 
addition there has been evidence of recovery of BMD in long-term users (Petitti et al, 
2000; Tang et al, 2000; Taneepanichskul et al, 1997).  There is no information available 
on the effect of norethisterone enanthate (NET-EN) on bone mass; however, published 
studies on norethisterone (NET) have shown a positive effect on BMD (Horowitz et al 
1993; Eldred et al, 1992; Riis et al, 1990). Combined oral contraceptives (COCs) have 
not been found to be associated with loss of bone mass (De Cherney, 1996; Mehta, 1993), 
with some studies indicating that COCs are bone-sparing (Mehta, 1993; Kleerkoper et al, 
1991).  
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Few studies have investigated the effect of hormonal contraceptives on BMD in 
premenopausal long-term users of hormonal methods in their 40s, and none have 
investigated the effect of  NET-EN on BMD. 
 
DMPA and NET-EN are effective contraceptives with low failure rates (WHO, 1983). In 
South Africa, hormonal injectable contraceptive use is high, with about 60% of Black 
African women practising contraception using either DMPA or NET-EN (SADHS, 
1998).  Of the two available injections, older women mainly use DMPA and often 
continue to use this method into their late 40s.  Use of COCs is lower with the method 
predominantly used by white and Asian women. As menopause is known to be associated 
with bone loss (Ahlborg et al, 2001), it would be important to know if hormonal methods 
of contraception could further contribute to bone loss in older women. 
 
The aim of this study was to determine if long term use of hormonal contraceptives 
(COCs, DMPA and NET-EN)  is associated with  change in bone mass in women aged  
40-49 years. 
 
Subjects and Methods 
A cohort of women aged 40 to 49 years old using DMPA, NET-EN, or COCs, and 
nonusers of hormonal contraception were recruited from a large family planning clinic in 
Durban, South Africa. Recruitment commenced in 2000 and was completed in 2003.   
For inclusion as a hormonal contraceptive user, women had to have used either DMPA, 
NET-EN or COCs for at least one year.  For inclusion in the nonuser control group 
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women should not have used any form of hormonal contraception in the past year. All 
DMPA users were on a regimen of 150mg every 12 weeks and NET-EN users on 200mg 
every 8 weeks. The COCs used by women included a range of formulations, with most 
(93%) using formulations containing between 30-40mcg of estrogen. Women were 
eligible to participate if they had not lactated or delivered in the past 6 months, were not 
currently or had never used medication known to affect calcium metabolism for more 
than 3 months and did not have a chronic disease affecting calcium metabolism. Women 
who were postmenopausal were excluded from the study at screening as the aim of the 
study was to follow-up women through their natural menopause. Menopause was 
classified as amenorrhoea for at least one year. For injectable hormonal contraceptive 
users this criterion could not always be used as women commonly experienced 
amenorrhoea induced by the method. Therefore, in addition  to amenorrhea,  follicle-
stimulating hormone (FSH) levels from blood samples were measured. An FSH level of 
≥25.8 milli International Units per milliliter (mIU/mL) was considered to be in the 
menopausal range (King Edward VIII Hospital Durban; Chemical Pathology Laboratory 
criteria using Roche Elecsys FSH expected values).  
 
On recruitment, a questionnaire was administered by a trained research nurse to elicit 
information on lifetime contraceptive history, fertility history, menopausal symptoms and 
regularity of the menstrual cycle.  Questions were also asked on smoking, diet, exercise 
and caffeine and alcohol intake.  The examination included height, weight, blood 
pressure and waist and hip measurements using a standard protocol. Body mass index 
(BMI) was calculated from the weight and height as kg/m2. Forearm BMD was measured 
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by dual energy x-ray absorptionmetry (DXA model DTX-200),  Osteometer MediTech 
A/S Co, Rodovre, Denmark).  BMD was measured in grams/centimetre2 (g/cm2) at two 
sites in the distal  forearm (radius and ulna). The distal site contains predominantely  
trabecular bone and the cortical bone predominates in the ulna. The DXA equipment was 
standardized daily using a phantom as prescribed by the manufacturers instructions.  
Accuracy to the standard during the recruitment period was 0.53%. and in vivo precision 
was 0.94%.  Study participants are currently being followed-up at six-monthly intervals 
for a total of five years. Women will be completing their five-year follow-up visit 
between 2005 and 2006. The findings presented in this paper are based on the baseline 
data collected at the recruitment visit and are cross-sectional in nature. 
 
The characteristics of women in the study were quantified as means + SD, medians, or 
percentages. Follicle-stimulating hormone levels were divided into two categories 
according to laboratory cut-off levels for premenopausal (<25.8 mIU/mL) and peri-
menopausal/menopausal (≥25.8 mIU/mL). Differences in BMD between contraceptive 
groups, and the associations between BMD and selected characteristics of the study 
participants by contraceptive group were assessed using one-way analysis of variance and 
multiple variable linear regression for BMD measured at the two anatomic sites. The 
proposed study aims to be able to detect a half standard deviation difference in bone mass 
between users and nonusers of injectable contraceptives. This would be of biological 
significance as this difference would translate into a large difference in the risk of 
fracture in the older woman. Information on the mean and standard deviation of cross-
sectional measurements of forearm  bone mass  in white, European, premenopausal 
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women reported by Nordin (Nordin, 1987) was used to estimate sample size.  The sample 
size calculated assuming a two-tailed statistical test with a significance level of 5% and 
with  power of 80% was 63 subjects in each contraceptive group. Loss to follow-up was 
estimated at approximately 10-15% per year. Therefore, sample size after adjusting for 
loss to follow-up was at least 100 women in each category.  
 
 Data were analysed using the statistical package STATA (V.8 College station, TX, 
USA). Ethical approval was granted by the University of the Witwatersrand, Human 
Subjects Research Committee, and by the Scientific and Ethical Review Group of the 
World Health Organization. 
 
Results 
In total, 496 women were recruited. Baseline information about these women is 
summarised in Table 3.6.1. Although the groups using hormonal contraception were 
similar in age, the nonusers of hormonal contraception were on average 2 years older 
than DMPA users (p<.001).  Norethisterone enanthate users were the youngest group 
with a mean age of 43 years. Almost all women were African except for the COC group 
which included around a quarter (26%) of Indian women. This resulted in a significant 
difference in ethnicity between the groups (p=.007).  
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Table 3.6.1 Socio-demographic and lifestyle  characteristics of subjects in the 40-49 
year age range by contraceptive method use. 
Characteristics DMPA 
(n=127) 
NET-EN 
(n=102) 
COC 
(n=106) 
Non user 
controls  
(n=161) 
 
P value 
Mean age, years (SD) 43.6 (2.7) 43.0 (2.2) 43.7 (2.5) 45.4 (2.5) <0.0001 
Mean highest Education Grade 
(SD) 
Marital status % 
              Married/cohabiting  
              Reg partner-not cohabiting 
              Casual partner 
              No partner 
 
Employment status % 
                Employed full/part-time 
                Unemployed 
                Housewife                 
                 
 
Ethnicity %   
                African 
                Coloured 
                Indian 
  
Exercise 
                No regular exercise (%) 
               At least once a week (%) 
 
Dieted in last 6 months (%) 
 
Caffeine consumption* 
               Never (%) 
               1-2 cups/day (%) 
               > 2 cups (%) 
8.5 (3.3) 
 
 
46.1 
3.2 
38.9 
11.9 
 
 
44.5 
   54 
 1.6 
 
 
 
98.4 
  1.6 
  0 
 
 
96.9 
  3.1 
 
    0 
 
 
9 
75 
15 
9.8 (3.1) 
 
 
52.1 
7.7 
36.5 
2.9 
 
 
73.5 
19.6 
  6.9 
    
 
 
95.2 
1.0 
3.8 
 
 
96.0 
  4.0 
 
    0 
 
 
18 
62 
19 
9.8 (2.4) 
 
 
 57.1 
  5.7 
28.6 
  7.6 
   
 
71.5 
23.8 
  4.8 
      
 
 
67.0 
  7.5 
25.5 
 
 
94.3 
  5.7 
 
 4.7 
 
 
19 
69 
12 
9.1 (2.7) 
 
 
41.0 
 3.7 
25.5 
29.8 
 
 
63.4 
33.5 
 3.1 
  
 
 
94.4 
  2.5 
  3.1 
 
 
93 
  7 
 
<1 
 
 
12 
75 
12 
0.012 
 
<0.0001 
 
 
 
 
 
<0.0001 
 
 
 
 
 
0.007 
 
 
 
 
0.48 
 
 
 
0.003 
 
 
0.08 
 
Ever smoked cigarettes (%) 11.0 10.3 10.4 16.1 0.17 
Current smoker (%) 
 
4.7   5.6 5.7 9.9 0.23 
*Tea or coffee 
DMPA= depot medroxyprogesterone acetate; NET-EN = Norethisterone enanthate; 
COC= combined oral contraceptive;   SD= standard deviation;  
P value indicates differences between all groups 
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The reproductive characteristics of the woman are shown in Table 3.6.2. A number of 
other differences were noted between the groups including a significant difference in age 
of menarche, FSH, parity, employment, marital status and education. There were no 
differences in smoking history, exercise (Table 3.6.1) or years of lactation (Table 3.6.2).   
 
Table 3.6.2 Reproductive characteristics by contraceptive method user group 
 
Characteristics DMPA 
(n=127) 
NET-EN 
(n=104) 
COC 
(n=106) 
Nonuser 
(n=161) 
P value 
Parity (median) 
Ever lactated % 
Mean age at menarche, years(SD) 
Lactation (yrs) median 
 FSH  
          < 25.8  mIU/mL, % 
          > 25.8  mIU/mL, %          
Use of group method* 
      Median use in last 5 yrs (months)   
      Median lifetime use (months )    
      Mean age at first use (years)  
4 
88.2 
15.2+1.7 
3.5 
 
72 
28 
 
53 
84 
36 
3 
91.3 
15.5+1.7 
3.2 
 
94 
6 
 
45 
49 
37 
3 
87.7 
14.8+1.7 
3.0 
 
66 
34 
 
52 
 89 
 36 
3 
83.2 
14.8+1.6 
3.2 
 
90 
10 
 
NA 
NA 
NA 
0.04 
0.34 
0.014 
0.06 
<0.0001 
 
* Only group method shown i.e. group to which women using that method at the time of recruitment were 
allocated. Contraceptive history of nonuser group not shown. 
 
All women using hormonal methods had used the method for at least 1 year at 
recruitment. The average length of lifetime use for DMPA was 9.3 years with a number 
of women (n=13) having used the method for 15 years or more (Table 3.6.2).  
Norethisterone enanthate users had been using the method on average for 5.6 years and 
COC users for 8.6 years.  
 
There was no significant difference in BMD between the four contraceptive user groups 
at the radius (p=.26) or the ulna site (p=.21), with and without adjustment for age (Table 
3.6.3). Although a small decrease in BMD was noted over the age range (40 to 49 years) 
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this was not statistically significant (p=.7).  Length of use of method in the last 5 years 
and total lifetime use was not associated with difference in BMD. Although differences 
were noted between the contraceptive groups, most were not associated with BMD 
except for BMI, ethnic group and FSH level. A statistically significant difference in 
BMD was found between the Indian and African women (p=.014); however after 
adjusting for BMI the difference in BMD was no longer significant. 
  
Bone mineral density  was found to be associated with BMI (p=<.0001) and with FSH 
level at the radius (p=.029) and ulna (p=.022). An increase of one unit of BMI was 
associated with  an increase of 0.0044 g/cm2 in  radius and 0.0041 g/cm2  in ulna  BMD. 
Follicle-stimulating hormone level > 25.8 mIU/mL was associated  with a decrease of 
0.017  g/cm2 in radius BMD (Table 3.6.3) relative to women with FSH  <25.8 mIU/mL. 
 
 
Table 3.6.3 Factors potentially associated with Radius BMD (unadjusted) 
 
Factors  
Radius BMD g/cm2 
95% CI 
P value 
Contraceptive group 
      DMPA 
      NET-EN 
      COC 
      Nonuser 
Ethinicity 
       African 
       Indian 
       Coloured 
 
Age, per year 
 
BMI, change per kg/m2 
 
FSH  
         < 25.8  mIU/mL, % 
         > 25.8  mIU/mL, %   
 
0.514 (0.501-0.527) 
0.514 (0.499-0.528) 
0.500 (0.486-0.514) 
0.518 (0.506-0.529) 
 
0.516 (0.509-0.523) 
0.491 (0.451-0.531) 
0.479 (0.456-0.503) 
 
-0.0017 (-0.0041-0.0008) 
 
0.0044 (0.0036-0.0052) 
 
 
0.516 (0.508)-0.524) 
0.498 (0.483-0.512) 
0.26 
 
 
 
 
 
 
0.007 
 
 
0.188 
 
<0.001 
 
0.029 
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Body mass index, FSH level (equal to and above 25.8 mIU/mL versus below 25.8 
mIU/mL) and interaction of BMD with FSH level were all significantly associated with 
BMD in a multiple regression model (r2 =0.2). According to this model, for women of 
median BMI of 33.9 units, mean radius BMD varied from 0.514 g/cm2 [95% CI 0.507-
0.521]  with FSH < 25.8 mIU/mL, to 0.501 g/cm2 [95% CI 0.488-0.513]  for women  
with FSH  >25.8 mIU/mL, (p=0.066).  The effect of FSH on BMD was significantly 
modified by BMI, and vice-versa (p=.006). For women with FSH < 25.8 mIU/mL, BMD 
increased by 0.0038 [95%CI 0.0028-0.0047] (g/cm2) per unit increase in BMI, whereas 
for women  with FSH >25.8 mIU/mL, BMD increased by 0.0067 g/cm2 [95% CI 0.0048-
0.0086] for each unit increase in BMI (Table 3.6.4). Similar results were obtained for 
ulna BMD (data not shown). 
 
 
Table 3.6.4 Results of multiple regression model with BMI and FSH level 
  
 
Factors  
Radius BMD units 
95% CI 
P value 
Effect of *FSH (for women of 
median BMI= 33.9 kg/m2)  
          < 25.8  mIU/mL 
>25.8  mIU/mL 
         
Effect of BMI, unit BMD per 
unit change in BMI 
For FSH< 25.8  mIU/mL 
For FSH >25.8  mIU/mL 
 
 
 
0.514 (0.507-0.521) 
0.501 (0.488-0.513) 
 
 
 
0.0038(0.0028-0.0047) 
0.0067 (0.0048-0.0086) 
 
 
<0.066 
 
 
 
<0.001 
 
* Significant interaction between FSH level and BMI (p=0.006) 
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Follicle-stimulating hormone level was found to be significantly different between user 
groups (p=<0.0001). However, after adjusting for age, the difference between the 4 
groups was no longer significant (p=0.13).  An increase of one year in age increased  
FSH level by 3 mIU/mL (p<0.001).   
 
Discussion 
The findings of this cross-sectional study of older woman show no evidence of a 
significant difference in BMD between the three contraceptive users and nonuser control 
groups. This is in agreement with some studies that have found no difference in BMD in 
long-term users of DMPA compared to nonuser controls (Petitti et al, 2000; 
Taneepanichskul et al, 1997) and the normal population mean (Gbolade et al, 1998). 
Some of these studies (Petitti et al, 2000; Gbolade et al, 1998) suggest that any bone loss 
would occur in approximately the first three years of use but that this effect could be 
reversible. However, other studies have shown that loss of BMD persists in long term 
users (Cundy et al, 2002; Pavia et al, 1999). The mechanism involved in reversing a 
hormonally initiated  loss of BMD is not clear. It has been suggested (Petitti et al, 2000) 
that a homeostatic mechanism operates that reverses bone loss after prolonged hormonal 
stimulation. Women using contraceptives in the study reported here were mainly long 
term users and it may be that any initial loss of BMD associated with use of DMPA had 
been recovered.  
 
While this study did not show that COC use was  beneficial with respect to bone mass, 
some studies have shown a positive association of BMD with COCs (Taneepanichskul et 
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al, 1997; Kleerkoper et al, 1991). It could be speculated that a short-term increase in 
BMD as a result of COC use may return to the BMD levels of nonusers after some time.  
In support of this several studies have found that there is no difference in BMD in long-
term users of COCs (Perrotti et al, 2001; Petitti et al, 2000). 
 
This is the first study to include data on the 2-monthly injectable NET-EN. It is suggested 
that norethisterone (NET) may protect against calcium loss via a direct topic effect on 
bone or by the action of oestrogenic metabolites (Christiansen et al, 1985).  
Norethisterone enanthate can be considered to be similar in action to NET, as the 
enanthate (EN) is added primarily to give it its depot characteristics. Although the studies 
that have included NET (Horowitz et al, 1993; Eldred et al, 1992; Riis et al, 1990) have 
shown a positive effect on BMD, no positive effect of NET-EN was seen compared to 
other groups in this study.  
 
Published studies have followed up women on treatment with NET for a year or less and 
therefore there are no data demonstrating that the positive effect of NET would be 
sustained in long term use. The lack of data on the effect of NET-EN on BMD may be 
because the method is not as widely used as DMPA. However in South Africa this 
method has increased in popularity in recent years and is often the method of choice for 
younger women (Smit et al, 2001). 
 
No previous studies have reported on the relationship between FSH level and BMD 
which may be more important than age, as raised FSH is an indicator for menopause. In 
165 
 
our study, women with an FSH level of  25.8 mIU/mL or above had a significantly lower 
BMD at both distal sites. We have found a significant interaction between BMI and FSH 
in their effect on BMD. As a result of this, the loss in BMD for an increase in FSH level 
above 25.8 mIU/mL will be greater for women of lower BMI than for their counterparts 
with relatively higher BMI. For example, a woman with BMI at the 25th percentile of 
BMI in our sample (28.9 units) will lose 0.0285 g/cm2 [95% CI-0.0462 to-0.0108] of 
BMD when moving from the lower category of FSH. By contrast, a woman at the 75th 
percentile of BMI (38.54 units) will lose only 0.000312 g/cm2 [95% CI-0.018 to 0.0175]  
of BMD when her FSH level increases to more than 25.8 mIU/mL according to this 
model. In other words loss in BMD as a result of menopause is  diminished by the effect 
of BMI. 
 
In women with FSH > 25.8 IU/mL BMD increased by 0.0067 g/cm2 per unit increase of 
BMI whereas  in women with FSH levels below 25.8 mIU/mL, BMD increased by 
0.0038 g/cm2 per unit increase in BMI. This means that the effect of BMI on bone density 
is greater for women with raised FSH levels, compared to women with FSH < 25.8 
mIU/mL. Using the cut-off of FSH of 25.8 mIU/mL as a marker of menopause, the 
protective effect of BMI is greater for postmenopausal women (FSH >25.8 mIU/mL) 
than it is for pre-menopausal women (FSH <25.8 mIU/mL). 
 
Since it has been suggested that there are differential effects of progestogen on cortical 
and trabecular bone (Gallager et al, 1991), with the protective effect being greater on 
cortical bone, differences in measurement sites and their composition may explain some 
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of the differences in effect of DMPA.  In one study that found  loss of BMD persisted in 
long-term use (Cundy et al , 2002), significant bone loss was found in only two of the 
four sites measured (trochanter and lumber spine). No significant loss was found at the 
femoral neck and Ward’s triangle sites. Similarly, another study (Gbolade et al, 1998) 
found there was a significant effect at the lumber spine but no effect at the femoral neck. 
The distal forearm contains a greater proportion of cortical bone and some studies that 
have not found a difference in BMD with long term use have only used the forearm as a 
site of measurement (Petitti, et al 2000; Taneepanichskul et al, 1997). The issue of 
measurement site may be difficult to resolve as larger epidemiological studies may 
choose to take advantage of equipment that measures forearm BMD, which is less costly 
to purchase and maintain.  This sort of equipment is not usually available in a clinical 
diagnostic setting where there is preference for measuring the hip and spine. 
 
Investigation of women in this age range was considered important as any loss of BMD 
during short term use of DMPA could be exacerbated by age. There is, however, some 
debate around the extent of age related bone loss (Ahlborg et al 2001; Sowers et al 1993).  
One review (Nilas 1991) documents few studies demonstrating bone loss related to age in 
premenopausal women in the forearm, however, 8 of the 17 studies reviewed found that 
there was loss in the spine or femur. There was a small nonsignificant difference in BMD 
with  age noted in the population in our study. Since the age range of our participants was 
narrow (10 years) and the forearm used as the only site of measurement,  a significant 
difference in BMD and age may not have been expected.   
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This study confirms the association of BMD with BMI (Petitti et al, 2000; Tang et al, 
2000; Pavia et al, 1999).  African women had a significantly higher  BMI and BMD 
compared to the Indian women in our study. Ethnicity itself has been reported to affect 
BMD with premenopausal black women having a greater BMD compared to white 
women (Liel et al, 1988). In the same study, further analysis restricted to both black and 
white non-obese women found that BMD was still higher in black women.   Pettiti et al, 
(2000) found that the Black African women in Harare had a higher mean BMI and that 
ethnic differences in BMD persisted even after adjustment for BMI.  However in our 
study differences in BMI explained the ethnic differences in BMD. Differences in BMI 
by racial groups have been reported previously in South Africa (Department of Health, 
South Africa, 2006). 
 
The World Health Organization has developed a classification system which uses the 
population mean as a reference against which a BMD measurement can be compared to 
obtain a T-score. The T-score is expressed in the number of standard deviations (SDs) of 
difference  from the normal population mean. The definition of normal BMD is regarded 
as no more than 1 SD below the young adult normal value. Osteopenia (low bone mass) 
is defined as 1  to 2.5 SDs below the population mean and below this level osteoporosis is 
diagnosed. The reference population used for the DXA equipment in this study included 
20,000 Danish women with a mean distal (radius and ulna combined)  BMD of 0.500 
g/cm2. There were no available population data in South Africa to compare this study 
group against. Using the data from this study the mean distal BMD (0.508 g/cm2) in the 
African population was slightly higher than the reference group. Both the coloured 
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(n=13) and Indian groups (n=38) had a lower distal BMD compared  to the reference 
group (0.482 and 0.463 g/cm2 respectively). However, the numbers in these two groups is 
low and may not be a good representation of these ethnic groups.   Although a significant 
effect of DMPA on BMD has been reported elsewhere (Petitti et al, 2000 and Gbolade et 
al,1998) this may not necessarily translate into  concern of clinical importance so long as 
the deficit is still within the 1 SD of the normal value. 
 
Although some studies have reported that bone loss is associated with lactation (Lamke et 
al, 1976), there appears to be recovery in the long term (Lamke et al, 1976). Length of 
lactation and its association with BMD is also unresolved (Sowers et al, 1993). Our study 
found no association between length of lactation and BMD.    
 
In conclusion, long term use of hormonal methods in this study population does not 
negatively impact on BMD and there should not be concerns about allowing women to 
continue using this method until they reach menopause. Further,  African women in our 
study had higher BMIs then other population groups however after adjusting for BMI 
there was no difference between the population groups in this age groups.  
 
Limitations of the study 
 The cross-sectional nature of the study is a limitation. The women recruited are now 
contributing to a longitudinal study with five years  follow-up.  BMD measurements were 
limited to the forearm and therefore findings may not be applicable to other skeletal sites. 
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Introduction 
Most studies have found  that current users of depot-medroxyprogesterone acetate 
(DMPA) have lower bone mineral density (BMD) compared to nonusers (Curtis & 
Martins, 2006, Wanichsetakul et al, 2002; Petitti et al, 2000; Scholes et al, 1999; Cundy 
et al, 1996; Cundy et al, 1991). There is  limited information in women over 40 years of 
age (Sanches et al, 2008, Beksinska et al, 2005, Tang et al, 2000, Tang et al, 1999, 
Gbolade et al, 1998) as few studies have included women in this age group. Results of 
these studies have been mixed with some finding no differences  in BMD between  older 
DMPA users and  nonusers or normal population means (Sanches et al, 2008, Beksinska 
et al, 2005, Gbolade et al, 1998) and those that have found a negative effect of DMPA on 
BMD compared to nonusers (Rosenburg et al, 2007, Tang et al, 2000, Tang et al, 1999)   
 
Studies investigating COC use in  perimenopausal users have not found any negative 
impact on BMD compared to nonusers of COCs (Martins et al, 2006). Two  cross-
sectional studies  have looked at BMD in norithisterone enanthate users (NET-EN)  
(Rosenburg et al, 2007, Beksinska et al, 2005). In one of these studies (Rosenburg et al, 
2007) current NET-EN users aged 40-44 had lower ultrasound measures in the calcaneus 
compared to nonusers, while the second study found no difference in forearm BMD 
between current users and controls (Beksinska et al, 2005). This study aimed to 
investigate BMD in older users (40 to 49 years) of  DMPA, NET-EN, COC and nonusers 
of contraception in a 4-5 year follow-up study. 
 
172 
 
Subjects and Methods 
A cohort of women aged 40 to 49 years old using DMPA, NET-EN, or COCs, and 
nonusers of hormonal contraception were recruited from a large family planning clinic in 
Durban, South Africa. Recruitment commenced in 2000 and was completed in 2003.  
Details of the study methodology are described in chapter 3.6 and previously published 
(Beksinska, 2005). Briefly, for inclusion as a hormonal contraceptive user, women had to 
have used either DMPA, NET-EN or COCs for at least one year.  For inclusion in the 
nonuser control group women should not have used any form of hormonal contraception 
in the past year. Women who were postmenopausal were excluded from the study at 
screening using menstrual history and  follicle-stimulating hormone (FSH) levels from 
blood samples. An FSH level of ≥25.8 milli International Units per milliliter (mIU/mL) 
was considered to be in the menopausal range (King Edward VIII Hospital Durban; 
Chemical Pathology Laboratory criteria using Roche Elecsys FSH expected values).  
 
On recruitment, a questionnaire was administered  to elicit information on lifetime 
contraceptive history, fertility history, menopausal symptoms and regularity of the 
menstrual cycle.  The examination included height, weight, blood pressure and waist and 
hip measurements using a standard protocol. Forearm BMD was measured by dual 
energy x-ray absorptionmetry (DXA model DTX-200).  Osteometer MediTech A/S Co, 
Rodovre, Denmark).  BMD was measured in grams/centimetre2 (g/cm2) at two sites in the 
distal  forearm (radius and ulna).  The DXA equipment was standardized daily using a 
phantom as prescribed by the manufacturers instructions.  Accuracy to the standard 
during the recruitment period was 0.53%. and in vivo precision was 0.94%.  Study 
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participants were followed-up at six-monthly intervals for a total of four to five years 
depending on time of recruitment. Women completed their  follow-up visit between 
August 2005 and April 2006. 
 
The characteristics of women in the study were quantified as means + SD, medians, or 
percentages. Follicle-stimulating hormone levels were divided into two categories 
according to laboratory cut-off levels for premenopausal (<25.8 mIU/mL) and peri-
menopausal/menopausal (≥25.8 mIU/mL). Differences in BMD between contraceptive 
groups, and the associations between BMD and selected characteristics of the study 
participants by contraceptive group were assessed using one-way analysis of variance and 
multiple variable linear regression. The sample size calculated assuming a two-tailed 
statistical test with a significance level of 5% and with  power of 80% was 63 subjects in 
each contraceptive group. Sample size after adjusting for potential loss to follow-up was 
at least 100 women in each category.  Data were analysed using the statistical package 
STATA (V.10 College station, TX, USA). Ethical approval was granted by the 
University of the Witwatersrand, Human Subjects Research Committee, and by the 
Scientific and Ethical Review Group of the World Health Organization. 
 
Results 
In total, 496 women were recruited. Baseline information about these women is 
summarised in Table 3.7.1. Although the groups using hormonal contraception were 
similar in age (43 years), the nonusers of hormonal contraception were on average 2 
years older than DMPA users (p<.001).   Almost all women were African except for the 
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COC group which included around a quarter (26%) of Indian women. Most women had 
started using the group method in their mid-thirties on completion of desired family size 
and had used for approximately 4 years on recruitment. Few women were current 
smokers.    
 
Table 3.7.1 Baseline  characteristics of subjects in the 40-49 year age range by 
contraceptive method use 
 
Characteristics DMPA 
(n=127) 
NET-EN 
(n=102) 
COC 
(n=106) 
Non user 
controls  
(n=161) 
 
P value 
Mean age, years (SD) 
                
Ethnicity %   
                African 
                Coloured 
                Indian 
  
Exercise 
                No regular exercise (%) 
               At least once a week (%) 
 
Dieted in last 6 months (%) 
 
Current smoker (%) 
Parity (median) 
Ever lactated % 
Mean age at menarche, years(SD) 
Lactation (yrs) median 
 FSH  
          < 25.8  mIU/mL, % 
          > 25.8  mIU/mL, %          
  
Use of group method 
Median use in last 5 yrs (months)       
      Median lifetime use (months )      
       
Radius BMD g/cm2 
43.6 (2.7) 
 
 
98.4 
  1.6 
  0 
 
 
96.9 
  3.1 
 
    0 
 
4.7 
4 
88.2 
15.2+ 1.7 
3.5 
 
72 
28 
 
 
53 
84 
 
0.514 
43.0 (2.2) 
   
 
95.2 
1.0 
3.8 
 
 
96.0 
  4.0 
 
    0 
 
  5.6 
3 
91.3 
15.5+1.7 
3.2 
 
94 
6 
 
45 
49 
37 
 
0.514 
43.7 (2.5) 
      
 
67.0 
  7.5 
25.5 
 
 
94.3 
  5.7 
 
 4.7 
 
5.7 
3 
87.7 
14.8+1.7 
3.0 
 
90 
10 
 
52 
 89 
 36 
 
0.500 
45.4 (2.5) 
 
 
94.4 
  2.5 
  3.1 
 
 
93 
  7 
 
<1 
 
9.9 
3 
83.2 
14.8+1.6 
3.2 
 
68 
32 
 
NA 
NA 
NA 
 
0.518 
<0.001 
 
0.007 
 
 
 
 
 
0.48 
 
 
0.003 
 
0.23 
0.04 
0.34 
0.014 
0.06 
 
<0.0001 
 
 
 
 
 
 
0.26 
* Only group method shown i.e. group to which women using that method at the time of 
recruitment were allocated. Contraceptive history of nonuser group not shown. 
 
DMPA= depott medroxyprogesterone acetate; NET-EN = Norethisterone enanthate; 
COC= combined oral contraceptive;   SD= standard deviation;  
 
175 
 
There was no significant difference in BMD at baseline between the four contraceptive 
user groups at the radius (p=.26) or the ulna site (p=.21), with and without adjustment for 
age. Although a small decrease in BMD was noted over the age range (40 to 49 years) 
this was not statistically significant (p=.7).  Length of use of method in the last 5 years 
and total lifetime use was not associated with difference in BMD. 
 
Although differences were noted between the contraceptive groups, most were not 
associated with BMD except for BMI, ethnic group and FSH level. A statistically 
significant difference in BMD was found between the Indian and African women 
(p=.014); however after adjusting for BMI the difference in BMD was no longer 
significant. 
 
During follow-up all nonusers of hormonal contraception remained as nonusers, however 
many women in the user groups continued participation in the study but ceased using a 
contraceptive method. At baseline 32% of women recruited were nonusers of 
contraception, this increased to 71% after  three years of follow-up  and by end of the 
follow-up period  the majority of women (87%) had ceased using a method of 
contraception. Due to small numbers of hormonal contraceptive users from 3 years of 
follow-up, comparison of user groups was conducted at the 2.5 year visit. At this follow-
up visit 278 women continued with the same method they were using at baseline. Women 
were excluded from the analysis if they stopped or changed their method. No difference 
was found in BMD between the groups at this interim analysis  (Table 3.7.2).  
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Table 3.7.2 Mean  Radius BMD at 2.5 years by contraceptive group* 
 
 
N Radius BMD g/cm2 
(SD) 
 
P value 
Contraceptive group  
      DMPA 
      NET-EN 
      COC 
      Nonuser 
 
63 
38 
48 
129 
 
0.511 (.071) 
0.501 (.081) 
0.500 (.082) 
0.504 (.075) 
 
0.522 
 
 
 
 
*Only women continuing with the same method from baseline were included in this 
analysis 
 
Further analysis is underway to complete this paper 
 
Discussion 
This longitudinal study found no difference in forearm BMD between users and nonusers 
of hormonal contraception after 2.5 years of follow-up. This is in agreement with  data 
collected at baseline in our study (Beksinska et al, 2005). The populations investigated in 
studies looking at the effect of DMPA and NET-EN  have included women using the 
method in their 40s but there is limited information in this  age group specifically. The 
age ranges of women in some studies have included users up to the age of 52, however 
the numbers have been small. In one cross-sectional study older DMPA users were 
disaggregated in the data (Gbolade et al, 1998) and no differences were found in BMD in 
women aged between 40-49 and a slightly older group of 50-52 compared to a normal 
population mean in the lumber spine and femoral neck. The population of women in the 
Tang et al (1999) cross-sectional study were generally older than other studies with a 
mean age of 43 years. In this study those who had used DMPA for 5 years or more had 
significantly lower BMD in the spine, femoral neck, trochanter and ward’s triangle 
compared to never users.  From the initial cross-sectional sample of 67 women, 59 were 
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followed up in the 3-year prospective component of the study (Tang et al, 2000). Small 
losses were noted of less than 1% in all sites but not the trochanter. In addition there was 
no effect seen with duration of use aside from a weak negative  between BMD in the 
femoral neck and duration of use. One longitudinal study (Sanches, 2008) followed up 
women who had been long-term users of  either DMPA or the IUD until menopause. This 
study found no difference in forearm BMD between these two groups at each of the three 
sites at one-year follow-up post-menopause. 
 
In summary there is limited data available on DMPA use in this group of older women 
due to the low prevalence of use in this age group and information in this age group has 
come from studies including a wider age range of women. However, loss of BMD has 
been found in these older DMPA users. 
 
Two  cross-sectional studies  have looked at BMD in norithisterone enanthate users 
(NET-EN)  (Rosenburg et al, 2007, Beksinska et al, 2005). In one of these studies 
(Rosenburg et al, 2007) a similar negative effect was found in current  DMPA and NET-
EN users aged 40-44 who had lower ultrasound measures in the calcaneus compared to 
nonusers, while the second study found no difference in forearm BMD between current 
NET-EN users and controls (Beksinska et al, 2005). Both cross-sectional and longitudinal 
studies investigating COC use in  perimenopausal users have not found any negative 
impact on BMD compared to nonusers of COCs (Martins et al, 2006). Further analysis of 
the older woman in this dataset will consider menopausal status and also look at changes 
in BMD in women who ceased using hormonal contraception during follow-up. 
178 
 
 
3.8 Detection of raised FSH levels amongst older women using 
depot-medroxyprogesterone acetate and norethisterone 
enanthate 
 
Mags E Beksinska, Jenni A Smit1,  Immo Kleinschmidt2,  Helen V. Rees1,  
Timothy MM Farley3,  Franco Guidozzi4 
 
 
 
This paper has been published in Contraception 2003; vol.68, no.5, pp.339-43. 
(Appendix 8) 
 
 
1The Reproductive Health Research Unit, Department of Obstetrics and Gynaecology, 
University of the Witwatersrand, Suite 1301, Maritime House, 143 Salmon Grove, 
Durban, South Africa  
2 Family Health International, P.O Box 13950, Research Triangle Park  NC 27709, USA 
3Special Programme for Research, Development and Research Training in Human 
Reproduction, Department of Reproductive Health and Research, World Health 
Organisation, Geneva, Switzerland. 
Department of Obstetrics and Gynaecology, Johannesburg Hospital, University of the 
Witwatersrand, Johannesburg, South Africa 
179 
 
Abstract 
Background: The objective of this study was to investigate whether follicle-stimulating 
hormone (FSH) levels can be used reliably to indicate approaching menopause in older 
(aged 40-49) long-term users of depot-medroxyprogesterone acetate (DMPA) and 
norethisterone enanthate (NET-EN).   
Study design: One-hundred and seventeen women using DMPA, 60 NET-EN users and 
161 nonusers of contraception were recruited.  At recruitment, serum FSH levels were 
measured and questions were asked regarding menopausal symptoms, menstrual cycle and 
date of last injection.   
Results: Results of the recruitment blood test showed that 32% of the nonusers had FSH 
levels in the menopausal range >25.8 milli International units per milliliter (>25.8 
mIU/mL) compared to 28% of the DMPA users and 9% of the NET-EN group. After 
adjusting for age, there was no significant difference between the 3 groups (p=0.13).  An 
increase of one year in age increased the FSH level by 3 mIU/mL (p<0.001).  All the 
hormonal contraceptive users were between one day and 12 weeks of their injection 
interval. Many had been using the injectable contraceptive method for over 10 years and 
almost all were amenorrheic at the time of recruitment.  
Conclusion: The data show that a raised FSH level can be detected during use of DMPA 
and NET-EN and could be used as a menopausal indicator without interrupting method use 
in this group of contraceptive users. 
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Introduction 
Depot-medroxyprogesterone acetate (DMPA) and norethisterone enanthate (NET-EN) are 
effective contraceptives with low failure rates (WHO, 1983).    One of the common side 
effects of these methods is amenorrhea, which increases in incidence over time (WHO, 
1983).   In older users it may be difficult to distinguish between amenorrhea associated 
with approaching menopause and that induced by the method.  Detection of menopause or 
perimenopause, therefore, presents a challenge in this group of contraceptive users. 
Traditional textbook management of an older woman using oral hormonal contraception 
recommends measurement of follicle-stimulating hormone (FSH) on the seventh day of the 
pill-free interval (Guillebaud, 1993). Advice for DMPA and NET-EN users is less clear; 
however, in the absence of data documenting efficacy it has been suggested that they 
should change to a nonhormonal method of contraception, as menopausal symptoms will 
be masked, and measurement of FSH levels may be unreliable (Guillebaud,1993). 
 
DMPA and NET-EN are known to inhibit the mid-cycle surge of FSH and luitenising 
hormone (LH), but the tonic release of these gonadotrophins continues at luteal phase 
levels (Mishell, 1972; Franchimont, 1970).  A few studies have also shown that DMPA 
and NET-EN suppresses  raised FSH and LH levels in postmenopausal women (Perez-
Palacois, 1981; Fotherby, 1977). While limited information exists on the duration of the 
suppression of raised FSH and LH levels associated with menopause, in both these studies 
(Perez-Palacois, 1981; Fotherby, 1977),  the lowest FSH and LH levels occurred between 
14-30 days after injection. The majority of suppressed levels were still high enough to be 
classified as in the menopausal range.  Thereafter, FSH and LH levels started to rise, and in 
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one of these studies (Perez-Palacois; 1981), FSH levels started rising back to pre-
suppression levels between 40-80 days after injection.  
 
In South Africa, hormonal injectable contraceptive use is high, with about 60% of Black 
African women practicing contraception using either DMPA or NET-EN (Department of 
Health, South Africa, 1999).  Of the two available injections, older women almost 
exclusively use DMPA and often continue to use this method into their late 40s.  
 
 While the primary aim of this study was to investigate bone density in older women using 
hormonal contraceptives, a secondary objective was to investigate whether FSH levels 
could be used as an indicator of menopausal status in injectable users. This was due to the 
high prevalence of amenorrhea in the two injectable groups which made it impossible to 
use the menstrual cycle as an indicator of menopausal status.   This paper presents the 
results of the latter component of the study. 
 
Materials and methods 
A cohort of older women using DMPA (150 mg at 3-monthly intervals), NET-EN (200 mg 
at 2-month intervals), combined oral contraceptives (COCs) and nonusers of contraception 
were recruited from a large family planning clinic in Durban, South Africa, between 
September 2000 and November 2001. For inclusion as an injectable user, women had to be 
aged between 40 and 49 years and had to have used the injectable hormonal contraceptive 
for at least one year. On recruitment, a questionnaire was administered which elicited 
information on contraceptive history, menopausal symptoms and regularity of the 
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menstrual cycle. Since women were recruited at different times in the injection cycle, date 
of last injection was recorded. A sub-sample of injectable users with FSH levels >25.8 
mIU/mL at recruitment were contacted and asked to return for a second test to confirm 
their earlier result. If the recruitment measurement was taken later in the injection cycle, 
the woman was asked to return for a repeat test in the expected peak suppression period in 
her next injection cycle (14-30 days). If the recruitment measurement was taken during 
time of expected peak suppression she was asked to return after this time in the next 
injection cycle.  FSH measurements are repeated yearly for the 5-year duration of the 
study. 
 
A serum sample was obtained at the recruitment visit, and serum FSH levels were 
determined by immunoassay on the Roche MODULAR ANALYTICS E170 (Elecsys 
module) immunoassay analyser. Repeated samples from each subject were always 
analyzed in the same FSH assay batch. In total, 8 assays were conducted during the time of 
data collection for this study.  For the purposes of this study, an FSH level between 25.8 
and 135 milli International Units per milliliter (mIU/mL) was considered to fall into the 
menopausal range (King Edward VIII Hospital Durban; Chemical Pathology Laboratory 
criteria using Roche Elecsys FSH expected values). Assay specificity: With respect to 
analytical specificity, the following cross reactions with other hormones have been 
determined for the monoclonal antibody used: leutenising hormone, thyroid stimulating 
hormone, human chorionic gonadotropin, human growth hormone and human placental 
lactogen at <0.1%. Assay sensitivity: The lower detection limit  is <0.10 mIU/ml. The 
detection limit represents the lowest FSH level that can be distinguished from zero. It is 
183 
 
calculated as the concentration lying two standard deviations above that of the lowest 
standard. The maximum of the measuring range is 200 mIU/ml. Values above this figure 
are reported as >200 mIU/ml. All samples analyzed for this study were above the lower 
detection limit and no sample was reported over 200 mIU/ml. Test precision 
(reproducibility): The within-assay coefficients of variation ranged between 0.78 and 1.5% 
for QCs with mean values of 9.53 and 33. Between assay variability ranged from 3.5 to 
7.6% depending on the serum FSH concentration. 
  
To investigate whether DMPA and NET-EN interfered with the FSH assay, control test 
samples and patient samples with high and low values of FSH were spiked with both 
contraceptives at levels above the highest circulating levels of MPA and NET described in 
the literature (Mishell, 1996; Fotherby, 1980). The results of this showed that only very 
small differences were observed, which fell into the quoted within-run precision of the test.   
 
In this article we present the data collected up to November 2001 relating to the injectable 
hormonal users.  Data on COC users will be analyzed separately.  Mean and median FSH 
levels were compared between nonusers and each of the 2 injectable user groups, by means 
of Student’s t-test and the Wilcoxon test, respectively, using the statistical package 
STATA (V.7 College Station, TX, USA). Multiple regression was done to investigate the 
effect of hormonal injectable use on FSH, adjusted for age. Ethical approval was granted 
by the University of the Witwatersrand, Human Subjects Research Committee. 
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Results 
In total, 117 DMPA and 60 NET-EN users were recruited.  Fewer women were recruited in 
the NET-EN group, as this method is not as popular in older women.   Baseline 
information about these women and 161 nonusers of contraception is summarized in Table 
3.8.1. Nonusers of hormonal contraception were on average 2 years older than DMPA 
users (p<0.001).  NET-EN users were the youngest group with a mean age of 42.5 years.  
All women using either DMPA or NET-EN had been using the method for at least one 
year at recruitment. The average length of lifetime use for DMPA was 9.3 years, with a 
number of women (n=13) who had used the method for 15 years or more.   
 
Table 3.8.1  Baseline information  
 Nonusers 
N=161 
DMPA Users 
N=117 
NET-EN Users 
N=60 
Mean Age (yrs) (p<0.001) 
Median 
Range 
45.3 
46 
41-49 
43.6 
43 
41-49 
42.5 
42 
41-49 
Mean FSH mIU/mL (p=0.013) 
Median (P=0.013) 
Range 
26.4 
12.6 
0.2-115 
22.1 
10.1 
0.1-114 
11.6 
7.2 
0.2-51.1 
 
 
 
NET-EN users had been using the method on average for 5.6 years. The majority of 
subjects had started using DMPA or NET-EN immediately after the birth of their last 
child, as they had attained their desired family size. Very few women using DMPA 
reported regular menstrual cycles (8%); women not reporting a regular cycle were in 
almost all cases experiencing spotting or amenorrhea. More women in the NET-EN 
group (48%) reported regular cycles.  Results of the recruitment blood test showed that 
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32% of the nonusers had FSH levels in the menopausal range (>25.8mIU/mL) compared 
to 28% of the DMPA users and 9% of the NET-EN group. FSH was associated with a 
woman’s age (p=0.013), and Figure 3.8.1 shows a plot of FSH levels by age predicted 
from the regression model. After adjusting for age, there was no significant difference in 
FSH levels among the 3 groups (p=0.13).  An increase of one year in age increased the 
FSH levels by 3 mlU/mL (p<0.001).  
 
Figure 3.8.1 Observed and fitted FSH levels by age. 
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Of the total 33 women using DMPA and 6 using NET-EN who had an FSH level greater 
than 25.8 mIU/mL on their recruitment visit, 12 DMPA and 2 NET-EN users were able 
to return during their next injection cycle after being contacted by telephone. Table 3.8.2 
shows the 2 results in each of these participants. In total, 7 women had one of the 2 FSH 
measurements  taken in the time of expected peak suppression (14-30 days). In 3 of these 
measurements the FSH level fell below the menopausal range (<25.8mIU/mL) while the 
other 4 still remained in the menopausal range  
 
Table 3.8.1 Individual FSH levels of the sub-group of users of DMPA and NET-EN 
with raised FSH levels at recruitment 
Subject 
number 
Days post –injection 
earlier 
measurement  
FSH 
(mlU/mL) 
Days 
Post- injection 
later 
measurement 
FSH 
(mlU/mL) 
DMPA 
391 
584 
628 
629 
632 
703 
706 
734 
740 
792 
822 
833 
NET-EN 
639 
724 
 
50 
42 
27 
14 
14 
25 
76 
55 
52 
17 
5 
1 
 
15 
10 
 
52.9 
38.7 
28.6 
113 
22.9 
9.3 
32.7 
54.3 
54.6 
67.9 
30.8 
50.2 
 
21.3 
27.4 
 
85 
48 
37 
42 
90 
72 
90 
93 
91 
36 
14 
28 
 
38 
60 
 
71.8 
37.4 
57.9 
99.7 
45.6 
93.3 
45.1 
68.2 
50.5 
69.4 
33.4 
41.5 
 
28.5 
51.2 
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 (>25.8mIU/mL). The levels in most cases differed considerably depending on the time 
post-injection. The level taken later in the injection cycle was higher in 10 of the 14 cases.  
In 2 subjects (629,792), similar FSH levels were observed during expected peak 
suppression (14-30 days) and later in the injection cycle. 
 
Discussion 
Previous studies have been limited due to their small sample sizes and the inclusion of 
subjects who received only one dose of MPA or NET-EN (Perez-Palacois, 1981; Fotherby, 
1977). These studies concluded that the baseline values of FSH and LH in postmenopausal 
women declined from the day of injection to reach their lowest levels between 14 and 30 
days and then rose back to pre-suppression levels between about 40 and 80 days post-
injection.  In one of these studies (Fotherby, 1977), one of the subjects received a second 
dose of NET-EN and results indicated that the suppression of FSH was not as pronounced 
as that of the first dose.  Further, the degree of suppression of FSH is reported to vary 
considerably between women, with suppression ranging between 30-75% of baseline 
values (Fotherby, 1977).  Although a great deal of variability between women was shown, 
a similar pattern of suppression after injection and return to baseline values later in the 
dosing cycle was exhibited (Fotherby, 1977). 
 
Our study supports the earlier work, in that in almost all cases, DMPA and NET-EN did 
suppress FSH  levels in the first 30 days after injection. Where 2 samples were taken in the 
same subject, the levels of FSH measured in the sample taken sooner post-injection were 
lower in almost all cases. In 2 cases, the gonadotrophin levels were measured on day 1 
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(subject 833) and day 5 (subject 822) post-injection,   probably before peak suppression 
occurred.  In one case (833) the level taken subsequently at day 28 during the time of 
expected peak suppression was found to be lower, while in the other (822) the level was 
slightly higher.  It may be that in this subject the FSH level was already suppressed by day 
5 and by day 14 it was recovering. 
 
In some subjects both measurements were taken after the time of expected peak 
suppression and in these cases the differences between the 2 measurements was smaller; 
however, the measurement taken later in the cycle was similar or higher. The subject with 
the highest FSH level (subject 629) showed little difference between her level at 13 days 
(113) and that taken at  42 days (99.7). It may be that the peak suppression of FSH 
occurred between these 2 times or that gonadotrophin levels in this subject only responded 
marginally in terms of suppression.  This subject had been using the method for 14 years in 
total. 
 
This is the first study which examines FSH levels in long-term users of DMPA and NET-
EN.  Raised FSH levels were found in women during use of the method and this indicates 
that measurement of gonadotrophins could be used as an indicator of onset of menopause.  
This also supports earlier work where gonadotrophin levels rarely fell  below a peak level 
of 20 mIU/mL in postmenopausal women ( Perez-Palacois, 1981; Fotherby, 1977), again 
suggesting that the suppression would not necessarily make gonadotrophin levels 
unreliable indicators of menopause in hormonal injection users.  It does suggest, however, 
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that the measurement should be taken as late as possible in the 2- or 3-month injection 
cycle to ensure that the gonadotrophin levels were approaching baseline levels.  
 
There are no local guidelines in South Africa on how to deal with a woman using 
injectable contraception in her later reproductive years; however, the policy at a large 
provincial hospital in Durban is to refer users reaching 50 years, or users who report 
menopausal symptoms, for FSH measurement at the end of a 3-month DMPA injection 
cycle (King Edward Hospital, Durban, personal communication).  If an FSH level is found 
to be in the menopausal range, the woman will be counselled to consider changing her 
method of contraception to a barrier method to see if  menses returns.   Raised levels of 
FSH with accompanying menopausal symptoms have been documented at this facility 
amongst hormonal injection users. This finding has important implications for guiding 
family-planning providers in the management of older women using hormonal injectable 
contraception.  Women could possibly have gonadotrophin levels measured  without 
discontinuing the method, as long as the test is  taken later in the injection cycle for both 
NET-EN and DMPA. A good time to measure levels is on return for the next injection 
dose before the gonadotrophin levels are reduced.    
 
The transition to menopause described as the perimenopause has been estimated to be just 
under 4 years in some populations (McKinley, 1992).  As a woman moves into the 
perimenopause, FSH can fluctuate between pre- and post-menopausal values and 
menopausal symptoms such as erratic menstrual cycles, and hot flushes will be 
experienced (Sherman, 1975).  The variability of FSH levels during this time has called 
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into question the reliability of using the FSH measure to diagnose or predict menopause 
(Burger, 1994).  However, in injectable users, it is the only means of assessing the 
menopause and, based on our findings, it should still be considered an option. 
 
Further work will be done in a more in-depth study on this issue, which will involve taking 
multiple samples in a smaller subset of women who have agreed to participate in having 
repeat samples taken at short intervals within the dosing interval. 
 
 Limitations of the study 
 This study had a number of limitations. Subjects were part of another study which was not 
set up for taking  multiple blood samples which would be required to obtain an in-depth 
picture of gonadotrophin suppression. The researchers aimed to get subjects to come once 
during the peak gonadotrophin suppression period  and once towards the end of a 2-  or 3- 
month injection cycle. This was not always possible as many women were only 
contactable by letter and it was therefore difficult to remind them to come at the exact time 
scheduled. The laboratory had not developed its own reference ranges for the FSH test.  
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4.0 CONCLUSION AND RECOMMENDATIONS 
This conclusion briefly summarizes overarching issues from the discussion sections of 
the main papers and highlights the key evidence emerging from this thesis. This study has 
added to the existing body of evidence on the effect of hormonal contraception on BMD. 
It has provided new data on the effect of the injectable contraceptive NET-EN and it has 
investigated BMD in mixed hormonal contraceptive users. It is one of few studies on 
BMD undertaken amongst African users of hormonal contraceptives. Through 
publication and other modes of dissemination, the findings have been made available to 
the wider scientific community and policy makers at national and international level.  
 
In summary, this study found that although radius BMD increased during follow-up in 
adolescents and young women in both non-user and hormonal contraceptive users, there 
was evidence of lower bone mass in NET-EN and COC groups compared to the non-user 
group. Although DMPA users had a lower yearly increase in forearm BMD compared to 
non-users, this was not significant. Other studies using the forearm as a measurement site 
have generally not found significant differences between DMPA users and controls 
(Bahamondes, et al, 1999, Tharnprisarn & Taneepanichskul, 1999).  
 
At the end of the follow-period in this study the adolescent group were aged between 19 
and 24 years old. A final measurement of BMD in the hip, spine and femoral neck was 
taken in a sub-sample of 96 woman in group which found evidence of lower BMD values 
in injectable users (including mixed injectable users) compared to non-users of hormonal 
contraception, but not among those women who had used COCs in combination with 
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injectables. This is in agreement with other longitudinal studies of BMD in adolescents 
using DMPA alone (Cromer et al, 1996, Cromer et al, 2004, Larra-Torre, 2004). 
 
The longitudinal component of the  study has added evidence that use of COCs in 
adolescents may result in lower bone growth. In the cross- sectional component of the 
study, there were not enough women continuing use of COCs exclusively to comment on 
BMD change. The group that had mixed COC users with injectable use over a 4-5 year 
period had lower BMD values but this was not significantly different from the non-users 
and the sample was small.  
 
 Our study shows some evidence of a recovery in growth in  BMD in a very small sample 
of  NET-EN discontinuers who did not use another hormonal method of contraception 
after cessation. Although no other longitudinal data exists on women who have 
discontinued use of NET-EN, this is in agreement with the only cross-sectional study that 
investigated women who commenced NET-EN during adolescence  and then ceased 
using the method (Rosenburg, et al).  
 
In the older users aged 40-49 years there were no differences found in BMD between 
users of DMPA, NET-EN and COCs and non- users of hormonal contraception at 
baseline. Many women had been using hormonal methods for more than 10 years at 
recruitment. No difference was noted in BMD between the groups in an interim analysis 
at 2.5 years. In this age group BMD was found to be associated with FSH level and raised 
FSH levels were detected in users of hormonal contraception. As mentioned above 
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studies measuring the forearm have been less likely to find an effect of hormonal 
contraception on BMD. Due to cost issues it was not possible to include older woman in 
the final cross-sectional measurement of the central sites.  
  
Several regulatory bodies have cautioned against long-term use of DMPA (FDA, 2004, 
MHRA,2004, WHO, 2006).  In the absence of evidence on NET-EN the WHO applied 
the same criteria for NET-EN use (WHO,2006).  No restriction has been placed on use of 
other  progestogen-only or combined hormonal contraceptive methods. There are now 
concerns that these recommendations need to be reviewed in the light of emerging 
evidence of BMD reductions in low-dose COC users (Alberatzzi et al, 2006, Berenson et 
al, 2008). In addition as evidence grows on recovery of BMD post discontinuation of 
DMPA and NET-EN there is a need to balance loss of BMD  against the benefit of using  
effective contraception, especially in adolescents.  
 
Recommendations for future research 
The issue of recovery of BMD in ex-users of DMPA and NET-EN requires longitudinal 
studies, with larger sample sizes and longer periods of follow-up. Although data is 
showing adolescents recover BMD on cessation of use of DMPA and this study has 
shown recovery in adolescents discontinuing NET-EN, follow-up is needed beyond 
acquisition of peak bone mass  to determine if full recovery of BMD is made in women 
who use DMPA, NET-EN and low dose COCs as adolescents.  A study to address longer 
term follow-up is currently in the planning stage and will commence in 2010.  
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The mechanism by which DMPA can reduce BMD is well documented (Ortiz et al, 
1977), however there is less information on NET-EN and the mechanisms by which it 
could affect BMD and this needs to be investigated further. 
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APPENDIX 1 
 
CONSENT FORMS AND INFORMATION SHEETS 
(ENGLISH AND ZULU) 
 
SUBJECT INFORMATION SHEETS: ENGLISH 
Aged 15 – 19 users of hormonal contraceptives 
Aged 15 -19 non-users of hormonal contraceptives 
Aged 40 – 49 users of hormonal contraceptives 
Aged 40 -49 non-users of hormonal contraceptives 
 
SUBJECT INFORMATION SHEETS: ZULU 
Aged 15 – 19 users of hormonal contraceptives 
Aged 15 -19 non-users of hormonal contraceptives 
Aged 40 – 49 users of hormonal contraceptives 
Aged 40 -49 non-users of hormonal contraceptives 
 
CONSENT FORMS: ENGLISH 
Aged 15 – 19 users of hormonal contraceptives 
Aged 15 -19 non-users of hormonal contraceptives 
Aged 40 – 49 users of hormonal contraceptives 
Aged 40 -49 non-users of hormonal contraceptives 
 
CONSENT FORMS: ZULU 
Aged 15 – 19 users of hormonal contraceptives 
Aged 15 -19 non-users of hormonal contraceptives 
Aged 40 – 49 users of hormonal contraceptives 
Aged 40 -49 non-users of hormonal contraceptives 
 
CONSENT FORMS: ENGLISH & ZULU: SUBSTUDY OF SPINE/HIP/NECK DEXA 
Information sheet, Consent form English and Zulu 
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 SUBJECT INFORMATION SHEET 
(15-19 age group, users of hormonal contraceptives) 
 
INJECTABLE AND ORAL CONTRACEPTIVE BONE MASS STUDY 
 
What is this study about? 
The injectable contraceptives Depo Provera and Nuristerate and oral contraceptives (pills) 
have been used by women in this country for many years. The Reproductive Health Research 
Unit based in the Department of Obstetrics and Gynaecology of Baragwanath Hospital is 
undertaking a study to look at the effect of these contraceptives on the bones of the skeleton 
(bone mass). 
 
What will be involved If I take part in this study? 
We are looking for women volunteers aged between 15 and 19  who want to use the injectable 
Depo-Provera, Nuristerate or oral contraceptives to take part in this study. If you decide to 
volunteer, A nurse will interview you to collect information on your  medical history, 
contraceptive history, and other reproductive information including pregnancies and 
breastfeeding.  The nurse will then take some physical measurements including height and 
weight and a machine will measure the bone mass of your arm. The bone mass measurement 
involves taking an X ray of your forearm, is painless and will only take about five minutes. 
The exposure to X-rays during this measurement is minimal and will not affect your health in 
any way. Every six months when you return to the clinic for your repeat injection or re-supply 
of pills we will  interview you and repeat the height, weight and bone mass measurement. The 
total length of the study is five years and we would want you to stay in the study for the whole 
of the five year period. If you know this will not be possible because you are planning to move 
away from the area in the next few years please inform the study nurse.  
 
What if I want to stop using the injection/pill or withdraw from the study? 
 Participation in the study is entirely voluntary and you may withdraw at any time. This will 
not affect your future treatment at the clinic. All the information you give us will be treated in 
confidence. We will reimburse any travel costs you incur during the course of the study. 
 
 
For more information on the study, the following people can be contacted: 
 
Mags Beksinska / Fikile Mbatha,  family planning Clinic, Commercial Road – 307 2781 
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 SUBJECT INFORMATION SHEET 
(15-19 age group, non-users of hormonal contraceptives) 
 
INJECTABLE AND ORAL CONTRACEPTIVE  BONE MASS STUDY 
 
What is this study about? 
The injectable contraceptives Depo Provera and Nuristerate and oral contraceptives (pills) 
have been used by women in this country for many years. The Reproductive Health Research 
Unit based in the Department of Obstetrics and Gynaecology of Baragwanath Hospital is 
undertaking a study to look at the effect of these contraceptives on the bones of the skeleton  
(bone mass). 
 
What will be involved If I take part in this study? 
We are looking for women volunteers aged between 15 and 19 who have never used the 
injection or the pill (hormonal contraceptives). If you decide to volunteer, A nurse will 
interview you to collect information on your medical history, contraceptive history, and other 
reproductive information including pregnancies and breastfeeding.  The nurse will then take 
some physical measurements including height and weight and a machine will measure the 
bone mass of your arm. The bone mass measurement involves taking an X ray of your 
forearm, is painless and will only take about five minutes. The exposure to X-rays during this 
measurement is minimal and will not affect your health in any way. We will ask you to come 
to the clinic every six months for another interview  and we will repeat the height, weight and 
bone mass measurement. The total length of the study is five years and we would want you to 
stay in the study for the whole of the five year period. If you know this will not be possible 
because you are planning to move away from the area in the next few years please inform the 
study nurse.  
 
What if I want to start using the injection/pill or withdraw from the study? 
 Participation in the study is entirely voluntary and you may withdraw at any time. This will 
not affect your future treatment at the clinic. All the information you give us will be treated in 
confidence. We will reimburse any travel costs you incur during the course of the study. 
 
 
For more information on the study, the following people can be contacted: 
 
Mags Beksinska / Fikile Mbatha,  family planning Clinic, Commercial Road – 307 2781  
 
 
 
 
 
 
 
 
 
 
 
 
198
 
 SUBJECT INFORMATION SHEET 
(40-49 age group, users of hormonal contraceptives ) 
 
INJECTABLE AND ORAL CONTRACEPTIVE BONE MASS STUDY 
 
What is this study about? 
The injectable contraceptives Depo Provera and Nuristerate and oral contraceptives (pills) 
have been used by women in this country for many years. The Reproductive Health Research 
Unit based in the Department of Obstetrics and Gynaecology of Baragwanath Hospital is 
undertaking a study to look at the  effect of these contraceptives on the  bones of the skeleton 
(bone mass). 
 
What will be involved If I take part in this study? 
We are looking for women volunteers aged between 40 and 49 who are current users of  
Depo-Provera, Nur-isterate or oral contraceptives to take part in this study. If you decide to 
volunteer, A nurse will interview you to collect information on your medical history, 
contraceptive history, and other reproductive information including pregnancies and 
breastfeeding.  The nurse will then take some physical measurements including height and 
weight and a machine will measure the bone mass of your arm. The bone mass measurement 
involves taking an X ray of your forearm, is painless and will only take about five minutes. 
The exposure to X-rays during this measurement is minimal. Many women begin to 
experience symptoms of menopause between the ages of 40 and 50 so we will also ask you 
some questions about any menopausal symptoms you may have experienced and take a blood 
test to check if you may be menopausal. Every six months when you return to the clinic for 
your repeat injection or re-supply of pills we will  interview you and repeat the height, weight, 
bone mass measurement and blood test. The total length of the study is five years and we 
would want you to stay in the study for the whole of the five year period. If you know this will 
not be possible because you are planning to move away from the area in the next few years 
please inform the study nurse.  
 
 
What if I want to stop using the injection/pill or withdraw from the study? 
 Participation in the study is entirely voluntary and you may withdraw at any time. This will 
not affect your future treatment at the clinic. All the information you give us will be treated in 
confidence. We will reimburse any travel costs you incur during the course of the study. 
 
 
For more information on the study, the following people can be contacted: 
 
Mags Beksinska / Fikile Mbatha  family planning Clinic, Commercial Road – 307 2781 
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 SUBJECT INFORMATION SHEET 
(40-49 age group, non-hormonal contraceptive users) 
 
INJECTABLE AND ORAL CONTRACEPTIVE  BONE MASS STUDY 
 
What is this study about? 
The injectable contraceptives Depo Provera and Nuristerate and oral contraceptives (pills) 
have been used by women in this country for many years. The Reproductive Health Research 
Unit based in the Department of Obstetrics and Gynaecology of Baragwanath Hospital is 
undertaking a study to look at the effect of these contraceptives on the bones of the skeleton  
(bone mass). 
 
What will be involved If I take part in this study? 
We are looking for women volunteers aged between 40 and 49 who are not using the injection 
or the pill (hormonal contraceptives) to take part in this study. If you decide to volunteer, A 
nurse will interview you to collect information on your  medical history, contraceptive history, 
and other reproductive information including pregnancies and breastfeeding.  The nurse will 
then take some physical measurements including height and weight and a machine will 
measure the bone mass of your arm. The bone mass measurement involves taking an X ray of 
your forearm, is painless and will only take about five minutes. The exposure to X-rays during 
this measurement is minimal. Many women begin to experience symptoms of menopause 
between the ages of 40 and 49 so we will also ask you some questions about any menopausal 
symptoms you may have experienced and take a blood test to check if you may be 
menopausal. We will ask you to come to the clinic every six months for another interview and 
repeat the height, weight, bone mass measurement and blood test. The total length of the study 
is five years and we would want you to stay in the study for the whole of the five year period. 
If you know this will not be possible because you are planning to move away from the area in 
the next few years please inform the study nurse.  
 
 
What if I want to start using the injection/pill or withdraw from the study? 
 Participation in the study is entirely voluntary and you may withdraw at any time. This will 
not affect your future treatment at the clinic. All the information you give us will be treated in 
confidence. We will reimburse any travel costs you incur during the course of the study. 
 
 
For more information on the study, the following people can be contacted: 
 
Mags Beksinska / Fikile Mbatha, family planning Clinic, Commercial Road – 307 2781 
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 Zulu subject information sheet aged 15 – 19 age group users of hormonal contraceptives 
 
ISAZISO MAYELANA NOCWANINGO 
(15 -19 iminyaka) 
 
UCWANINGO NGESISINDO SAMATHAMBO OLUPHATHELENE NOHLELO 
MNDENI OLUNJENGOMJOVO KANYE NAMAPHILISI. 
 
INGABE LUMAYELANA NANI LULUCWANINGO/UPHANDO?      
 
Izinhlobo zokuhlela imindeni ezinjengemijovo (depo provera, kanye namaphilisi) ziye 
zasetshenziswa ngabesifazane kuleli lakithi iminyaka eminingi. I-REPRODUCTIVE 
HEALTH RESEARCH UNIT exhumane ne Department Of Obstertric and Gynaecolocy ese 
Chris Hani Baragwanath Hospital yenza uphando mayelana nendlela izinhlobo zokuhlela 
imindeni ezithintana ngayo nesimo samathambo (isisindo samathambo). 
 
KUXHOMEKANI UKUTHATHA KWAMI UHLANGOTHI KULOLUPHANDO? 
 
Sifuna abantu besifazane abazozinikela ngokuzithandela abaphakathi kweminyaka engu 15 
kuya kweyi-19 abafuna ukusebenzisa imijovo (depo provera, nur-isterate noma amaphilisi 
okuhlela) ukuba bangenele loluphando.  Uma ufisa ukuzinikela ngokuzithandela, 
umhlengikazi uyobe esekubuza imibuzo ngempilo yakho/izifo, uhlelo mndeni owake 
walusebenzisa, imibuzo ephathelene nembeleko yakho kanye nokuncelisa.  Umhlengikazi 
uyobe esekukala ubude, isisindo futhi umshini uyosetshenziswa ukukala isisindo sengalo 
yakho.  Lokhu ukukalwa kwamathambo kubandakanya ukuhlolwa kwamathambo engalo (x-
ray), akubuhlungu futhi kuthatha imizuzu emihlanu nje kuphela kanti akunangozi. Njalo nje 
emva kwezinyanga eziyisithupha uma usubuyela emtholampilo ukuzohlaba noma uzolanda 
amaphilisi akho okuhlela uyobuzwa imibuzo uphinde ukalwe ubude, isisindo kanye nesisindo 
samathambo futhi nokuhlolwa kwegazi mayelana nokuvaleka kwakho ungasayi esikhathini 
(menoupause). Siyothanda ukukubona iminyaka emihlanu ucwaningo selulonke. 
 
 
Kuyokwenzekani uma sengiyeka ukusebenzisa lolu hlelo mndeni noma 
ngihoxa kuloluphando? 
 
Ukuthatha uhlangothi kuloluphando kungukuzithandela futhi ungahoxa noma yinini uma 
ungasafuni. Lokhu angeke kuphazamise ukusebenzisa  kwakho umtholampilo ngokuzayo. 
Yonke into ositshela yona iyogcinwa njengeyimfihlo. Futhi siyobhekana nezindleko zakho 
zokugibela eziyokwenzakala phakathi naloluphando. 
 
Uma ufuna ukwazi kabanzi ngalolucwaningo/uphando, thintana nalaba 
abalandelayo: 
Mags Beksinska / Fikile Mbatha Family Planning Clinic, Commercial Road – 307 2781 
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Zulu subject information sheet – age 15-19 non - users of hormonal contraceptives 
ISAZISO MAYELANA NOCWANINGO 
(15 -19 iminyaka) 
 
UCWANINGO NGESISINDO SAMATHAMBO OLUPHATHELENE NOHLELO 
MNDENI OLUNJENGOMJOVO KANYE NAMAPHILISI. 
 
INGABE LUMAYELANA NANI LULUCWANINGO/UPHANDO       
 
Izinhlobo zokuhlela imindeni ezinjengemijovo (depo provera, kanye namaphilisi) ziye 
zasetshenziswa ngabesifazane kuleli lakithi iminyaka eminingi. I-REPRODUCTIVE 
HEALTH RESEARCH UNIT exhumane ne Department Of Obstetric and Gynaecolocy ese 
Chris Hani Baragwanath Hospital yenza uphando mayelana nendlela izinhlobo zokuhlela 
imindeni ezithintana ngayo nesimo samathambo (isisindo samathambo). 
 
KUXHOMEKANI UKUTHATHA KWAMI UHLANGOTHI KULOLUPHANDO? 
 
Sifuna abantu besifazane abazozinikela ngokuzithandela abaphakathi kweminyaka engu 15 
kuya kweyi-19 abangazange basebenzisa izinhlobo zohlelo mndeni kungaba imijovo noma 
amaphilisi ukuba bangenele lolu phando. Uma ufisa ukuzinikela ngokuzithandela, 
umhlengikazi uyobe esekubuza imibuzo ngempilo yakho/izifo, uhlelo mndeni owake 
walusebenzisa, imibuzo ephathelene nembeleko yakho kanye nokuncelisa.  Umhlengikazi 
uyobe esekukala ubude, isisindo futhi umshini uyosetshenziswa ukukala isisindo sengalo 
yakho.  Lokhu ukukalwa kwamathambo kubandakanya ukuhlolwa kwamathambo engalo (x-
ray), akubuhlungu futhi kuthatha imizuzu emihlanu nje kuphela kanti akunangozi. Njalo nje 
emva kwezinyanga eziyisithupha uma usubuyela emtholampilo ukuzohlaba noma uzolanda 
amaphilisi akho okuhlela uyobuzwa imibuzo uphinde ukalwe ubude, isisindo kanye nesisindo 
samathambo futhi nokuhlolwa kwegazi mayelana nokuvaleka kwakho ungasayi esikhathini 
(menoupause). Siyothanda ukukubona iminyaka emihlanu ucwaningo selulonke. 
 
Kuyokwenzekani uma sengiyeka ukusebenzisa lolu hlelo mndeni noma 
ngihoxa kuloluphando? 
 
Ukuthatha uhlangothi kuloluphando kungukuzithandela futhi ungahoxa noma yinini uma 
ungasafuni. Lokhu angeke kuphazamise ukusebenzisa kwakho umtholampilo ngokuzayo. 
Kanti uyokhuleka ukusebenzisa uhlelo mndeni phakathi naloluphando uma usufisa ukuhlela. 
Yonke into ositshela yona iyogcinwa njengeyimfihlo. Futhi siyobhekana nezindleko zakho 
zokugibela eziyokwenzakala phakathi naloluphando. 
 
Uma ufuna ukwazi kabanzi ngalolucwaningo/uphando, thintana nalaba 
abalandelayo: 
 
Mags Beksinska / Fikile Mbatha Family Planning Clinic, Commercial Road – 307 2781 
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Zulu subject information sheet 40 – 49 age group users of hormonal contraceptives 
ISAZISO MAYELANA NOCWANINGO 
40-49 IMINYAKA 
 
UCWANINGO NGESISINDO SAMATHAMBO OLUPHATHELENE NOHLELO MNDENI 
OLUNJENGOMJOVO KANYE NAMAPHILISI 
 
INGABE LUMAYELANA NANI LOLUCWANINGO/UPHANDO       
 
Izinhlobo zokuhlela imindeni ezinjengemijovo (depo provera, kanye namaphilisi) ziye 
zasetshenziswa ngabesifazane kuleli lakithi iminyaka eminingi. I-REPRODUCTIVE 
HEALTH RESEARCH UNIT exhumane ne Department of Obstetric and Gynaecology ese 
Chris Hani Baragwanath Hospital yenza uphando mayelana nendlela izinhlobo zokuhlela 
imindeni ezithintana ngayo nesimo samathambo (isisindo samathambo). 
 
KUXHOMEKANI UKUTHATHA KWAMI UHLANGOTHI KULOLUPHANDO? 
 
Sifuna abantu besifazane abazozinikela ngokuzithandela abaphakathi kweminyaka engu 40 
kuya kweyi-49 abasebenzisa imijovo (depo provera, nur-isterate) noma amaphilisi okuhlela 
ukuba bangenele lolu phando. Uma ufisa ukuzinikela ngokuzithandela, umhlengikazi uyobe 
esekubuza imibuzo ngempilo yakho/izifo, uhlelo mndeni owake walusebenzisa, imibuzo 
ephathelene nembeleko yakho kanye nokuncelisa.  Umhlengikazi uyobe esekukala ubude, 
isisindo futhi umshini uyosetshenziswa ukukala isisindo sengalo yakho.  Lokhu ukukalwa 
kwamathambo kubandakanya ukuhlolwa kwamathambo engalo (x-ray), akubuhlungu futhi 
kuthatha imizuzu emihlanu nje kuphela kanti akunangozi. 
 
Abesifazane abaningi baqala ukuvaleka ukuya esikhathini (MENOUPAUSE) beneminyaka 
engu 42 kuya kweyi-49, futhi sizokubuza nemibuzo mayelana nezimpawu owake 
wahlangabezana nazo ngesikhathi uvaleka ukuya esikhathini bese sithatha igazi ukuhlola 
ukuthi ingabe sewusezingeni lokuvaleka ungasayi esikhathini na.  Njalo nje emva 
kwezinyanga eziyisithupha uma usubuyela emtholampilo ukuzohlaba noma uzolanda 
amaphilisi akho okuhlela uyobuzwa imibuzo uphinde ukalwe ubude, isisindo kanye nesisindo 
samathambo futhi nokuhlolwa kwegazi mayelana nokuvaleka kwakho ungasayi esikhathini. 
Siyothanda ukukubona iminyaka emihlanu ucwaningo selulonke. 
 
Kuyokwenzekani uma sengiyeka ukusebenzisa loluhlelo mndeni noma ngihoxa 
kuloluphando? 
 
Ukuthatha uhlangothi kuloluphando kungukuzithandela futhi ungahoxa noma yinini uma 
ungasafuni. Lokhu angeke kuphazamise ukusebenzisa kwakho umtholampilo ngokuzayo. 
Kanti uyokhululeka ukusebenzisa uhlelo mndeni phakathi naloluphando uma usufisa ukuhlela. 
Yonke into ositshela yona iyogcinwa njengeyimfihlo. Siyobe futhi sesibhekana nezindleko 
zakho zokugibela eziyokwenzakala phakathi naloluphando. 
 
Uma ufuna ukwazi kabanzi ngalolucwaningo/uphando, thintana nalaba abalandelayo. 
Mags Beksinska / Fikile Mbatha Family Planning Clinic, Commercial Road – 031 307 
2781 
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Zulu subject information sheet aged 40 – 49 non –users of hormonal contraceptives 
 
ISAZISO MAYELANA NOCWANINGO 
40-49 IMINYAKA 
 
UCWANINGO NGESISINDO SAMATHAMBO OLUPHATHELENE NOHLELO 
MNDENI OLUNJENGOMJOVO KANYE NAMAPHILISI 
 
INGABE LUMAYELANA NANI LOLUCWANINGO/UPHANDO       
 
Izinhlobo zokuhlela imindeni ezinjengemijovo (Depo provera, kanye namaphilisi) ziye 
zasetshenziswa ngabesifazane kuleli lakithi iminyaka eminingi. I- REPRODUCTIVE 
HEALTH RESEARCH UNIT exhumane ne Department of Obstetric and Gynaecology ese 
Chris Hani Baragwanath Hospital yenza uphando mayelana nendlela iznhlobo zokuhlela 
imindeni ezithintana ngayo nesimo samathambo (isisindo samathambo). 
 
KUXHOMEKANI UKUTHATHA KWAMI UHLANGOTHI KULOLUPHANDO? 
 
Sifuna abantu besifazane abazozinikela ngokuzithandela abaphakathi kweminyaka engu 40 
kuya kweyi-49 abasebenzisa izinhlobo zokuhlela umndeni ezinjengemijovo (depo provera, 
nur-isterate noma amaphilisi okuhlela) ukuba bangenele lolu phando. Uma ufisa ukuzinikela 
ngokuzithandela, umhlengikazi uyobe esekubuza imibuzo ngempilo yakho/izifo, uhlelo 
mndeni owake walusebenzisa, imibuzo ephathelene nembeleko yakho kanye nokuncelisa.  
Umhlengikazi uyobe esekukala ubude, isisindo futhi umshini uyosetshenziswa ukukala 
isisindo sengalo yakho.  Lokhu ukukalwa kwamathambo kubandakanya ukuhlolwa 
kwamathambo engalo (x-ray), akubuhlungu futhi kuthatha imizuzu emihlanu nje kuphela kanti 
akunangozi. 
 
Abesifazane abaningi baqala ukuvaleka ukuya esikhathini (MENOUPAUSE) beneminyaka 
engu 42 kuya kweyi-49, futhi sizokubuza nemibuzo mayelana nezimpawu owake 
wahlangabezana nazo ngesikhathi uvaleka ukuya esikhathini bese sithatha igazi ukuhlola 
ukuthi ingabe sewusezingeni lokuvaleka ungasayi esikhathini na.  Njalo nje emva 
kwezinyanga eziyisithupha uma usubuyela emtholampilo ukuzohlaba noma uzolanda 
amaphilisi akho okuhlela uyobuzwa imibuzo uphinde ukalwe ubude, isisindo kanye nesisindo 
samathambo futhi nokuhlolwa kwegazi mayelana nokuvaleka kwakho ungasayi esikhathini. 
Siyothanda ukukubona iminyaka emihlanu ucwaningo selulonke. 
 
Kuyokwenzekani uma sengiyeka ukusebenzisa lolu hlelo mndeni noma ngihoxa 
kuloluphando? 
 
Ukuthatha uhlangothi kuloluphando kungukuzithandela futhi ungahoxa noma yinini uma 
ungasafuni. Lokhu angeke kuphazamise ukusebenzisa kwakho umtholampilo ngokuzayo. 
Kanti uyokhululeka ukusebenzisa uhlelo mndeni phakathi naloluphando uma usufisa ukuhlela. 
Yonke into ositshela yona iyogcinwa njengeyimfihlo. Siyobe futhi sesibhekana nezindleko 
zakho zokugibela eziyokwenzakala phakathi naloluphando. 
Uma ufuna ukwazi kabanzi ngalolucwaningo/uphando, thintana nalaba abalandelayo: 
Mags Beksinska / Fikile Mbatha Family Planning Clinic, Commercial Road – 307 2781 
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INFORMED CONSENT 
INJECTABLE AND ORAL  CONTRACEPTIVE BONE MASS STUDY 
(Age 15-19 hormonal contraceptive users) 
 
I have been informed that this  research study looks at the possible effect of some 
contraceptives on the microscopic structure and mineral content of skeletal bones (bone mass) 
of the body, and that some contraceptives may lower the bone mass during use and that the 
bone mass usually returns to normal after stopping use.  
 
I understand that I will be interviewed and have a medical history taken and complete a 
questionnaire. In addition an examination will include a weight, height and bone mass 
measurement. Every six months when I come back to the clinic for another injection/supply of 
pills I will  be interviewed again and the examinations will be repeated. I understand that the 
total length of  the study is five years. 
 
 
I further more have been informed that the bone mass measurement  exposes me to a minimal  
dose of x-rays that will not affect my health, and that if I fall pregnant at any time during the 
follow-up period I will no longer be able to continue in the study. 
 
I understand that there is no direct benefit to me from participation in this research.  I can stop  
or change my method of contraception at any time. I can withdraw from the study at any time 
and this will not, in any way, affect my future treatment at the clinic.  
 
I have had the study explained to me and I have read the information sheet and this form or 
had it read to me. I have had the opportunity to ask questions on the study and what is 
involved if I take part. 
 
I agree voluntarily to participate in this study. 
 
 
 
 
Signed:____________________________ 
 
Witness:___________________________ 
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INFORMED CONSENT 
INJECTABLE AND ORAL  CONTRACEPTIVE BONE MASS STUDY 
(Age 15-19 non hormonal contraceptive users) 
 
I have been informed that this  research study looks at the possible effect of some 
contraceptives on the microscopic structure and mineral content of skeletal bones (bone mass) 
of the body, and that some contraceptives may lower the bone mass during use and that the 
bone mass usually returns to normal after stopping use.  
 
I understand that I will be interviewed and have  a medical history taken and complete a 
questionnaire. In addition  an examination will include a weight, height  and bone mass 
measurement. I will be asked to come to the clinic  every  six  months to   be interviewed 
again and the examinations will be repeated. I understand that the total length of  the study is 
five years. 
 
 
I further more have been informed that the bone mass measurement  exposes me to a minimal  
dose of x-rays that will not affect my health, and that if I fall pregnant at any time during the 
follow-up period I will no longer be able to continue in the study. 
 
I understand that there is no direct benefit to me from participation in this research.  I can stop  
or change my method of contraception at any time. I can withdraw from the study at any time 
and this will not, in any way, affect my future treatment at the clinic.  
 
I have had the study explained to me and I have read the information sheet and this form or 
had it read to me. I have had the opportunity to ask questions on the study and what is 
involved if I take part. 
 
I agree voluntarily to participate in this study. 
 
 
  
 
Signed:____________________________ 
 
Witness:___________________________ 
 
 
Place:_____________________________ 
 
Date:_____________________________ 
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INFORMED CONSENT 
INJECTABLE AND ORAL  CONTRACEPTIVE BONE MASS STUDY 
(Age 40-49 hormonal contraceptive users) 
 
I have been informed that this research study looks at the possible effect of some 
contraceptives on the microscopic structure and mineral content of skeletal bones (bone mass) 
of the body, and that some contraceptives may lower the bone mass during use and that the 
bone mass usually returns to normal after stopping use.  
 
I understand that I will be interviewed and have  a medical history taken and complete a 
questionnaire. In addition  an examination will include a blood test, weight, height  and bone 
mass measurement. Every six months when I come back to the clinic for another 
injection/supply of pills I will  be interviewed again and the examinations will be repeated. I 
understand that the total length of  the study is five years. 
 
 
I further more have been informed that the bone mass measurement  exposes me to a minimal  
dose of x-rays that will not affect my health, and that if I fall pregnant at any time during the 
follow-up period I will no longer be able to continue in the study. 
 
I understand that there is no direct benefit to me from participation in this research.  I can stop  
or change my method of contraception at any time. I can withdraw from the study at any time 
and this will not, in any way, affect my future treatment at the clinic.  
 
I have had the study explained to me and I have read the information sheet and this form or 
had it read to me. I have had the opportunity to ask questions on the study and what is 
involved if I take part. 
 
I agree voluntarily to participate in this study. 
 
 
Signed:____________________________ 
 
Witness:___________________________ 
 
 
Place:_____________________________ 
 
Date:_____________________________ 
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INFORMED CONSENT 
INJECTABLE AND ORAL  CONTRACEPTIVE BONE MASS STUDY 
(Age 40-49 non hormonal contraceptive users) 
 
I have been informed that this  research study looks at the possible effect of some 
contraceptives on the microscopic structure and mineral content of skeletal bones (bone mass) 
of the body, and that some contraceptives may lower the bone mass during use and that the 
bone mass usually returns to normal after stopping use.  
 
I understand that I will be interviewed and have  a medical history taken and complete a 
questionnaire. In addition  an examination will include a weight, height  and bone mass 
measurement. I will be asked to return to the clinic every six months to  be interviewed again 
and the examinations will be repeated. I understand that the total length of  the study is five 
years. 
 
 
I further more have been informed that the bone mass measurement  exposes me to a minimal  
dose of x-rays that will not affect my health, and that if I fall pregnant at any time during the 
follow-up period I will no longer be able to continue in the study. 
 
I understand that there is no direct benefit to me from participation in this research.  I can stop  
or change my method of contraception at any time. I can withdraw from the study at any time 
and this will not, in any way, affect my future treatment at the clinic.  
 
I have had the study explained to me and I have read the information sheet and this form or 
had it read to me. I have had the opportunity to ask questions on the study and what is 
involved if I take part. 
 
I agree voluntarily to participate in this study. 
 
 
 
Signed:____________________________ 
 
Witness:___________________________ 
 
 
Place:_____________________________ 
 
Date:_____________________________ 
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Zulu Informed consent form  
Age group 15 -19 hormonal contraceptives users 
 
 
ISIVUMELEWANO EMVA KWENCAZELO 
 
UPHANDO MAYELANA NESISINDO SAMATHAMBO OKUTHINTANA NGAKHO 
NEZINHLELO MNDENI EZINJENGEMIJOVO KANYE NAMAPHILISI. 
(15 - 19 yeminyaka yabangasebenzisi izinhlobo zokuhlela umndeni) 
 
Ngiyezwisisa ukuthi lolucwaningo/uphando lubheke indlela ezinye izinhlobo zokuhlela 
ezithinta ngayo isimo samathambo. Ngiyaqonda futhi ukuthi ezinye izinhlelo mndeni zehlisa 
isisindo samthambo ngesikhathi zisasetshenziswa kanti isisisindo sibuyela endaweni uma 
seziyekiwe ukusetshenziswa. 
 
Ngiyaqonda nokuthi ngiyobe sengibuzwa imibuzo mayelana nempilo yami futhi ngigcwalise 
ne fomu. Ngaphezu kwalokho ukuhlolwa komzimba/kwempilo kuyobandakanya ukukalwa 
kwesisindo, ubude kanye nesisindo samathambo. Ngiyaqonda nokuthi lonke 
lolucwaningo/uphando luyothatha imiyaka emihlanu seyiyonke. 
 
Ngiyezwisisa nokuthi lolukalo lwamathambo luzokwenza nokuthi ngingene emshinini 
wokuhlola amathambo (x-ray). Lokhu akubuhlungu futhi akunabungozi futhi kuthatha 
isikhashana nje. 
 
Ngiyezwa nokuthi uma ngingakhulelwa phakathi nalophando angeke ngisakhona ukuqhubeka 
ngiyingxenye yaloluphando. 
 
Ngiyaqonda nokuthi akukho nzuzo ngokuqondile engiyoyizuza ngokungenela loluphando. 
Ngingayeka/hoxa noma ngishintshe uhlobo lohlelo mndeni noma yinini uma ngingasathandi.  
Ngingahoxa noma yinini ekubeni yingxenye yalolucwaningo/ uphando futhi lokhu, angeke 
kuphazamise ukusebenzisa kwami umtholampilo ngokuzayo. 
 
Ngizwile konke okushiwo ngalolucwaningo futhi ngizifundele ipheshana lesaziso noma 
bangifundele. Ngitholile nethuba lukuzibuzela imibuzo mayelana nalolucwaningo nokuthi 
kuxhomekeni ukuthatha kwami uhlangothi kuloluphando/ucwaningo. 
 
Ngizivumela ngokuzithandela ukungenela loluphando/ucwaningo. 
 
Isayinwe                ………………………………………….. 
 
Ufakazi                 …………………………………………… 
 
Indawo                   …………………………………………… 
 
Usuku        …………………………………….. 
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Zulu informed consent form 
Age 15-19 age group non-hormonal contraceptive users 
 
ISIVUMELEWANO EMVA KWENCAZELO 
 
UPHANDO MAYELANA NESISINDO SAMATHAMBO OKUTHINTANA NGAKHO 
NEZINHLELO MNDENI EZINJENGEMIJOVO KANYE NAMAPHILISI. 
(15-19 yeminyaka) 
 
Ngiyezwisisa ukuthi lolucwaningo/uphando lubheke indlela ezinye izinhlobo zokuhlela 
ezithinta ngayo isimo samathambo. Ngiyaqonda futhi ukuthi ezinye izinhlelo mndeni zehlisa 
isisindo samthambo ngesikhathi zisasetshenziswa kanti isisisindo sibuyela esimweni uma 
seziyekiwe ukusetshenziswa. 
 
Ngiyaqonda nokuthi ngiyobe sengibuzwa imibuzo mayelana nempilo yami futhi ngigcwalise 
ne fomu. Ngaphezu kwalokho ukuhlolwa komzimba/kwempilo kuyobandakanya ukukalwa 
kwesisindo, ubude kanye nesisindo samathambo. Njalo nje ezinyangeni eziyisithupha uma 
sengibuyela emtholampilo ukuzohlaba noma ukulanda amaphilisi ngiyophinde ngibuzwe 
imibuzo, futhi ngihlolwe ngokwempilo.  Ngiyaqonda nokuthi lonke lolucwaningo/uphando 
luyothatha iminyaka emihlanu selulomke. 
 
Ngiyezwisisa nokuthi lolukalo lwamathambo luzokwenza nokuthi ngingene emshinini 
wokuhlola amathambo i (X-ray). Lokhu akubuhlungu futhi akunabungozi futhi kuthatha 
isikhashana nje. 
 
Ngiyezwa nokuthi uma ngingakhulelwa phakathi nalophando, angeke ngisaqhubeka 
ngiyingxenye yaloluphando. 
 
Ngiyaqonda nokuthi akukho nzuzo ngokuqondile engiyoyizuza ngokungenela loluphando. 
Ngingayeka/hoxa noma ngiyeke ukusebenzisa uhlelo mndeni noma yinini uma 
ngingasathandi.  Ngingahoxa noma yinini futhi lokhu, angeke kuphazamise ukusebenzisa 
kwami umtholampilo ngokuzayo. 
 
Ngizwile konke okushiwo ngalulucwaningo futhi ngizifundele ipheshana lesaziso noma 
bangifundele. Ngitholile nethuba lukuzibuzela imibuzo mayelana nalolucwaningo nokuthi 
kuxhomekeni ukuthatha kwami uhlangothi kuloluphando/ucwaningo. 
 
Ngizivumela ngokuzithandela ukungenela loluphando/ucwaningo. 
 
Isayinwe                ………………………………………….. 
 
Ufakazi                 …………………………………………… 
 
Indawo                   …………………………………………… 
 
Usuku        …………………………………………….. 
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Zulu informed consent form 
Age group 40-49 hormonal contraceptive user  
 
ISIVUMELEWANO EMVA KWENCAZELO 
 
UPHANDO MAYELANA NESISINDO SAMATHAMBO OKUTHINTANA NGAKHO 
NEZINHLELO MNDENI EZINJENGEMIJOVO KANYE NAMAPHILISI. 
(40-49 yeminyaka) 
 
Ngiyezwisisa ukuthi lolucwaningo/uphando lubheke indlela ezinye izinhlobo zokuhlela 
ezithintana ngayo namathambo. Ngiyaqonda futhi ukuthi ezinye izinhlelo mndeni zehlisa 
isisindo samathambo ngesikhathi zisasetshenziswa kanti isisisindo sibuyela endaweni uma 
seziyekiwe ukusetshenziswa. 
 
Ngiyaqonda nokuthi ngiyobe sengibuzwa imibuzo mayelana nempilo yami futhi ngigcwalise 
ne fomu. Ngaphezu kwalokho ukuhlolwa komzimba/kwempilo kuyobandakanya ukuhlolwa 
kwegazi (ukuze sikwazi ukuthola ukuthi ingabe sewusezingeni lokuvaleka ungasayi 
esikhathini,) ukukalwa kwesisindo, ubude kanye nesisindo samathambo. Ezinyangeni 
eziyisithupha uma sengibuyela emtholampilo ukuzohlaba noma ukulanda amaphilisi okuhlela 
ngiyobe sengibuzwa futhi imibuzo, ukuhlolwa ngempilo/umzimba kuyophindwa. Ngiyaqonda 
nokuthi lonke lolucwaningo/uphando luyothatha imiyaka emihlanu seyiyonke. 
 
Ngiyezwisisa nokuthi lolukalo lwamathambo luzokwenza nokuthi ngingene emshinini 
wokuhlola amathambo (x-ray). Lokhu akubuhlungu futhi akunabungozi futhi kuthatha 
isikhashana nje. 
 
Ngiyezwa nokuthi uma ngingakhulelwa phakathi nalophando angeke ngisakhona ukuqhubeka 
ngiyingxenye yaloluphando. 
 
Ngiyaqonda nokuthi akukho nzuzo ngokuqondile engiyoyizuza ngokungenela loluphando. 
Ngingayeka/ngihoxe noma ngiyeke ukusebenzisa uhlelo mndeni noma yinini uma 
ngingasathandi.  Ngingahoxa noma yinini futhi lokhu, angeke kuphazamise ukusebenzisa 
kwami umtholampilo ngokuzayo. 
 
Ngizwile konke okushiwo ngalulucwaningo futhi ngizifundele ipheshana lesaziso noma 
bangifundele. Ngitholile nethuba lukuzibuzela imibuzo mayelana nalolucwaningo nokuthi 
kuxhomekeni ukuthatha kwami uhlangothi kuloluphando/ucwaningo. 
 
Ngizivumela ngokuzithandela ukungenela loluphando/ucwaningo. 
 
Isayinwe                ………………………………………….. 
 
Ufakazi                 …………………………………………… 
 
Indawo                   …………………………………………… 
 
Usuku         …………………………………………….. 
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Zulu informed consent form 
Age 40-49 non hormonal contraceptive users  
 
ISIVUMELEWANO EMVA KWENCAZELO 
 
UPHANDO MAYELANA NESISINDO SAMATHAMBO OKUTHINTANA NGAKHO 
NEZINHLELO MNDENI EZINJENGEMIJOVO KANYE NAMAPHILISI. 
(40-49 yeminyaka abangasebenzisi izinto zokuhlela/zokuvimbela inzalo) 
 
Ngiyezwisisa ukuthi lolucwaningo/uphando lubheke indlela ezinye izinhlobo zokuhlela 
ezithintana ngayo namathambo. Ngiyaqonda futhi ukuthi ezinye izinhlelo mndeni zehlisa 
isisindo samthambo ngesikhathi zisasetshenziswa kanti isisisindo sibuyela endaweni uma 
seziyekiwe ukusetshenziswa. 
 
Ngiyaqonda nokuthi ngiyobe sengibuzwa imibuzo mayelana nempilo yami futhi ngigcwalise 
ne fomu. Ngaphezu kwalokho ukuhlolwa komzimba/kwempilo kuyobandakanya ukuhlolwa 
kwegazi, (ukuze kutholakala ukuthi ingabe sengisezingeni lokuvaleka ngingasayi esikhathini) 
ukukalwa kwesisindo, ubude kanye nesisindo samathambo. Ngiyaqonda nokuthi lonke 
lolucwaningo/uphando luyothatha imiyaka emihlanu seyiyonke. 
 
Ngiyezwisisa nokuthi lolukalo lwamathambo luzokwenza nokuthi ngingene emshinini 
wokuhlola amathambo (X-ray). Lokhu akunabungozi futhi kuthatha isikhashana nje. 
 
Ngiyezwa nokuthi uma ngingakhulelwa phakathi nalophando angeke ngisakhona ukuqhubeka 
ngiyingxenye yaloluphando. 
 
Ngiyaqonda nokuthi akukho nzuzo ngokuqondile engiyoyizuza ngokungenela loluphando. 
Ngingayeka/ngihoxe noma ngiyeke ukusebenzisa uhlelo mndeni noma yinini uma 
ngingasathandi.  Ngingahoxa noma yinini futhi lokhu, angeke kuphazamise ukusebenzisa 
kwami umtholampilo ngokuzayo. 
 
Ngizwile konke okushiwo ngalulucwaningo futhi ngizifundele ipheshana lesaziso noma 
bangifundele. Ngitholile nethuba lukuzibuzela imibuzo mayelana nalolucwaningo nokuthi 
kuxhomekeni ukuthatha kwami uhlangothi kuloluphando/ucwaningo. 
 
Ngizivumela ngokuzithandela ukungenela loluphando/ucwaningo. 
 
Isayinwe                ………………………………………….. 
 
Ufakazi                 …………………………………………… 
 
Indawo                   …………………………………………… 
 
Usuku         …………………………………………….. 
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Informed consent for spine/hip/femoral neck DEXA scan sub-study 
 
INFORMED CONSENT 
INJECTABLE AND ORAL  CONTRACEPTIVE BONE MASS STUDY 
 
 
I have been informed that the bone mass research study that there maybe some possible effect 
of some contraceptives on the microscopic structure and mineral content of skeletal bones 
(bone mass) of the body, and that some contraceptives may lower the bone mass during use 
and that the bone mass usually returns to normal after stopping use.  
 
I understand that I will have one additional  bone mass measurement  to the six-monthly 
forearm measurement at Commercial city clinic. This additional measurement will be done at 
the Westridge Medical centre in Durban. This measurement will be of the hip and spine. I 
have been informed that the bone mass measurement  will expose me to a minimal  dose of x-
rays that will not affect my health. 
 
 
I have had the study explained to me and I have read the information sheet and this form or 
had it read to me. I have had the opportunity to ask questions on the study and what is 
involved if I agree to take part in this extra component of the study. 
 
I agree voluntarily to participate in this study. 
 
 
 
 
Signed:____________________________ 
 
Witness:___________________________ 
 
 
Place:_____________________________ 
 
Date:_____________________________ 
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BONE MASS STUDY INFORMATION SHEET SEPT 2005 
 
 
 
Dear participant 
 
 
We would like to thank you for taking part in the bone mass study for the last five years. The 
study has now entered its 6th and final year of follow-up. We have so far measured the bone 
mineral density of your forearm. There is some concern that this site is not as sensitive to the 
effects of  contraception. The World Health Organisation who fund the study have asked us to 
measure the hip and spine of a number of our participants. We do not have the equipment to 
do this at commercial city clinic, however in our main offices in Westridge there is a group of 
specialist diagnostic radiologists (Jackpersad and partners inc) where this could be done. This 
would be a one off measurement and would require an additional visit. The study nurse would 
be present and the scan will take about 1 minute to conduct. The equipment is similar to that 
used for your current measurement but we will ask you this time to lie on a bed. The 
measurement uses similar equipment to that used at commercial city clinic which is safe and 
uses very low radiation. You will not feel anything during the measurement. We have drafted 
an additional consent form for you to read and sign if you are willing to volunteer for this 
component of the study.   You will receive an additional R50 for this visit to cover your 
transport costs. The study nurse Mrs Fikile Mbatha will explain what is involved and will 
book an appointment for you  at a convenient time.  
 
 
 
Kind regards 
 
 
 
 
Mags Beksinska, Study manager  Fikile Mbatha ,  Study Nurse co-ordinator 
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Zulu informed consent for spine/hip/femoral neck DEXA scan sub-study 
 
ISIVUMELWANO EMVA KWENCAZELO 
 
Uphando/ucwaningo maqondana nesisindo samathambo, nokusebenzisa 
izinhlelo-mndeni ezinjengemijovo kanye namaphilisi. 
 
Ngichazeliwe, ngazwisisa ngokuthintana kwesisindo samathambo, nokusebenza 
kwezinhlelo-mndeni ezicutshini eziyinhlanganisela ezenza ithambo lomuntu. 
 
Kuzwakele futhi ukuthi ezinye izinhlobo zezinhlela-mndeni zenza isisindo 
sethambo lithi ukwehla kancane; kodwa uma umuntu eseyekile ukuhlela sibuye 
(isisindo) sibuyele njenga njalo umuntu engakaqali umhlela-mndeni. 
 
Ngiyavuma futhi ukuthatha esinye isisindo samathambo phezulu kwalezi 
ebengizenza njalo emva kwezinyanga eziyisithupha e Commercial City Clinic. 
Umahluko walesi ukuthi sona sizokwenzelwa e Westridge Medical Centre 
khona lapha eThekwini. 
 
Sizothatha isisindo samathambo; amanyongo nomqolo. Mincane imisebe ye 
Xray engena kimi futhi akunabungozi empilweni yami. 
 
Ngichazelwe nganeliseka ngocwaningo, futhi ngiyifundile incazelo ngalo, 
ngafundiswa ngaqonda kahle. Ngithole ithuba ngabuza imibuzo yami 
yaphenduleka. 
 
Ngiyavuma ngokuphelele ukuzibandakanya nokwenzekayo ngololuhlobo 
lwocwaningo. 
 
Ovumayo: ________________________ 
Ufakazi: __________________________ 
Indawo: __________________________ 
Usuku: ___________________________ 
 
 
 
 
 
215
CONFIDENTIAL ADDRESS FORM 
 
 
 
 
 
 
Can we contact you? ( 1=yes; 2=no) 
 
 
 
Home address ___________________________________ 
 
    ____________________________________ 
 
____________________________________ 
 
____________________________________ 
 
 
 
Home tel no  _________________________ 
 
 
 
 
Work tel no  _________________________ 
 
 
Name of contact          _________________________ 
 
His/Her tel no              __________________________ 
 
If we need to get in touch with you would you prefer we contacted you at work or home?  
(Tick in home or work box above) 
 
 
 
If you stop using the injection or you do not return to the clinic for any reason we would 
like to be able to contact you to find out why? We will be keeping a separate register with 
your name and telephone number if you have one. It will not be possible for anybody to 
link your name, etc. with your questionnaires 
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APPENDIX  2 
 
QUESTIONNAIRES 
 
 
 SCREENING QUESTIONNAIRE (SCR) 
 ADMISSION QUESTIONNAIRE (ADM) 
 EXAMINATION QUESTIONNAIRE (EXM) 
 FOLLOW-UP QUESTIONNAIRE (FOL) 
 DISCONTINUATION QUESTIONNAIRE (DIS) 
 FOLLOW-UP NON-ATTENDANCE QUESTIONNAIRE (NON) 
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SCREENING QUESTIONNAIRE 
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Screening number                                                                                                Date of interview 
                                                                                                                                          
                                                                                                                                                                 Day           Month        Year 
 
 
1.  How old were you at your last birthday?  AGE IN COMPLETED YEARS 
 
2.  In what month and year were you born?  MONTH                                                                 YEAR 
 
                                                  NO         YES             
3.  Have you ever used a hormonal method of contraception before? (pill or injection) 
       (15-19 age group only) 
 
4.  Are you still menstruating? 
      (40-49 age group only) 
 
5.  Are you currently breastfeeding?   
  
6.    Have you breastfed in the last six months? 
 
6. Have you been pregnant in the last six months?  
 
8. Have you had a hysterectomy or oophrectomy?   
 
9. Are you planning to move out of the area in the next five years?  
 
10.  Does subject have a history of any of the following?  Tick box that applies            NO        YES                                            
 
a) Liver disease (including chronic hepatitis)  
 
b) Diabetes mellitus  
 
c) Chronic kidney disease  
 
d) Thyroid condition or disease  
 
e) Parathyroid condition or disease  
 
f) Cancer  
 
g) Pituitary disease  
 
h) Sarcoidosis  
 
i) Bed rest for 6 weeks or longer in the last 12 months  
 
j) Bone disease (including reckets)  
 
k) Bone fracture in the last year 
 
l) Weight loss (5kg or more in the last six months)  
 
m) Chronic diarrhoea (in the last six months)  
 
n) Lympadenopathy  
 
o) Tuberculosis  
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Screening number    
 
 
12. Are you currently taking, or have you in the past taken for more than 3 months,              YES    NO 
any of the following medications? 
 
a) Anticonvuisants   
 
b) Systematic corticosteroids  
 
c) Drugs for hypo- or hyper-thyroidism 
 
d) Drugs for hypo- or hyper-parathyroidism         
  
e) Vitamin D or C   
 
f) Thiazide diuretics 
 
g) Calcium supplements (except during pregnancy or lactation)  
 
h) Antacids  
 
 
IF THE ANSWER TO ANY OF THE ABOVE ARE YES, EXCLUDE SUBJECT FROM THIS STUDY 
 
13. a)  (45 –49)  Which contraceptive method are you currently using? 
      b)   (15 –19)  Which method have you started taking?  
 
 NONE…………0 
                                                          DEPO…………1 
 NURISTERATE…………2 
 COMBINED ORAL PILLS...……….3        
                      PROGESTIN- ONLY PILLS…………4   
 IUD..………..5       
 FEMALE STERILIZATION………….6 
 BARRIER METHODS………….7       
 NATURAL METHODS….………8         
                         MALE STERILIZATION…...……..9 
 OTHER…..……99  
                                                                                                                                                                YES        NO  
14.  Screened for normal range but does not wish to take part        
 
Subject study number 
 
Interviewers Name: ……………………………………..   
 
Signature:       ------------------------------------------- 
 
219  
 
REPRODUCTIVE 
HEALTH  
RESEARCH UNIT 
 
INJECTABLE AND ORAL CONTRACEPTIVE 
BONE MASS STUDY 
ADMISSION QUESTIONNAIRE 
ADM
Page 1 
 
Subject study number                                      Date of interview    
                         Day        Month          Year 
 
1. How old were you at your last birthday?                                             8a.  Are you currently taking any  
                          Long term medication? 
AGE IN COMPLETED YEARS                                                                                                    NO……..1 
                                                                                                                                                         YES……2 ------Part  
2. What is your ethnic group?           
   BLACK……..1 
         COLOURED……..2                8b.  If yes, what medication are you taking 
               INDIAN………3 
                                                                                                                                 LIST 
3. What is the highest level of education        _______________________________  
    That you have reached?                                       _______________________________ 
 
STANDARD 
 
             GRADE                                                                We would like to ask you some questions about 
                                                                                           your Menstrual cycle and any pregnancies you  have  had.  
  
POST MATRIC ________________                9.  How old were you when you had your first Menstrual         
            period? 
        EMPLOYED FULL / PART TIME……….1                                                                                                   YEARS 
                          EMPLOYED CASUAL……….2 
                                   UNEMPLOYED……….   3                                           10.  Do you menstruate regularly? 
                     HOUSEWIFE / AT HOME……….4               
                                  STUDENT………5                                                                          NO……..1 
                                        SCHOLAR………6                                                                        YES……..2 
 
4.  What is your household income per month?                 REGULAR CYCLE DEFINED AS A PERIODIC  
        CYCLICAL BLEEDING OCCURRING AT  
                                 R      INTERVALS BETWEEN 21-35 DAYS 
5.   What is your current relationship / 
       Marital status? 
   MARRIED (TRAD OR LEGAL)……….1                              11. Average length of the last three spontaneous 
                               COHABITING………..2                                   menstrual cycles  
  REG PARTNER (NOT COHAB)………..3 
                            CASUAL PARTNER………..4                                                                                         DAYS         
      SINGLE (NO PARTNER)………..5                                    
                                                                                                                            12.  Since the age of 16, have you ever missed 
7a.  Do you have a long standing illness?                                                               a menstrual period for one year or more 
                                         NO……….1  Q8                                      (excluding the time you were  pregnant,                                              
                       
                                       YES……….2   Part b                                                         breastfeeding or used DMPA Or NETEN)? 
 
7b.  If yes, can you tell us what this illness is? 
         
LIST DISEASE / S 
   ____________________________                                                                        NO ………1---------Q14 
                                                                                            
                                                                                                    ICD 10                                     YES ……….2---------Q14 
       
   _____________________________       
 
     ICD 10 
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  Subject study number   
           Q13 AGE GROUP 1 ONLY (OLDER WOMEN) We would like to ask you some more details about 
theContraceptive method you may be using now and those 
that you have used in the past and how long you used 
them for. 
                  Have you experienced any of the                          YES  NO     17.  Which contraceptive method are you  
Following in the last three months                                                             currently using? 
 
a) Hot flushes          NONE……..0 
  
            DEPO……..1 
b) Night sweats                   NURISTERATE….…..2 
                  COMBINED ORAL PILLS……...3                      
c) Skin changes              PROGESTIN-ONLY PILLS….…..4 
                                          IUD……...5 
c) Dry vagina             FEMALE STERILIZATION………6 
      BARRIER………7 
                     NATURAL METHODS……….8 
13. How many pregnancies have you               MALE STERILIZATION………. 9 
Had, including miscarriages and abortions?              OTHER……… 99 
 
         18.  Date of last injection   
 
   NO OF PREGNANCIES      19a.  Do you know the name of the brand  
                  of pills you are now using? 
IF NEVER BEEN PREGNANT GO TO Q17                      ask to see packet or check clinic card records 
 
14. How many times have you given birth?      BRAND NAME  
 NO OF BIRTHS                                          
Did you breast feed any of your children?                          Nordette……………………….2 
        Ovral………………………….3 
NO………1---------Q17           Marvalon……………………....4 
               YES………2              
 
Children Month and Year  Total breast feeding  19b.  Time in pill cycle    
of birth   (months)     
                  taking active pill ……….1 
1st child                 7 day interval…………….2 
 
 
2nd child 
 
 
3rd child 
 
 
4th child 
 
5th child 
 
 
6th child 
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Subject study number   
 
19.   We would like to know what methods of contraception you have used in the last five years? 
 
ENTER METHOD CODE FROM THE LIST BELOW IN THE CALENDAR BELOW 
 
A = ABORTION / MISCARRIAGE   J = FEMALE STERILIZATION 
B = DELIVERY     K = VASECTOMY 
C = BREAST FEEDING    L = MALE / FEMALE CONDOMS 
D = PREGNANCY     M = IUD 
E = DEPO                       N = NATURAL FAMILY PLANNING SAFE PERIOD 
F = NURISTERATE                      O = RHYTHM METHOD, WITHDRAWAL 
G = COMBINED ORAL PILLS                     P = SEX WITH NO CONTRACEPTIVE METHOD 
H = PROGESTOGEN-ONLY PILLS   Q = ABSTINENCY 
      R = OTHER, SPECIFY ________________________________ 
(If two or more methods were used during the name period, please mark all the methods) 
              AGE AT 
YEAR    1 JAN         JAN        FEB     MAR       APR     MAY       JUN     JUL        AUG      SEP    OCT         NOV   DEC NOTES 
   
 
2002    
 
2001 
  
2000 
 
  
1999 
  
1998 
  
1997 
 
 
1996 
 
19.  Summary of duration of contraceptive use 
                                                                       
                                                                             AGE AT  TOTAL DURATION DURING      TOTAL LIFETIME 
    FIRST USE     LAST 5YEARS                  DURATION 
 
Method         Years  Years  Months   Years  Months 
 
COMBINED ORAL CONTRACEPTIVES      
PROGESTOGEN-ONLY PILLS 
DMPA 
NURISTERATE 
IUD 
CONDOM 
FEMALE STERILIZATION 
VASECTOMY 
NATURAL FAMILY PLANNING 
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Subject study number 
 
We would like to ask you some questions about smoking,   26.  Have you dieted in the last year   
 alcohol and caffeine.         No………..1 
              Yes……….2   
19. Have you ever smoked tobacco / cigarettes?            
NO………1-----------Q25 
             YES………2-----------Q22                                                                         
Are you a current smoker?                   27.  Do you exercise regularly at least once a    
        week                               
                          NO……….1------------Q24                No………….1 
           YES……….2-----------Q23      Yes…………2 
20. What is the average number of cigarettes you have               
Smoked per day in the last month?     28.  FSH 
                    
       NUMBER PER DAY       29.  LH:    
 If no longer smoking now, at what age did          
You stop?         
      
  YEARS      
21. How many cups / bottles of the following beverages    Study group:      
Do you drink in a typical week:  (code 00 if none) 
a) Coffee with caffeine  cups    Interviewers Name: _______________________ 
b) Decaffeinated coffee  cups   
c) Tea    cups      
d) Rooibos   cups    Remarks : 
Fizzy drinks  250 – 340ml 
e) Cola/  bottles / cans 
f) Other fizzy drinks bottles / cans 
BRANDS _______________________  
Alcoholic drinks   
g) Beer  bottles / cans   
h) Wine           glasses 
i) Spirits   25 ml shots 
j) Cider  bottles/cans    
223  
REPRODUCTIVE  
HEALTH  
RESEARCH 
UNIT 
INJECTABLE AND ORAL CONTRACEPTIVE 
BONE MASS STUDY 
ADMISSION QUESTIONNAIRE 
ADM 
Extra page 
 
 
 
Subject study number   
 
                                      
     
Children   Month and Year    Total breast feeding 
    of birth     (months) 
 
7th child           
 
8th child          
 
9th child           
 
10th child    
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Subject study number                Visit code                                Date of examination   
               Day    Month       Year 
 
 
1.  Height   CM               .  8.  Blood drawn for FSH measurement   
 
2.  Weight   KG              .     NO………1 
                                                                                                                                                            YES…...….2 
 
3.  Blood pressure Systolic (mmHg)    9.  Any evidence of disease in the following        YES  NO  
               Diastolic (mmHg)          systems 
 
                                                                                                                   a)  Cardiovascular     
4. Bone mass measurement          Specify -------------- 
 
Previous Fracture  L or R               
    No…………1 
    Yes………..2 
 
1.  RADIUS   BMC   .  b)  Respiratory      
             Specify -------------- 
    BMD                . 
        c)  Hepatic      
                AREA   .       Specify -------------- 
 
                                                                                                     d)  Renal      
2.  ULNA   BMC   .       Specify --------------- 
 
    BMD   .   e)  Gastrointestinal     
                                                                                                                 Specify -------------- 
                AREA                     . 
                                                                                                            f)  Neurological      
3.  DISTAL   BMC     .        Specify -------------- 
 
    BMD     .   g)  Endocrinological     
             Specify -------------- 
                AREA                    .  
 
 
5.  Arm circumference   CM              .  Remarks: 
     (midpoint of upper arm) 
 
 
6.  Waist circumference   CM              . 
 
 
7.  Hip circumference   CM              .  
                                                                                                                   Interviewers name 
 
        Signature:  ------------------------------------ 
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Subject study number     Study group                                    Date of interview    
 
Visit number                      Day      Month        Year 
 
 
 
1a)  Are you currently using a method of                  5.  Since we last saw you have you          YES  NO 
       contraception?           Experienced any of the following? 
 
    NONE…………0  a)  Hot flushes      
    DEPO…………1 
             NURISTERATE………….2  b)  Night sweats      
         COMBINED ORAL PILLS………….3------1b 
 PROGESTOGEN-ONLY PILLS………….4------1b  c)  Skin changes      
      IUD………….5 
      FEMALE STERILIZATION…………..6  d)  Dry vagina      
        BARRIER…………...7 
             NATURAL METHODS…………..8 
          MALE STERILIZATION…………..9   6.  Has subject had any of the following          YES  NO 
            OTHER…………99         since their last visit? 
 
1b)  Brand of pill  ------------------------------------------  a)  Weight loss      
             (5 kg or more in the last six months)   
2. Has contraceptive method changed, stopped 
or started since last visit?     b)  Chronic diarrhoea     
              (in the last six months) 
    NO…………..1-------Q5 
                 YES……………2   c)  Lympadenopathy     
 
3. When did you change method?    D)  Tuberculosis 
 
MONTH   We would like to ask you about any changes in your,  
    smoking, alcohol , tea and coffee drinking since we last. 
   YEAR                                            saw you. 
      
  
4. What did you change from -----------------(method)  7.  Are you a current smoker? 
 
NONE…………0    NO…..1….. Q10   
DEPO…………1                              
             NURISTERATE…………2    YES…..2…..Q8 
        COMBINED ORAL PILLS…………3                   
             PROGESTOGEN-ONLY PILLS………...4 
        IUD…………5  8.  What is the average number of cigarettes you 
      FEMALE STERILIZATION…………6        smoked per day  in the last month ?                  
          BARRIER…………7 
              NATURAL METHODS…………8     NUMBER PER DAY      
           MALE STERILIZATION…………9                   
              OTHER………..99  9.  If no longer smoking, at what age did you stop? 
 
         YEARS     
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Subject study number   
 
Visit number     
 
 
10.  How many cups/bottles of the following beverages                      13b).  If yes, can you tell us what this illness is? 
    
a).  Coffee with caffeine  cups     LIST DISEASE 
 
b)  Decaffeinated coffee  cups        ICD 10 
         -------------------------------------------------- 
c)  Tea    cups     -------------------------------------------------- 
 
d)  Rooibos tea   cups       14a).  Are you currently taking any long term 
                                      medication? 
FIZZY DRINKS   250-340ml 
 
e)  Cola    bottles/cans    NO……..1 
         YES……..2--------Part b 
f)  Other fizzy drinks  bottles/cans  
 
BRANDS ____________________________                      14b)  If yes, what medication are you taking? 
     
Alcoholic drinks        LIST ----------------------------------------------- 
 
g)  Beer    bottles/cans             ------------------------------------------------ 
 
h)  Cider    bottles/cans       15.)   Are you pregnant? 
    
i)  Wines   bottles/cans                      NO……..1 
         YES...……2 
j)  Spirits   25ml shots     
 
 
11.  Have you dieted in the last six  months?     16.  What is your last date of 
           menstruation?    Day      Month    Year 
   NO……..1 
 YES...……2        16b)  Date of last injection        
                           Day      Month    Year 
 
12.   Do you exercise regularly atleast once a week?     17.  Previous fracture L or  R      
      
 NO……..1       NO……..1 
 YES...……2       YES...……2 
 
13a)  Do you have a long standing illness?      18.  FSH  
 
 NO……..1 
 YES...……2        19.  LH 
                                                                                                                                       
                                                                                                                                       Remarks: 
 
                                                 Interviewers name:  ---------------------------------
-- 
                                                 Signature:   -------------------------------------- 
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Subject study number       Study group   
 
Visit number       
 
 
 
1. Date of follow-up terminated     
 
         Day    Month    Year 
 
2. (a)  Reason for termination 
 
1 = end of study 
2 = moved out of area 
3 = death 
4 = personal 
5 = other reason     
 
      (b)  If “other reason”,  or personal specify 
 
_________________________________________ 
                  CODE 
 
3. If “DEATH”,      Remarks and additional information:   
 
(a)  Date of death    
      
     Day   Month   Year 
 
       (b)  Cause of death 
 
 (i)  ________________________                            . 
 
 
 (ii)  ________________________                           . 
 
 
 (iii)  _______________________                    . 
 
                   ICD code  
 
 
 
 
 
                                           Name of investigator:  ___________________________ 
 
   Signature:  ____________________________________ 
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NON 
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Subject study number          Study group   
 
Visit number    
 
 
 
 
 
 
 
1.  Date of follow-up           Remarks and additional information: 
 
                   Day   Month   Year 
 
 
 
2.  Follow-up number      
 
 
3.  Mode of follow-up     1 = telephone 
2 = home visit 
 
 
4.  Subject contacted  1 = No 
    2 = Yes 
 
 
If yes, what was the outcome?    
 
 1 = discontinued  (complete discontinuation form)  
2 = arranged new appointment 
 
 
If no, indicate in remarks section action to be taken 
    
 
 
 
 
 
 
 
 
 
 
 
                                            Name of investigator:  _________________________ 
                  Signature:  __________________________________
229  
Explanatory notes on the questionnaires 
A. General Principle 
All  blank boxes on the Forms must be filled in except: 
 
(i) When the form permits you to skip questions, or part of questions, indicated by an  
“IF ….., GO TO Q …..” instruction; 
When the question contains an “IF ….., LEAVE BLANK” instruction. 
When the number of digits in the code being entered is less than the number of boxes 
provided, a leading zero (O) should be put in the remaining boxes. For example, in the case of 
a subject, who has had 2 pregnancies, the coding should be 02, Q14 of admission form. 
Please note that no digits after the decimal point should be entered, except where a decimal 
point is printed on the form (e.g. for recording of waist and hip in Q7 and 8 of examination 
form).  When numbers need to be rounded off, 5 or greater should be rounded off upwards, 4 
or less downwards. 
 
When filling out the forms, interviewers should preferably first circle the correct answer from 
the list of options provided, and then enter the appropriate code in the boxes.  This will 
facilitate cross checking of the codes. 
 
If the answer to a question is not known, code 9, 99, 999, etc. should be used depending on the 
number of boxes provided.  The same applies also when part of the answer is unknown, e.g., if 
only the year of birth is known (1958), Q1 of the Screening Form should be coded 9958.  
Although the use of 9, 99, 999, etc. codes for “don’t knows” is not likely to lead to confusion 
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with actual numbers, interviewers are requested to also write down on the forms “don’t know” 
when using these codes. 
 
Corrections to forms 
Any information recorded inaccurately should be crossed out and correct answer written in red 
pen next to the incorrect.The correction should be initiated by the member of staff who made 
the change. Any information added to the questionnaires at a later date e.g. coding COD 
codes, should be written in green pen to indicate added information.  
 
B. Notes about the individual forms 
 
SCREENING QUESTIONNAIRE (SCR)  
These forms were used to screen potential candidates for the study.  The Screening Form 
contains, in questionnaire form, the selection criteria for participation and ensures that only 
those women were recruited, who fulfill all criteria. All completed screening forms were kept, 
including those of women not enrolled in the study.  This provided information on the number 
of women screened and the number eventually recruited. 
 
ADMISSION QUESTIONNAIRE (ADM) 
 
This form was completed at the time of admission. The  subject number in the form should be 
filled in by the interviewer. 
 
231  
For the main phase of the study, subject numbers should be used sequentially, starting from 
001, without taking in to consideration the serial numbers used for the pilot phase. 
 
QUESTIONS THAT MERIT SOME COMMENT ARE: 
Q1.  (Age at last birthday) 
Enter the age in completed years at her last birthday. 
Q3a and b (Highest level of education) 
Enter either highest grade or standard passed.  If she has further qualifications enter highest 
qualification passed in part b. 
Q4  (Main Occupation) 
Type of occupation not required only classify type of occupation listed. 
Student is classified as someone pursuing further qualifications i.e. has completed schooling. 
Q5  Income – This should be total household income and not just income of subject 
If not known put in 9999 
Q6  Relationship status. 
If a women is divorced or widowed and has no current partner enter option “5” single (no 
partner).  If she now has a new partner use option 1-4 to classify her current relationship. 
Q10  Do you menstruate regularly? 
Regular menstruation is defined as periodic cyclical bleeding occurring at intervals of between 
21-35 days. 
Q16  (Breast-feeding) 
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The questions should be as asked only for children breast- fed.  Space in the form has been 
provided for 6 children.  If more than 6 children were breast-fed, information may be provided 
on a separate sheet. 
(a) Record date the child was born 
(b) Enter number of months, the child was either exclusively or partially fed breast milk 
(supplementation). 
Q17  Which contraceptive method are you currently using? 
For women in the 15-19 age group this question will act as a check to screening forms.  For 
women in this age group who accept a hormonal method on that day the response should be 
either coded as None or any other non-hormonal method in the list (e.g. barrier on natural 
method).  The hormonal method started on that day will be recorded on the screening form 
Q10 & Q19 of the Admission form. 
Q18  Name of the Pill 
Check list provided on form.  Remember that POP users are not included. 
Q19 (History of contraceptive use in the last five years) 
These questions relate to past and present use of contraception.  Since contraceptive use may 
be interrupted by events like pregnancy or personal reasons, space has been provided to enter 
details for each episode of the method used. 
15 – 19 age group:-  Probe for hormonal method use in the past that may not have been 
indicated in screening.  Record any method used such as condoms or sex with no method. 
Q20 Assist the woman in identifying the method that she used in the past. 
Study Group: The study involves recruitment of subjects in 8 groups.  Following codes 
should be used to indicate the group, the subject has been assigned to: 
           Code A  -  15-19 new user DMPA 
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B   -  15-19 new user NET-EN 
C   -  15-19 non-user hormonal contraceptives 
D   -  15-19 new user  COC’s 
E    -  40-49 DMPA use 
F    -  40-49 NET-EN user 
G    -  40-49 non-user 
H    -  40-49  COC user 
Q25  Beverages 
 It may be difficult for the women to be exact about the number of can or bottles of these 
drinks she drinks in a week.  Probe for regular consumption and if only beverage is mentioned 
not on the list, put brand in the other section and this will be investigated and recorded at a 
later date.  Bottle / can quantity relate to those between  
250–340 ml.  Ensure that the subject is aware of this size.  If larger bottles are mentioned  
(1-2l L) revise entry i.e. 1 litre bottle = 3 cans (340ml) or 4 bottles (250ml). 
 
Q27  Regular exercise 
For purposes of this study exercise is defined as a distinct activity i.e. aerobics, jogging etc. 
 
EXAMINATION QUESTIONNAIRE (EXA)  
To avoid interobserver variation: One person from the study was responsible for conducting 
the examination, especially anthropometry (height, weight, arm/waist/hip circumference).  In 
the event of leave or sickness, the principal investigator or another trained member of staff  
conducted the examination.  
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FOLLOW-UP QUESTIONAIRE (FOL) 
Q2. Check original group and last visit to validate information given by subject. 
Q6.a Weight loss to be cross-checked with past visit examination form.    
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APPENDIX 3 
 
INFORMATION ON DEXA EQUIPMENT 
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January 1998, 1 MAN0617-A00 
 
2. INTRODUCTION 
 
2.1 DTX-200 Technology  
 
The Osteometer DTX-200 estimates the bone mineral content (BMC, grams) and bone mineral 
density (BMD, grams/cm²) in the distal section of the forearm (radius and ulna). 
 
Technology:  
The DTX-200 uses the technique of X-ray absorptiometry. The X-ray tube is supplied with a 
high voltage of 55 Kv. The beam is filtered with tin (Sn), yielding two effective energy levels 
for separation of bone and soft tissue (fat, muscle, etc). 
 
How the DTX-200 works: 
The forearm is placed in a container during the examination. The X-ray source is located on 
one side of the forearm and a detector is located on the other side. During an examination, the 
source and the detector move synchronously in a number of scan paths across the distal 
forearm. The mechanical set-up provides an automatic line by line internal reference 
calibration during scanning in order to achieve drift-free measurements. No calibration is 
necessary by the operator. The X-ray signal registered at the detector is inversely proportional 
to the bone mineral content of the forearm. When more bone is present, fewer X-rays are 
detected. When the bone mass is low, more X-rays are detected. The bone mass results are 
automatically calculated. 
 
Quality control (QC): 
The quality control (QC) is a procedure for verifying that the DTX-200 is operating properly. 
This procedure must be carried out each day before the first patient is scanned. Refer to 
chapter 6 where the quality control is fully described.  
 
NOTE: The DTX-200 automatically corrects for amounts of fat mass in the forearm. 
 
NOTE:  If the patient is under adequate estrogen therapy there is no current evidence that 
serial bone mass measurements need to be performed. 
 
 2.2 Precision and Accuracy 
 
Precision:  
The precision is the ability to scan a patient or a phantom and obtain the same result each time. 
The In Vivo precision of DTX-200 measurements were estimated by measuring the distal area 
of the non-dominant foreman in 15 volunteers 5 times each with repositioning between all 
replicate measurements. The In Vivo precision is not only dependent on the intrinsic machine 
precision of the equipment, but also on the cooperativeness of the subject (ability to remain 
still) and the positioning techniques. 
 
 
 
241  
The In Vivo Precision for the above measurements: 
 
Distal                                       BMC                               0.68 % 
Distal                                       BMD                               0.87% 
n.ROI                                       BMD                               1.11% 
 
Serial patient measurements should be perfomed on the same service. 
 
 
Accuracy: 
The accuracy is defined as the degree of conformity of a measure to standard or true value. 
To assess the accuracy of the DTX-200 Bone Densitometer, repeated findings using a 
phantom have been done. The accuracy for the DTX-200 Bone Densitometer is within ± 0.5% 
when measuring the bone mineral content of an Osteometer forearm phantom. 
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Prof Cleaton Jones 
Chairman 
Human subjects Ethics Committee 
Wits University 
 
 
2 nd September 05 
 
Dear Prof Cleaton Jones 
 
RE: protocol number 981001:Bone Density and use of Progestogen-only injectable 
Contraceptives or Combined oral contraceptives, Durban. 
 
The above study has now entered its 6th and final year of follow-up. Bone mineral density is 
currently measured at a forearm site. There is some concern that this site is not as sensitive to 
the effects of progestogen only contraception. The WHO who fund the study have therefore 
requested that the study measures the hip and spine of a subsample of participants (approx 
n=150). We do not have the equipment to do this however in our office building there are a 
group of specialist diagnostic radiologists (Jackpersad & partners inc)where this measurement 
could be done. This would be a one off measurement and would require an additional visit by 
the participant. The study nurse would be present and the scan will take about 1 minute to 
conduct.  The equipment is a Hologic QDR4500 and poses no risk to the participant. This 
method is safe and uses low radiation DEXA (dual-energy X-ray absorptiometry. We have 
drafted an additional consent form for the participant (attached) and a letter explaining the 
procedure and asking them if they wish to volunteer. The study nurse will explain what is 
involved and will book an appointment for the participant at a time convenient for them and 
will provide a map. The existing study site is about 1 km away from the medical centre. 
 
We request that the ethics committee considers the documents supplied and  grants us an 
ammendment to the existing protocol. 
 
Kind regards 
Mags Beksinska 
Director Durban  
Reproductive Health and HIV Research Unit 
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APPENDIX 5 
 
FLYERS AND POSTERS USED IN RECRUITMENT  
 
CONTRACEPTIVE STUDY 
 
AGE GROUP 15-19 
 
The Reproductive Health Research Unit is undertaking a study on the effect of 
contraceptives on the bone mass (bones of the skeleton). 
 
The study would like to involve women participants who are: 
Between 15 and 19 years, new acceptors of injectables, oral contraceptives and 
condoms. 
 
The Research Nurse will conduct a short interview on general health related 
issues. She will also measure your bone mass which involves one of your 
forearms.  Your height, weight and blood pressure will be part of the routine 
check.  The whole procedure, including interview and bone mass measurements 
will take  20 –25 minutes of your time. 
 
The transport cost will be covered by the study. 
 
For more information on the study, contact the nurses: 
Family Planning Clinic, Commercial Road  031 307 2781 
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CONTRACEPTIVE STUDY 
 
AGE GROUP 40-49 
 
The Reproductive Health Research Unit is undertaking a study on the effect of 
contraceptives on the bone mass (bones of the skeleton). 
 
The study would like to involve women participants who are: 
Between 40 and 49 years, on injectables, oral contraceptives, condoms, loop and 
those who are sterilized. 
 
The Research Nurse will conduct a short interview on general health related 
issues. She will also measure your bone mass which involves one of your 
forearms.  Your height, weight and blood pressure will be part of the routine 
check.  A blood sample will be taken to check if you are menopausal.  The whole 
procedure, including interview and bone mass measurements will take  25 –30 
minutes of your time. 
 
The transport cost will be covered by the study. 
 
For more information on the study, contact the nurses: 
Family Planning Clinic, commercial Road 031 307-2781 
 
246  
 
APPENDIX 6 
 
REFERRAL LETTERS 
 
 
 
Referral letter for General Practitioner 
 
Age 40-49 
 
Doctor ………………………… 
 
Dear Doctor ………………………………… 
 
RE:  Bone Density and use of Depot Medroxyprogesterone Acetate 
(DMPA), Norethisterone Enanthate (NET-EN) and Combined Oral 
Contraceptives 
 
Your patient Ms……………………..has been involved in the above study at the 
Commercial City Family Planning Clinic, Commercial Road, Durban.  The study 
measurements include a bone mass scan of the forearm, height, weight, blood 
pressure, waist / hip / forearm measurement and blood test.  The study has found 
that:- 
 
(Reason for referral) 
 
We attach details on the findings for you.  Please contact us at the above if you 
require any further information. 
 
Yours sincerely 
 
 
 
----------------------------------------- 
M. Beksinska 
Provincial Director  
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Referral letter for General Practitioner 
 
Age 15 - 19 
 
Doctor ………………………… 
 
Dear Doctor ………………………………… 
 
RE:  Bone Density and use of Depot Medroxyprogesterone Acetate 
(DMPA), Norethisterone Enanthate (NET-EN) and Combined Oral 
Contraceptives 
 
Your patient Ms………………………..has been involved in the above study at 
the Commercial City Family Planning Clinic, Commercial Road, Durban.  The 
study measurements include a bone mass scan of the forearm, height, weight, 
blood pressure, and waist / hip / forearm measurement.  The study has found 
that:- 
 
(Reason for referral) 
 
We attach details on the findings for you.  Please contact us at the above if you 
require any further information. 
 
Yours sincerely 
 
 
 
----------------------------------------- 
M. Beksinska 
Provincial Director 
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APPENDIX 7 
COLLABORATORS 
 
 
1. World Health Organisation 
1211 Geneva 27 
Switzerland 
Contact:  Dr Tim Farley 
Nature of collaboration: 
 
 Technical support and advice 
 Funding 
 
 
2. Professor J Moodaley / Dr Maharaj / Dr M Popis 
Dept of Obstetrics & Gynaecology 
Medical School 
King Edward Hospital 
Umbilo Road 
Durban 
 
Nature of collaboration: 
 Referral 
 Technical support and advice 
 General interest in study 
 
3. Dr Trudie Machattie 
Addington Hospital 
Dept of Chemical Pathology 
Prince Street 
Durban 
 
Nature of collaboration: 
 Analysis of blood samples 
 
4. Carol McIntosh 
Addington Hospital 
Dept of Chemical Pathology 
Prince Street 
Durban 
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Nature of collaboration: 
 Processing and storage of blood samples 
 
 
5. Mrs Krystal Kaiser 
Dept of Health KwaZulu Natal 
 
Nature of collaboration: 
 Participation of clinic and provision of consulting space for study 
 Clinic staff support of study 
 
 
 
6. Mark Roulliard 
4001-4006 Juniper House 
92 Overport Drive 
Overport 
Durban 
4001 
Telephone:  031-201 1321 
 
Nature of collaboration 
 Maintenance and servicing of equipment 
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Bone mineral density in a cohort of adolescents during use of
norethisterone enanthate, depot-medroxyprogesterone acetate or combined
oral contraceptives and after discontinuation of norethisterone enanthate☆
Mags E. Beksinskaa,⁎, Immo Kleinschmidtb, Jenni A. Smita, Timothy M.M. Farleyc
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cUNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction,
Department of Reproductive Health and Research, World Health Organization, CH 1211 Geneva 27, Switzerland
Received 31 October 2008; revised 11 November 2008; accepted 17 November 2008Abstract
Background: Depot medroxyprogesterone acetate (DMPA), norethisterone enanthate (NET-EN) and combined oral contraceptives (COCs)
have been shown to have a negative effect on bone mineral density (BMD) in adolescents. The aim of this study was to investigate BMD in
15- to 19-year-old new users of DMPA, NET-EN and COCs.
Study Design: This 5-year longitudinal study followed up new users of DMPA (n=115), NET-EN (n=115) and COCs (n=116) and 144
nonuser controls. BMD was measured at the distal radius using dual-energy X-ray absorptiometry.
Results: BMD increased in all groups (annual percent increase: nonusers, 1.49%; DMPA, 1.39%; NET-EN, 1.03%; COCs, 0.84%) during
follow-up (pb.001). There was evidence for lower BMD increases per annum in NET-EN (p=.050) and COC (p=.010) users compared to
nonusers but no difference between DMPA and nonusers (p=.76). In 14 NET-EN discontinuers, an overall reduction of 0.61% per year BMD
was followed upon cessation by an increase of 0.69% per year (p=.066).
Conclusion: This study suggests that BMD increases in adolescents may be less in NET-EN and COC users; however, recovery of BMD in
NET-EN users was found in the small sample of adolescents followed post-discontinuation.
© 2009 Elsevier Inc. All rights reserved.Keywords: Bone mineral density; DMPA; NET-EN; COCs; Adolescents1. Introduction
Depot medroxyprogesterone acetate (DMPA) has been
found to have a negative effect on bone mineral density
(BMD) in adult premenopausal women [1–5] and in
adolescents [6–13]. Limited data on the effect of norethis-
terone enanthate (NET-EN) have found a negative effect on
BMD in adult [14] and adolescent users [15]. A compre-
hensive review concluded that combined oral contraceptive
(COC) use in adult premenopausal women was not
associated with changes in BMD [16]. However, emerging☆ This study was supported by a grant from the World Health
Organization, The William and Flora Hewlett Foundation and The
Department for International Development UK (DFID).
⁎ Corresponding author. Tel.: +27 31 261 8840; fax: +27 31 261 8868.
E-mail address: mbeksinska@rhru.co.za (M.E. Beksinska).
0010-7824/$ – see front matter © 2009 Elsevier Inc. All rights reserved.
doi:10.1016/j.contraception.2008.11.009data show that BMD may be compromised in adolescent
users of low-dose COCs [10,17,18].
Studies that have followed women after discontinuation
of DMPA have found that BMD recovers in adult
premenopausal women within approximately 2–3 years of
cessation of the method [19,20]. Two studies have followed
up adolescent users of DMPA post-discontinuation [12,13],
and in both these studies, a significant increase in BMD was
found in adolescents who discontinued DMPA. No long-
itudinal data are available on recovery of BMD in adolescent
NET-EN and low-dose COC users. More evidence is needed
to show if the recovery of BMD found in adult users of
hormonal contraception is replicated in adolescents. The
objective of this study was to determine if long-term use of
hormonal contraceptives (COC, DMPA and NET-EN),
compared to nonuse, was associated with a change in bone
mass in women aged 15–19 years.
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This was a prospective longitudinal study of adolescents
aged 15 to 19 years who had never used hormonal
contraception prior to recruitment to the study. Initiators of
DMPA, NET-EN, and COCs and nonusers of contraception
were enrolled from a family planning clinic in Durban, South
Africa. The study cohort was recruited between July 2000
and July 2002 and follow-up continued until April 2006. All
DMPA users were started on a regimen of 150 mg every
12 weeks, and NET-EN users were started on a regimen of
200 mg every 8 weeks. Both DMPA and NET-EN were
administered intramuscularly. The COCs used by women
included a range of formulations, with almost all (93%)
using low-dose formulations containing between 30 and
40 mcg of estrogen. Women were eligible to participate if
they had not lactated or delivered in the past 6 months, were
not currently or had never used medication known to affect
calcium metabolism for more than 3 months and did not have
a chronic disease affecting calcium metabolism. At the
baseline visit, participants' height, weight and blood pressure
were measured using a standard protocol and a questionnaire
was administered to elicit information on demographic
characteristics, regularity of the menstrual cycle, smoking,
diet, exercise and caffeine and alcohol intake.
Forearm BMD was measured by dual-energy X-ray
absorptiometry (DEXA model DTX-200, Osteometer Med-
iTech A/S Co., Rodovre, Denmark). BMD was measured in
grams per square centimeter at the distal radius in the
forearm. The DEXA equipment was standardized daily using
a phantom as prescribed by the manufacturer's instructions.
Accuracy to the standard during the recruitment and follow-
up period was 0.53%.
Study participants were followed up at approximately six
monthly intervals. Forearm BMD, height and weight were
measured at each follow-up visit. History of contraceptive
use since last visit was recorded. Those recruited between
July 2000 and April 2001 and who continued to participate
until the end of the study completed 5 years of follow-up.
Those recruited after April 2001 who continued until the
end of the study completed between 4 and 5 years of
follow-up. Follow-up could not continue beyond April 2006
when project funding came to an end. Women continued the
same follow-up schedule even if they stopped, changed or
started another contraceptive method in order to investigate
issues of recovery of BMD post-discontinuation of a
hormonal method.
The characteristics of women in the study were quantified
as means±SD, medians or percentages. The study was
powered to detect a half SD difference in bone mass between
users and nonusers of hormonal contraceptives. This would
be of biological significance as this difference is expected to
translate into a large difference in the risk of fracture in older
women. Information on the mean and SD of cross-sectional
measurements of forearm bone mass in White, European,
premenopausal women reported by Nordin [21] was used toestimate sample size. A sample of 63 participants per
contraceptive group was required, assuming a two-tailed
statistical test with a significance level of 5% and a power of
80%. Allowing for 10–15% loss to follow-up per year, this
sample was increased to at least 110 women in each group to
ensure adequate numbers in long-term follow-up. The
nonuser group was overrecruited compared to other groups
as, in addition to loss to follow-up, it was anticipated that
some of these women would commence a method of
contraception or become pregnant.
Differences in BMD between contraceptive groups and
the associations between BMD and selected characteristics
of the study participants by contraceptive group were
assessed using one-way analysis of variance and multiple
variable linear regression. BMD was measured in users
and discontinuers.
Follow-up of all women was cumulated up to their last
visit or up to the visit preceding a visit at which they reported
a change in contraceptive method, whichever occurred first.
Interim analysis of this study found that BMI was
significantly associated with radius BMD [15]. To assess the
effect of contraceptive method on radius BMD and to allow
for within-subject correlation of responses while controlling
for the confounding effect of changes in BMI, we used
random-effects linear regression methods with radius BMD
at the time of a study visit as the response variable and
contraceptive method, duration of follow-up and BMI at time
of the visit as explanatory variables (STATA V.10, College
Station, TX, USA). Differences in rate of change in radius
BMD per year between methods were calculated by
including interaction terms in the model for method and
follow-up time. Additionally, we investigated whether
change in radius BMD varied between two time periods by
including an interaction term between follow-up time up to
the last visit occurring before 2.5 years and follow-up time
between 2.5 and 5 years, for each user group separately.
These two time periods were chosen as the literature
indicates that the greatest loss of BMD as a result of
hormonal contraceptive use occurs over the first 2 years of
use [22] and then loss continues at a slower rate and appears
to stabilize. Finally, we investigated BMD in women who
discontinued hormonal contraception.
Ethical approval was granted by the University of the
Witwatersrand, Human Subjects Research Committee (Pro-
tocol Number M981001), and by the Scientific and Ethical
Review Group of the World Health Organization (WHO).3. Results
In total, 490 women aged 15–19 years were recruited. All
women including those in the DMPA, NET-EN and COC
groups had no past use of hormonal contraception before
recruitment into the study. Baseline information about these
women is summarized in Table 1. Mean age was just under
18 years and most women were still in full-time education.
Table 2
Mean BMD and BMI at admission by contraceptive group
DMPA
(n=115)
NET-EN
(n=115)
COC
(n=116)
Nonuser
(n=144)
p
value
Radius
BMD
(g/cm2)
0.459 (0.06) 0.446 (0.06) 0.460 (0.05) 0.455 (0.05) .196
Body
weight
(kg)
59.1 (12.1) 59.5 (9.8) 56.7 (11.4) 59.7 (11.6) .13
Height
(cm)
154.8 (5.2) 156.1 (5.7) 156.2 (7.5) 155.9 (7.3) .30
BMI
(kg/m2)
24.63 (4.77) 24.31 (3.75) 23.18 (4.97) 24.61 (5.85) .097
BMI, body mass index.
Data are expressed as mean±SD.
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group, which included 22% of women of Indian origin and
21% “Colored” (mixed race). More than a quarter of women
(29.3%) in the DMPA user group had ever been pregnant
compared to low prevalence of pregnancy in the other
groups. COC users were more likely to be smokers than
other method users, although smoking generally was low
across all groups.
In total, 277 women continued with the same method of
contraception for at least two follow-up visits, while the rest
had changed method or stopped using contraception. Total
same-method follow-up time was 648 person-years in these
277 participants. Women who continued in the study using a
different method of contraception, or stopped using contra-
ception, were included up to the visit they changed method.
Overall, 64% of women continued in the study for between 2
and 3 years and 43% completed between 4 and 5 years of
follow-up depending on time of recruitment. Main reasons
for discontinuation from the study included pregnancy,
illness that could have affected BMD such as tuberculosis
and moving out of the area.
Table 2 shows mean BMD and BMI at enrolment for each
group. Radius BMD was similar in all four contraceptive
user groups at baseline (p=.196). The regression model
showed that BMI was the only baseline characteristic
associated with radius BMD (pb.001). BMI increased
consistently by 0.11 kg/m2/year (95% CI=0.04 to 0.18) in
all user groups with no evidence of differences in growth
between groups (p=.14).Table 1
Sociodemographic, lifestyle and reproductive characteristics of subjects aged 15–
Characteristics DMPA
(n=115)
NET-EN
(n=115)
Mean (SD) age (years) 17.8 (1.4) 17.4 (1.3)
Mean (SD) highest education grade 10.9 (1.5) 10.5 (1.5)
Marital status (%)
Married/Cohabiting 5.3 5.2
Regular partner—not cohabiting 92.1 83.8
Casual partner 2.6 5.2
No partner 0 0.9
Employment status (%)
Employed full-/part-time 6.2 2.6
Unemployed 11.4 10.5
Student/Scholar 82.5 86.8
Ethnicity (%)
African 94 89
Colored 5 7
Indian 1 4
Ever pregnant (%) 29.3 3
Ever lactated (%) 16.7 0.9
Lactation (years) median b1 b1
Mean (SD) age at menarche (years) 13.9 (1.3) 13.8 (1.2)
Exercise (%)
No regular exercise 78.1 72.8
At least once a week 21.9 27.2
Dieted in last 6 months (%) 3.5 2.6
Ever smoked cigarettes (%) 9.6 11.3
Current smoker (%) 6.0 7.0Radius BMD increased in all groups during follow-up
(Table 3), even after adjusting for changes in BMI (pb.001),
with an overall increase for all women combined of 1.39%
per annum (95% CI=1.19% to 1.59%). In nonusers, BMD
increased by 1.49% per annum; in the DMPA, NET-EN and
COC users, the increases were less: 1.39% (p=.76), 1.03%
(p=.05) and 0.84% (p=.01), respectively (Table 3). There
was moderate to strong evidence for smaller increases per
annum in NET-EN (p=.050) and COC (p=.010) users
compared to nonusers. There was no evidence of a difference
in BMD between DMPA and nonusers (p=.76) (Table 3).
There was no evidence of a difference in change in radius
BMD in the two time periods (up to 2.5 years and 2.5 years19 years by contraceptive user group, at baseline
COC
(n=116)
Nonuser controls
(n=144)
p value
17.8 (1.0) 17.4 (1.2) .0002
11.3 (0.8) 10.3 (1.4) .0001
.0001
10.3 12.8
87.1 63.5
2.6 23.0
0 0.7
b.0001
9.5 2.7
8.5 7.4
79.1 98.8
b.0001
57 92
21 4
22 4
6 2 b.0001
2.6 1.4
b1 b1
13.6 (1.48) 13.5 (1.29) .19
.0001
64.9 77.7
35.1 22.3
5.3 2.0 .54
27.3 4.8 b.001
13.9 3.4 .006
Table 3
Factors associated with radius BMD at study visit, estimated from random-
effects linear regression model
Variable % change in
BMD (95% CI)
per annum
% change in BMD
per method relative
to nonuser (p)
n Time
at risk
(years)
Use of contraceptive
method, per yeara
Nonuser
(reference)
1.49 (1.25–1.72) 0 96 311
DMPA 1.39 (0.79–1.98) −0.10 (.76) 51 76
NET-EN 1.03 (0.63–1.44) −0.45 (.050) 71 146
COC 0.84 (0.39–1.28) −0.65 (.010) 59 116
Effect of BMI,
per unit change
in BMI
(% per kg/m2)b
0.267 (0.157–0.377) 277 648
a Adjusted for BMI.
b Adjusted for contraceptive method.
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NET-EN, p=.7; nonusers, p=.46; COC, p=.06).
We investigated changes in BMD in a group of 14NET-EN
users who discontinued use of the method without restarting
another method during the course of the study. An overall
reduction in radius BMD of 0.61% (95% CI=−2.53% to
1.34%) per year was seen in the 14 NET-EN users during use
of the method, followed upon cessation of method by an
increase of 0.69% (95%CI=−0.18% to 1.56%) per year. After
adjusting for BMI, there was some evidence of a difference in
rate of BMD change before and after use of NET-EN
(p=.066). Most COC and DMPA discontinuers restarted other
methods; thus, there were too few to conduct a group analysis.4. Discussion
Our results show that radius BMD increased during
follow-up in the nonuser and all three user groups after
adjusting for BMI. There was some evidence of less increase
in NET-EN and COC groups compared to the nonuser group.
Our results confirm those obtained from an interim analysis
of this study [15] in regard to NET-EN. However, in the
preliminary analysis, COC users did not show any
differences in BMD increase from nonusers, possibly
because the interim analysis lacked power.
In the only other study that has previously investigated
the effect of NET-EN use [14], BMD was measured in the
left calcaneus in a large cross-sectional sample of adult
premenopausal women. NET-EN users had similar values to
DMPA users, and these were both significantly lower
compared to never users.
We found no evidence of any change in BMD growth in
the period up to 2.5 years of use compared to the period from
2.5 years of use. Several studies have reported that the rate of
loss of BMD in DMPA users is greatest in the first 2 years of
use [4,12,13,22]. Only one of these studies has investigated
rate of change in adolescents [12].Several longitudinal studies have found that adolescent
users of low-dose COCs may gain bone mass at a slower rate
compared to nonusers [10,17,18]. The COC formulations in
our study were similar to those reported in these studies. Our
study also showed that COC users gained BMD at a slower
rate than nonusers. Although DMPA users had a lower yearly
increase in BMD compared to nonusers, this was not
significant. Other studies measuring BMD at central sites
such as the hip and spine have found that adolescent DMPA
users have lower BMD values compared to nonusers [6–13].
Studies using the forearm as a site of BMD measurement
have generally not found significant differences between
DMPA users and controls [23,24]. Our study has found
similar results to others measuring the forearm with respect
to DMPA. The forearm may be more sensitive to the effect of
NET-EN and COC and it may be that these results would be
magnified if measured at a central site such as the hip or
spine. No studies have measured BMD at central sites in
NET-EN users.
Our study shows some evidence of a recovery in growth
in BMD in a very small sample of NET-EN discontinuers
who did not use another method of contraception after
cessation. The cross-sectional study that investigated women
who commenced NET-EN during adolescence (18 years and
younger) and then ceased using the method [14] found no
difference in BMD values between those who had ceased use
2–3 years before and never users regardless of whether they
were early starters (adolescents) or late starters (post-
adolescence). It was not possible to make any statement
about BMD recovery in the COC and DMPA discontinuers
in our study as numbers were so small.
DMPA suppresses estradiol production, leading to estro-
gen deficiency [25]. This leads to greater bone resorption and,
hence, loss of BMD. There is less information on NET-EN
and themechanisms bywhich it could affect BMD. Studies on
NETalone have not found a negative effect on BMD [26–28].
There are now limited data available on recovery of BMD in
women who commence DMPA in adolescence [12,13]. This
is the first longitudinal study that has included NET-EN users
and discontinuers. Further evidence is needed to ensure that
any losses of BMD as a result of DMPA and NET-EN in
adolescence are fully recovered and peak bone mass is not
compromised. Until that time, the recommendations for
DMPA and NET-EN in adolescents will continue to caution
long-term use in young women.
The third edition (2004) of the Medical Eligibility Criteria
for Contraceptive Use of the WHO [29] has changed the
classification of use of DMPA and NET-EN for women
below 18 years and above 45 years from Category 1 (no
restriction for the use of the contraceptive method) to
Category 2 (advantages of using the method generally
outweigh the theoretical or proven risks). This is backed up
in the document by a number of statements reporting on
current evidence of the effect of DMPA on BMD. The WHO
has recommended that in the absence of evidence on NET-
EN, the same restrictions should apply to NET-EN users.
349M.E. Beksinska et al. / Contraception 79 (2009) 345–349Our study shows that although BMD continues to
increase in adolescent users of NET-EN and COCs, these
increases are lower than that in nonusers. Although the
percent yearly increase in DMPA users was lower than that in
nonusers, there was no evidence of a significant difference
and this may have been because this group had the lowest
number of years at risk included in the analysis.
4.1. Limitations
Longitudinal studies of adolescent users of hormonal
contraception are often limited by method discontinuation.
This was the case in our study where few women remained
on hormonal contraception for more than 2 years without a
change of method or stopping use of contraception
altogether. Concerns regarding long-term use of DMPA
and NET-EN in adolescents should take this into considera-
tion as many young women will have discontinued use
before the 2-year review suggested on the patient labeling.
Our study has used the forearm as its site of measurement,
which may be less sensitive than the hip and spine to changes
in BMD resulting from hormonal contraceptive use.
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Abstract
Background: Use of depot-medroxyprogesterone acetate (DMPA), norethisterone enanthate (NET-EN) and low-dose combined oral
contraceptives (COCs) has been associated with loss of bone mineral density (BMD) in adolescents. However, the effect of using a
combination of these methods over time in this age group is limited. The aim of this cross-sectional study was to investigate BMD in young
women (aged 19–24 years) with a history of mixed hormonal contraceptive use.
Study Design: BMD was measured at the spine, hip and femoral neck using dual X-ray absorptiometry. Women were classified into three
groups: (1) injectable users (DMPA, NET-EN or both) (n=40), (2) mixed COC and injectable users (n=13) and (3) non-user control (n=41).
Results: Women in the injectables-only user group were found to have lower BMDs compared to the non-user group at all three sites, and
there was evidence of a difference in BMD between these two groups at the spine after adjusting for body mass index (p=.042), hip (p=.025)
and femoral neck (p=.023). The mixed COC/injectable user group BMD values were lower than those for controls; however, there was no
evidence of a significant difference between this group and the non-user group at any of the three sites.
Conclusion: This study suggests that BMD is lower in long-term injectable users but not when women have mixed injectable and COC use.
© 2009 Elsevier Inc. All rights reserved.
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1. Introduction
The long-acting progestogen injectable contraceptives
depot-medroxyprogesterone acetate (DMPA) and norethis-
terone enanthate (NET-EN) have been found to have a
negative effect on bone mineral density (BMD) in adult
premenopausal women [1–5] and in adolescents [6–15]. The
effect of combined oral contraceptives (COCs) on BMD has
been found to be variable with no effect reported in adult
premenopausal women [16], but there is growing evidence
that low-dose COCs may be detrimental to BMD in
adolescents and young women [10,17,18].
Although recovery of BMD following discontinuation of
DMPA is documented in adult premenopausal women [19,20]
and in adolescent users [12,13], concerns regarding bone loss
in DMPA users resulted in a US Food and Drug Adminis-
tration Black Box warning for DMPA, stating its use may
impair BMD [21]. In the UK, the Medicines and Healthcare
Products Regulatory Agency (MHRA) suggests that another
contraceptivemethod be used after 2 years of DMPA use [22].
Much less information is available on recovery in NET-EN
users as it is not as widely used as DMPA and not available in
the United States or UK. Limited data have found recovery of
BMD in adolescent NET-EN users [14,23].
More evidence is needed on long-term use of hormonal
contraception and, in particular, on women who switch from
hormonal injectables to another hormonal method of
contraception. The objective of this study was to determine
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if long-term use of hormonal contraceptives, including
mixed use (COCs and/or, DMPA and/or NET-EN), was
associated with a change in bone mass in women aged 19–24
years compared to non-users.
2. Subjects and methods
This cross-sectional study of young women aged 19–24
years measured BMD in the hip, spine and femoral neck. All
the women had been recruited 4–5 years previously into a
longitudinal study where the BMD in the distal radius had
been measured at 6-month intervals. Details of the long-
itudinal study methodology and results are described else-
where [15]. At the end of the follow-up period, additional
funds allowed for 100 single measurements of the central
BMD sites providing an opportunity for measurements at
other sites. A subsample of women attending their final
longitudinal follow-up visit were informed about this
additional component of the study at their last cohort visit
and were invited to participate. This subsample included all
women completing the study over a 5-month period.
At the start of the 5-year longitudinal study, initiators of
DMPA, NET-EN, COCs and non-users of contraception
were enrolled from a family planning clinic in Durban, South
Africa. All women recruited had no history of hormonal
contraceptive use prior to enrolment (n=490). The study
cohort was recruited between July 2000 and July 2002, and
follow-up continued until April 2006. All DMPA users were
started on a regimen of 150 mg every 12 weeks and NET-EN
users on 200 mg every 8 weeks. Both DMPA and NET-EN
were administered intramuscularly. The COCs used by
women included a range of formulations, with almost all
(93%) using low-dose formulations containing between 30
and 40 mcg of estrogen. Women were eligible to participate
if they had not lactated or delivered in the past 6 months,
were not currently using and had not used medication known
to affect calcium metabolism for more than 3 months, and
did not have a chronic disease affecting calcium metabolism.
At the baseline and follow-up visits, participants' height,
weight and blood pressure were measured using a standard
protocol, and a questionnaire was administered to elicit
information on demographic characteristics, regularity of the
menstrual cycle, smoking, diet, exercise and caffeine and
alcohol intake. It was from this cohort that the 100 women
were recruited for the cross-sectional study reported here.
History of contraceptive use had been recorded in the
longitudinal study over the total follow-up period at
approximately six-monthly intervals. Women in the cohort
continued the same follow-up schedule even if they stopped,
changed or started a contraceptive method. The additional
visit to measure the hip, spine and femoral neck BMD was
conducted between October 2005 and February 2006. The
DEXA equipment used in the cross-sectional substudy to
measure hip, spine and femoral neck was a Hologic QDR
discovery, version 12.6, model: Discovery w(s/n) 49369
(Hologic Inc, USA). The DEXA equipment was standar-
dized daily using a phantom, and accuracy to the standard
during the measurement phase was 0.44%.
The characteristics of women in the study were quantified
as means±SD, medians or percentages. Differences in BMD
and weight between contraceptive groups, and the associa-
tions between spine, hip and femoral neck BMD and
contraceptive group were assessed using one-way analysis of
variance and multiple variable linear regression. Data were
analyzed using the statistical package STATAV.10 (College
Station, TX, USA).
Ethical approval was granted by the University of the
Witwatersrand Human Subjects Research Committee (pro-
tocol no. M981001) and by the Scientific and Ethical Review
Group of the World Health Organization.
3. Results
A group of 100 women who had completed follow-up in
the longitudinal phase agreed to participate in the cross-
sectional substudy. Of these, 96 women attended their
appointment and 4 women were unable to attend due to work
commitments. The contraceptive history of these women
varied considerably as women had not been discontinued
from the longitudinal study if they changed or stopped a
method. Thirty women presented with a history of mixed
contraceptive use, including women who had used at least
two of the study methods (DMPA, NET-EN, COCs) in the
preceding 4–5 years. Of these 30, 17 women had used both
DMPA and NET-EN, 10 had mixed COCs and either DMPA
or NET-EN and 3 women had used all three methods. Far
fewer women presented as exclusive users of one method at
the end of the follow-up period (DMPA n=9, NET-EN n=14,
COC users n=2). The remaining 41 women were non-users
of hormonal contraception.
The small number of women who had used one method
only made data difficult to analyze, and we therefore
classified the women into three broad groups for analysis,
according to their contraceptive history over the previous 4–
5 years in the longitudinal component of the study. The first
group (n=40) included all users of injectable hormonal
contraception, regardless of whether they had used only one
or both of the injection types. The second user group is
composed of women who mixed COCs with injections
(n=13). Finally, the nonhormonal contraceptive users (n=41)
included 22 never users of hormonal contraception and 19
ex-users. The ex-users had not used a hormonal method for
approximately 2 years or longer, and almost all had less than
1 year of lifetime use. These women had started a method on
recruitment into the longitudinal study and had subsequently
discontinued use. We excluded the two exclusive COC users
as they could not be classified into any of the three groups.
Fig. 1 shows details of the three groups.
Baseline information about these women is summarized
in Table 1. Mean age was approximately 22 years in all
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groups, and the majority of women were African. Few
women participated in any regular exercise, and only one
woman was a current smoker. Alcohol consumption was low
across all groups.
There was evidence that BMD was associated with body
mass index (BMI) for all three sites, with one unit of BMI
corresponding to an average increase in BMD of 0.010
(0.006–0.015), 0.014 (0.009–0.017) and 0.017 (0.012–
0.021) g/cm2 for spine, hip and femoral neck, respectively.
Table 2 shows mean BMD at the three sites
measured. Women in the injectables-only user group
were found to have lower BMDs compared to the non-
user group at all three sites. There was some evidence of
a significant difference in BMD between the injectable
and non-user groups at the spine (p=.042), hip (p=.025)
and femoral neck (p=.023) after adjusting for BMI. In
the mixed COC and injectable group, the BMD values
were lower than in the non-users at all sites; however,
there was no evidence of a significant difference between
this group and the non-users (spine p=.54, hip p=.15,
femoral neck p=.43).
Weight in the non-user group remained similar to that at
baseline, while women in the injectable user group had
gained on average 6.7 kg and the mixed COC/injectable
group gained 1.9 kg (data not shown) over the 4- to 5-year
follow-up.
4. Discussion
Our results show evidence of significantly lower BMD
values in the hip, spine and femoral neck between the
adolescent users of injectable hormonal methods and non-
users but not those women who have used COCs in
combination with injectables. The absence of a significant
difference in BMD between this group and the non-users
may be due to the small number in this group (n=13). Over
the follow-up period, this mixed-use group used COCs
before and after injectable use and some moved between
these methods several times. However, this group had less
Table 1
Characteristics of subjects aged 19–24 years by contraceptive user group
Characteristics Injectable
users (n=40)
Mixed COC
and injectable
users (n=13)
Non-users
(n=41)
p
Mean age (years) SD 22.3 (1.4) 22.1 (1.2) 22.0 (1.6) .7
Ethnicity (%)
African 90.0 100.0 97.6 .5
Colored 7.5 0 2.4
Indian 2.5 0 0
Ever pregnant (%) 12.5 0 4.8 .23
Mean age at menarche
(years) SD
13.9 (1.5) 13.8 (1.2) 13.7 (1.3) .47
Exercise at least once
a week (%)
5.1 16.7 5.4 .05
Dieted in last 6 months (%) 2.5 0 0 .52
Current smoker (%) 0.0 0 2.6 .51
Alcohol consumption,
units per week (%)⁎
Never 92.5 100.0 73.2 .17
1–2 units 7.5 0 22.0
3–4 units 0 0 4.9
⁎ 1 unit=one small glass wine/one measure of spirits.
Fig. 1. Participant contraceptive history by study analysis group.
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overall injectable exposure over the follow-up period
compared to the injectable-only group.
Although we are unable to comment on any specific
method, our sample consisted of a representative group of
women completing follow-up in the longitudinal study
during a specific time period. At the end of our study, the
mixed hormonal contraceptive users were found to be far
more common than the exclusive users. Few women stayed
on one hormonal method and many had discontinued
hormonal contraception altogether. Although the study was
not designed to collect reasons for discontinuation of
method, anecdotal reports indicated that various side effects
and change in relationship status resulted in breaks and
changes in method.
The literature has shown that discontinuation rates among
adolescent DMPA users are particularly high, and continua-
tion rates as low as 27% at 1 year have been found in the
United States [24]. In the longitudinal component of our
study, there was an incidence of 37% method change per
person-year for DMPA and 26% for NET-EN [15]. Although
concerns remain regarding hormonal contraceptive use in
adolescents, data indicate that few women are long-term
exclusive users of one method of contraception. If mixed
users are more prevalent, as was seen in our study, it would
be important to include them in studies looking at hormonal
contraceptive use and BMD.
Two studies have studied young women who com-
menced low-dose COCs after use of DMPA and found they
were at risk for loss of BMD [25,26]. Our study could not
confirm this finding as our numbers using DMPA followed
by COCs was too small. In addition, the ethinyl estradiol
(EE) formulations used by the COC users in our study was
30–40 mcg, whereas studies that have found a detrimental
effect of COCs on BMD have used even lower (20 mcg)
EE formulations [10,17,18,25,26]. The MHRA (UK)
guidelines [22] recommend changing from DMPA to
another method of contraception after 2 years of use;
however, there is no advice as to what would be the most
suitable method post-discontinuation. As the body of
evidence on recovery of BMD in adult and adolescent
women post discontinuation of DMPA increases [27], this
recommendation may need to be reviewed and balanced
against the benefit of using DMPA as a long-term effective
contraceptive. The third edition of the WHO Medical
Eligibility Criteria for contraceptive Use [28] states the
advantages of using DMPA generally outweigh the
theoretical or proven risks in relation to BMD. A position
paper published in 2006 by the Society of Adolescent
Medicine [29] supports the WHO position on DMPA for
woman aged 18–45 years and states that with existing
evidence, the advantages of using DMPA in women below
18 years outweigh the disadvantages.
Limited data on recovery of BMD on cessation of
hormonal contraceptive use in adolescents have been
reported in exclusive users of DMPA [12,13] and NET-EN
[14,23]. Further evidence is needed to show that any loss of
BMD, resulting from hormonal contraceptive use in
adolescence, is fully recovered, and peak bone mass is not
compromised. Until this time, the recommendations for
DMPA and NET-EN use in adolescents will continue to
caution long-term use in young women.
4.1. Limitations
This study was unable to analyze the individual effects of
any of the three hormonal methods used as the sample size of
exclusive users was too small for analysis.
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Abstract
Purpose: Most studies have shown a negative effect of depot-medroxyprogesterone acetate (DMPA) on the bone mineral density (BMD) of
adolescents. There is no information available on the effect of norethisterone enanthate (NET-EN) on BMD in adolescents and the effect of
combined oral contraceptives (COCs) on adolescent BMD is inconclusive. The aim of this longitudinal study was to investigate BMD in
adolescent (aged 15–19 years) new users of hormonal contraception (DMPA, NET-EN and COCs).
Method: New users of DMPA (n =115), NET-EN (n =115), COCs (n=116) and 144 nonuser controls were recruited. BMD was measured at
the distal radius and midshaft of the ulna using dual X-ray absorptiometry.
Results: In total, 275 women were included in this interim analysis and total follow-up time was 553 person-years. There was no significant
difference in radius BMD between users of different contraceptive methods at baseline (p= .40). Overall, an increase in radius BMD of
0.00522 per person-year was observed. This result was similar when adjusting for BMI in the random effects regression model (p=.88). The
regression model showed that BMI was significantly associated with radius BMD, with each unit increase in BMI corresponding to an
increase of 0.0029 g/cm2 in BMD (95% CI 0.0023 to 0.0036, pb .001). Interaction between contraceptive method and follow-up time
adjusted for BMI was not significant (p= .07). The increase in BMD for NET-EN users of 0.0013 g/cm2 per person-year (95% CI 0.0017 to
0.0043) was significantly lower than that of nonusers (p= .017). For DMPA and COC users, the increase in BMD was not significantly
different compared to the nonusers. This study suggests that NET-EN users had lower increase in BMD over time compared to the other
user groups.
D 2007 Elsevier Inc. All rights reserved.
Keywords: Bone mineral density; Depot-medroxyprogesterone acetate; Norethisterone enanthate; Combined oral contraceptives; Adolescents1. Introduction
Studies undertaken to investigate the effect of hormonal
contraception on bone mineral density (BMD) have mostly
found that depot-medroxyprogesterone acetate (DMPA) has0010-7824/$ – see front matter D 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.contraception.2007.02.001
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Department of Epidemiology and Population Health, Keppel Street,
London WC1E 7HT, UK.a negative effect on bone mass [1–5], although some have
shown minimal or no effect [6–8]. There is limited
information available on the effect of norethisterone
enanthate (NET-EN) on BMD [9]. The evidence for the
effect of combined oral contraceptives (COCs) in premen-
opausal women has shown that in general COCs are not
associated with changes in BMD [10–12].
A number of studies have investigated the effect of
hormonal contraceptives on BMD in adolescents aged less
than 20 years [13–19] and almost all of these have found
that DMPA has an adverse effect on BMD [14–19]. No
studies have looked at adolescent NET-EN users. Emerging
data in young COC users are showing that BMD may be75 (2007) 438–443
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Studies of adolescent users of hormonal contraception have
often been limited by small sample sizes [15,16] and follow-
up in longitudinal studies on adolescents is often poor due to
method discontinuation [16,17].
DMPA and NET-EN are effective contraceptives with
low failure rates [21]. In South Africa, use of both hormonal
injectable contraceptives is high amongst adolescents, with
about 70% of Black African women aged 15–19 years
practicing contraception using either DMPA or NET-EN
[22]. Adolescence is a period of rapid growth and women
gain 40–50% of their skeletal mass during this time [23].
Loss of bone mass as a result of hormonal contraceptive use
may have more serious implications in these women who
have yet to achieve peak bone mass. It would be important
to know whether using hormonal methods of contraception
interferes with the process of bone mineralization. The
objective of the study was to determine whether long-term
use of hormonal contraceptives (COCs, DMPA and NET-
EN) compared to nonuse is associated with a change in bone
mass in women aged 15–19 years.2. Subjects and methods
A cohort of adolescent never-users of hormonal
contraception aged 15 to 19 years starting use of DMPA,
NET-EN, COCs, and nonusers of hormonal contraception
were recruited from a large family planning clinic in
Durban, South Africa. All eligible women were informed
about the study and invited to participate if they wished.
Recruitment commenced in July 2000 and was completed
in 2003. For inclusion into the study, women had to have
no history of hormonal contraceptive use. All DMPA users
were started on a regimen of 150 mg every 12 weeks and
NET-EN users on 200 mg every 8 weeks. Both DMPA and
NET-EN were administered intramuscularly. The COCs
used by women included a range of formulations, with
most (93%) using formulations containing between 30 and
40 Ag of estrogen. Women were eligible to participate if
they had not lactated or delivered in the past 6 months;
were not currently or had never used medication known to
affect calcium metabolism for more than 3 months; and did
not have a chronic disease affecting calcium metabolism.
On recruitment, a questionnaire was administered by a
trained research nurse to elicit information on lifetime
contraceptive history, fertility history and regularity of the
menstrual cycle. Questions were also asked on smoking,
diet, exercise and caffeine and alcohol intake. The
examination included height, weight and blood pressure
using a standard protocol.
Body mass index (BMI) was calculated from the weight
and height as kilograms per square meter. Forearm BMDwas
measured by dual energy X-ray absorptiometry (DEXA mo-
del DTX-200, Osteometer MediTech A/S Co, Rodovre,
Denmark). BMD was measured in grams per square centi-
metre at two distal sites in the forearm (radius and ulna). Thedistal site contains approximately 25% trabecular bone and
75% cortical bone. The DEXA equipment was standardized
daily using a phantom as per manufacturers instructions.
Accuracy to the standard during the recruitment and follow-
up period was 0.53%, and in vivo precision was 0.94%.
Study participants are being followed-up at six monthly
intervals for a total of 5 years. Forearm BMD, height and
weight were measured at each follow-up visit. The findings
presented in this paper are based on an interim analysis and
data collected up to the end of 2004 are included. Those
recruited early in the study had completed over 3 years of
follow up; however, those recruited in 2002 have approxi-
mately 18 months of follow-up. Women were not excluded
from the study if they stopped, changed or started a
contraceptive method. This was done to investigate issues
of recovery of BMD post discontinuation of a hormonal
method. The method of contraception used was recorded at
each follow-up visit. Women were assigned to the contra-
ceptive method they were using until their next follow-up
visit. If at any visit a change was recorded, the woman would
be assigned according to the new contraceptive method.
Thus, each woman could contribute to more than one of the
exposure categories.
This interim analysis is conducted on all women who
remained on the same method for at least two visits
inclusive of the baseline visit (minimum 6 months) and
data are included up to the time the method was changed.
Ethical approval was granted by the University of the
Witwatersrand, Human Subjects Research Committee, and
by the Scientific and Ethical Review Group of the World
Health Organization.
2.1. Statistical analysis
The characteristics of women in the study were
quantified as meansFSD, medians or percentages. The
study was powered to be able to detect a half standard
deviation difference in bone mass between users and
nonusers of hormonal contraceptives. This could be of
biological significance as this difference would translate into
a large difference in the risk of fracture in the older woman.
Information on the mean and standard deviation of cross-
sectional measurements of forearm bone mass in white,
European, premenopausal women reported by Nordin [24]
was used to estimate sample size. A sample of 110 partic-
ipants per contraceptive group was required assuming a
two-tailed statistical test with a significance level of 5%,
power of 80%, and allowing for 10–15% loss to follow-up
per year. The nonuser group was over-recruited compared to
other groups as in addition to loss to follow-up it was
anticipated that some women would commence a method of
contraception or become pregnant.
Differences in BMD between contraceptive groups, and
the associations between BMD and selected characteristics
of the study participants by contraceptive group were
assessed using one-way analysis of variance and multiple
variable linear regression.
Table 1
Sociodemographic, lifestyle and reproductive characteristics of subjects aged 15–19 years by contraceptive user group, at baseline
Characteristics DMPA (n=115) NET-EN (n=115) COC (n=116) Nonuser controls (n=144) p value
Mean age, years (SD) 17.8 (1.4) 17.4 (1.3) 17.8 (1.0) 17.4 (1.2) .0002
Mean highest education grade (SD) 10.9 (1.5) 10.5 (1.5) 11.3 (0.8) 10.3 (1.4) .0001
Marital status, %
Married/cohabiting 5.3 5.2 10.3 12.8 .0001
Reg partner-not cohabiting 92.1 83.8 87.1 63.5
Casual partner 2.6 5.2 2.6 23.0
No partner 0 0.9 0 0.7
Employment status, %
Employed full/part-time 6.2 2.6 9.5 2.7 b .0001
Unemployed 11.4 10.5 8.5 7.4
Student/scholar 82.5 86.8 79.1 98.8
Ethnicity, % b .0001
African 94 89 57 92
Colored 5 7 21 4
Indian 1 4 22 4
Ever pregnant, % 29.3 3 6 2 b .0001
Ever lactated, % 16.7 0.9 2.6 1.4
Lactation (yrs), median b1 b1 b1 b1
Mean age at menarche, years (SD) 13.9F1.3 13.8F1.2 13.6F1.48 13.5F1.29 .19
Exercise
No regular exercise, % 78.1 72.8 64.9 77.7 .0001
At least once a week, % 21.9 27.2 35.1 22.3
Dieted in last 6 months, % 3.5 2.6 5.3 2.0 .54
Ever smoked cigarettes, % 9.6 11.3 27.3 4.8 N .00001
Current smoker, % 6 7.0 13.9 3.4 .006
DMPA=depot medroxyprogesterone acetate; NET-EN= norethisterone enanthate; COC=combined oral contraceptive, SD=standard deviation.
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visit, or up to the visit preceding a visit at which they
reported a change in contraceptive method, whichever
occurred first. To assess the effect of contraceptive method
on radius BMD, and to control for the confounding effect of
changes in BMI, a random effects linear regression model
was set up using STATA (V.8, College Station, TX, USA)
with radius BMD at the time of a study visit as the response
variable, and contraceptive method, follow-up since last
study visit and BMI at time of the visit as explanatory
variables, and allowing for within-subject correlation of
responses. Differences in rate of change in radius BMD per
year between method were assessed by including interaction
terms in the model for method and follow-up time.3. Results
In total, 490 women aged 15–19 years were recruited. All
women including those in the DMPA, NET-EN and COC
groups had no past use of hormonal contraception before
recruitment into the study. Baseline information about these
women is summarized in Table 1. Mean age was 18, with
the DMPA and COC groups being 4 months older than theTable 2
Mean BMD and BMI at admission by contraceptive group
DMPA n=115 NET-EN n=115
Radius BMD g/cm2 (SD) 0.459 (0.06) 0.446 (0.06)
Ulna BMD g/cm2 (SD) 0.443 (0.06) 0.432 (0.06)
Mean BMI (kg/m2) (SD) 24.63 (4.77) 24.31 (3.75)nonuser and NET-EN groups (p=.0002). Almost all women
were African except in the COC group which included
about a quarter (22%) of Indian women. This resulted in a
significant difference in ethnicity between the groups.
Incidence of smoking was low across all groups.
The reproductive characteristics of the woman are
summarized in Table 1. Few women had ever been pregnant
(teenage pregnancies) except in the DMPA group with a
quarter of women (29%) reporting that they were ever
pregnant. Age of menarche was similar in all groups and
at recruitment; all had regular menstrual cycles, between
21 and 35 days’ duration (data not shown).
Table 2 shows mean BMD at both sites and BMI at
enrolment for each group. There was no significant
difference in radius (p=.196) and ulna (p=.0534) BMD
between the four contraceptive user groups at baseline. The
COC group had a slightly lower mean BMI at baseline but
this was not significant.
Table 3 shows the baseline mean BMD of women by age
at enrolment. The increase in radius and ulna BMD of
approximately 3% per year of age was significant.
In this interim analysis period, 401 women had attended
at least once for follow-up (82%). Of these women,COC n=116 Nonuser n=144 p value
0.460 (0.05) 0.455 (0.05) .196
0.429 (0.05) 0.436 (0.06) .0534
23.18 (4.9) 24.61 (5.8) .097
Table 3
Mean BMD and BMI by year of age in 15–19 age group at admission
15, n=36 16, n=57 17, n=101 18, n=173 19, n=123 p value
Radius g/cm2 (SD) 0.412 (0.049) 0.443 (0.054) 0.457 (0.053) 0.455 (0.52) 0.472 (0.056) b .00001
Ulna g/cm2 (SD) 0.405 (0.054) 0.419 (0.053) 0.440 (0.053) 0.436 (0.053) 0.452 (0.062) b .00001
Mean BMI (kg/m2) (SD) 23.59 22.97 24.23 24.26 24.89 .169
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continue in the study. Pregnancy was the main reason for
discontinuation and this was high in the nonuser control
group. In total, 76% (n=370) of women completed their
second visit. Main reasons for discontinuation from the
study included pregnancy, illness that could have affected
BMD, e.g., tuberculosis, and moving out of the area. Of
those who continued participation in the study, 50%
changed, stopped or started a method at least once during
their follow-up. Some women (15%) changed, stopped or
started a new method at least twice. Incidence of method
change per year is shown in Table 4. Reasons given for
method change were mainly change in relationship status or
complaints about side effects of the method. This was
lowest in the nonuser group where 19% started a method of
contraception during their follow-up and highest in the
DMPA group where 74% changed or stopped use. DMPA
users often changed to NET-EN which is the more popular
choice amongst young women.
In total, 275 women had continued the same method
for at least 6 months (two visits). Some women had
contributed seven study visits (approximately 3.5 years).
Total follow-up time was 553 person-years for 275
participants (Table 4).
Overall, an increase in radius BMD of 0.00522 per person-
year was observed. Mean BMD of the women in this analysis
was 0.45 g/cm2 (SD=0.053) at baseline. There was no
significant difference in radius BMD between prospective
users of different contraceptive methods at baseline (p=.40)
(Table 4). This result was similar when adjusting for BMI in
the random effects regression model (p=.88). The regression
model showed that BMI was significantly associated with
radius BMD, with each unit increase in BMI corresponding to
an increase of 0.0029 g/cm2 in BMD (95% CI 0.0023 to
0.0036, pb .001) (Table 5). Interaction between contraceptive
method and follow-up time adjusted for BMI was marginally
nonsignificant overall (p=.07). For DMPA users, the increase
in radius BMD of 0.0069 g/cm2 per person-year (95% CI
0.0028 to 0.011) was nonsignificantly different compared toTable 4
Radius BMD at baseline, follow-up time and incidence of method change by con
Method N Follow-up time
in person years
Incidence
method ch
per person
DMPA 51 75.42 0.37
NET-EN 68 125.68 0.26
Nonuser 96 248.65 0.004
COC 60 103.67 0.19
Total 275 553the increase of 0.0055 g/cm2 per person-year (95% CI 0.0037
to 0.0073) for nonusers (p=.55). Similarly, the increase of
0.0053 g/cm2 per person-year (95% CI 0.0022 to 0.0085) for
COC users was nonsignificantly different from the controls.
The increase in BMD for NET-EN users of 0.0013 g/cm2 per
person-year (95% CI 0.0017 to 0.0043) was significantly
lower than that of nonusers (p=.017), and not inconsistent
with the null hypothesis of no increase in BMD over time for
these women (p=.40).4. Discussion
Women in the 15–19-year age group have yet to reach
peak bone mass and our baseline data indicate that there is a
small yearly increase of approximately 2–3% per year in a
population that had no exposure to hormonal methods of
contraception on recruitment into the study. This increase
would be expected in women in this age range [23] and our
data indicate that forearm BMD is sensitive enough to
document this increase.
The multiple variable analysis shows that BMD is
strongly related to BMI (pb .001). BMD in the nonuser
reference group, the DMPA user group and the COC user
group increased significantly during follow-up, by similar
amounts (0.0055, 0.0069 and 0.0053 g/cm2 per year,
respectively) after adjusting for BMI. By contrast, the
NET-EN group differed significantly from the nonuser
group (p=.017), achieving no significant growth in BMD
during follow-up. This is the first study to date that has
investigated the effect of NET-EN on BMD. NET-EN was
the only group where there was no significant increase in
BMD found over time (p=.4). No significant difference was
found between either the COC and the nonuser control
group or the DMPA and the nonuser control group.
Our study has used the forearm as the site of measure-
ment and it may be that differences in the lumber spine and
hip are more sensitive and any decreases are magnified at
these sites. Other studies [7,13] using the forearm as the site
of measurement found no significant differences betweentraceptive group
of
ange
-year
Radius BMD g/cm2 (unadjusted) at baseline
(SD) p value
0.46 (0.06) .40
0.44 (0.06)
0.45 (0.05)
0.46 (0.05)
Table 5
Factors associated with radius BMD at study visit, estimated from random
effects liner regression model
Variable Effect on
radius BMD
95% Confidence
interval
p
BMI, change in radius
BMD per unit change
in BMI (g/cm2 per kg/m2)
0.0029 0.0023 to 0.0036 b .001
Method relative
to nonuser (g/cm2)
Nonuser (reference) 0
DMPA, 0.0058 -0.011 to 0.022 .69
NET-EN -0.0022 -0.017 to 0.013 .77
COC 0.0026 -0.013 to 0.018 .74
Change in radius BMD
over time (g/cm2
per person-year)a
Nonuser 0.0055 0.0037 to 0.0073 b .001
DMPA, 0.0069 0.0028 to 0.011 .001
NET-EN 0.0013 -0.0017 to 0.0043 .40
COC 0.0053 0.0022 to 0.0085 .001
In a model without BMI, interaction between method and follow-up time
was significant with p= .036.
a Interaction effect of change in radius BMD over time and
contraceptive user groups was marginally significant, p= .07.
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in users of DMPA have mainly used the hip and spine for
measurement of BMD.
The loss of BMD in the case of DMPA use has been
associated with estrogen deficiency [25]. Some studies show
that these negative changes may be reversible and there is a
return to pre-use levels on discontinuation of DMPA [1,26].
In addition, there seems to be recovery of BMD in long-term
users of DMPA [1,6]. However, there are no long-term data
on women who commence DMPA in adolescence
and, therefore, there is a need to investigate whether the
recovery seen in older age groups applies to this younger
group whose BMD may be compromised prior to achieving
peak bone mass. It has been suggested that norethisterone
(NET) on its ownmay protect against calcium loss via a direct
topic effect on bone or by the action of estrogenicmetabolites.
The studies that have included oral NET [27–29] have
shown a positive effect on BMD; however, NET-EN may be
different in that the depot characteristics are added to this
compound through the addition of EN. The lack of data on
the effect of NET-EN on BMD may be due to the method
not being as widely used internationally as DMPA.
However, in South Africa, this method has increased in
popularity in recent years and is often the method of choice
for younger women [22,30].
In 2004, the US FDA required the addition of a black
box warning in the product labeling stating that DMPA use
may impair BMD [31] and adolescents were mentioned as
a group that could be particularly at risk of bone loss. The
following year the WHO issued a statement on hormonal
contraception and bone health [32]. Recommendations
with regard to bone metabolism are that there should be
no restriction on the use of DMPA and its duration of usein women aged 18–45 years. Evidence around potential
safety concerns for women under 18 years using DMPA
was not considered adequate at the time and therefore the
WHO stated that the advantages of using DMPA out-
weighed the concerns regarding fracture risk. Recommen-
dations for DMPA applied to NET-EN use. No restriction
was placed on use of other progestogen-only or combined
hormonal contraceptive methods. A position paper pub-
lished in 2006 by the Society of Adolescent Medicine [33]
supports the WHO position on DMPA use for women aged
18–45 years and states that with existing evidence, the
advantages of using DMPA in women below 18 years
outweigh the disadvantages. The lack of evidence on the
consequences of long-term use of DMPA was acknowl-
edged, and until data became available, it was recom-
mended that prescribing DMPA to adolescents should be
considered on a case-by-case basis. A recently published
paper [34] has cautioned against the recommendation made
by the UK Medicines and Healthcare Products Regulatory
Agency (MHRA) [35] that DMPA users should switch to
another method of contraception after 2 years of use. Data
in the Albertazzi et al. [34] paper shows that women using
COCs after DMPA may be particularly at risk for loss of
BMD. This present study suggests that DMPA and COC
do not affect BMD in younger women, but raises questions
about the effect of NET-EN on BMD in younger users.
Future analysis on completion of our study will include
information from a larger sample with longer follow-up and
may clarify the effect of NET-EN further. In addition, we
will be able to examine potential recovery in those who stop
using hormonal contraceptive methods. A subsample of
women in our study will have hip and spine BMD
measurements, but these data are not yet available.
The main limitations to our study were that long-term
follow-up in our adolescent women has been affected by
frequent method change and discontinuation. Our study has
used the forearm as the site of measurement which may be
less sensitive than the hip and spine to changes in BMD
resulting from hormonal contraceptive use.
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Abstract
Most studies show that depot-medroxyprogesterone acetate (DMPA) has a negative effect on bone mass. There are conflicting reports
with respect to recovery of bone mass with long-term use of DMPA. No information is available on the effect of norethisterone enanthate
(NET-EN) on bone mass, and combined oral contraceptives (COCs) have not been found to be associated with loss of bone mass. The aim of
this study was to investigate bone mineral density (BMD) in older women (40–49 years) in relation to use of DMPA, NET-EN and COCs for
at least 12 months preceding recruitment into the study.
One-hundred twenty-seven users of DMPA, 102 NET-EN users and 106 COC users were compared to 161 nonuser controls. Bone
mineral density was measured at the distal radius and midshaft of the ulna using dual X-ray absorptiometry.
There was no significant difference in BMD between the four contraceptive user groups (p=.26) with and without adjustment for age.
Although a small decrease in BMDwas noted in the age range of 40–49 years, this was not statistically significant (p=.7). The BMDwas found
to be significantly associated with body mass index (BMI) (pV.0001) at both measurement sites, with an increase of one unit of BMI translating
to an increase of 0.0044 g/cm2 in radius BMD. Follicle-stimulating hormone (FSH) level z25.8 mIU/mL was associated with a decrease of
0.017 g/cm2 in radius BMD relative to women with FSH b25.8 mIU/mL. Significant interaction between FSH and BMI in their effect on BMD
was observed (p=.006). This study found no evidence that long-term use of DMPA, NET-EN and COCs affects BMD in this population.
D 2005 Elsevier Inc. All rights reserved.
Keywords: Depot-medroxyprogesterone acetate; Norethisterone enanthate; Combined oral contraceptives; Bone mineral density1. Introduction
Cross-sectional studies undertaken to investigate the effect
of hormonal contraceptives on bone mineral density (BMD)
have produced conflicting reports [1–7]. Most have indicated
that depot-medroxyprogesterone acetate (DMPA) has a
negative effect on bone mass [1–5], and some have shown
minimal or no effect [6–8]. The loss of BMD in the case of
DMPA has been associated with estrogen deficiency [9].
Some of these studies show that these negative changes are
reversible and there is a return to pre-use levels on0010-7824/$ – see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.contraception.2004.09.003
* Corresponding author. Tel.: +27 31 304 8383; fax: +27 31 304 8468.
E-mail address: m.beksinska@rhru.co.za (M.E. Beksinska).discontinuation of the method [1,10]. In addition, there has
been evidence of recovery of BMD in long-term users
[1,6,11]. There is no information available on the effect of
norethisterone enanthate (NET-EN) on bone mass; however,
published studies on norethisterone (NET) have shown a
positive effect on BMD [12–14]. Combined oral contra-
ceptives (COCs) have not been found to be associated with
loss of bone mass [15,16], with some studies indicating that
COCs are bone-sparing [16,17].
Few studies have investigated the effect of hormonal
contraceptives on BMD in premenopausal long-term users
of hormonal methods in their 40s, and none have
investigated the effect of NET-EN on BMD.
Depot-medroxyprogesterone acetate and norethisterone
enanthate are effective contraceptives with low failure rates71 (2005) 170–175
M.E. Beksinska et al. / Contraception 71 (2005) 170–175 171[18]. In South Africa, hormonal injectable contraceptive use
is high, with about 60% of Black African women practicing
contraception using either DMPA or NET-EN [19]. Of the
two available injections, older women mainly use DMPA
and often continue to use this method into their late 40s. Use
of COCs is lower with the method predominantly used by
white and Asian women. As menopause is known to be
associated with bone loss [20], it would be important to
know if hormonal methods of contraception could further
contribute to bone loss in older women.
The aim of this study was to determine if long-term use
of hormonal contraceptives (COCs, DMPA and NET-EN) is
associated with change in bone mass in women aged 40–49
years.2. Subjects and methods
A cohort of women 40–49 years old using DMPA,
NET-EN or COCs and nonusers of hormonal contraception
were recruited from a large family planning clinic in
Durban, South Africa. Recruitment commenced in 2000
and was completed in 2003. For inclusion as a hormonal
contraceptive user, women had to have used DMPA, NET-
EN or COCs for at least 1 year. For inclusion in the nonuser
control group, women should not have used any form of
hormonal contraception in the past year. All DMPA users
were on a regimen of 150 mg every 12 weeks and NET-EN
users on 200 mg every 8 weeks. The COCs used by women
included a range of formulations, with most (93%) usingTable 1
Sociodemographic and lifestyle characteristics of subjects in the 40 to 49 year ag
Characteristics DMPA (n =127) NET-EN (n
Mean age, years (SD) 43.6 (2.7) 43.0 (2.2)
Mean highest education grade (SD) 8.5 (3.3) 9.8 (3.1)
Marital status (%)
Married/cohabiting 46.1 52.1
Regular partner-not cohabiting 3.2 7.7
Casual partner 38.9 36.5
No partner 11.9 2.9
Employment status (%)
Employed full/part-time 44.5 73.5
Unemployed 54.0 19.6
Housewife 1.6 6.9
Ethnicity (%)
African 98.4 95.2
Colored 1.6 1.0
Indian 0 3.8
Exercise
No regular exercise (%) 96.9 96.0
At least once a week (%) 3.1 4.0
Dieted in last 6 months (%) 0 0
Caffeine consumptiona
Never (%) 9.1 18.8
1–2 cups/day (%) 75.3 62.2
N2 cups (%) 15.6 19.0
Ever smoked cigarettes (%) 11.0 10.3
Current smoker (%) 4.7 5.6
a Tea or coffee.formulations containing between 30 and 40 Ag of estrogen.
Women were eligible to participate if they had not lactated
or delivered in the past 6 months, were not currently or had
never used medication known to affect calcium metabolism
for more than 3 months and did not have a chronic disease
affecting calcium metabolism. Women who were postmen-
opausal were excluded from the study at screening as the
aim of the study was to follow-up women through their
natural menopause. Menopause was classified as amenor-
rhea for at least 1 year. For injectable hormonal contracep-
tive users this criterion could not always be used as women
commonly experienced amenorrhea induced by the method.
Therefore, in addition to amenorrhea, follicle-stimulating
hormone (FSH) levels from blood samples were measured.
An FSH level of z25.8 mIU/mL was considered to be in
the menopausal range (King Edward VIII Hospital Durban;
Chemical Pathology Laboratory criteria using Roche
Elecsys FSH expected values).
On recruitment, a questionnaire was administered by a
trained research nurse to elicit information on lifetime
contraceptive history, fertility history, menopausal symp-
toms and regularity of the menstrual cycle. Questions were
also asked on smoking, diet, exercise and caffeine and
alcohol intake. The examination included height, weight,
blood pressure and waist and hip measurements using a
standard protocol. Body mass index (BMI) was calculated
from the weight and height as kg/m2. Forearm BMD was
measured by dual energy X-ray absorptiometry (DEXA
model DTX-200; Osteometer MediTech, Rodovre, Den-e range by contraceptive method use
=102) COC (n =106) Nonuser (n =161) p value
43.7 (2.5) 45.4 (2.5) b .0001
9.8 (2.4) 9.1 (2.7) .012
b .0001
57.1 41.0
5.7 3.7
28.6 25.5
7.6 29.8
b .0001
71.5 63.4
23.8 33.5
4.8 3.1
.007
67.0 94.4
7.5 2.5
25.5 3.1
.48
94.3 93.0
5.7 7.0
4.7 b1 .003
19.0 12.3 .08
69.1 75.2
12.0 12.6
10.4 16.1 .17
5.7 9.9 .23
Table 2
Reproductive characteristics by contraceptive method user group
Characteristics DMPA (n =127) NET-EN (n =104) COC (n =106) Nonuser (n =161) p value
Parity (median) 4 3 3 3 .04
Ever lactated (%) 88.2 91.3 87.7 83.2 .34
Mean age at menarche, years (SD) 15.2 (1.7) 15.5 (1.7) 14.8 (1.7) 14.8 (1.7) .014
Lactation (years), median 3.5 3.2 3.0 3.2 .06
FSH b .0001
b25.8 mIU/mL (%) 72 94 66 90
N25.8 mIU/mL (%) 28 6 34 10
Use of group methoda
Median use in last 5 years (months) 53 45 52 NA
Median lifetime use (months) 84 49 89 NA
Mean age at first use (years) 36 37 36 NA
a Only group method shown, that is, group to which women using that method at the time of recruitment were allocated. Contraceptive history of nonuse
group not shown.
Table 3
Factors potentially associated with radius BMD (unadjusted)
Factors Radius BMD g/cm2 (95% CI) p value
Contraceptive group .26
DMPA 0.514 (0.501–0.527)
NET-EN 0.514 (0.499–0.528)
COC 0.500 (0.486–0.514)
Nonuser 0.518 (0.506–0.529)
Ethnicity .007
African 0.516 (0.509–0.523)
Indian 0.491 (0.451–0.531)
Colored 0.479 (0.456–0.503)
Age, per year 0.0017 (0.0041 to 0.0008) .188
BMI, change per kg/m2 0.0044 (0.0036–0.0052) b .001
FSH .029
b25.8 mIU/mL (%) 0.516 (0.508–0.524)
N25.8 mIU/mL (%) 0.498 (0.483–0.512)
M.E. Beksinska et al. / Contraception 71 (2005) 170–175172mark). BMD was measured in g/cm2 at two sites in the
distal forearm (radius and ulna). The distal site contains
approximately 25% trabecular bone and 75% cortical bone.
The DEXA equipment was standardized daily using a
phantom as prescribed by the manufacturer’s instructions.
Accuracy to the standard during the recruitment period was
0.53% and in vivo precision was 0.94%. Study participants
are currently being followed-up at six monthly intervals for
a total of 5 years. Women will be completing their 5-year
follow-up visit between 2005 and 2008. The findings
presented in this paper are based on the baseline data
collected at the recruitment visit and are cross-sectional in
nature.
The characteristics of women in the study were quantified
as meansFSD, medians or percentages. Follicle-stimulating
hormone levels were divided into two categories according to
laboratory cut-off levels for premenopausal (b25.8 mIU/mL)
and perimenopausal/menopausal (z25.8 mIU/mL). Differ-
ences in BMD between contraceptive groups and the
associations between BMD and selected characteristics of
the study participants by contraceptive group were assessed
using one-way analysis of variance and multiple variable
linear regression for BMD measured at the two anatomic
sites. The proposed study aims to be able to detect a half
standard deviation difference in bone mass between users and
nonusers of injectable contraceptives. This would be of
biological significance as this difference would translate into
a large difference in the risk of fracture in the older woman.
Information on the mean and standard deviation of cross-
sectional measurements of forearm bone mass in white,
European, premenopausal women reported by Nordin [21]
was used to estimate sample size. The sample size, calculated
assuming a two-tailed statistical test with a significance level
of 5% and with power of 80%, was 63 subjects in each
contraceptive group. Loss to follow-up was estimated at
approximately 10–15% per year. Therefore, sample size after
adjusting for loss to follow-up was at least 100 women in
each category.
Data were analyzed using the statistical package STATA
(V.8; College Station, TX, USA). Ethical approval wasrgranted by the University of the Witwatersrand, Human
Subjects Research Committee, and by the Scientific and
Ethical Review Group of the World Health Organization.3. Results
In total, 496 women were recruited. Baseline information
about these women is summarized in Table 1. Although the
groups using hormonal contraception were similar in age,
the nonusers of hormonal contraception were on average 2
years older than DMPA users (pb .001). Norethisterone
enanthate users were the youngest group with a mean age of
43 years. Almost all women were African except for the
COC group which included around a quarter (26%) of
Indian women. This resulted in a significant difference in
ethnicity between the groups (p=.007). The reproductive
characteristics of the woman are shown in Table 2. A
number of other differences were noted between the groups
including a significant difference in age of menarche, FSH,
parity, employment status, marital status and education.
There were no differences in smoking history, exercise
(Table 1) or years of lactation (Table 2).
All women using hormonal methods had used the
method for at least 1 year at recruitment. The average length
Table 4
Results of multiple regression model with BMI and FSH level
Factors Radius BMD
units (95% CI)
p value
Effect of FSHa
(for women of median
BMI=33.9 kg/m2)
b25.8 mIU/mL 0.514 (0.507–0.521) b .066
N25.8 mIU/mL 0.501 (0.488–0.513)
Effect of BMI, unit BMD
per unit change in BMI
b .001
FSHb25.8 mIU/mL 0.0038 (0.0028–0.0047)
FSHN25.8 mIU/mL 0.0067 (0.0048–0.0086)
a Significant interaction between FSH level and BMI (p= .006).
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women (n=13) having used the method for 15 years or
more (Table 2). Norethisterone enanthate users had been
using the method on average for 5.6 years and COC users
for 8.6 years.
There was no significant difference in BMD between the
four contraceptive user groups at the radius (p=.26) or the
ulna site (p=.21), with and without adjustment for age
(Table 3). Although a small decrease in BMD was noted
over the age range (40–49 years), this was not statistically
significant (p=.7). Length of use of method in the last 5
years and total lifetime use were not associated with
difference in BMD.
Although differences were noted between the contracep-
tive groups, most were not associated with BMD except for
BMI, ethnic group and FSH level (Table 3). A statistically
significant difference in BMD was found between the
Indian and African women (p= .014); however, after
adjusting for BMI, the difference in BMD was no longer
significant.
Bone mineral density was found to be associated with
BMI (pV .0001) and with FSH level at the radius (p=.029)
and ulna (p=.022). An increase of one unit of BMI was
associated with an increase of 0.0044 g/cm2 in radius and
0.0041 g/cm2 in ulna BMD. Follicle-stimulating hormone
level N25.8 mIU/mL was associated with a decrease of
0.017 g/cm2 in radius BMD (Table 3) relative to women
with FSHb25.8 mIU/mL.
Body mass index, FSH level (z25.8 vs. b25.8 mIU/mL)
and interaction of BMDwith FSH level were all significantly
associated with BMD in a multiple regression model (r2=.2).
According to this model, for women of median BMI of 33.9
units, mean radius BMD varied from 0.514 g/cm2 (95% CI,
0.507–0.521) with FSH b25.8 mIU/mL, to 0.501 g/cm2
(95% CI, 0.488–0.513) for women with FSH N25.8 mIU/mL
(p=.066). The effect of FSH on BMD was significantly
modified by BMI and vice versa (p=.006). For women with
FSH b25.8 mIU/mL, BMD increased by 0.0038 (95% CI,
0.0028–0.0047) (g/cm2) per unit increase in BMI, whereas
for women with FSH N25.8 mIU/mL, BMD increased by
0.0067 g/cm2 (95% CI, 0.0048–0.0086) for each unitincrease in BMI (Table 4). Similar results were obtained
for ulna BMD (data not shown).
Follicle-stimulating hormone level was found to be
significantly different between user groups (pV .0001).
However, after adjusting for age, the difference between
the four groups was no longer significant (p=.13). An
increase of 1 year in age increased mean FSH level by
3 mIU/mL (pb .001).4. Discussion
The findings of this cross-sectional study of older women
(40–49 years) show no evidence of a significant difference
in BMD between the three contraceptive users and nonuser
control groups. This is in agreement with some studies that
have found no difference in BMD in long-term users of
DMPA compared to nonuser controls [1,6] and the normal
population mean [8]. Some of these studies [1,8] suggest
that any bone loss would occur in approximately the first 3
years of use but that this effect could be reversible.
However, other studies have shown that loss of BMD
persists in long-term users [22,23]. The mechanism
involved in reversing a hormonally initiated loss of BMD
is not clear. It has been suggested [1] that a homeostatic
mechanism operates that reverses bone loss after prolonged
hormonal stimulation. Women using contraceptives in the
study reported here were mainly long-term users and it may
be that any initial loss of BMD associated with use of
DMPA had been recovered.
While this study did not show that COC use was
beneficial with respect to bone mass, some studies have
shown a positive association of BMD with COCs [6,17]. It
could be speculated that a short-term increase in BMD as a
result of COC use may return to the BMD levels of nonusers
after some time. In support of this, several studies have
found that there is no difference in BMD in long-term users
of COCs [1,24].
This is the first study to include data on the two-monthly
injectable NET-EN. It is suggested that NET may protect
against calcium loss via a direct topic effect on bone or by
the action of estrogenic metabolites [25]. Norethisterone
enanthate can be considered to be similar in action to NET,
as the enanthate (EN) is added primarily to give it its depot
characteristics. Although the studies that have included
NET [12–14] have shown a positive effect on BMD, no
positive effect of NET-EN was seen compared to other
groups in this study.
No previous studies have reported on the relationship
between FSH level and BMD which may be more important
than age, as raised FSH is an indicator for menopause. In our
study, women with an FSH level of z25.8 mIU/mL had a
significantly lower BMD at both distal sites. We have found
a significant interaction between BMI and FSH in their effect
on BMD. As a result of this, the loss in BMD for an increase
in FSH level N25.8 mIU/mL will be greater for women of
lower BMI than for their counterparts with relatively higher
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of BMI in our sample (28.9 units) will lose 0.0285 g/cm2
(95% CI, 0.0462 to 0.0108) of BMD when moving from
the lower category of FSH. By contrast, a woman at the 75th
percentile of BMI (38.54 units) will lose only 0.0003 g/cm2
(95% CI, 0.018 to 0.0175) of BMD when her FSH level
increases to more than 25.8 mIU/mL according to this
model. In other words, loss in BMD as a result of menopause
is diminished by the effect of BMI.
In women with FSH 25.8 IU/mL, BMD increased by
0.0067 g/cm2 per unit increase of BMI, whereas in women
with FSH levels b25.8 mIU/mL, BMD increased by
0.0038 g/cm2 per unit increase in BMI. This means that
the effect of BMI on bone density is greater for women with
raised FSH levels, compared to women with FSH b25.8
mIU/mL. Using the cut-off of FSH of 25.8 mIU/mL as a
marker of menopause, the protective effect of BMI is greater
for postmenopausal women (FSH N25.8 mIU/mL) than it is
for premenopausal women (FSH b25.8 mIU/mL).
Investigation of older women was considered important
as any loss of BMD during short-term use of DMPA could
be exacerbated by age. There is, however, some debate
around the extent of age-related bone loss [20,26]. There
was a small nonsignificant difference in BMD with age
noted in the population in our study. Since the age range of
our participants was narrow (10 years) a significant
difference in BMD and age may not have been expected.
This study confirms the association of BMD with BMI
[1,11,23]. In our study, African women had a significantly
higher BMI and BMD compared to the Indian women. Petitti
et al. [1] found that the Black African women in Harare had a
higher mean BMI and that ethnic differences in BMD
persisted even after adjustment for BMI. However, in our
study, differences in BMI explained the ethnic differences in
BMD.
In conclusion, long-term use of hormonal methods in this
study population does not negatively impact on BMD and
there should not be concerns about allowing women to
continue using this method until they reach menopause.
Further, since African women have generally higher BMIs
than other population groups, their risk of osteoporosis may
be lower.
4.1. Limitations of the study
The cross-sectional nature of the study is a limitation.
The women recruited are now contributing to a longitudinal
study with 5 years of follow-up. Bone mineral density
measurements were limited to the forearm and, therefore,
findings may not be applicable to other skeletal sites.
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Abstract
The objective of this study was to investigate whether follicle-stimulating hormone (FSH) levels can be used reliably to indicate
approaching menopause in older (aged 40–49), long-term users of depomedroxyprogesterone acetate (DMPA) and norethisterone enanthate
(NET-EN). One-hundred and seventeen women using DMPA, 60 NET-EN users and 161 nonusers of contraception were recruited. At
recruitment, serum FSH levels were measured and questions were asked regarding menopausal symptoms, menstrual cycle and date of last
injection. Results of the recruitment blood test showed that 32% of the nonusers had FSH levels in the menopausal range 25.8 mIU/mL
compared to 28% of the DMPA users and 9% of the NET-EN group. After adjusting for age, there was no significant difference between
the 3 groups (p  0.13). An increase of 1 year in age increased the FSH level by 3 mIU/mL (p  0.001). All the hormonal contraceptive
users were between 1 day and 12 weeks of their injection interval. Many had been using the injectable contraceptive method for over 10
years and almost all were amenorrheic at the time of recruitment. The data show that a raised FSH level can be detected during use of DMPA
and NET-EN and could be used as a menopausal indicator without interrupting method use in this group of contraceptive users. © 2003
Elsevier Inc. All rights reserved.
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1. Introduction
Depomedroxyprogesterone acetate (DMPA) and nore-
thisterone enanthate (NET-EN) are effective contraceptives
with low failure rates [1]. One of the common side effects
of these methods is amenorrhea, which increases in inci-
dence over time [1]. In older users it may be difficult to
distinguish between amenorrhea associated with approach-
ing menopause and that induced by the method. Detection
of menopause or perimenopause, therefore, presents a chal-
lenge in this group of contraceptive users. Traditional text-
book management of an older woman using oral hormonal
contraception recommends measurement of follicle-stimu-
lating hormone (FSH) on the 7th day of the pill-free interval
[2]. Advice for DMPA and NET-EN users is less clear;
however, in the absence of data documenting efficacy, it has
been suggested that they should change to a nonhormonal
method of contraception, as menopausal symptoms will be
masked, and measurement of FSH levels may be unreliable
[2].
DMPA and NET-EN are known to inhibit the mid-cycle
surge of FSH and luteinizing hormone (LH), but the tonic
release of these gonadotrophins continues at luteal phase
levels [3,4]. A few studies have also shown that DMPA and
NET-EN suppress raised FSH and LH levels in postmeno-
pausal women [5,6]. While limited information exists on the
duration of the suppression of raised FSH and LH levels
associated with menopause, in both these studies [5,6], the
lowest FSH and LH levels occurred between 14 and 30 days
after injection. The majority of suppressed levels were still
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high enough to be classified as in the menopausal range.
Thereafter, FSH and LH levels started to rise, and in one of
these studies [6], FSH levels started rising back to presup-
pression levels between 40 and 80 days after injection.
In South Africa, hormonal injectable contraceptive use is
high, with about 60% of Black African women practicing
contraception using either DMPA or NET-EN [7]. Of the
two available injections, older women almost exclusively
use DMPA and often continue to use this method into their
late 40s.
While the primary aim of this study was to investigate
bone density in older women using hormonal contracep-
tives, a secondary objective was to investigate whether FSH
levels could be used as an indicator of menopausal status in
injectable users. This was due to the high prevalence of
amenorrhea in the two injectable groups, which made it
impossible to use the menstrual cycle as an indicator of
menopausal status. This paper presents the results of the
latter component of the study.
2. Materials and methods
A cohort of older women using DMPA (150 mg at
3-month intervals), NET-EN (200 mg at 2-month intervals),
combined oral contraceptives (COCs) and nonusers of con-
traception were recruited from a large family-planning
clinic in Durban, South Africa, between September 2000
and November 2001. For inclusion as an injectable user,
women had to be aged between 40 and 49 years and had to
have used the injectable hormonal contraceptive for at least
1 year. On recruitment, a questionnaire was administered
that elicited information on contraceptive history, meno-
pausal symptoms and regularity of the menstrual cycle.
Because women were recruited at different times in the
injection cycle, date of last injection was recorded. A sub-
sample of injectable users with FSH levels 25.8 mIU/mL
at recruitment were contacted and asked to return for a
second test to confirm their earlier result. If the recruitment
measurement was taken later in the injection cycle, the
woman was asked to return for a repeat test in the expected
peak suppression period in her next injection cycle (14–30
days). If the recruitment measurement was taken during
time of expected peak suppression she was asked to return
after this time in the next injection cycle. FSH measure-
ments are repeated yearly for the 5-year duration of the
study.
A serum sample was obtained at the recruitment visit,
and serum FSH levels were determined by immunoassay on
the Roche Modular Analytics E170 (Elecsys module) im-
munoassay analyzer. Repeated samples from each subject
were always analyzed in the same FSH assay batch. In total,
eight assays were conducted during the time of data collec-
tion for this study. For the purposes of this study, an FSH
level between 25.8 and 135 mIU/mL was considered to fall
into the menopausal range (King Edward VIII Hospital
Durban; Chemical Pathology Laboratory criteria using
Roche Elecsys FSH expected values).
2.1. Assay specificity
With respect to analytical specificity, the following cross
reactions with other hormones have been determined for the
monoclonal antibody used: LH, thyroid-stimulating hor-
mone, human chorionic gonadotropin, human growth hor-
mone and human placental lactogen at 0.1%.
2.2. Assay sensitivity
The lower detection limit is 0.10 mIU/mL. The detec-
tion limit represents the lowest FSH level that can be dis-
tinguished from zero. It is calculated as the concentration
lying two standard deviations above that of the lowest
standard. The maximum of the measuring range is 200
mIU/mL. Values above this figure are reported as 200
mIU/mL. All samples analyzed for this study were above
the lower detection limit and no sample was reported over
200 mIU/mL.
2.3. Test precision (reproducibility)
The within-assay coefficients of variation ranged be-
tween 0.78% and 1.5% for QCs with mean values of 9.53
and 33. Between assay variability ranged from 3.5% to
7.6%, depending on the serum FSH concentration.
To investigate whether DMPA and NET-EN interfered
with the FSH assay, control test samples and patient sam-
ples with high and low values of FSH were spiked with both
contraceptives at levels above the highest circulating levels
of MPA and NET described in the literature [8,9]. The
results of this showed that only very small differences were
observed, which fell into the quoted within-run precision of
the test.
In this article we present the data collected up to No-
vember 2001 relating to the injectable hormonal users. Data
on COC users will be analyzed separately. Mean and me-
dian FSH levels were compared between nonusers and each
of the two injectable user groups, by means of Student’s t
test and the Wilcoxon test, respectively, using the statistical
package STATA (V.7 College Station, TX, USA). Multiple
regression was done to investigate the effect of hormonal
injectable use on FSH, adjusted for age. Ethical approval
was granted by the University of the Witwatersrand, Human
Subjects Research Committee.
3. Results
In total, 117 DMPA and 60 NET-EN users were re-
cruited. Fewer women were recruited in the NET-EN group,
as this method is not as popular in older women. Baseline
information about these women and 161 nonusers of con-
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traception is summarized in Table 1. Nonusers of hormonal
contraception were on average 2 years older than DMPA
users (p  0.001). NET-EN users were the youngest group
with a mean age of 42.5 years. All women using either
DMPA or NET-EN had been using the method for at least
1 year at recruitment. The average length of lifetime use for
DMPA was 9.3 years, with a number of women (n  13)
who had used the method for 15 years or more. NET-EN
users had been using the method on average for 5.6 years.
The majority of subjects had started using DMPA or
NET-EN immediately after the birth of their last child, as
they had attained their desired family size. Very few women
using DMPA reported regular menstrual cycles (8%);
women not reporting a regular cycle were in almost all cases
experiencing spotting or amenorrhea. More women in the
NET-EN group (48%) reported regular cycles. Results of
the recruitment blood test showed that 32% of the nonusers
had FSH levels in the menopausal range (25.8 mIU/mL)
compared to 28% of the DMPA users and 9% of the
NET-EN group. FSH was associated with a woman’s age (p
 0.013), and Fig. 1 shows a plot of FSH levels by age
predicted from the regression model. After adjusting for
age, there was no significant difference in FSH levels
among the three groups (p  0.13). An increase of 1 year in
age increased the FSH levels by 3 mIU/mL (p  0.001).
Of the total 33 women using DMPA and 6 using
NET-EN who had an FSH level greater than 25.8 mIU/mL
on their recruitment visit, 12 DMPA and 2 NET-EN users
were able to return during their next injection cycle after
being contacted by telephone. Table 2 shows the two results
Table 1
Baseline information
Nonusers
(n  161)
DMPA users
(n  117)
NET-EN users
(n  60)
Mean Age (y) (p  0.001) 45.3 43.6 42.5
Median 46 43 42
Range 40–49 40–49 40–49
Mean FSH mIU/mL
(p  0.013)
26.4 22.1 11.6
Median (p  0.013) 12.6 10.1 7.2
Range 0.2–115 0.1–114 0.2–51.1
Fig. 1. Observed and fitted FSH levels by age.
Table 2
Individual FSH levels of the subgroup of users of DMPA and NET-EN
with raised FSH levels at recruitment
Subject no. Days
postinjection
(earlier
measurement)
FSH
(mIU/mL)
Days
Postinjection
(later
measurement)
FSH
(mIU/mL)
DMPA
391 50 52.9 85 71.8
584 42 38.7 48 37.4
628 27 28.6 37 57.9
629 14 113 42 99.7
632 14 22.9 90 45.6
703 25 9.3 72 93.3
706 76 32.7 90 45.1
734 55 54.3 93 68.2
740 52 54.6 91 50.5
792 17 67.9 36 69.4
822 5 30.8 14 33.4
833 1 50.2 28 41.5
NET-EN
639 15 21.3 38 28.5
724 10 27.4 60 51.2
341M.E. Beksinska et al. / Contraception 68 (2003) 339–343
in each of these participants. In total, 7 women had one of
the two FSH measurements taken in the time of expected
peak suppression (14–30 days). In three of these measure-
ments the FSH level fell below the menopausal range
(25.8 mIU/mL) while the other four still remained in the
menopausal range (25.8 mIU/mL). The levels in most
cases differed considerably depending on the time postin-
jection. The level taken later in the injection cycle was
higher in 10 of the 14 cases. In two subjects (subject nos.
629 and 792), similar FSH levels were observed during
expected peak suppression (14–30 days) and later in the
injection cycle.
4. Discussion
Previous studies have been limited due to their small
sample sizes and the inclusion of subjects who received
only one dose of MPA or NET-EN [5,6]. These studies
concluded that the baseline values of FSH and LH in post-
menopausal women declined from the day of injection to
reach their lowest levels between 14 and 30 days and then
rose back to presuppression levels between about 40 and 80
days postinjection. In one of these studies [5], one of the
subjects received a second dose of NET-EN and results
indicated that the suppression of FSH was not as pro-
nounced as that of the first dose. Further, the degree of
suppression of FSH is reported to vary considerably be-
tween women, with suppression ranging between 30% and
75% of baseline values [5]. Although a great deal of vari-
ability between women was shown, a similar pattern of
suppression after injection and return to baseline values
later in the dosing cycle was exhibited [5].
Our study supports the earlier work, in that in almost all
cases, DMPA and NET-EN did suppress FSH levels in the
first 30 days after injection. Where two samples were taken
in the same subject, the levels of FSH measured in the
sample taken sooner postinjection were lower in almost all
cases. In two cases, the gonadotrophin levels were measured
on day 1 (subject no. 833) and day 5 (subject no. 822)
postinjection, probably before peak suppression occurred.
In one case (subject no. 833) the level taken subsequently at
day 28 during the time of expected peak suppression was
found to be lower, while in the other (subject no. 822) the
level was slightly higher. It may be that in this subject the
FSH level was already suppressed by day 5 and by day 14
it was recovering.
In some subjects, both measurements were taken after
the time of expected peak suppression and in these cases the
differences between the two measurements was smaller;
however, the measurement taken later in the cycle was
similar or higher. The subject with the highest FSH level
(subject no. 629) showed little difference between her level
at 13 days (113 mIU/mL) and that taken at 42 days (99.7
mIU/mL). It may be that the peak suppression of FSH
occurred between these two times or that gonadotrophin
levels in this subject only responded marginally in terms of
suppression. This subject had been using the method for 14
years in total.
This is the first study which examines FSH levels in
long-term users of DMPA and NET-EN. Raised FSH levels
were found in women during use of the method and this
indicates that measurement of gonadotrophins could be used
as an indicator of onset of menopause. This also supports
earlier work where gonadotrophin levels rarely fell below a
peak level of 20 mIU/mL in postmenopausal women [5,6],
again suggesting that the suppression would not necessarily
make gonadotrophin levels unreliable indicators of meno-
pause in hormonal injection users. It does suggest, however,
that the measurement should be taken as late as possible in
the 2- or 3-month injection cycle to ensure that the gona-
dotrophin levels were approaching baseline levels.
There are no local guidelines in South Africa on how to
deal with a woman using injectable contraception in her
later reproductive years; however, the policy at a large
provincial hospital in Durban is to refer users reaching 50
years, or users who report menopausal symptoms, for FSH
measurement at the end of a 3-month DMPA injection cycle
(King Edward Hospital, Durban, personal communication).
If an FSH level is found to be in the menopausal range, the
woman will be counseled to consider changing her method
of contraception to a barrier method to see if menses returns.
Raised levels of FSH with accompanying menopausal
symptoms have been documented at this facility amongst
hormonal injection users. This finding has important impli-
cations for guiding family-planning providers in the man-
agement of older women using hormonal injectable contra-
ception. Women could possibly have gonadotrophin levels
measured without discontinuing the method, as long as the
test is taken later in the injection cycle for both NET-EN
and DMPA. A good time to measure levels is on return for
the next injection dose before the gonadotrophin levels are
reduced.
The transition to menopause described as the perimeno-
pause has been estimated to be just under 4 years in some
populations [10]. As a woman moves into the perimeno-
pause, FSH can fluctuate between pre- and postmenopausal
values and menopausal symptoms such as erratic menstrual
cycles, and hot flashes will be experienced [11]. The vari-
ability of FSH levels during this time has called into ques-
tion the reliability of using the FSH measure to diagnose or
predict menopause [12]. However, in injectable users, it is
the only means of assessing the menopause and, based on
our findings, it should still be considered an option.
Further work will be done in a more in-depth study on
this issue, which will involve taking multiple samples in a
smaller subset of women who have agreed to participate in
having repeat samples taken at short intervals within the
dosing interval.
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4.1. Limitations of the study
This study had a number of limitations. Subjects were
part of another study which was not set up for taking
multiple blood samples, which would be required to obtain
an in-depth picture of gonadotrophin suppression. The re-
searchers aimed to get subjects to come once during the
peak gonadotrophin suppression period and once towards
the end of a 2- or 3-month injection cycle. This was not
always possible, as many women were only contactable by
letter and it was therefore difficult to remind them to come
at the exact time scheduled. The laboratory had not devel-
oped its own reference ranges for the FSH test.
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